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Abrogating GRP78 function as a strategy to increase apoptosis of 
tumour cells 
Abstract. 
The endoplasmic reticulum (ER) is the major site for protein synthesis, folding and 
trafficking, as well as lipid synthesis and Ca2+ storage. To maintain ER integrity, 
homeostatic response mechanisms to stimuli which perturb ER function, known as the 
unfolded protein response (UPR) have evolved. Cancer cells can be exposed to 
extremes of environmental conditions as a direct consequence of their mechanisms of 
origin, and may have increased cellular proliferation, coupled with poor vascularisation 
leading to deficiencies in glucose, oxygen and metabolite requirements for efficient cell 
growth and survival. When ER function is disrupted, the UPR activates pro-survival 
mechanisms, such as the induction of chaperones and other folding machinery. 
However, the UPR also activates pro-death stimuli, to remove cells where the stress is 
to severe or persists for too long. Glucose regulated protein 78 (GRP78) is the major 
stress regulator and central hub of the UPR, as well as a key chaperone of the ER. 
GRP78 bind to and inhibits the activation of; protein kinase-like ER kinase (PERK), 
inositol requiring element 1 (IRE1) and activating transcription factor 6 (ATF6), known 
as the UPR activators. Solid tumours, such as melanoma and glioblastoma, may have 
increased expression of GRP78 correlating with disease stage and resistance to 
chemotherapy. Conversely, increased GRP78 expression in neuroblastoma has been 
associated with improved prognosis. 
To test the hypotheses that abrogating GRP78 function increases apoptosis of tumour 
cells and that GRP78 is a biomarker for the outcome of ER-stress in differing cancer 
types, neural-crest derived cancers were compared by stoichiometric analysis of GRP78 
and the UPR activators, and the downstream components of the UPR, activating 
transcription factor 4 (ATF4) and X-box binding protein 1 (XBP-1). To determine the 
importance of GRP78 across cancer types, changes in sensitivity to the ER stress 
inducers fenretinide or bortezomib with respect to cell death (propidium iodide stained 
flow cytometry) or inhibition of cell viability (MTS assay) were assessed in response to 
siRNA mediated knock-down, GRP78 over-expression and GRP78 inhibition. 
IV 
 
There were differences in cellular concentrations of GRP78 between cell lines 
representing different cancer types; however the expression of UPR activators did not 
correlate with GRP78 levels. Stoichiometric analysis of the ratio between GRP78 and 
the UPR activators demonstrated a significant difference between melanoma and 
glioblastoma, to that of neuroblastoma. Mapping the activation of the UPR by either 
fenretinide or bortezomib showed cancer-specific and stress-inducer-dependent 
responses. Importantly, melanoma and glioblastoma demonstrated significantly greater 
ATF4 induction whereas neuroblastoma showed prolonged XBP-1 splicing. Testing the 
effect of altering GRP78 expression on sensitivity to ER-stress-induced cell death 
demonstrated that high expression of GRP78 in melanoma and glioblastoma correlated 
with resistance and with neuroblastoma GRP78 over-expression enhanced sensitivity. 
Investigating the effect of inhibiting GRP78 activity on fenretinide- and bortezomib-
induced cell death demonstrated enhanced sensitivity in melanoma and glioblastoma, 
but no significant enhancement in neuroblastoma. 
Thus, down-regulating GRP78 or its function increased the death of melanoma and 
glioblastoma cells in response to ER stress; however there are differences in UPR 
signalling between cancer types, which ultimately results in contrasting prognosis as 
demonstrated in neuroblastoma. Although all three cancer types responded to ER-stress 
induced death, interpretation of the relationship between GRP78 and the UPR activators 
is essential for determining dependence on GRP78. The data suggest that melanoma and 
glioblastoma demonstrate increased sensitivity when GRP78 is inhibited due to a shift 
in the dynamic equilibrium of the UPR, promoting activation and downstream cell 
death. However cancer types expressing higher UPR activator concentrations compared 
to that of GRP78 do not respond positively to the inhibition of GRP78.  
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Due to the notorious resistance of cancer cells to cell death, cancer research has shifted 
to focus on interpreting the mechanisms of specific cell signalling pathways that are 
responsible for either protecting against or inducing death stimuli. Cancer cells have 
robust signalling mechanisms to adapt and cope with sub-optimal conditions within 
their microenvironment. In this context, triggering cancer cell death by inducing 
cytoplasmic stress through targeting the functionality of the endoplasmic reticulum (ER 
stress) represents a novel mechanism to enhance death of cancer cells resistant to 
conventional death-receptor- or mitochondrial-mediated apoptosis.  
One consequence of ER stress is the activation of the homeostatic response mechanism 
known as the unfolded protein response, which is based around the key chaperone 
GRP78. The unfolded protein response characteristically induces pro-survival 
chaperones and protein folding machinery, however, also induces factors capable of 
activating cell death. Glucose regulated protein 78 is the sensory hub of the unfolded 
protein response, and therefore gaining a better understanding of the function and 
regulation of this protein, as well as the pathway in cancer cells may harness ER stress 
as a novel therapeutic strategy. Additional target identification will also define the most 
appropriate use of ER stress-inducing agents that to date have no beneficial effect as 
single agent therapeutics.  
The poor survival rates of patients suffering from metastatic melanoma and 
glioblastoma are a direct result of a lack of successful treatments. Interestingly, both of 
these cancer types demonstrate an increase in GRP78 expression with disease stage and 
therefore may rely on the prevention of the UPR or an increase in UPR signalling 
capability for survival. However, neuroblastoma also demonstrates an increase in 
GRP78 in the later disease stages, yet these patients demonstrate an increase in cell 
death and a more favourable prognosis. Therefore, a comparison of these neural-crest-
derived cancer types may allow for differences in signalling to be determined, to help 
manipulate the unfolded protein response to increase the effect of ER stress for cancer 
therapy. 
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1.1:  Neurulation and the neural-crest. 
1.1.1: Neurulation. 
Gastrulation within vertebrates generates an embryo that consists of an internal 
endodermal layer, intermediate mesodermal layer and an external ectoderm. A key 
event in human development is the interaction between the dorsal mesoderm and the 
overlying ectoderm, as this initiates organogenesis. This interaction results in the 
ectoderm forming a hollow neural tube. Cells of the neural tube begin to develop into 
neural-crest cells, which eventually will differentiate to form the brain and spinal cord. 
The process that results in the formation of a neural tube from the flat ectoderm is 
termed “neurulation” [1].  Neurulation can be sub-divided into four key events: neural 
plate formation, shaping of the neural plate, bending of the neural plate and closure of 
the neural groove to form a tube. The neural tube separates from the ectoderm by a shift 
in the relative expression of adhesion proteins, such as E-cadherin and N-cadherin [2].  
The progression of the neural tube into the central nervous system (CNS) occurs by the 
constriction of the neural tube to form an anatomically distinct brain and spinal cord, 
along with a rearrangement of cells within the wall of the neural tube, giving rise to 
multifunctional regions of the CNS [1]. Within the neural tube, neuro-epithelial cells 
differentiate into the numerous types of neurons and supportive cells present within the 
body [3]. Different regions of the neural-crest give rise to different cell types. Research 
using avian models has described neural-crest cells as pluripotent, differentiating to a 
diverse number of cell types often depending on their starting location in the neural tube 
[4]. Neural-crest cells will also begin to migrate underneath the ectoderm to form 
pigment cells or migrate ventrally to give rise to the autonomic nervous system [5]. 
Despite this migration, all regions of the neural-crest give rise to supportive cells, such 
as glial and pigment secreting melanocytes [6]. However, the pluripotent phenotype of 
neural-crest cells diminishes with migration. 
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1.1.2:  Neural-crest development. 
The neural-crest is a transient embryonic structure derived from the ectoderm during the 
process of neurulation. Neural-crest cells are formed from the border between the neural 
plate and the epidermal ectoderm [7]. During neural tube closure the multi-potent 
neural-crest cells that leave the dorsal neural tube and migrate, as well as differentiate, 
give rise to a variety of different cell lineages such as: melanocytes, glia, sensory and 
sympathetic neurons, endocrine cells, enteric ganglion and cartilage [8].  
 
Figure 1.1: Developmental lineages derived from the neural-crest, including 
melanocytes and glia cells, as well as the genesis of neuroblastoma. Diagram adapted 
from Nakagawara and O’Hira (2004). 
Neural-crest cells originate from the dorsal end of the neural tube, migrating and 
differentiating to form vital components of the nervous system, including the medulla 
and adrenal glands [9]. Due to the vast importance and number of varying cell types that 
neural-crest cells can differentiate into, the fate of a neural-crest cell depends ultimately 
on where it resides and this may explain, for example, why the symptoms of 
neuroblastoma are so diverse. 
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With such importance, comes extensive regulation. Neural-crest cells are regulated by a 
set of transcription factors known as the homeobox (Hox) genes [10]. Found in most 
eukaryotes, this family is highly expressed during neurulation, with distinct regions 
showing expression of different dominant family members, influencing not only the 
development of different neural specific chambers but also the fate of cells [11].  
1.2: Cancers of the neural-crest. 
Although derived from the ectoderm, the neural-crest has been called the fourth germ 
layer, due to the high number of differing cell types it differentiates into. A number of 
cancers originate either by direct dysfunction of neurulation or downstream due to 
mutations and adaptations in the differentiated cell types. Three well-documented 
cancer types include melanoma, glioma and neuroblastoma (Figure 1.1). 
1.2.1:  Melanogenesis and melanoma. 
Ultraviolet (UV) radiation can cause acute damage to the skin in the form of sun burn 
but can also cause long term accumulative DNA damage within the skin, resulting in 
early aging [12]. To help prevent this, the skin stimulated by UV light produces 
pigmentation, known as melanin [12]. Melanin, the pigment produced by melanocytes, 
upon stimulation by keratinocytes in the basal epidermis of the skin comes in the form 
of black/brown eumelanin or red/yellow pheomelanin [13]. This polymorphous, 
multifunctional biopolymer with photo-stabling properties confers a protective effect to 
the cell by shielding nuclear DNA during times of UV exposure [12]. 
Melanocytes are found predominantly in the basal layer of the skin but are not fixed in 
their location and migrate within the epidermis [14]. Stimulation by keratinocytes 
renders the melanocyte into a highly dendritic cell type, capable of interacting with 
numerous keratinocytes at any one time, increasing the export routes for melanosomes 
(granules containing melanin) [15]. The extraordinary properties of melanocytes stems 
from their lineage as neural-crest cells [13].  Melanoblasts have been discovered as 
early as the second month of embryogenesis [16]. These melanocyte precursors migrate 
and differentiate throughout the mesenchyme of a developing embryo, residing in the 
basal epidermis and hair follicles [17]. Once established at the dermal-epidermal 
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boarder melanoblasts are stimulated into their final step of differentiation, resulting in 
the formation of melanocytes. 
Pigmentation is the outcome of two important cellular events, synthesis of melanin by 
melanocytes and the trafficking of melanosomes to surrounding keratinocytes [18]. The 
obligatory step in the synthesis of melanin is the hydroxylation of tyrosine to 
dopaquinone by tyrosinase. It is this point within melanin production that eumelanin 
and pheomelanin pathways differ. In stimulated melanocytes, nascent melanosomes 
receive all their required proteins; both structural and enzymatic, from the golgi before 
undergoing four maturation stages resulting in a competent melanosome before export 
[13]. Upon transport, the melanosome requires active uptake into keratinocytes. This is 
predominantly carried out by protease-activated receptor 2 (PAR2) before the 
melanosomes are positioned on the sun exposed side of the nucleus, to provide relief 
[19]. 
Under periods of UV radiation, melanogenesis becomes hyper-activated due to an 
increase in melanocyte stimulating hormone (αMSH) and adrenocorticotrophic hormone 
(ACTH) by the surrounding keratinocytes. These hormones bind and agonise the 
melanocortin 1 receptor (MC1R) of melanocytes [20]. MC1R receptor is a G-protein 
coupled receptor that activates adenylyl cyclase, inducing the production of cyclic 
adenosine monophosphate (cAMP), which results in the phosphorylation of cAMP 
responsive element binding protein (CREB) and the transcription of the microphthalmia 
transcription factor (MITF) [21]. MITF is essential for the expression of pigment 
enzymes required in the production of melanin [22]. Variants of the MC1R receptor 
have been identified in humans and are associated with a red hair and fair skin 
phenotype, stemming from the reduced binding capacity present within these variants 
which results in an individual who is somewhat impaired in their ability to tan and 
therefore at a greater risk of DNA damage and developing melanoma [23]. 
In normal skin, melanocytes exist in an even distribution within the basal epidermis and 
hence differences in pigmentation are due to the expression of melanosomes present in 
keratinocytes encompassing the melanocytes with variable eumelanin and pheomelanin 
[24]. Tanned or pigmented skin has been shown to protect the skin against 
carcinogenesis by an approximate 500 to 1000 fold [25]. Occasionally mutations arise, 
allowing melanocytes to escape the control of keratinocytes and they proliferate 
uncontrollably, producing clusters within the basal epidermis. These clusters are the 
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formation of benign neavus, more commonly known as moles. Further mutations within 
these benign nevi can result in melanoma [26]. 
Melanoma is a malignant neoplasm of the melanocytes. As the most aggressive form of 
skin cancer, the incidence has increased faster than any other malignancy in the last 40 
years [27]. According to the world health organisation (WHO), more than 160 000 new 
cases of melanoma are diagnosed each year worldwide with a colossal 48 000 deaths 
per annum [27]. Data retrieved from the Surveillance, Epidemiology and End Results 
program of the National Cancer Institute shows the incidence of melanoma at 20 
persons per 100 000 among white populations, where a greater incidence is seen in 
males. Incidence rates of 24.4 and 16.8 per 100 000 are seen in men and women 
respectively [28, 29]. Alarmingly, melanoma is the most common form of cancer in the 
15 – 34 age groups, demonstrating a disproportionate mortality rate in younger aged 
individuals and emphasising the acute need for novel therapeutic strategies. 
     1) Normal mole or neavi    2) Malignant change            3) Local metastatic disease 
 
Figure 1.2: Malignant transformation of a normal mole or lesion.   Photomicrographs 
representing: a normal mole (1), a mole displaying malignant change (2) and a 
malignant mole (3). 
Risk factors for the development of malignant melanoma include skin pigmentation; 
pale skin colour and freckling all of which predispose to a higher risk [28, 30], but also 
include, sunlight sensitivity, exposure to ultraviolet light and genetic mutations [28]. 
Like all neoplasms, melanoma arises from the accumulation of mutations in the cell 
cycle regulatory system, acquiring both mutations in proto-oncogenes and tumour 
suppressor genes [31]. The most well-defined mutation in melanocytes is a single point 
mutation in the B-RAF gene occurring in 50-70% of all melanomas, which results in the 
constitutive activation of extracellular regulated kinase (ERK) contributing to cell 
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proliferation, survival and resistance to apoptosis [32]. However, benign nevi also 
frequently harbour mutations in the BRAF gene [33], suggesting additional events are 
required for transformation. 
 
Stage Definition 5-year survival (%) 
I primary tumour  <1mm 93 
II primary tumour >1mm 68 
III regional metastasis 45 
IV systemic metastasis 11 
Table 1.1:  The AJCC staging system for melanoma, indicating estimated survival rates 
for the differing stage melanomas [34]. 
The prognosis for melanoma differs dramatically according to disease stage. Malignant 
change is linked with a change in shape and/or colour of a mole or nevus (Figure 1.2). 
Disease progression is associated with metastasis, initially to regional lymph nodes [35] 
and in late stage disease with systemic metastasis, frequently to the lungs and/or liver. 
This progression results in the poor survival rates for patients with advanced stage 
melanoma (Table 1.1). According to the American Joint Committee on Cancer (AJCC) 
staging system the prognosis for stage I melanoma is a promising 93% survival rate 
after 5 years, compared to a mere 11% for those patients diagnosed with stage IV 
systemic disease [34].  
1.2.2:  Neuroblastoma. 
Neuroblastoma arises early in neuro-embryogenesis when neural-crest cells which 
normally form into sympathetic ganglia or adrenal glands are blocked from entry into a 
terminal differentiate state. Neuroblastoma is the most common extra cranial solid 
cancer in childhood and the most common cancer in infants, with an annual incidence of 
about 7 - 12 per million [36]. As a neuroendocrine tumour, arising from any neural-crest 
element of the sympathetic nervous system (SNS), close to 50% of neuroblastoma cases 
occur in children younger than two years of age. A branch of the autonomic nervous 
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system (ANS), the SNS is a nerve network that carries messages from the brain 
throughout the body and is responsible for the fight-or-flight response and production of 
adrenaline. Solid tumours commonly begin in the adrenal glands, though they can also 
develop in nerve tissues in the neck, chest, abdomen, or pelvis.  
Symptoms of neuroblastoma are often subtle and may include fatigue, loss of appetite 
or fever [37]. Later symptoms are dependent on the location of the tumour:  
 In the abdomen, a tumour may cause a swollen stomach, resulting in 
constipation.  
 A tumour in the chest may cause breathing difficulties.  
 Mass on the spinal cord cause a feeling of weakness.  
 Bone lesions in the legs and hips often cause pain and limping.  
 A tumour in the head may cause the eyes to start to bulge outwards and turn 
black due to the pressure exerted from behind.  
Often because symptoms are so diverse and unclear, 50 to 60% of all neuroblastoma 
have already metastasised by the time a diagnosis has been made [38]. Like melanoma, 
the prognosis for neuroblastoma is related to the stage of the disease, with patients 
suffering from early stage disease having a greater chance of survival compared to 
individuals with late stage disease. The "International Neuroblastoma Staging System" 
(INSS) established in 1986 and revised in 1988 classifies neuroblastoma depending on 
its anatomical presence at diagnosis [39].  
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Stage Diagnosis 5-year survival (%) 
1 Localised disease  
90 - 95 
2A 
Localised disease that cannot be 
completely removed 
2B 
Localised disease that may or may not  
be completely removed 
3 
Tumour cannot be removed and has 
spread to local lymph nodes 
70 - 80 
4 
Tumour has spread to distant lymph 
nodes 
30 - 40 
4S 
Tumour has spread to skin, liver and 
bone marrow in infants less than 1 year 
Table 1.2: The International Neuroblastoma Staging System and estimated survival 
rates for the differing stage neuroblastoma 
When a lesion is localized, it is generally curable, however despite aggressive 
multimodal therapy, long-term survival for children with advanced disease older than 
18 months is poor [39]. Biological and genetic characteristics have been identified, 
which, when added to classic clinical staging, has allowed patient assignment into risk 
groups for treatment intensity [40]. These criteria include the age of the patient, extent 
of disease spread, microscopic appearance, and several other biological features, most 
importantly MYCN oncogene amplification [41]. Taking all criteria into consideration 
patients are grouped into low, intermediate, and high risk disease states [42]. With 
current treatments, patients with low and intermediate risk disease have an excellent 
prognosis with cure rates above 90% for low risk and 70%-80% for intermediate risk. In 
contrast, therapy for high-risk neuroblastoma results in a survival rate of approximately 
30% (Table 1.2) [43].  
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1.2.3: Glia and glioma. 
Glial cells are non-neuronal cells that provide support and nutrition, maintain 
homeostasis, form myelin, and participate in signal transmission in the nervous system 
[44]. In the human brain, glial cells are estimated to outnumber neurons by 
approximately 10 to 1 [44]. Some glial cells do function as the physical support for 
neurons [44]. Others regulate the internal environment of the brain, especially the fluid 
surrounding neurons and their synapses, and provide nutrition to nerve cells [44]. Glial 
cells have important developmental roles, guiding migration of neurons in early 
development, and producing molecules that modify the growth of axons and dendrites 
[44]. Recent findings in the hippocampus and cerebellum have indicated that glia are 
also active participants in synaptic transmission, regulating clearance of 
neurotransmitters from the synaptic cleft [45], releasing factors such as ATP which 
modulate presynaptic function [46], and even releasing neurotransmitters themselves 
[47]. Glia also forms the insulating myelin sheath that coats neurons to aid conductivity 
[44]. Unlike the neuron, which is generally considered permanently post-mitotic, glial 
cells are capable of mitosis [48]. 
Traditionally glia had been thought to lack certain features of neurons. For example, 
glia cells were not believed to have chemical synapses or to release neurotransmitters 
[44]. They were considered to be the passive bystanders of neural transmission. 
However, recent studies contradict these findings. For example, astrocytes are crucial in 
clearance of neurotransmitter from within the synaptic cleft, which provides distinction 
between the arrival of an action potentials and prevents toxic build-up of 
neurotransmitters, such as glutamate (excitotoxicity)[44, 47]. Furthermore, at least in 
vitro, astrocytes can release the neurotransmitter glutamate in response to certain 
stimulation. Another unique type of glia, the oligodendrocyte precursor cells, have very 
well defined and functional synapses from at least two major groups of neurons [44]. 
The only notable differences between neurons and glia, by modern scrutiny, are the 
ability to generate action potentials and the polarity of neurons, namely the axons and 
dendrites which glia lack. 
Therefore, it is inaccurate to consider glia as 'glue' in the nervous system as the name 
implies; rather, they should be considered more as the partner of the neuron. They are 
also crucial in the development of the nervous system and in processes such as synaptic 
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plasticity and synaptogenesis [49]. Glia cells have a role in the regulation of repair of 
neurons after injury [50]. In the CNS glia suppress repair. Astrocytes enlarge and 
proliferate to form a scar and produce inhibitory molecules that inhibit regrowth of a 
damaged or severed axon [50]. In the parasympathetic nervous system (PNS) Schwann 
cells promote repair. After axon injury Schwann cells regress to an earlier 
developmental state to encourage regrowth of the axon [51]. This difference between 
PNS and CNS raises hopes for the regeneration of nervous tissues within the CNS. 
Arising from glial cells of the central nervous system, glioma is the most common form 
of brain cancer, with Astrocytes and oligodendrocytes being most noted cell types in 
glioma development [52]. To date glioma is responsible for 60% of all brain cancers, 
which themselves make up 1.4% of all cancers diagnosed.  
The clinical manifestation of glioma can be appreciated in terms of tumour location, 
growth rate and size. There are three issues to consider in terms of symptomatology. 
First, tumour location plays a significant role in the focal neurological symptoms 
exhibited by patients. For example, if the tumour is located in the frontal lobe, 
presentation may be related to motor, mood or personality changes. Similarly, tumours 
located in the dominant temporal region may be associated with speech or memory 
disturbances. Fast growing glioma often results in increased intra cranial pressure (ICP). 
Elevated ICP can be the result of obstructive hydrocephalus or oedema, in addition to 
tumour burden and failure of cerebral compensatory mechanisms to accommodate the 
volume. Increased pressure will often result in complaints of headache, visual changes, 
vomiting, and nausea. Lastly, patients often present with seizures, especially in the case 
of oligodendroglioma. Again, the anatomical location of the mass would determine the 
type of seizure (e.g., motor based seizures with fronto-temporal tumours and visual 
based seizures with occipital). In many instances, tumours are discovered by cranial 
imaging studies when a patient is seeking treatment for an unrelated health issue or 
following a head injury (benign, slow growing tumours). 
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Stage Diagnosis Example tumour types 5 year Survival (%) 
I 
Lowest grade 
tumours 
Pilocytic astrocytoma,  
Subependymal giant cell 
astrocytoma, 
 Protoplasmic astrocytoma,  
Ganglioglioma,  
Xanthomatous astrocytoma, 
 Subependymoma . 
60 -80 
II 
Lower grade 
malignancies 
Fibrillary (gemistocytic, 
protoplasmic) astrocytoma  
Ependymoma  
Oligodendroglioma  
Mixed oligo-astrocytoma  
Optic nerve glioma  
50 - 60 
III 
Higher grade 
malignancies 
Anaplastic astrocytoma  
Anaplastic oligodendroglioma  
Anaplastic mixed glioma  
20 – 40 
IV 
Highest grade 
malignancies 
Glioblastoma multiforme  
Gliosarcoma  
Gliomatosis cerebri  
5 -15 
Table 1.3: The American association of surgeons grading system for glioma tumours 
and estimated survival rates for the differing stages. Glioma is a general term for any 
tumour that arises from tissues of the brain other than nerve cells and blood vessels. 
Due to the diversity and location of glioma, a more physical interpretation of cancer 
type is required. The table also indicates the estimated survival rates for the differing 
stage glioma. 
Glioma like other neuro-ectodermal derived tumours has a prognosis dependent upon 
the disease stage. Glioma is an incurable disease, with individuals suffering from stage 
one and two having a life expectancy of five to ten years, stage three brings a solemn 
three years and for those individuals with stage 4 disease, such as glioblastoma 
multiforme a mere one year survival (Table 1.3) [53]. Further complications to the 
prognosis arise with factors such as age and primary tumour location.  
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1.3: Chemotherapy. 
1.3.1: Current treatment strategies. 
Currently, the most common therapeutic agents used for metastatic melanoma include 
dacarbazine, temozolamide and fotemustine [54, 55]. These drugs have been tried alone 
or in combination with each other and/or with adjuvant immunotherapy  (interferon and 
interleukin-2) [56]. However, to date no combination has proved more beneficial than 
single agent dacarbazine which remains limited by a poor response rate of 16%, rarely 
affective after 6 months [34]. Due to the diverse nature of neuroblastoma, intensive 
chemotherapy, surgery, radiation therapy, stem cell transplant, differentiation agent 
isotretinoin also called 13-cis-retinoic acid, and frequent immunotherapy with an anti-
GD2 monoclonal antibody therapy, as well as therapy with platinum compounds 
(cisplatin, carboplatin), alkylating agents (cyclophosphamide, ifosfamide, melphalan), 
topoisomerase II inhibitor (etoposide), anthracycline antibiotics (doxorubicin) and vinca 
alkaloids (vincristine) are commonly used. Newer regimens include topoisomerase I 
inhibitors (topotecan and irinotecan) which have been found to be effective against 
recurrent disease. However, regardless of the chemotherapeutic regime used, only 30% 
of patients with late stage survive [39].  
Glioma therapy encompasses an intensive combination of surgery, radiotherapy and 
chemotherapy. Surgical removal is the primary goal, to allow for histological analysis 
of the mass, identifying tumour origin and stage as well as to remove the mass, 
decreasing any adverse side effects of the tumour. For post-surgical therapy to have any 
effect on the outcome of treatment, 95% of the tumour mass must be removed. 
Normally fractionated radiation therapy is used with a specific margin around the 
resected tumour area to treat any remaining neoplastic cells. More recently, intensity 
modulated radiation therapy which allows for more homogeneous field coverage of an 
irregular tumour region. Radiotherapy is combined with chemotherapeutics to 
accentuate their chance of success, but agents must be able to cross the blood brain 
barrier. Temozolomide is one agent used in glioma therapy, with little to no success 
[57]. With the lack of a treatment which works, chemotherapy has moved towards 
prevention of growth, invasion and metastasis by combining the already existing drugs 
with agents to prevent vascularisation and angiogenesis. Combination therapies have 
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shown some success in clinical trials, but still this approach does not represent a 
successful clinical treatment for glioma. Novel combinational therapies  combining the 
ER stress-inducing agent tetrahydrocannabinol (THC), an active cannabinoid with 
temozolamide have shown promising effects in animal studies with phase 1 trials now 
underway [58].  
Considering the poor outcomes for melanoma, neuroblastoma and glioma, clearly novel 
therapeutic approaches are urgently required. These cancers all differ in symptoms and 
mass localization, but share a poor prognosis and have origins tied to the neuro-
ectodermal stem cell. For all three tumour types no treatment exists which shows a 
significant effect on tumour progression or late stage disease. Further understanding of 
the apoptotic pathways of these cancers and their homeostatic survival mechanisms may 
thus give further insight into how more successful treatment strategies may be 
developed. 
1.3.2: Targeting cellular components of a cell. 
The poor response of melanoma, glioblastoma and neuroblastoma to current 
chemotherapeutic intervention likely arises from the notorious resistance of such 
tumours to apoptosis [34]. For example, advanced metastatic melanoma is highly 
invasive and has developed many different molecular mechanisms to aid its survival 
against both immunological and cytotoxic regulation.  
Classically, agents capable of targeting and damaging DNA have been used to induce 
cancer cell death, and as such DNA damage remains the focus of most common 
chemotherapeutics, as a mechanism to disrupt cellular homeostasis and activate death 
pathways. Consequently, there is a lack in diversity, with regards to targets, and many 
cancer types are able to make adaptations within classical cell death pathways which 
result in their poor response to such therapies. 
1.3.2.1: Apoptosis and cellular development of resistance. 
Apoptosis is a recognised form of programmed cell death and involves a diverse range 
of cell signals which may originate from outside (extrinsic) or within (intrinsic) the cell 
(Figure 1.3) [59]. Extrinsic inducers of apoptosis include; hormones and growth factors, 
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as well as nitric oxide and cytokines [59]. To induce apoptosis via an external signal, 
the signalling molecule must either be capable of crossing the cell membrane or be able 
to transduce the response via an intermediate, for example by activating a member of 
the death-receptor family [60]. Intrinsically, apoptosis can be activated as a result of 
direct stress or damage to the mitochondria or the endoplasmic reticulum (ER) or 
indirectly from stimuli originating from damage to DNA content that activates 
downstream mitochondrial induced apoptosis [61].  
 
Figure 1.3: Extrinsic and intrinsic pathways of apoptosis. Apoptosis mediated through 
the ligation of death receptors or via mitochondria or endoplasmic reticulum converge 
at the activation of caspases to induce apoptosis. 
1.3.2.2:  Death-Receptor-induced apoptosis. 
Apoptosis can be induced through the activation of death receptors including: Fas 
(CD95), TNFαR, DR3, DR4, and DR5 by their respective ligands [60]. Death receptor 
ligands characteristically initiate signalling via receptor oligomerization, which in turn 
results in the recruitment of specialized adaptor proteins and activation of caspase 
cascades [62]. Binding of Fas ligand (FasL) induces Fas trimerization, which recruits 
initiator procaspase-8 via the adaptor protein FADD [63]. Procaspase-8 then 
oligomerizes and is activated via autocatalysis. Activated caspase-8 stimulates apoptosis 
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via two parallel cascades: it can directly cleave and activate caspase-3, or alternatively, 
it can cleave Bid, a pro-apoptotic Bcl-2 family protein [64]. Truncated Bid (tBid) 
translocates to the mitochondria, inducing cytochrome c release, which sequentially 
activates caspase-9 and -3 [64].  
Death receptor regulation can occur through a variety of different mechanisms, at 
differing stages of formation of the death-inducing-signalling-complex (DISC). Firstly, 
death receptors can be regulated by preventing procaspase 8 from binding to the death 
effector domain of Fas- associated death domain protein (FADD), decreasing levels of 
active caspase 8 produced [65]. For example, FADD – like ice inhibitory proteins (FLIP) 
which contain 2 death effector domains competes directly with procaspase 8 for FADD 
interaction and therefore represents a natural regulator of caspase activation.  
The mammalian form of FLIP known as cFLIP not only competes for the FADD 
binding, but can also directly interact with procaspase 8 via its death effector domain 
[66]. Therefore cFLIP can inhibit both components required for caspase activation; 
enzyme and substrate. Also death receptor activation can be inhibited by a mechanism 
that is dependent upon the binding of the death receptor ligand. Decoy receptors closely 
resembling death receptors exist to sequester death ligands, preventing them binding to 
and activating death receptors [67]. Finally, death-receptor-induced apoptosis can be 
regulated by inhibiting the activation of procaspase 8 [65]. The silencer of death domain 
(SODD) protein, a 60 kDa inhibitor of procaspases, inhibits the proteolytical activation 
of procaspases directly [68]. 
1.3.2.3: Mitochondrial-induced apoptosis. 
The mitochondria are sometimes described as the cellular power plant of the cell 
because they generate most of a cell's supply of adenosine triphosphate (ATP), used as a 
source of chemical energy [69]. In addition to supplying cellular energy, mitochondria 
are involved in a range of other processes, such as signalling, cellular differentiation, 
cell death, as well as the control of cell cycle and growth [70].  
Mitochondrial-induced apoptosis is regulated by the B-cell lymphoma 2 (BCL-2) family 
[71]. BCL-2 family members can be either pro or anti apoptotic, with the pro apoptotic 
group being sub divided further into inhibitors of anti-apoptotic BCL-2 members or 
18 
 
initiators of apoptosis (Figure 1.4). The crucial factor for mitochondrial-induced 
apoptosis is membrane permeability. Mitochondria have two membranes: an outer 
(outer mitochondrial membrane (OMM)) and an inner (inner mitochondrial membrane 
(IMM)) mitochondrial membrane [72]. BCL-2 family members such as BCL-2, BCl-xL 
and MCL-1 reside within the mitochondria due to their hydrophobic C terminals, 
stabilising the barrier function of the mitochondrial membranes, preventing apoptogenic 
factors from being released [72, 73]. Pro-apoptotic BCL-2 family members such as Bad, 
Bid, NOXA and can shuttle between mitochondrial localisation. When apoptosis is 
induced these pro-apoptotic proteins localise in the mitochondria, binding and inhibiting 
the function of the anti-apoptotic members [73] which allows for the activation, by 
conformational change, of apoptotic initiator members Bax and Bak. When activated, 
Bax and Bak enter the mitochondrial membranes resulting in membrane disruption and 
the release of cytochrome c and other pro apoptotic stimuli [74]. 
 
Figure 1.4: Interactions of the opposing BCL-2 family members in the initiation of 
apoptosis. Binding of pro apoptotic members of the BCL-2 family to the opposing anti 
apoptotic members inhibiting their effect on mitochondrial membrane stability and their 
inhibitory effect on apoptosis initiating family members Bax and Bak [75].Image 
adapted from Youle and Strasser et al (2008). 
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There are conflicting theories explaining the role by which the apoptotic initiator 
members of the BCL-2 family Bax and Bak induce of apoptosis; from homo-
oligomerisation following cleavage by caspases and channel formation [74], to the 
interaction with already present channels, such as the adenine nucleotide translocator 
(ANT) or the voltage-dependant anion channel (VDAC) altering their function, 
resulting in the permeabilisation of mitochondrial membranes [73, 76]. Although the 
mechanism of these members is not yet fully understood, their consequence within the 
mitochondrial membranes has been a well-known characteristic of mitochondrial-
induced apoptosis for many years [77]. 
A well-accepted model to date is the formation of a four Bax pore within the OMM 
allowing the release of pro apoptotic factors such as Cytochrome c, Apaf1 and SMAC 
DIABLO (an inhibitor of the inhibitor of apoptosis protein family (IAP’s)) by simple 
diffusion. Upon release Cytochrome c binds to apoptotic protease activating factor 1 
(Apaf 1) forming the apoptosome which can now bind and process procaspase 9 due to 
allosteric changes that occur during apoptosome formation. This  results in an increase 
in active caspase 9 levels [78] which activates executioner caspases increasing 
proteolysis and free DNase to digest chromatin [79]. 
1.3.2.4. Targeting cytoplasmic stress. 
As for the deoxyribonucleic acid (DNA)-containing nucleus, cytoplasmic components 
on the cell are also vital for survival. The importance of DNA in cell survival has 
resulted in a number of control mechanisms to identify and repair damage to DNA [80]. 
If the damage cannot be rectified, signalling cascades are activated and death stimuli 
induced to remove the cell and save the integrity of the surrounding tissues (Figure 1.5) 
[81]. This concept also applies to a number of differing cell components, including 
organelles and the cell membrane, where damage results in the activation of 
homeostatic mechanisms to repair the functionality of the cellular component, however 
if the damage is too severe, actively remove the cell [82, 83]. 
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Figure 1.5: Comparing nuclear to cytoplasmic induced stress as targets for cancer 
treatment. Stress or damage to the nucleus or components of the cytoplasm results in 
the induction of homeostatic repair mechanisms, capable of inducing cell death in cells 
where the damage is too severe or persists for too long. 
Although, in a high number of cancer types, DNA damaging agents have shown success, 
these agents often result in collateral damage to normal cells which results in severe 
adverse side effects from therapy, as well as a high risk of developing a secondary 
cancer. Characteristics of cancer cells, such as high proliferation rate, coupled with poor 
environmental conditions increases the load present upon organelle productivity [84, 
85]. This sensitizes cancer cells to stress. Therefore, using agents capable of targeting 
cytoplasmic stress rather than nuclear stress or combining agents to target both cellular 
regions, may allow for a reduction in the dose of DNA damaging agents and therefore a 
reduction in the side effects and an increase in therapeutic success. Due to the 
importance of the endoplasmic reticulum (ER) in protein production, coupled with 
success of the current chemotherapeutic bortezomib in multiple myeloma [86], this 
study will focus on targeting the ER to induce cytoplasmic stress. 
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1.4. The Endoplasmic reticulum and the regulation of homeostatic stress. 
The ER is a eukaryotic organelle that forms an interconnected network of tubules, 
vesicles and cisternae within cells, making up approximately 10% of a cells inner mass 
[87]. These complex structures are responsible for several specialized functions such as: 
protein translation and folding, as well as the transport of proteins that are to be used 
both within the cellular membrane (transmembrane receptors and other integral 
membrane proteins), or secreted (exocytosed) from the cell (e.g. digestive enzymes) 
[88]. The ER is also responsible for sequestration of Ca
2+
; and the production and 
synthesis of glycogen, steroids and other macromolecules [89]. Ribosomes that are 
present upon the cytosolic surface of the ER membrane are responsible for the 
monopoly of protein translation within eukaryotic cells [90]. Regulation of protein 
translation is a key step in ER stress homeostasis [91]. 
1.4.1: Protein translation 
Translation, the decoding of messenger ribonucleic acid (mRNA) by ribosomes to 
produce an amino acid chain known as a polypeptide, is comprised of four stages; 
activation, initiation, elongation and termination [92]. Translation begins after the 
formation of a complex structure, where eukaryotic initiation factor (eIF) 2 bound to 
guanidine triphosphate (GTP) and Met-tRNAimet associates with the 40S ribosomal 
subunit (in complex with eIF1A and eIF3), this interaction forms the 43S pre-initiation 
complex [92]. When a transfer RNA (tRNA) carrying a methionine and the pre-
initiation complex bind to messenger (m)RNA, close to the start codon (a series of three 
adjacent bases in one polynucleotide chain of a DNA or RNA molecule, which codes 
for a specific amino acid) the initiation complex is complete [92]. Upon activation of 
the initiation complex, the large 60s subunit of the ribosome binds to the complex, aided 
by eIF5 and eIF2-guanadine diphosphate (GDP), resulting in the formation of the 80S 
subunit [93, 94]. The formation of the 80S results in the release of the initiation factors 
from the complex [92]. 
The large subunit of the ribosome has three sites where interaction with tRNA occurs, 
known as site A, site P and site E. Site A is the location where aminoacyl-tRNA 
anticodon pairs up with mRNA, to ensure that only the correct amino acid is inserted 
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into the growing polypeptide chain. Site P is where the amino acid is added to the 
growing polypeptide chain and finally site E is the location where the empty tRNA 
resides before release [92]. 
To translate the mRNA fully into the amino acids that form the polypeptide chain, the 
ribosomal based initiation complex must be exposed to the complete mRNA sequence 
and therefore a physical movement is required to shift the complex to the next codon, in 
a 5’ to 3’ direction [92]. This process is known as the elongation stage, where the full 
mRNA sequence is processed by the active ribosome. For movement of the ribosome 
(translocation), elongation factor G is required. After translocation the next tRNA can 
interact with site A within the ribosome. This process requires elongation factors (EG-
Tu and EG-Ts) as well as GTP [62]. Upon binding of the tRNA amino acid complex in 
site A of the ribosome, GTP is cleaved to form GDP generating the energy required for 
elongation [95]. Elongation persists until the ribosomal based initiation complex reaches 
a stop codon; one of three specific sequences which have no tRNA based anti-codon 
sequence [95]. In place of tRNA, a release factor can bind and facilitate the release of 
the polypeptide. 
1.4.1.1: Cap dependent or independent translation initiation. 
During protein synthesis, the cap serves as a tag, highlighting where the 40s ribosomal 
subunit interacts. Important in this process is the eIF4F complex, formed from eIF4A, 
eIF4E, eIF4G [96, 97]. The formation of the eIF4F complex enhances the activity of 
each component. Initiation factor eIF4A is a helicase, which couples ATP hydrolysis 
with RNA binding and duplex separation, unwinding any secondary structures that may 
have formed [97]. EIF4E is the cap binding protein and is therefore essential for cap 
dependent translation. Finally eIF4G acts as scaffolding, aiding the assembly of the 
initiation complex, which leads to the recruitment of the template mRNA to the 
translation machinery [97, 98]. 
Translation of the uncapped mRNA is also achievable, mediated by an RNA structure 
which allows assembly of the translational machinery close to or directly at the start 
codon [99]. This is known as the internal ribosome entry segment (IRES). IRES 
mediated translation has been shown to be independent of 5’ end of RNA and does not 
require a cap, however IRES allows for the recruitment of the 40s ribosomal subunit, 
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independently of the 5’ and 3’ ends of the RNA [97]. IRES elements are not yet fully 
understood, but are believed to contain a Y-shaped, double hairpin structure which is 
followed by a smaller hairpin, forming a RNA motif [100]. These have been found 
upstream of the start codon in a variety of IRESs. To be functional, IRES requires IRES 
trans acting factors (ITAFs) [97]. IRES have been found in a number of cellular 
mRNAs, and although often capped, some mRNAs which encode important initiation 
factors, transcription factors, survival proteins, as well as oncogenes, growth factors and 
homeotic genes contain IRES elements [98]. This adaptation in translation may allow 
for the induction of vital cellular components, when protein synthesis is impaired. 
IRES mediated translation has been shown in some models to require the eIF4F 
complex, as well as ATP. However, eIF4E is not essential within the complex [98]. The 
involvement of the 48s is not found for all IRESs. The generally accepted theory is that 
the ribosomal P site is orientated into the proximity of the initiation codon and then 
eIF2-GTP/Met-tRNAi complex is recruited to the 40S/IRES complexes, forming the 
48s ribosomal subunit [98]. 
1.4.1.2: Protein folding and misfolding. 
Protein folding is the process by which a polypeptide assumes its functional 
conformation. Protein folding is a physical mechanism were a polypeptide folds into a 
complex three-dimensional structure from a random coil. Once the protein has taken its 
nascent polypeptide form a signal sequence within its amino acid sequence is detected 
by signal recognition particles in the cytosol, trafficking of the polypeptide to the sec61 
aqueous pore complex within the ER membrane [101]. Polypeptides reach protein 
secondary structural status due to the presence of the unique intrinsic properties held 
within each amino acid in the polypeptide sequence. This can start to interact and fold 
up, while the remaining polypeptide chain is still being synthesised. This is then 
followed by active bond addition and fragment amalgamation to form fully synthesised 
and functioning protein [102].  
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Figure 1.6: Protein folding and the structures that can be formed by polypeptide chains 
on route to functionality. An unstructured chain, for example newly synthesized on a 
ribosome, can fold to a monomeric native structure, often through one or more partly 
folded intermediates. It can, however, experience other fates such as degradation or 
aggregation. An amyloid fibril is just one form of aggregate, but it is unique in having a 
highly organized ‘misfolded’ structure. Other assemblies, including functional 
oligomers, macromolecular complexes and natural protein fibres, contain natively 
folded molecules. The populations and inter-conversions of the various states are 
determined by their relative thermodynamic and kinetic stabilities under any given 
conditions. In living systems, however, transitions between the different states are 
highly regulated by the environment and by the presence of molecular chaperones, 
proteolytic enzymes and other factors. Failure of such regulatory mechanisms is likely 
to be a major factor in the onset and development of misfolding diseases. Image 
adapted from Dobson et al (2004) [103] 
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Due to the complexity and number of possible interactions present within a polypeptide 
a number of different structures can be generated from a single polypeptide and 
therefore tight regulation of protein folding is essential to ensure the outcome of 
functional proteins (Figure 1.6) [104]. Approximately 90% of all proteins are of 
sufficient size (> 100 amino acids) to collapse in aqueous solutions to non-native 
conformations [105]. These confirmations may be a required intermediate state, a 
“stepping stone” to the correct conformation, or a kinetically stable misfolded state 
[105]. Recent research has shown that even for small polypeptides, that ultimately reach 
their folded state on a sub-second timescale, pass through structural intermediates [105].   
Partially folded or misfolded proteins tend to aggregate, as a direct consequence of 
exposed hydrophobic amino acid residues, as well as regions of unstructured 
polypeptide backbones. These regions are buried in a correctly folded protein [106]. 
Aggregation of protein intermediates and misfolded proteins primarily results in 
amorphous structures [107], due to the non-specific interactions required to bury 
exposed hydrophobic regions, but larger organised fibrillar aggregates called amyloid 
are also known to occur [105]. Somatic mutations in the gene sequence of a protein or 
errors in transcription/translation can lead to the translation of a mutant protein unable 
of adopting the native state [107]. Studies have indicated that protein intermediates are 
more likely to aggregate in the crowded environment (300 – 400 g/l of protein and other 
macromolecules), found in a cell. This increased likelihood may explain the 
requirement of chaperones [92]. 
1.4.1.3: Endoplasmic reticulum stress, quality control and homeostasis. 
The protein folding process has been shown not to involve a fixed series of steps 
between specific partly folded states, but is comprised of a random search of the many 
possible conformations accessible to the individual polypeptide chain, depending on the 
charges and their distributions [32]. Therefore, incompletely folded proteins must 
expose to the surroundings at least some regions of the structure which would normally 
be buried in their native state, in the quest for the correct confirmation, leaving them 
prone to inappropriate interactions within their own peptide structure or with other 
molecules within the crowded environment of a cell [92]. The most frequent outcome 
for misfolded proteins is aggregation [92]. This unwanted outcome is known as ER 
stress and can be enhanced by cellular insults that disrupt the balance between protein 
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synthesis, folding and trafficking within the lumen of the ER [107]. For example, 
reduction in glucose or oxygen can affect the ability of cells to produce functional 
proteins [108].  
Due to the toxic effect of ER stress, a range of strategies have evolved to help prevent 
unwanted interactions and improve the efficiency of protein folding. Folding catalysts 
such as peptidylproylyl isomerases and protein disulphide isomerases (PDI) are 
enzymes that increase the rate of folding, as they physically implant bonds within a 
peptide structure to form the tertiary state. Molecular chaperones are present in all types 
of cells and in all compartments, play important roles within protein folding and as an 
adaptive response under times of ER stress [109]. Molecular chaperones do not 
themselves increase the rate of protein folding, but increase the efficiency by which a 
protein is folded by interacting with exposed residues, helping to orientate the peptide 
structure in the optimal way for processing by foldases [110]. Molecular chaperones 
also aid protein folding by reducing the probability that the immature protein 
intermediates interact, forming aggregates and therefore reduce the chance of a toxic 
insult damaging the functionality of the cell. Evidence for the importance of molecular 
chaperones for homeostasis has demonstrated a significant increase in their expression 
during periods of stress or damage. In particular, the heat shock protein family (HSP) 
has been well documented to play a key role under both periods of normal physiology 
and stress [110]. One important member of The HSP family is HSPA5, also known as 
glucose regulated protein 78 (GRP78), which is the central sensory hub of a cell based 
homeostatic response mechanism to ER stress known as the unfolded protein response 
(UPR) [91, 111]. Neural-crest-derived melanoma, glioblastoma and neuroblastoma have 
all previously been shown to respond to ER stress [82, 112, 113] however studies 
suggest that differences exist between these cancer types, in the context of GRP78 
regulation [113-116]. 
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1.5: Unfolded protein response. 
The UPR is activated in response to an accumulation of unfolded or misfolded proteins 
within the ER. This homeostatic response is made up of three cascades,  stemming from 
the central stress sensor protein: GRP78 [87]. The desired effect of the UPR is to govern 
the survival response of the ER by reducing the load upon it, yet at the same time hold 
in place routes through which to remove the cell and minimize the damage to the tissue 
as a whole. There are many consequences of the pro-survival response of the UPR, such 
as cell cycle and protein synthesis arrest, reducing the requirement/production of 
proteins and allow ER folding machinery time to recover. Also ER resident chaperones 
are activated, aiding the ER folding machinery and buffering unfolded or misfolded 
protein levels. Finally, the activation of ER-associated degradation (ERAD) eliminates 
unwanted proteins to aid the ER under times of stress [117, 118]. The ability of PERK, 
IRE1 and ATF6 to fight against stress, stems from the activation of these three proteins 
by GRP78 (Figure 1.7) [119]. 
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Figure 1.7: The role of GRP78 as the central regulatory force of the UPR. When there 
is an increase in unfolded proteins in the ER, GRP78 dissociates from; IRE1, PERK 
and ATF6, allowing for their activation. IRE1 homodimerises forming a competent 
RNase domain allowing for the processing of X-box binding protein 1 (XBP-1) mRNA to 
make an active splice variant sXBP-1. sXBP-1 is the active transcription factor and 
translocates into the nucleus where it induces the expression of chaperones by binding 
to ER response elements within appropriate promoter sites. PERK, like IRE1, is 
activated under stress by autophosphorylation and homodimerisation to form an active 
kinase. PERK phosphorylates eukaryotic initiation factor 2α (eIF2α), this 
phosphorylation blocks the translation of normal protein synthesis but allows activating 
transcription factor 4 (ATF4) and other essential mediators of the stress response to be 
translated. ATF4 translocates to the nucleus and induces genes involved in homeostasis 
and apoptosis. Upon release, AFT6 translocates to the Golgi apparatus where it is 
processed by site 1 and site 2 proteases (S1P, S1P), into an active transcription factor 
ATF6f, which is a fragment of the cytosolic domain. ATF6f can up regulate the 
expression of chaperone proteins, ERAD, XBP1 and P58IPK (an inhibitor of PERK). 
Image adapted from Stankiewicz et al [120]. 
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1.5.1: Glucose regulated protein 78. 
Glucose regulated protein 78 (GRP78), also known as immunoglobulin heavy chain 
binding protein (BiP), is encoded by the HSPA5 gene (chromosome 19q33.3). GRP78 is 
a 78 kDa member of the glucose regulated protein (GRP) family, induced when cells are 
deprived of glucose, and a member of the heat shock protein (HSP) family [121]. 
GRP78 shares 61% amino acid sequence homology with human HSP70 [122] and 
consists of an N-terminal containing a single ATPase catalytic site and a substrate 
binding C-terminus (Figure 1.8) [123]. GRP78 is translated in a cap-independent 
manner and exists within the cell in multiple forms. Post-translational modification by 
phosphorylation or ADP ribosylation results in inactivation of GRP78 by 
oligomerisation into chains in the ER [124]. This inactive form, representing a neutral 
reservoir within the ER which can be re-activated, allows fast action upon realization of 
ER stress, this increases a cells chance of survival [124].  
GRP78va, a novel isoform of GRP78 has been described. GRP78va is induced during 
ER stress, when GRP78 enhances the retention of intron 1 of the GRP78 transcript, 
resulting in a GRP78 molecule without an ER localisation sequence (signal peptide 
sequence) [125]. GRP78va exhibits a more cyto-protective role, but still regulates the 
UPR from the cytosol. Evidence is rapidly accumulating for the existence of cell surface 
GRP78 [126]. Research demonstrated this sub-population in pathological tissues, such 
as cancer or in cells under stress [125]. This surface-localised GRP78 is too distant to 
regulate ER-based UPR activators PERK, IRE1 and ATF6 and has been implicated in 
oncogenic signalling and metastasis [127].  
Populations of GRP78 have also been discovered in the nucleus, following over-
expression or ER stress, as well as in the mitochondria. These populations, although 
expressed at a much lower level than the ER localised GRP78 have been implicated in 
prevention of DNA-damage-induced cell death signalling and regulation of energy 
within the mitochondria during periods of ER stress [125]. 
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Figure 1.8: Depiction of GRP78 structure and binding sites. This figure shows the 
ATPase and substrate binding domains of GRP78 connected together by a di-leucine 
bridge. The Ion binding domain present within the ATPase N-terminal region of GRP78 
is also indicated. 
Evidence for the importance of GRP78 can be seen by its sequence conservation 
between species. From yeast (Saccharomyces cerevisiae) to humans, GRP78 sequence 
homology is highly conserved [128]. For example sequence analysis of GRP78 in rats 
and hamsters has shown 99.4% identity [129]. This therefore demonstrates the vital role 
to which GRP78 plays in the survival of life, for it to be so highly conserved from more 
basic life forms such as Porifera [128], to the more complicated life of multi-cellular 
organisms. Further evidence for the vital role of GRP78 on life, is its expression in early 
embryonic development. Expression of the UPR master regulator and ER stress sensor 
GRP78 has been detected at the two-cell stage of embryonic development, with high 
concentrations present at the blastocyte stage [130]. GRP78 is believed to be important 
in proliferation and survival of the inner cell mass [131, 132], which is the precursor of 
the pluripotent stem cell. More-recent studies have discovered the presence of glucose 
regulated proteins in cardiac tissue and their involvement in the development and 
differentiation of these tissues, along with the alleviation of cardiac cell metabolic stress 
due to hypoglycaemia [133].  
In healthy unstressed cells, GRP78 exists bound to the luminal domain of protein 
kinase-like ER kinase (PERK), inositol-requiring element 1 (Ire1) and activating 
transcription factor 6 (ATF6) [131]. When ADP is bound to GRP78 it has higher 
affinity for protein substrates with slower off rates than with ATP [134]. When bound to 
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a substrate, not only are they locked in a specific conformation but this interaction with 
the substrate results in the dissociation of PERK, IRE1 and ATF6. Also the binding of 
protein substrates to GRP78 stimulates its ATPase activity, resulting in the replacement 
of ADP with ATP [134]. ATP binding also causes a decrease in GRP78 affinity for 
protein substrates which in turn results in substrate release [135]. GRP78 processing of 
ATP occurs in a cycling system, therefore a constant supply of ATP is required [123]. 
Cycling of ATP/ADP within GRP78 therefore effects the association of both protein 
substrates and UPR proteins as they are dependent upon this for interaction.  
Increased levels of unfolded or misfolded proteins in the ER result in an increased level 
of GRP78 bound to these substrates, resulting in a greater level of UPR proteins being 
free within the ER. However, the role of GRP78 with respect to cell survival does not 
end with the activation of the UPR, although this is seen as a major contributing factor. 
Binding of substrates to GRP78 is not simply an activator of a stress response 
mechanism. GRP78 holds a substrate, preventing structural changes and allowing ER 
folding machinery to work more efficiently to fold or recovery these proteins. E.g. 
GRP78 holds a protein in an optimal orientation to allow PDI to remodel bonds within 
misfolded proteins. Finally the interaction of GRP78 with incorrectly folded proteins or 
nascent polypeptides prevents or decreases their rate of aggregation into insoluble 
masses within the ER, which would exert extra pressure upon an already stressed 
system by interfering with transport, as well as associating with newly synthesised 
proteins.  
The C-terminal binding site of GRP78 is also capable of also binding and sequestering 
calcium (Ca
2+
). Although this interaction is on a one to one scale, this property could 
help to stall Ca
2+
 release from the ER, an early indicator of ER stress and also helps 
preserve Ca
2+
 homeostasis [136]. Buffering Ca
2+ 
release from the ER can reduce the 
chance of apoptosis induction, increasing the time the ER has to recover before the cell 
is condemned to death [79]. With only a single binding site, GRP78 ion binding 
potential is low but with a sufficiently high expression within the cell, coupled with 
other chaperone family members, along with the cycling of binding potential, to 
significantly prevent or slow the flow of Ca
2+
 stores from the ER.  
GRP78 has been shown as a diverse protein capable of preventing the induction of 
apoptosis by buffering characteristic attributes which would normally result in apoptosis.  
Within the UPR, growth arrest and DNA damage 153 (GADD153 or CHOP) is a critical 
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component of the pro-apoptotic arm. Induction of GADD153 signals that a level of 
stress beyond repair has existed for too long. Induction of GADD153 indicates initiation 
of a cell to apoptosis [137]. Studies in glioma indicate that GRP78 was a crucial factor 
in GADD153 induction [138]. This research demonstrated that in the presence of 
GRP78 knockdown a clear up regulation of GADD153 was present, demonstrating an 
inhibitory relationship that exists between GRP78 and UPR-stimulated GADD153 
induction and the eventual activation of apoptosis [138].  
Like GADD153, the fate of the executioner caspase 7 is also coupled to GRP78 activity 
[139]. GRP78 present within the ER membrane forms a complex with procaspase 7 
preventing it from being activated or released into the cytoplasm [140]. This area is not 
yet understood fully but it is known that GRP78 can only halt the release of caspase 7 
for approximately 24 hours [141]. The reasoning behind this reversible inhibition is still 
under debate with conflicting ideas arising, from correlation to the half-life of GRP78 
(which is approximately 24 hours) to the proteolytic cleavage of GRP78 by caspase 7 
[139] or simply the as a consequence of the cycling kinetics of GRP78, which ensures 
GRP78 itself is never irreversibly inhibited. During periods of ER stress, GRP78 has 
been shown to localize to different areas of the ER and cell including the ER membrane, 
cytoplasm, nucleus and cell membrane [125]. Conflicting explanations exist for this 
observation, suggesting that there is a planned redistribution of GRP78 to help the cell 
under stress, another theory is that GRP78 increased presence around the ER and other 
regions of a cell is a consequence of protein up-regulation [139].  
1.5.2: Protein kinase-like endoplasmic reticulum kinase 
Double-stranded RNA-activated protein-kinase-like ER kinase (PERK) also known as 
eukaryotic initiation factor 2 alpha kinase 3 (E2AK3) and is located on chromosome 
2p12. PERK is a type I transmembrane protein and one of the unfolded protein response 
stress sensors or activators that exerts a key role within cell survival. Dissociation from 
GRP78 allows activation of PERK by homodimerization and autophosphorylation [142] 
creating an active cytosolic Serine/threonine-kinase domain. PERK kinase activity is 
involved in the prevention of global protein synthesis [143, 144], while allowing 
selective mRNA translation to commence [145] resulting in up-regulation of stress 
response proteins. The inhibition of cap-dependent translation (global protein synthesis) 
decreases the load placed upon the ER by reducing protein translation, as well as halting 
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proliferation. For example inhibition of protein production can cause cell cycle arrest 
due to the reduction of integral proteins such as Cyclin D1 [146]. Active PERK is a 
major contributing force along with haem regulated inhibitor (HRI), double stranded 
RNA activated protein kinase (PKR) and “general control non-repressed 2” (GCN2) 
that determine the phosphorylation state of eukaryotic initiation factor 2 alpha (eIF2α), 
as well as phospho-regulation the bZIP cap and collar transcription factor NF-E2 p45-
related factor 2 (Nrf2) [147].  
Phosphorylated eIF2α at serine 51 interferes with the formation of a 43S translation-
initiation complex by inhibiting the guanidine nucleotide exchange factor for the eIF2 
complex (eIF2B), reducing global mRNA translation [148]. Therefore PERK is 
responsible for the up-regulation in translation of ER stress response genes to help the 
ER recover. Activating transcription factor 4 (ATF4), is one key protein under uORF 
translation, which when translated becomes an important bZIP transcription factor that 
can influence both pro –survival and -death signalling [149]. EIF2α activation results in 
the incomplete formation of the 43S translation-initiation complex which is capable of 
binding and scanning ATF4 mRNA at a differing 5’ open reading frame site [150]. 
ATF4 can bind to and activate ER stress response elements (ERSE I + II) and unfolded 
protein response elements (UPRE). Genes incorporating these response elements 
encode an array of proteins required to aid a cell under times of ER stress. ATF4 
stimulates the synthesis of chaperones such as GRP78 and GRP94, as well as other 
proteins that are involved in amino acid production/recovery and the regulation of 
homeostasis [151]. GADD153, the bZIP transcription factor associated with pro-
apoptotic aspects of the UPR is also up regulated by the PERK/ eIF2α/ ATF4 pathway 
under times of severe or prolonged stress [152]. The level of GADD153 mRNA within 
a normal cell is relatively low. ER stress-induced transcription to translation of 
GADD153 therefore takes longer, than the IRES translation of GRP78 and other key 
components of the pro-survival response. This represents a time delay in the stimulation 
of pro-apoptotic stimuli, providing a cell with the chance to recover from a perturbation 
in function. 
Nrf2 in non-stressed cells is anchored to the cytoskeletal protein Kelch-like ECH-
associated protein 1 (Keap1) in a cytoplasmic complex [147]. PERK phosphorylates 
Nrf2 allowing it to dissociate from Keap1 and migrate to the nucleus where this 
transcription factor activates the antioxidant response element (ARE) [153], a 
characteristically pro-survival response.  With PERK holding great influence upon the 
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rate of protein synthesis, PERK itself is negatively regulated by HSP40 to ensure 
protein synthesis can be restored, once stress has diminished. HSP40, also known as 
P58
IPK
, is induced late within the UPR and binds to and inhibits the kinase domain of 
PERK, relieving UPR based inhibition of protein translation [154]. EIF2α is also 
regulated to prevent an irreversible inhibition of translation, which would be as fatal to a 
cell as the stress to which it was induced from. Nck-1, a phosphatase results in eIF2α 
de-phosphorylation, restoring global protein synthesis [155].  
1.5.3: Inositol requiring element 1 
ER stress sensor inositol requiring element 1 (IRE1) is the oldest component of the UPR 
and is present within all eukaryotic cells.  IRE1 is encoded by the ER to nucleus 
signalling 1 (ERN1) gene on chromosome 17q24.2. GRP78 holds IRE1 inactive by 
masking the required motifs for homo-dimerization. Once released, sequences within its 
alpha domain are exposed allowing phosphorylation and oligomerization to an active 
state [123]. IRE1 encodes a type 1 transmembrane protein kinase endoribonuclease  
(IRE1p) [156]. There are two forms of IRE1: α and β. IRE1α is the primary copy of 
IRE1, expressed throughout the organism and has been implicated in embryonic 
development [157]. Whereas expression of IRE β on the other hand is localized to the 
gut and has not yet been linked with cell development but has been implicated in 
resistance of the gut to stress induced by xenobiotics [158]. IRE1 has also been 
implicated in chaperone and ER activated degradation (ERAD) induction, as well as the 
activation of cell death via GADD153 and JNK activation [159].   
A luminal dimerization domain, kinase domain, ATP binding domain and finally an 
RNase domain are the main components of IRE1 transmembrane protein [123]. IRE1 
can undergo oligomerization and autophosphorylation to activate its RNase domain 
[160]. Active IRE1 results in splicing of the bZIP transcription factor XBP-1. Splicing 
of XBP-1 (XBP-1s) causes a frame shift and the formation of an alternative C-terminus, 
holding greater transcriptional activation potential [123], within a transcription factor 
now capable of entering the nucleus [161]. XBP-1s regulates a selection of ER-resident 
chaperones involved in protein folding and importantly the tagging of terminally-
mutated proteins for degradation.  
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IRE1 kinase activity results in the phosphorylation of tumour necrosis factor receptor 2 
(TRAF2) [162]. The TRAF family have no known enzymatic activity and are known as 
signal adapters [163]. When TRAF2 is in complex with IRE1, c-Jun N-terminal kinase 
(JNK) is recruited and phosphorylated to an active state. TRAF2 appears to be 
specifically important in this regard, as deletion of the gene abolishes JNK activation 
[159]. TRAF2 can also complex with nuclear factor-Kappa B (NF-kB), activating anti-
apoptotic signalling [164]. Active JNK can induce cell death, as well as tumourgenesis, 
cell migration and inflammation. JNK inhibition of BCL-2, by phosphorylation, results 
in BAX activation as a result of a decrease in BCL-2 regulation, allowing BAX 
translocation and dimerization/oligimerization into mitochondrial membranes and the 
release of pro-apoptotic factors, such as cytochrome c and APAF1 [165]. Activation of 
JNK also induces caspase 8 independent cleavage of Bid at a distinct site to generate the 
Bid cleavage product jBid [166]. Translocation of jBid to the mitochondria results in the 
release of Smac/DIABLO [166]. This release of Smac/DIABLO then disrupts the 
TRAF2-cIAP1 complex. The JNK pathway is therefore required to relieve the inhibition 
imposed by TRAF2-cIAP1 on caspase 8 activation and induction of apoptosis [166]. 
JNK has also been described to activate up-regulation of genes, such as c-jun and 
nuclear factor of activated T cells (NFATs) [167]. 
1.5.4: Activating transcription factor 6 
Originally activating transcription factor 6 (ATF6) was isolated as a member of the 
leucine zipper protein family which are capable of forming heterodimers with DNA. 
Upon ATP binding to GRP78, ATF6 is released, migrating to the golgi apparatus [168]. 
When ATF6 reaches the golgi it is cleaved by site 1 proteases (S1P) at its luminal 
domain before it is cleaved by S2P at its N-terminal anchor domain [161]. These 
modifications to a 670 amino acid molecule result in the release of a basic leucine 
zipper transcription factor, which was embedded within ATF6’s N terminus [169]. 
ATF6 binds ERSE 1 and 2, as well as binding the ATF/CRE element [123]. ATF6 has 
regulatory control over a number of important molecules within the UPR such as 
molecular chaperone GRP78, XBP-1 and GADD153 [170].  
Research has revealed the existence of two forms of ATF6: α and β, both individually 
regulate the translation of molecular chaperones and ER folding machinery positively 
[123]. ATF6 is encoded by the ATF6 gene on chromosome 1q23.3 or 6p21.33 
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depending on the form of protein. Complexes of combined α and β forms result in 
repression of GRP78 by binding its promoter, preventing the required complex 
formation for transcription. ATF6 has a variety of functions that are also present within 
the other two UPR cascades. This overlap in activities could be present as an 
evolutionary backup within the UPR, preventing any of the important functions from 
being lost by having more than one route to their activation. For example, molecular 
chaperones and/or GADD153 have been shown to be regulated by PERK, IRE1 and 
ATF6. ATF6 activation results in the induction of XBP-1 mRNA synthesis helping to 
up regulate XBP-1, providing ample substrate for the IRE-1 cascade [120]. On the other 
hand, the overlap in response outcomes may allow for changes in response strength, as 
well as diversity in response type, depending on the type of stress.  
One function within the UPR which ATF6 holds alone, is the inhibition of lipogenesis 
[123]. Forming a heterodimer with the basic helix-loop-helix transcription factor sterol 
response element binding protein 2 (SREBP2), ATF6 inhibits the lipogenic activity of 
SREBP2 by recruiting histone deacetylase complex 1 (HDAC1) [171].   
1.5.5: Feedback mechanisms of the unfolded protein response. 
The UPR holds great responsibility for the fate of a cell and its surrounding tissues 
during times of ER stress. Being capable of defending the integrity of a cell under times 
of stress makes the UPR a vital process in the physiology of living organisms.  
One of the most important components of the UPR is the induction of key transmitter 
proteins XBP-1 and ATF6. A consequence of UPR activation is the downstream 
processing of XBP-1 and ATF6 to active transcription factors, thus the regeneration of 
cellular expression is essential to reset the dynamic equilibrium of the UPR during 
periods of prolonged stress or after homeostasis has be restored. Without this 
replenishment the dynamic equilibrium present between GRP78 and the UPR 
transmembrane proteins would be skewed in favour of activation, ultimately pushing 
the cell towards death. Therefore, evolution of mechanisms within the UPR, to reduce 
the activity of the cascades, is also essential for life. Endogenous expression of XBP-1 
is regulated by both positive and negative feedback mechanisms. XBP-1s can itself 
activate XBP-1 mRNA transcription, amplifying the response to the stress signal from 
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IRE1. On the other hand, this response is quickly inhibited as newly synthesized XBP-1 
protein acts to mediate the degradation of XBP-1s.  
Research into the field of viral infection has identified P58
IPK
 as an inhibitor of PERK 
[172]. Primarily, data has shown that the activation of P58
IPK
 inhibits PKR-mediated 
translational arrest by binding to and inactivating the kinase domain of PKR, thereby 
ensuring that cellular protein-synthesis machinery remains available to synthesize viral 
proteins. Following on from this work, studies have demonstrated that P58
IPK
 inhibited 
PERK phosphorylation of eIF2α, a key step in the activation of the UPR and inhibition 
of global protein synthesis [172]. This research has highlighted the presence of a key 
regulatory step within the UPR that ensures that global protein synthesis can re-
commence following the stabilisation of the ER, as a downstream consequence of UPR 
activation. 
The importance of re-establishment of protein synthesis again highlights the negative 
feedback loop present within the PERK arm of the UPR. GADD34 demonstrates the 
ability to influence the phosphorylation state of eIF2α by binding to and activating 
phosphprotein phosphatase 1 (PP1). Insights into the function of GADD34 were 
highlighted through the use of ATF4 deficient mice embryonic fibroblasts [173], 
demonstrating prolonged eIF2α phosphorylation when ATF4 was knocked out. 
Researching the role that ATF4 plays in GADD34 mediated eIF2α de-phosphorylation 
showed that ATF4 was capable of regulating GADD34 transcription by directly binding 
to the conserved ATF site within the GADD34 promoter and inducing GADD34 
expression under periods of ER stress or amino acid deprivation [173]. Therefore, 
within the UPR there have been various adaptations to ensure the replenishment of the 
UPR, as well as the mechanisms to help the cell recover from the consequences of UPR 
activation. The complexity of the UPR demonstrates the importance of this homeostatic 
response. 
One major problem with this widely adapted process is that it cannot distinguish 
between normal and cancerous cells. One of the many factors that aid a cancer cell 
under periods of therapy is the up-regulation of vital components of the UPR such as 
GRP78 or PDI. Therefore translational research has now shifted; focusing on 
combination therapies of novel UPR inhibitors with already established 
chemotherapeutic agents to induce an imbalance within the UPR cascades, resulting in 
an insufficient homeostatic response and an increase in ER stress-induced cell death. 
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1.5.6. Endoplasmic reticulum-induced protein degradation 
The recognition of misfolded or mutated proteins depends on the detection of 
substructures within proteins, such as hydrophobic regions, unpaired cysteine residues 
and immature glycans [174]. In mammalian cells for example, there exists a mechanism 
called glycan processing [175], whereby the lectin-type chaperones calnexin/calreticulin 
(CNX/CRT) provide immature glycoproteins the opportunity to reach their native 
conformation [176]. They can do this by way of re-glycosylating glycoproteins by an 
enzyme called UDP-glucose-glycoprotein glucosyltransferase [176]. Terminally 
misfolded proteins, however, must be extracted preventing their accumulation in the 
ER, to decrease ER load and stress levels. This is carried out by ER Degradation 
Enhancing alpha-Mannosidase-like Protein (EDEM) and ER mannosidase I [177]. This 
mannosidase removes one mannose residue from the glycoprotein and this is recognized 
by EDEM, which targets these misfolded glycoproteins for degradation [178]. Because 
the ubiquitin-proteasome system (UPS) is located at the cytoplasm, terminally 
misfolded proteins have to be transported from the ER back into the cytoplasm. It seems 
that a protein complex, called Sec61, an ER membrane translocator containing the 
channel necessary for the transport of misfolded proteins to the cytoplasm is important 
in the removal of ubiquitin-tagged proteins for degradation [178, 179]. Furthermore, 
due to the involvement of this transporter in importing polypeptides to the ER, this 
translocation of misfolded proteins requires a driving force to determine the direction of 
transport. Since poly-ubiquitination is essential for the export of substrates, it is likely 
that this is the driving force. One of these ubiquitin-binding factors is the Cdc48p-
Npl4p-Ufd1p complex [180]. Cdc48 (which is also known as valosine-containing 
protein (VCP) or p97) recognises ubiquitin tails and transports substrates from the ER to 
the cytoplasm with its ATPase activity to aid degradation of substrates by the 26S 
proteasome [178].  
The ubiquitination of terminally misfolded proteins is caused by a cascade of enzymatic 
reactions. The first of these reactions takes place when ubiquitin-activating enzyme E1 
hydrolyses ATP and forms a high-energy thioester linkage between a cysteine residue in 
its active site and the C-terminus of ubiquitin. The resulting activated ubiquitin is then 
passed on to E2, which is a ubiquitin-conjugating enzyme. Another group of enzymes, 
more specifically ubiquitin protein ligases called E3, bind to the misfolded protein 
[178]. Next they align the protein and E2, thus facilitating the attachment of ubiquitin to 
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lysine residues of the misfolded protein. Following successive addition of ubiquitin 
molecules to lysine residues of the previously attached ubiquitin, a poly-ubiquitin chain 
is created. A poly-ubiquitin tagged protein is produced and this is recognized by 
specific subunits in the 19S capping complexes of the 26S proteasome. Hereafter, the 
polypeptide chain is fed into the central chamber of the 20S core region that contains 
the proteolytically active sites. Ubiquitin is cleaved before terminal digestion by de-
ubiquitinating enzymes. This third step is very closely associated with the second one, 
since ubiquitination takes place during the translocation event [178, 181].  
1.6: Endoplasmic reticulum stress-induced apoptosis. 
There are many factors that can result in perturbation of ER function such as hypoxia, 
decreased glycosylation or glucose availability, disruption in calcium (Ca
2+
) 
homeostasis and primarily a disruption in the equilibrium of protein synthesis to folding 
and trafficking. ER stress occurs when the balance between protein synthesis and the 
folding capacity of the ER is disrupted, resulting in an accumulation of unfolded or 
misfolded proteins in the lumen of the ER [119]. Failure of the ER to maintain this 
balance can be critical, not only to the cell in which the defect has occurred but the 
surrounding tissues.  If the folding capacity of the ER cannot match the rate of 
translation it leads to a build-up of unfolded and misfolded proteins within the ER 
lumen. Proteins that have not been folded or misfolding of proteins leaves vacant 
charges within the protein structure giving it the capability to interact with structures 
outside its theoretical function, which can interfere with other cellular processes or 
aggregate together forming insoluble structures, jeopardising the integrity and survival 
state of the tissue [182]. Therefore mechanisms have evolved to provide an ER quality 
control mechanism that helps buffer out minor changes or insults to ER function or push 
the cell towards cell death when the integrity of the ER can no longer be recovered. This 
UPR homeostatic response mechanism is responsible for aiding the cell under times of 
mild to moderate stress and for pushing the cell towards apoptosis when severe stress 
prevents full recovery of the ER function [87].  
To date there is major controversy about how ER stress activates cell death. Research 
occurring in mice has identified the activation of Caspase 12 under periods of high 
stress [87] indicating apoptosis as the primary mechanism. The human homologue of 
caspase 12, caspase 4, has not yet been linked with ER stress; however research has 
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suggested a role for caspase 8 [183]. The accepted route of ER stress-induced apoptosis 
requires cross talk between the ER and the mitochondria. Studies have shown that 
members of the pro apoptotic arm of the BCL-2 family reside within the ER membrane 
(e.g. NOXA and Bim) [184]. Upon ER stress, NOXA induction and translocation to the 
mitochondria occurs, setting in motion the downstream mitochondrial-induced apoptotic 
cascade [185, 186]. Currently the full mechanism and role of the BCL-2 family in ER 
stress-induced apoptosis is not fully understood but research over-expressing anti 
apoptotic members (e.g. BCL-2, BCL-XL) abrogates the effect of ER stress-inducing 
stimuli [186]. Further studies have shown that expression of the homologous 
transcription factor GADD153 induced by the UPR results in the down regulation of 
BCL-2 under periods of severe stress [120]. 
1.6.1: Endoplasmic reticulum stress-inducing agents. 
ER stress can be induced by any stimulus that perturbs ER function. A number of 
modern day chemotherapeutics induce ER stress. Two examples are fenretinide and 
bortezomib (Figure 1.9). Inducing cell death via cytoplasmic stress may not have the 
same long-term repercussions to that of targeting DNA damage to induce cell death, as 
components of the cytoplasm are produced from the DNA blueprint rather than copied 
from the existing components, as for DNA. Therefore damage to cytoplasmic 
components will not be passed on during replication. This factor will reduce the risk of 
secondary cancers as a consequence of treatment. Both agents induce ER stress by very 
different mechanisms of action, therefore allowing for a more thorough interpretation of 
the effect of ER stress. 
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Figure 1.9: Structural depiction of ER stress-inducing agents fenretinide and 
bortezomib. 
Fenretinide or 4-hydroxy (phenyl) retinamide (4-HPR) is a synthetic derivative of 
retinoic acid. Retinoids are substances related to vitamin A [82]. It has been investigated 
for potential use in the treatment of cancer, as well as in the treatment of cystic fibrosis, 
rheumatoid arthritis, acne, psoriasis [187]. Phase III clinical trial data have suggested 
that fenretinide reduces breast cancer relapse in pre-menopausal women. Common side 
effects associated with fenretinide treatment include skin dryness and night-blindness, 
which is reversible upon cessation of treatment [188]. Current chemotherapy for the 
treatment of neuroblastoma includes the use of 13-cis retinoic acid [189]. However 
tumours are often resistant or become resistant to 13-cis retinoic acid. Fenretinide has 
the capability to induce cell death in these resistant tumours [189]. Currently fenretinide 
has shown success for the treatment of minimal residual disease in neuroblastoma 
patients [190]. 
In cancer studies, Fenretinide shows weak activation of nuclear retinoic acid receptors 
(RARs) and treatment may cause ceramide (a wax-like substance) to build-up in tumor 
cells and is associated with the accumulation of reactive oxygen species (ROS), 
resulting in cell death through apoptosis and/or necrosis [189]. Fenretinide accumulates 
preferentially in fatty tissue such as the breast, which may contribute to the 
effectiveness of fenretinide against breast cancer [188]. Specific types of cancer under 
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investigation include or have included ovarian, prostate, cervical, lung, renal, bladder, 
breast, glioma, skin, head and neck carcinoma, non-Hodgkin's lymphoma, 
neuroblastoma, and Ewing's sarcoma. 
Bortezomib (VELCADE®) is a dipeptydl, water soluble, boronic acid derivative that 
can reversibly and selectively binds the threonine residue and inhibits the 26S 
proteasome [191]. The 26S proteasome is important in protein degradation and vital for 
cancer cell survival. In particular bortezomib has been shown to have anti-tumour 
activity in B cell malignancies [192]. One central mechanism by which bortezomib 
functions in multiple myeloma is to inhibit the breakdown of inhibitory kappa B (IκB) 
and consequently the stabilization of the nuclear factor kappa B (NFκB) complex [193-
195]. This prevents NFκB translocation to the nucleus preventing the activation of 
multiple downstream pathways known to be important in myeloma cell signaling [194]. 
However, the inhibition of the 26S proteasome also results in an accumulation of 
unfolded or misfolded proteins in the ER that have been tagged for degradation. This 
build-up results in ER stress responses that can help aid a cell or sensitize it to death 
stimuli. 
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1.7: Aims. 
The central aim of the current study was to determine the relationship between GRP78 
and the UPR activators PERK, IRE1 and ATF6 across neural-crest-derived cancer types 
and to gain a better understanding of the influence of GRP78 on ER stress-induced 
apoptosis. To achieve this aim, specific objectives were to: 
1. Assess the basal expression of GRP78 to that of key regulators of the unfolded 
protein response PERK, IRE1 and ATF6 in neural-crest-derived cancer models and 
whether these are related to the dynamics of ER stress progression across the panel 
of cell lines used as cancer models.  
 
2. Investigate the role of GRP78 as a key regulator of the unfolded protein response 
and the role it has in the ER stress response of neural-crest-derived tumours. 
 
3. Assess the effect of a panel of GRP78 inhibitors for their effect on ER stress as well 
as the ability to enhance the efficacy of fenretinide or bortezomib. 
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Chapter 2: 
 
Materials and Methods 
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2.1: Growth and maintenance of cancer cell lines. 
CHL-1 and WM266-4 (ATCC #; CRL-9446, CRL-1676) human metastatic melanoma 
cells and U251 and MO59J human glioblastoma cell lines (a kind gift from Dr Gareth 
Veal and Prof Nicola Curtin, respectively) were cultured in high glucose (4.5 g/L) 
Dulbecco’s Modified Eagle’s Medium (DMEM; Sigma-Aldrich Co; Poole, UK) 
supplemented with 10% foetal calf serum (FCS; F7524, Sigma-Aldrich) (culture 
medium). SH-SY5Y and NGP  human neuroblastoma cell lines (a kind gift from Dr 
June Biedler and Prof Debbie Tweddle, respectively) were cultured in Roswell Park 
Memorial Institute 1640 medium (RPMI-1640, Sigma-Aldrich) supplemented with 10% 
foetal calf serum (FCS, Sigma-Aldrich).  
Melanoma cell lines were validated for B-RAF mutational status by single nucleotide 
polymorphism (SNP) genotyping assays for the presence of B-RAF
V600E
 or B-RAF
V600D 
genotypes. Validation of glioblastoma and neuroblastoma cancer cell lines was carried 
out by previous groups, before aliquots were stored in liquid nitrogen. Glioblastoma cell 
lines were validated by assessing the p53 mutational status and DNA-dependant protein 
kinase status of each cell line. Neuroblastoma cancer cell lines were validated by 
assessing MYCN, p53, MDM2 amplification and p14ARF deletion and methylation 
status of each cell line.  
Normal human melanocytes were obtained from human foreskin by selective 
trypsinisation, confirmed by immunohistochemical staining for the melanocyte 
differentiation antigen Melan-A (Abcam, Cambridge, UK) and cultured in medium 254 
supplemented with human melanocyte growth supplement-2  (Invitrogen Ltd; Paisley, 
UK).  
 All cells were maintained at 37°C, in a humidified atmosphere of 5% CO2 in air. All 
cell lines were cultured continuously up to a maximum of 50 passages, at which point 
fresh cells were taken from frozen stocks in 90% FCS and 10% DMSO stored in liquid 
nitrogen.  All immortalised cell lines were subjected to regular mycoplasma testing and 
were not infected.  
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2.2: Drug preparation and treatment regimes.   
ER stress-inducing agents fenretinide (Janssen-Cilag Ltd; Switzerland) and bortezomib 
(Velcade; Millenium, Janssen Cilag Ltd; High Wycombe, UK) were dissolved in 
ethanol (for fenretinide) or dimethyl sulfoxide (DMSO, for bortezomib) and added to 
experimental cell cultures, along with an equal volume of vehicle used to treat control 
cells. In all cases the volume of vehicle control did not exceed 0.01% of the total culture 
volume.  Bortezomib was stored at a stock concentration of 1 mM at -80
o
C for up to 12 
months; fenretinide was stored at a stock of 10 mM at -20
o
C for up to 1 month. 
Concentrations of fenretinide and bortezomib used in all experiments were within the 
clinically achievable range or fluctuated around a central clinically-achievable dose 
[196, 197].  
GRP78 inhibitors: Epigallocatacin gallate (EGCG, Sigma-Aldrich) and SubAB5 
subtilase cytotoxin were dissolved in phosphate buffered saline (PBS) or PBS 
containing 0.1% sodium azide). Research incorporating SubAB5 was carried out in 
comparison to the control, proteolytic inactive, mutant of SubAB5, known as 
SubAA272B5. SubAA272B5 contains a seine to alanine mutation within the active site at 
position 272. Honokiol (Sigma-Aldrich) was dissolved in DMSO (Sigma-Aldrich). All 
agents were added to final cultures alone or in combination with ER stress-inducing 
agents, with an equal volume of vehicle added to control cells. EGCG at a stock 
concentration of 1 mM was stored for up to 1 month at 4
o
C prior to use.  SubAB5 and 
SubAA272B5 was a kind gift from James Paton [198-200]. SubAB5 was stored at a stock 
concentration of 2 mg/ml at -20
o
C and diluted to an intermediate 5 µg/ml stock prior to 
experimental use. Honokiol was dissolved to a stock concentration of 20 mM and stored 
at -20
 o
C for up to 6 months prior to use.  
Standard experimental procedure for the treatment of cancer cell lines within this study 
was to expose cells to ER stress-inducing agents and GRP78 inhibitors for 24 hours (h) 
alone or in combination, before experiments were either stopped by fixation or dye 
added. To investigate the induction of ER stress over time, time-course experiments 
were carried out at 0, 1, 2, 4, 8 and 24 h time points. For experiments investigating the 
induction of reactive oxygen species, analyses were carried out over 0, 0.5, 1, 2, 3, 4, 5 
and 6 h. For the accumulation of ubiquitin-tagged proteins, experiments were carried 
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out at 0, 1, 2, 4, 6, 8 and 24 h time points. The effect of combining a GRP78 inhibitor 
on cell line susceptibility to ER stress-induced cell death was evaluated at 6 and 12 h.   
2.3: Cell viability assays. 
2.3.1: MTS assay. 
Cell viability was measured using a commercially-available colorimetric based 
metabolic assay (referred to subsequently as an MTS assay) relying on the reduction of 
a tetrazolium salt to a soluble formazan compound which absorbs at 490 nm. Cells were 
cultured in flat-bottomed 96-well tissue culture plates (Helena Biosciences; Gateshead, 
UK) at a density of 5000 cells per well in a final volume of 100 µl of tissue culture 
medium and allowed to attach overnight at 37°C, 5% CO2 prior to treatment. Cells were 
subsequently treated for 24 h with drugs either as single agents or in combination with 
other agents at given final concentrations, in a final volume of 100 µl per well. Cell 
viability was assessed by the addition of 20 µl of CellTiter 96 Aqueous One Solution 
reagent (Promega, Southampton, UK) to each well followed by incubation at 37°C for a 
further 4 – 6 h prior to the measurement of absorbance at 490 nm using a FLUOstar 
Omega (BMG labtech, Aylesbury, UK) plate reader. In viable cells, MTS is bioreduced 
by dehydrogenases, resulting in the conversion of the tetrazolium compound present to 
a coloured formazan product. 
2.3.2: Sulphorodamine B colorimetric cytotoxicity assay. 
An SRB assay was used for all experiments containing EGCG as this compound is auto-
fluorescent at 490 nm and interferes with the MTS assay. 
Cells were cultured on flat bottomed 96-well plates (Helena Biosciences) at a density of 
5000 cells per well in 100 μl of culture medium and allowed to attach overnight prior to 
treatment. Cells were subsequently treated for 24 h with drug or combination of drugs at 
given final concentrations. Cells were fixed by initially aspirating all media from the 
plates, followed by addition of 200 µl of cold PBS and 50 µl of cold 50% trichloroacetic 
acid (TCA, Sigma-Aldrich). After incubation at 4°C for 1 h, plates were washed and 
stored at 4°C prior to staining. 100 µl of SRB stain was added to each well followed by 
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incubation room temperature for 30 minutes (min). Excess dye was removed by rinsing 
5 times with 1% acetic acid (VWR; Lutterworth, UK). Rinsing was performed quickly 
but gently to avoid dislodging cells and prevent desorption of the protein-bound dye. 
Stained plates were air-dried overnight before addition of 10 mM Tris to solubilise the 
dye. Absorbance at 520 nm was measured using a FLUOstar Omega (BMG labtech) 
plate reader. 
2.4: Flow cytometry  
2.4.1: Flow cytometry of propidium iodide stained cells 
After confirmation of apoptosis in response to fenretinide, bortezomib by flow 
cytometry of annexin V stained cells, all subsequent experiments to measure apoptosis 
were performed by flow cytometry of fixed, propidium iodide-stained cells [201]. 
Cancer cells were seeded in flat bottomed 6-well plates (Corning, Sigma-Aldrich) at 1.5 
x 10
5
 cells per well for CHL-1 cells, or 2.0 x 10
5
 cells per well for U251, MO59J, SH-
SY5Y and NGP cells or 2.5 x 10
5
 cells per well for WM266-4 cells in a final volume of 
3 ml of relevant culture medium and allowed to attach overnight at 37
o
C. Cells were 
then treated with ER stress-inducing agents or GRP78 inhibitors alone or in 
combination for 24 h or a time course ranging over 24 h. After treatment, both cells and 
supernatant were harvested by trypsinization as previously described [202, 203]. Cells 
were pelleted by centrifugation at 330 x g (1200 revolutions per minute (RPM), mistral 
3000i centrifuge, MSE, London, UK) for 5 min at 4
o
C and washed twice in PBS. The 
pellet was then resuspended in 500 μl PBS and transferred to a 5 ml round-bottom test 
tube (Becton Dickenson (BD) Biosciences, Oxford, UK) before being fixed with an 
equal volume of cold methanol: acetone (4:1) solution, before storage at 4
o
C for up to 1 
week prior to analysis.  
To prepare samples for flow cytometry, cells were washed once with PBS and cells 
pelleted by centrifugation. Supernatant was aspirated before treatment with 100 μl 
RNase A (0.155 μg/ml in PBS; Sigma-Aldrich) for 20 min at 37oC. Finally, cells were 
stained by the addition of 300 μl of propidium iodide (PI; 100 μg/ml in PBS; Sigma-
Aldrich) and incubation continued for a further 25 min. Data were collected, using 
CellQuest version 3.3 software, with either a FACScan or FACScalibur flow cytometer 
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(BD immunocytometry systems, Oxford, UK) by recording the percentage of cells with 
hypodiploid DNA (sub-G1 peak) as a measure of cell death. Events were collected 
using a gated amplifier for FL2 (wavelength (λ) 625 nm), corresponding to emissions 
from PI and a signal threshold was applied for forward and side scatter to exclude debris. 
Double nuclei and aggregates were excluded by gating a plot of FL2-A (area) against 
FL2-W (width). Data were analysed using either WinMDI 2.8 for flow cytometry (Bio-
soft.net) or Cyflogic 1.2.1 (Cyflogic, Turku, Finland).  
2.4.2: Flow cytometry for the induction of Reactive Oxygen Species. 
Cancer cells were seeded in flat bottomed 6-well plates at 1.5 x 10
5
 cells per well for 
CHL-1, cells or 2.0 x 10
5
 cells per well for U251, MO59J, SH-SY5Y and NGP cells or 
2.5 x 10
5
 cells per well for WM266-4 cells in a final volume of 3 ml of preferred culture 
medium and allowed to attach overnight at 37
o
C. Cells were then treated with ER stress-
inducing agents over a time course of 6 h. Experiments were designed in such a way 
that the drug was added at differing times during the experiment, to allow all samples to 
reach their designated time point at the same time. After treatment the supernatant was 
removed and cells were washed twice in PBS before the cells were harvested by 
trypsinisation. Samples were pelleted by centrifugation at 330 x g for 5 min prior to 
resuspension in 500 µl of 5 µM of 5-(and-6)-Carboxy-2',7'-Dichlorofluorescein 
Diacetate (DCFDA, Sigma-Aldrich) and samples incubated at 37°C for 15 min. 
Samples were then washed twice in ice cold PBS by centrifugation at 330 x g to pellet 
cells and stored on ice prior to analysis by flow cytometry. All experiments were carried 
out with negative controls of unstained cells and working dye solution alone, as well as 
positive controls of cells treated with hydrogen peroxide at 25 µM and 50 µM for 6 h 
(H2O2, Sigma-Aldrich).  
Data were collected, using CellQuest version 3.3 software, with either a FACScan or 
FACScalibor flow cytometer (BD Immunocytometry systems). Events were collected 
using a gated amplifier for FL1 (λ 530/30 nm), corresponding to emissions from 
fluorescein and a signal threshold was applied for forward and side scatter to exclude 
debris.  Data were analysed using Cyflogic 1.2.1 (Cyflogic) for FL-1 peak area. 
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2.5: Western blotting 
2.5.1: Western blot analysis for relative protein expressions. 
Proteins from cultured cells were extracted from cell pellets using 200 μl of cell lysis 
buffer (0.1 M Tris-Hcl, pH 7.4, 0.1 M NaCl, 25 mM NaF, 1 mM benzamidine, 2 mM 
EDTA, 0.1 mM sodium orthovanadate, 0.1% Triton-X100, EDTA-free protease 
inhibitor cocktail) per well of a 6-well plate [184]. Cell lysates were incubated on ice for 
30 min and then probe sonicated for 2 pulses, each for 5 seconds with a sonicator 
(Soniprep150, MSE, UK) set to 7 microns amplitude. Quantification of protein 
concentration was performed using Bradford assay reagent (Pierce Biotech., Rockford, 
IL, USA) in a 96-well plate (Helena Biosciences) in comparison to a bovine serum 
albumin (BSA) standard curve of 0 – 6 mg/ml and absorbance measured at 595 nm 
using a FLUOstar Omega plate reader (BMG labtech).  
The mini-Protean tetra electrophoresis system (Bio-Rad laboratories; Hemel Hempstead, 
UK) was used to separate proteins by electrophoresis through a 4-20% mini-Protean 
Tris-glycine gel (Bio-Rad laboratories) with Tris-glycine running buffer (250 mM Tris 
base and 1.9 M glycine (Sigma-Aldrich) containing 1% SDS (Fisher Scientific; 
Loughborough, UK)). The gels were subsequently blotted onto immune-Blot 
polyvinylidene fluoride (PVDF) transfer membrane (Bio-Rad laboratories) using Tris-
glycine buffer containing 20% methanol (Fisher Scientific; Loughborough, UK) and 
0.1% SDS (Fisher Scientific). Blots were then washed in 5% non-fat milk for 1 h to 
block exposed hydrophobic sites and then subsequently probed with antibodies, diluted 
in 5% non-fat milk (TBS/T) to relevant concentration (Table 2.1), for either 1 h at room 
temperature or 4
 o
C overnight. Membranes to be probed with antibodies for 
phosphorylated proteins were blocked and antibodies diluted in 5% BSA (TBS/T). 
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Antibody Band size (~kDa) Company Dilution 
GRP78 C-Terminus 78 Santa Cruz 1:1000 
GRP78 N-Terminus 78 Santa Cruz 1:1000 
PERK 125 Santa Cruz 1:2000 
IRE-1 α 110 Santa Cruz 1:2000 
ATF6 α 90 Santa Cruz 1:500 
ATF4 39 Santa Cruz 1:500 
Gadd153 30 Santa Cruz 1:1000 
NOXA 11 Cell Signalling 1:500 
Phospho-eIF2 α 36 Cell Signalling 1:1000 
Cleaved Caspase 3 17, 19 Cell Signalling 1:500 
Ubiquitin 8.5* Cell Signalling 1:1000 
Actin 42 Sigma-Aldrich 1:5000 
Table 2.1: Primary antibody information for western blot analysis. List of all primary 
antibodies used and the relevant company and experimental information required. (* - 
In the case of ubiquitin, a band was detected at approximately 8.5 kDa but also a smear 
of ubiquitin-tagged proteins was detected across the gel with increased ER stress).  
To detect primary antibody binding, blots were incubated with horseradish peroxidase-
conjugated secondary antibodies (Upstate Biotechnology, Boston, USA; diluted 1:2000) 
and visualized using the ECL-plus system (Amersham Biosciences, Little Chalfont, UK) 
and imaged using a Fujifilm FLA-3000 fluorescence imager (Raytek Scientific Ltd, 
Sheffield, UK). Densitometric quantification of signal intensity was performed using 
Aida Image Analyser version 3.28 software and quantified relative to a loading control 
to correct for loading error. 
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2.5.2: Western blot analysis for cellular protein expression. 
Cellular lysates were formed using a Vi-Cell counter (Beckman Coulter, Dunstable, UK) 
to determine cell counts and allow for lysates to be generated containing 100 000 cells 
per 10 µl of lysis buffer (buffer same as previously described). Proteins were then 
separated using the same protocol as for relative protein expression, except for the 
addition of a purified protein standard curve present on all gels for the protein of interest. 
Protein standards were as follows: Full length GRP78 (His-tagged protein, a kind gift 
from Prof AR Hawkins (Newcastle University, UK). Purified protein fragments for 
PERK (Myc-tagged protein fragment corresponding to amino acids 1-581, 66.1 kDa, a 
kind gift from Prof AR Hawkins, Newcastle University, UK), IRE1 (proprietary-tagged 
protein fragment corresponding to amino acids 401-500, 36.6 kDa; Abcam), ATF6 
(His-tagged protein that corresponds to amino acids 567-670, 25 kDa; Abcam) and 
ATF4 (His-tagged protein corresponds to amino acids 123-351, 26 kDa; Abcam) were 
all used at the range of 10 µM – 1 nM.  
For detection, all antibodies were used as previously described and detected using the 
ECL plus system and imaged using a Fujifilm FLA-3000 fluorescence imager to ensure 
linear absorption (Raytek Scientific Ltd). Densitometry quantification of signal intensity 
was performed using Aida Image Analyser version 3.28 software and analysed by 
reverse prediction modelling using ChemCal, a statistical computer package for R 
2.14.1. Cell and nuclear diameters were determined using a micrometer stage for 
comparison to light microscopy (cell) or 4',6-diamidino-2-phenylindole (DAPI)  stained 
(nuclear) confocal microscopy images of detached spherical cells. Volumes were 
determined accordingly and the nuclear volume subtracted. 
2.6: Small interfering RNA (SiRNA)-mediated knockdown of GRP78 
expression using oligonucleotides. 
Silencing-mediated knockdown of target genes was performed using transfection of 
siRNA purchased from Qiagen (Crawley, UK). Occasionally non-specific effects will 
be triggered by experimental introduction of siRNA, however, all experiments looking 
for the effect of siRNAs on GRP78 expression were carried out alongside control 
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transfections with a scrambled siRNA as control. The control scrambled used in all 
experiments was also from Qiagen. 
Qiagen siRNA oligomers were supplied as annealed, lyophilised powders requiring re-
suspension in the supplied buffer. Each siRNA was pre-designed and validated to target 
a specific 21 nucleotide sequence (Table 2.2; Qiagen, Crawley, UK). Prior to use, 
siRNA from either source was heated to 90
o
C for 1 min followed by incubation at 37
o
C 
for 60 min to disrupt higher aggregates and maximise silencing potential. 
Human cancer cells were seeded overnight in a volume of 3 ml of appropriate culture 
medium in 6 well plates to achieve a desired cell density of 70-90%, corresponding 
approximately to 0.25 x 10
6
 cells per well for CHL-1, WM266-4, MO59J cells and 0.3 x 
10
6
 cells per well for NGP and SH-SY5Y neuroblastoma cell lines. Cells were gently 
washed in PBS and siRNA was transiently transfected using lipofectamine 2000 
according to the manufacturers’ specification for 8 h in 2.0 ml serum-free Opti-MEM 
growth medium (Invitrogen Ltd) to given final concentrations of 40 nM. Opti-MEM 
was replaced with 3.0 ml complete culture medium and incubation was continued 
overnight before transfection was repeated. Knockdown of the target gene was verified 
by Western blot analysis 24 h after the second transfection had ceased or subsequent 
cell viability and death assays were performed.  
 
 
Qiagen Sense Sequence Antisense Sequence 
 
Control 
 
UUCUCCGAACGUGUCACGUdTdT 
 
ACGUGACACGUUCGGAGAAdTdT 
 
  
GRP78 
 
GGGUGUGUGUUCACCUUCAdTdT 
 
UGAAGGUGAACACACACCCdTdA 
Table 2.2: Target sequences for siRNA to GRP78 as well as the scrambled control 
(Qiagen). Annealed double-stranded siRNA was introduced into cells using 
lipofectamine 2000-mediated transfection. 
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2.7: Reverse transcriptase Polymerase chain reaction 
2.7.1: RNA extraction and purification. 
Total RNA was extracted from cells using RNeasy Kit (Qiagen). Cells were washed 
with PBS and treated with 1 x Trypsin-EDTA (Sigma-Aldrich) to detach them from 
culture plate. Cells were then pelleted by centrifugation at 330 x g for 5 min. 
Supernatant was aspirated from pellets prior to washing with PBS and again pelleted by 
additional centrifugation. Supernatant was removed and 500 µl RLT cell lysis buffer 
(part of RNeasy kit), containing 10% β-mercaptoethanol, was added to the pellet and the 
suspension was and samples transferred to a microfuge tubes. Samples were sonicated 
for 30 seconds (s) and before addition of an equal volume of 70 % ethanol was added 
(diluted to 70% in RNase free water) and vigorous mixing by vortex. The sample was 
added to a mini-column (provided within RNeasy kit), placed within a mini collection 
tube (also provided) and centrifuged at 900 x g (10 000 rpm) for 15 s to collect the 
eluate. The eluate was discarded and column transferred to a new mini collection tube. 
500 µl of RPE wash buffer wash containing 80% ethanol (part of RNeasy kit) wash 
added to the column and centrifuged at 900 x g for 15 s. The eluate was again discarded 
and another 500 µl RPE wash buffer to the column prior to centrifugation at 900 x g for 
2 min. Again the eluate was discarded and 50 µl of RNase free water was added to the 
column. Finally the column was placed in a fresh eppendorf tube and centrifuged at 900 
x g for 1 min.  
 
Total RNA was collected and stored at -80°C for up to 1 year. The RNA concentration 
was determined using the NanoDrop ND-1000 spectrophotometer (NanoDrop 
Technologies, Wilmington, USA). RNA concentration for 1 µl of each sample was 
determined from an absorbance reading at 260 nm. RNA quality was determined by the 
ratio of 260:280 nm readings and should be between 0.9 and 2.1. 
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2.7.2: Generation of cDNA. 
RNA was reverse transcribed to cDNA using the superscript reverse transcripase 
method. 0.5 µg RNA was combined with 0.5 µg random oligo DT primers (Fermentas, 
St. Leon-Rot, Germany), 0.5 mM mixed of Deoxynucleotides (dNTPs; Fermentas), and 
RNase free water (Fermentas) to a final volume of 20 µl. The solution was incubated at 
65°C for 5 min followed by 1 min on ice. To the solution add 4 µl first strand buffer 
(Fermentas), 1 µl 0.1 M DTT (Fermentas), 1 µl RNase Inhibitor (Fermentas) and 1 µl 
Superscript Reverse Transcriptase (Fermentas) and the solution incubated at 55°C for 
60 min prior to 70°C for 15 min to inactivate the reaction. To the solution, 0.5 µl RNase 
H (of 5U/µl stock; Fermentas) was then added before further incubation for 20 min at 
37°C. The sample reaction was then inactivated by a further incubation of 10 min at 
65°C and cDNA stored at -20°C for up to 1 month. 
2.7.3: Quantitative Polymerase chain reaction. 
The cDNA from the reverse transcription was used in a real-time PCR reaction. Real-
time PCR reactions were carried out in 96 well plates in a final volume of 20 µl final 
per well. Primer probe sets for GRP78, XBP-1, XBP-1 spliced form (XBP-1 (S)) and β-
Actin (control) were all purchased from Sigma-Aldrich Co consisting of two unlabelled 
PCR primers per target (Table 2.3). A 2 x concentration of fast SYBR green master mix 
containing AmpliTaq fast DNA polymerase, SYBR Green-1 dye and deoxyneucleotide 
triphosphate (dNTPs) were purchased from Applied Biosystems (Carlsbad, California, 
USA). Master mixes containing diluted primer-probes and the SYBR Green master mix 
were produced for the number of reactions/well and this primer probe master mix was 
aliquoted into each well individually. The 2 x fast SYBR green master mix was diluted 
to a final 1 x concentration in each well. The real-time PCR plate was set-up in such a 
way that each sample was used in triplicate reactions for all primer sets. The plate was 
loaded into a 7500 fast real-time PCR machine with SDS software (Applied Biosystems) 
and subjected to specific thermocycling programs (Table 2.4). The PCR machine 
consisted of an argon laser that distributes light to the plate and CCD camera to detect 
emitted fluorescence between 500 and 600 nm wavelengths. Because SYBR Green can 
bind to any double stranded DNA, to confirm that only the desired PCR product has 
been amplified, melting curve analysis was performed. Melt curve analysis heats the 
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PCR reaction and measures a change in fluorescence as double stranded DNA 
dissociates.  
2.7.4: Quantitative Polymerase chain reaction analysis. 
Data obtained from the real time PCR machine were analysed using SDS2.2 software 
(Applied Biosystems). Amplification plots were generated for each well where 
magnitude was plotted against cycle number. The threshold level of expression was set 
to a value on the exponential phase of the amplification plot and was kept the same for 
all related primer-probe experiments. The number of PCR cycles taken to reach the 
threshold level of expression (Ct) for each sample was generated as mean ± 95% 
confidence intervals (CI). All mean Ct values for all investigative primer/probes were 
normalised to the β-Actin control data. Data were then normalised to the vehicle treated 
control samples. Data were statistically analysed using SPSS 17.0 and graphs plotted in 
SigmaPlot 11.0 or GraphPad Prism 5. 
 
 
Table 2.3: Primer sequences for XBP-1, XBP-1(s), GRP78 and control β-Actin. 
 
 
Target Forward Reverse 
 
XBP-1 
 
CCT TGT AGT TGA GAA CCA GG 
 
GGG CTT GGT ATA TAT GTG G 
 
XBP-1 (s) 
 
GGT CTG CTG AGT CCG CAG 
CAG G 
 
GGGCTTGGTATATATGTGG 
 
GRP78 
 
GTT CTT GCC GTT CAA GGT GG 
 
TGG TAC AGT AAC AAC TGC ATG 
 
β-Actin 
 
AAT CTG GCA CCA CAC CTT 
CTA CA 
 
CGA CGT AGC ACA GCT TCT CCT 
TA 
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Gene Stage 1 Stage 2 
(50 cycles) 
Stage 3 Stage 4 
 
GRP78 
 
95°C–10 min 
 
95°C – 15 sec 
60°C – 1 min 
 
 
95°C – 30 sec 
60°C – 1 min 
 
Melt 
Curve 
 
XBP-1 
 
95°C – 5 min 
 
95°C – 30 sec 
55°C – 30 sec 
72°C – 30 sec 
 
 
95°C – 30 sec 
60°C – 1 min 
 
 
XBP-1 (s) 
 
95°C – 5 min 
 
95°C – 30 sec 
55°C – 30 sec 
72°C – 30 sec 
 
 
95°C – 30 sec 
60°C – 1 min 
 
 
Actin 
 
95°C – 10 
min 
 
95°C – 15 sec 
60°C – 45 sec 
72°C – 30 sec 
 
 
95°C – 30 sec 
60°C – 1 min 
 
Table 2.4: Thermocycling programs for XBP-1, XBP-1(s), GRP78 and control β-Actin. 
2.8: Immunofluorescent staining of cell line cultures. 
Cancer cell lines were seeded into flat bottomed 6 well plates containing a sterile glass 
cover slip (18mm x 18mm, Fischer Scientific). Cells were seeded at 1.5 x 10
5
 cells per 
well for CHL-1, cells or 2.0 x 10
5
 cells per well for U251, MO59J, SH-SY5Y and NGP 
cells or 2.5 x 10
5
 cells per well for WM266-4 cells in a final volume of 3 ml of 
preferred culture medium and allowed to attach overnight at 37
o
C. For localisation 
experiments, cells were fixed after 24 h. For the effect of drug treatment on protein 
expression or localisation, cells were treated with ER stress-inducing agents for 24 h 
prior to fixation. Cells were fixed in either 100% ice cold methanol (Fisher) for 30 min 
or 4% paraformaldehyde (PFA; Sigma-Aldrich) for 20 min, before storage at 4
 o
C in 
PBS.  
For staining, cells were washed in PBS containing 0.05% Tween 20 (PBS/T; Sigma-
Aldrich) and then permeabilised in 0.2% Triton X100 (Sigma-Aldrich, diluted in PBS/T) 
for 30 min. Cells were then washed 3 times in PBS/T and then blocked by the addition 
of 2% bovine serum albumin (BSA, dissolved in PBS/T) and incubated for 1 h on a 
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platform shaker. After blocking, samples were again washed 3 times in PBS/T and then 
incubated with primary antibody, dissolved in 0.2% BSA-PBS/T for 1 h at room 
temperature (primary antibody dilutions described in table 2.5). Samples were then 
washed 3 times in PBS/T, followed by blocking in 10% secondary host-antibody-
specific serum (dissolved in PBS/T, Serums described in Table 2.5) for a minimum of 
30 min before samples were incubated in fluorescently-labelled secondary antibodies 
diluted in 1% host-specific serum for 1 h in the dark, at room temperature on a platform 
shaker (Secondary antibody information described in table 2.5). Again, samples were 
washed 3 times in PBS/T and then incubated with control nuclear stain DAPI (Sigma-
Aldrich, diluted in PBS/T) for 25 min in the dark, at room temperature. 
Antibody Company Dilution Fixative Host Blocking 
agent 
GRP78 Santa Cruz 1:500 Methanol Goat BSA 
IRE1 Santa Cruz 1:500 Methanol Rabbit BSA 
Cleaved Casp  3 Cell Signalling 1:500 4% PFA Rabbit BSA 
Calnexin Abcam 1:500 4% PFA Rabbit BSA 
DAPI Sigma-Aldrich 1:2000 either - - 
AlexaFluor 488 Invitrogen 1:1000 - Donkey Donkey 
Alexa Fluor 594 Invitrogen 1:1000 - Donkey Donkey 
Alexa Fluor 594 Invitrogen 1:1000 - Sheep Sheep 
Table 2.5: Antibody information for the immunostaining of fixed culture cells. 
The cover slip containing stained cells was then carefully removed from each well of a 
6 well plate and placed cell side down onto a glass slide (Fischer Scientific) with 5 µl of 
vector shield mounting medium (Vector Laboratories LTD, Peterborough, UK). 
Samples were then stored at 4
o
C in the dark and imaged within 24 h using a Zeiss LSM 
700 confocal inverted scanning microscope using Zen 2009 software (Zeiss, 
Hertfordshire, UK). All images were taken using an x48 objective with averaging of 4 
and a frame size of 1024 x 1024 pixels. The microscope consists of a 405, 488 and 530 
nm lasers and the appropriate laser was used for each fluorochrome throughout this 
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study. Each experiment included a negative control of unstained cells, as well as 
secondary antibody only to investigate non-specific binding. Laser power was optimised 
on control- stained cells and remained the same throughout each individual experiment. 
Colocalisation can be explained as the existence of two or more signals from the same 
pixel location. Although observation of colocalisation of multiple antigens does not 
provide direct proof of a functional relationship, it does highlight to researches a 
structural and function characteristic. Colocalisation is estimated using specifically 
developed algorithms which calculate a number of representative coefficients, 
containing different sensitivity and applicability. Data were analysed using the Zeiss 
software: Zen 2009 (Zeiss). 
2.9: Over-expression of GRP78 in a panel of neuroectodermal derived 
cancer cell lines. 
2.9.1: Plasmid amplification and purification. 
2.9.1.1: Bacterial transformation. 
Plasmid DNA was amplified by transformation into JM109 competent E-coli. JM109 
competent cells were thawed on ice prior to use. All DNA plasmids contained an 
antibiotic resistance gene for ampicillin. 100 ng of pcDNA3.1 (+) GRP78 or the control 
plasmid pcDNA3.0 were diluted to a volume of 30 µl in Luria Bertani broth (LB broth; 
10 g tryptone, 5 g yeast and 5 g NaCl in 1 L distilled water; Sigma-Aldrich) and added 
to 70 µl of competent JM109 cells. Cells were then incubated on ice for 20 min prior to 
heat shock at 42°C for 30 s. 400 µl of LB broth was then added and incubation 
continued at 37°C for 30 min. The cells were then pelleted by centrifugation at 2250 x g 
(5000 rpm) for 5 min before resuspension in 100 µl of LB broth. To select for 
transformed bacterial cells that had taken up the desired plasmid DNA and therefore 
expressed the relevant antibiotic resistance, the transformed samples were plated onto 
agar plates (10 g tryptone, 5 g yeast, 5 g NaCl and 15 g agar in 1 L distilled water; 
Sigma-Aldrich) containing 50 µg/ml ampicillin (Sigma-Aldrich) and incubated over 
night at 37°C. All transformations were carried out alongside a negative control, which 
consisted of competent bacterial cells alone. Large, isolated colonies were then picked 
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and amplified in 5 ml LB broth containing the appropriate antibiotics by overnight 
incubation in an orbital incubator (225 rpm) at 37°C. 
2.9.1.2: Plasmid purification from bacteria. 
Bacterial cultures were aliquoted into microfuge tubes and pelleted by centrifugation at 
15 000 x g (13 000 rpm) for 1 min. The supernatant was removed and 100 µl of ice-cold 
solution 1 (50 mM glucose, 25 mM Tris-HCL (pH 8.0), 10 mM EDTA (pH 8.0) added 
and samples vortexed and incubated on ice for 5 min. 200 µl of fresh solution 2 (200 
mM NaOH containing 10% SDS; Sigma-Aldrich) was subsequently added and samples 
mixed by inversion (but not vortexed) prior to incubation on ice for a further 5 min. 
Finaly, 200 µl of solution 3 (2.5 M potassium acetate containing 10% glacial acetic acid) 
was added and the samples vortexed prior to centrifugation at 11 000 x g (11 000 rpm) 
for 30 sec. The plasmid DNA-containing supernatant was transferred to a fresh 
microfuge tube containing 500 µl phenol : chloroform (1:1; Sigma-Aldrich) and 
samples again vortexed prior to centrifugation at 11 000 x g at 4°C for 2 min. The 
supernatant was then transferred to a new tube and 1 ml ethanol was added before 
incubation for 2 min and centrifugation at 11 000 x g at 4°C for a further 5 min and the 
supernatant discarded. The plasmid DNA pellet was then washed in 1 ml ice cold 70% 
ethanol prior to centrifugation at 11 000 x g at 4°C for 5 min. Plasmid DNA was then 
air dried and finally resuspended in 25 µl sterile distilled water and stored at -20°C. 
2.9.2: Plasmid concentration. 
The concentration of DNA per sample was determined using a NanoDrop 
spectrophotometer (The NanoDrop ND-1000 form NanoDrop technologies, Wilmington, 
USA). The NanoDrop requires 1 µl of sample to be loaded and concentration is 
calculated. The machine was blanked against sterile distilled water. The concentration 
of DNA was determined for the absorbance reading of each sample measured at a 
wavelength of 260 nm.  
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2.9.3: Plasmid confirmation by restriction digests. 
Single and double restriction digests were set up and incubated for either 1 h (final 
reaction volume 20 μl) or overnight (final reaction volume 50 μl) at 37 °C. Single and 
double digests used 1-2 μg of DNA, 0.5 Units of restriction enzyme and 1 x restriction 
digest buffer (restriction enzyme specific or universal buffer). Some restriction enzymes 
also required 1 x BSA in the restriction digest reaction. All restriction enzymes, 10 x 
Restriction digest buffers and 10 x BSA were purchased from New England Biolabs 
(New England Biolab, NEB; Hitchin, UK, Table 2.6).  
 
Enzyme NEB 
Buffer 
BSA Activity of Enzymes in Selected 
Buffer 
Hind III 2 - 100% activity 
XhoI 2 BSA 100% activity 
Hind III + 
XhoI 
2 BSA 100% activity 
Table 2.6: Enzyme information for restriction digests. 
2.9.4: Gel electrophoresis. 
Electrophoresis through 1 % agarose was used to visualise and check the size of the 
DNA and to separate DNA plasmids and fragments after restriction digest. Agarose 
solutions were prepared by dissolving the electrophoresis-grade agarose (Invitrogen Ltd, 
Paisley, UK) in 1 x Tris-Borate/EDTA (TBE) solution (10 x TBE stock: 54 g Tris-Base, 
27.5 g Boric acid, 20 ml 0.5 M EDTA pH 8.0 made up to 1 litre with double de-ionized 
water; final pH 8.3). The suspensions were boiled, using an 800 Watt microwave set at 
high-power, in a 500 ml glass beaker for 3 min or until the agarose had completely 
dissolved. The liquid was allowed to cool to approximately 60 °C and ethidium bromide 
added to a final concentration of 0.5 μg/ml. The mixture was poured onto a gel plate 
containing a well comb and allowed to set at room temp for approximately 20 min. The 
set gel was placed in an electrophoresis tank and the tank filled with 1 x TBE buffer 
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until the gel was submerged. An aliquot of each DNA sample was prepared by the 
addition of 6 x loading buffer (0.25% Bromophenol blue, 0.25% xylene cyanol FF, 30% 
glycerol in water) so that the total volume did not exceed 25 μl and the loading buffer 
was diluted to 1 x. Samples were loaded into separate wells. Gene Ruler 1 kb DNA 
molecular weight marker (Band sizes: 500-10 000 bp; Roche Diagnostics, Burgess Hill, 
UK) was used as a reference size marker. Electrophoresis was carried out at 100 V for 1 
h at room temperature for the 1% agarose gels. DNA bands were visualised using a UV 
light source. 
2.10: Stable over expression of pcDNA3.1 (+) GRP78. 
DNA constructs pcDNA3.0 (a kind gift from Professor Olaf Heidenreich) and 
pcDNA3.1 (+) GRP78 (a kind gift from Dr Randal Kaufman) were transfected into 
melanoma, glioblastoma and neuroblastoma cell lines. Transfected cells were selected 
by antibiotic selection and expanded into mixed cell clones. PcDNA3.0 and pcDNA3.1 
(+) GRP78 constructs both contain a mammalian resistance gene for neomycin. 
Neomycin resistance is conferred by utilizing the bacterial gene encoding the enzyme 
aminoglycoside 3' phosphor-transferase (APH).  Two distinct APH enzymes, encoded 
by the bacterial transposons Tn5 and Tn601, confer resistance to aminoglycoside 
antibiotics such as Kanamycin, Neomycin and Geneticin (G418), which inhibit protein 
synthesis in both prokaryotic and eukaryotic cells. For selection of positive constructs 
geneticin (G418; Invitrogen, Paisley, UK) was used at a final concentration of 1500 - 
2000 µg/ml. For experiments, G418 selection was removed from the cells 3 days prior 
to use. 
2.10.1: Transfection of DNA constructs. 
Melanoma, glioblastoma and neuroblastoma cancer cell lines were seeded in flat-
bottomed 6-well plates at 2.5 x 10
5
 cells per well for CHL-1, cells or 3.0 x 10
5
 cells per 
well for U251, MO59J, SH-SY5Y, NGP and WM266-4 cells in a final volume of 3 ml 
of relevant culture medium and allowed to attach overnight at 37°C. 4 µg of DNA (in 
approx. 8 µl) and 12 µl of Lipofectamine 2000 transfection reagent (Invitrogen) were 
mixed in separate tubes with 500 µl serum-free OptiMEM media (Invitrogen Ltd). The 
contents of both tubes were mixed together at room temperature for 15 min on the roller. 
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The DNA-Lipofectamine transfection mix was diluted by adding 1.5 ml serum-free 
OptiMEM media. Culture medium was removed from the cells seeded into the 6 well 
dishes and they were washed carefully with serum-free OptiMEM media. The 2 ml 
transfection mix was added to the cells and incubated for 24 h at 37°C. After 24 h the 
medium on the cells was replaced with 3 ml of preferred culture medium containing 
10% FBS and 2mM L-glutamine, and incubated for 48 h at 37°C before commencing 
antibiotic selection of transfected cells.  
2.10.2: Antibiotic selection of transfected cells. 
Dose-response experiments were carried out on non-transfected cells to determine the 
optimal dose of G418 for selection of cells transfected with pcDNA3.0 or pcDNA3.1 (+) 
GRP78. For the treatment of melanoma and glioblastoma cells, 2000 µg/ml G418 was 
required while 1500 µg/ml was used to select neuroblastoma cells. Transfected cells 
were maintained under G418 selection, except during experimentation where cells were 
placed in normal culture media for a minimum of 3 days prior to the start of each 
experiment. Over-expression of GRP78 was confirmed by both quantitative real time 
PCR and Western blot analysis for mRNA and protein expression, respectively.  
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2.11: Statistics 
Results were expressed as the mean of individual experiments +/- the 95% confidence 
intervals (95% CI) using Prism 5 (GraphPad Software Inc; La Jolla, CA, USA) or 
Sigma Plot 11 (Systat Software Inc; San Jose, CA, USA) software. The statistical 
significance of drug responses was compared by one- or two-way ANOVA with either 
Dunnett’s, Bonferroni’s or Tukey’s post-hoc tests using Prism 5 or SPSS release 17.0 
(IBM; Chicago, IL, USA) software. To analyse the synergistic effects of fenretinide and 
bortezomib alone or in combination with GRP78 inhibitors on induction of cell 
apoptosis or inhibition of cell viability, combination indices were generated using 
CalcuSyn software (Biosoft) as previously described [204]. Combination index (or 
indices (ci)) values obtained for the effect of drug interaction for either cell death or 
inhibition of cell viability are characterised as: ci > 1 are Inhibitory, ci = 1 are additive 
and ci < 1 are synergistic. In this study values were characterised as synergistic if the ci 
< 0.9 and inhibitory if the ci > 1.1.   
The combination index data were ranked and these ranked data analysed using R, 
initially with linear models to test for the effect of drug dose (not significant; P > 0.05) 
and then by nested ANOVA (cell line nested within cell type); pairwise comparisons of 
mean combination indices by cell line or cell type (depending on the results from the 
nested ANOVA) were carried out using Tukeys HSD after one-way ANOVA. Q-Q 
plots were used to assess the fit of residuals from the models 
To quantify protein expression in comparison to a specific protein standard curve, 
ChemCal for inverse prediction was carried out using R 2.14.1 [205]. Interpretation of 
dose response curves for EC50 and asymptote were carried out using R. For cell death 
work drc package with R was used. However, for viability drc was used to fit curves to 
data and extract parameters for further analysis by t-test or ANOVA. To determine the 
correlation between GRP78 expression and ROS, Pearson’s correlation was carried out 
using R. 
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Chapter 3: 
 
The effect of ER stress on the Unfolded 
Protein Response 
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3.1: Introduction. 
The ER is the primary site for protein synthesis, folding and trafficking and therefore an 
essential organelle of all eukaryotic cells [206]. Due to the importance of protein 
synthesis, the ER has established a complex and diverse homeostatic response 
mechanism to stimuli that hinder the productivity and quality of the ERs protein 
synthesis capacity (ER stress). The UPR is an evolutionary conserved and adaptive 
response mechanism to stress [207]. Mammals have preserved the basic components of 
the yeast UPR and then greatly developed it to manage the stress of a multi-cellular 
organism [208]. The mammalian UPR consists of three response activators; PERK, 
IRE1 and ATF6 that are held inactive by the UPR stress regulator GRP78 [168, 209, 
210]. GRP78 is a molecular chaperone which serves as a holdase of newly synthesised 
or mis-folded proteins within the lumen of the ER, resulting in optimal orientation of 
substrates for folding machinery [211]. 
GRP78 possesses high affinity for hydrophobic or hydrophilic regions exposed on the 
surface of unfolded or mis-folded protein substrates. On interaction with a substrate; 
PERK, IRE1 and ATF6 dissociate from GRP78 (Figure 3.1) [209, 210]. These free UPR 
activators no longer have critical sequences masked by their interaction with GRP78 
and therefore are capable of activation. For ATF6 the dissociation from GRP78 
unmasks Golgi localisation sequences that result in its migration and the eventual 
processing of ATF6 by S1P and S2P proteases to form an active transcription factor that 
is capable of translocation to the nucleus. In the case of PERK and IRE1 the 
dissociation from GRP78 allows both proteins to undergo homo-dimerization and auto-
phosphorylation to form active kinases, and in the case of IRE1 the formation of an 
active endoribonuclease [91, 111, 212].  
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Figure 3.1: The unfolded protein response. Schematic representation of the ER based 
homeostatic response mechanism to stress. Under periods of no stress, GRP78 binds to 
and inactivates PERK, IRE1 and ATF6. When cellular stress disrupts the homeostasis 
of the ER resulting in an increase in unfolded or mis-folded proteins in the lumen of the 
ER (ER stress), GRP78 binds to these substrates, simultaneously releasing PERK, IRE1 
or ATF6. Upon release these proteins result in the activation of three diverse cascades 
which alter ER functioning to try to save the cell. However, if the stress is to severe or 
persists for too long, cell death pathways are activated to remove the cell [213]. 
The activation of PERK into a functional kinase results in the phosphorylation of 
downstream eIF2α [214]. This act results in the inhibition of conventional protein 
synthesis by preventing the exchange of GTP for GDP, as well as blocking the 
recruitment of methionine tRNA [215] . However, via a non-conventional open reading 
frame, known as an internal ribosomal entry site (IRES), proteins capable of aiding a 
cells recovery from ER stress can still be translated. These proteins include chaperones 
such as GRP78 and GRP94, as well as the transcription factor ATF4 [91]. The induction 
of ATF4 translation helps to alleviated stress present upon the ER by two main 
mechanisms; stimulation of Nrf2 to increase amino acid recovery, and the activation of 
genes that have ERSE and UPRE response elements within their promoter sequences 
[216, 217]. These genes include chaperones and folding machinery such as the PDI 
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superfamily. A protein family important for the addition and removal of disulphide 
bonds during protein synthesis. The activation of IRE1, results in the formation of a 
functional endoribonuclease domain that processes XBP-1 substrate to an active splice 
variant (XBP-1s). XBP-1s is also a transcription factor which can result in the 
promotion of ER stress response genes [218, 219]. 
As well as inducing the transcription of genes that can aid the ER under periods of 
stress, ATF6, ATF4 and XBP-1s signalling also induce the transcription of Gadd153 
(also known as CHOP), which itself is a transcription factor that can stimulate pro-
apoptotic stimuli, to drive the cell to death, if the stress is too severe or persists for too 
long [220].  
Research into the role of GRP78 and the UPR has demonstrated the importance of this 
evolutionary conserved homeostatic response pathway for the survival of cancer cells. 
Neoplastic progression requires genetic alterations that allow a cell to ignore or evade 
growth controls and disable apoptotic stimuli. These characteristic attributes of cancer 
cells often result in an increased rate of proliferation and result in an ever expanding 
mass, which exhibits poor vascularisation [221]. A consequence of this is changes 
within tumour microenvironment, a harsh and inadequate cellular environment. Tumour 
cells are often exposed to highly acidic conditions which contain low oxygen, nutrients 
and glucose conditions and have altered Ca
2+
 levels, all essential for cell survival and 
growth [222]. This inadequate environment places added pressure upon the ER to 
maintain the high rate of protein synthesis required for turn-over and cellular division 
[208].  
As a solid tumour grows larger, cells respond by over producing pro-angiogenic factors 
to stimulate the formation and attraction of blood vessels [223]. Many studies have 
demonstrated the importance of hypoxia inducible factor 1 (HIF1) for the stabilisation 
of tumour microenvironments [208]. To date, there are abundant data to demonstrate the 
activation of the UPR in solid tumour models, indicating that the UPR is an important 
component of defence against hypoxia, allowing cancer cells to buffer periods of severe 
stress and deprivation, which would in the case of normal physiology have induced cell 
death to preserve the integrity of the organism. 
Data have demonstrated that within neural-crest-derived cancer cells, melanoma and 
glioblastoma, there is a direct correlation between expression of GRP78 and cancer 
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disease state and resistance to therapy [113, 224]. In contrast, however, neuroblastoma 
shows favourable prognosis for patients with high GRP78 expression [116]. Therefore, 
research looking at the activation of the UPR and cancer cells response to 
pharmacologically induced ER stress is required for a better understanding of the UPR 
with regards to cellular sensitivity to ER stress. 
Armstrong et al., investigating early events of ER stress signalling and response 
pathways induced by fenretinide and bortezomib demonstrated signals mediated by the 
eIF2α - ATF4 signalling pathway and highlighted differences within drug induction of 
ATF4 between cell types, as well as demonstrating differences between the ability of 
ER stress-inducing agents fenretinide and bortezomib to activate the UPR [112]. 
Previous work has highlighted the ability of ER stress-inducing agents to increase 
apoptosis of metastatic melanoma [82, 83]. However, the activation of the UPR hinders 
the ability of pharmacological agents to induce cell death, due to downstream up 
regulation of chaperones or folding machinery such as GRP78 or PDI respectively, 
which aid the cell under periods of ER stress [202]. Therefore for treatment of cancer 
cells with ER stress-inducing agents, the stress achieved must result in the induction of 
sufficient stress to ensure cell death, rather than the induction of pro-survival stimuli. 
Strategies to combine ER stress-inducing agents with specific inhibitors to important 
components of the UPRs pro-survival function (eg. GRP78 or PDI) may also prove 
successful in overcoming the pro-survival activity of the UPR.  
The importance of GRP78 and the UPR during stress has been well documented, as well 
as a possible role in cancer cell survival to host death stimuli and chemotherapy. 
However, to date limited data are available to explain the signalling mechanism behind 
the UPR ability to switch a characteristically pro-survival response, towards a signalling 
cascade that results in cell death. Previous work by Lin et al., and Hetz et al., has 
described the importance of time in determining the outcome of the UPR [225, 226]. 
These publications described a difference between PERK, IRE1 and ATF6 signalling 
time resulting in the loss of ATF6 pro-survival attributes first. This leaves PERK and 
IRE1 which are capable of down-stream Gadd153 induction and death signalling. 
Another time-dependent factor of the UPR is the induction of Gadd153 itself. Unlike 
the induction of chaperones and other transcription factors, such as ATF4, Gadd153 
induction is a secondary cycle of the UPR, requiring the induction and translation of 
ATF4 or processing of XPB-1 prior to induction. This therefore ensures a standardised 
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time for a homeostatic response to stabilise the ER prior to committing the cell to death. 
Research has also indicated that individual arms of the UPR may be activated to 
different degrees depending upon the type of stress [227]. These findings highlight the 
possibility of a more selective and sensitive UPR cascade than previously thought [227].  
Taking these data into consideration, further research is required to determine if the 
difference in clinical outcome of neural-crest-derived tumours correlates with GRP78 
expression, and is in part a consequence to differences in UPR signalling. Research 
investigating the balance between pro-survival and pro-death stimuli under 
pharmacological treatments, is therefore required to gain a better understanding of the 
threshold required to induce cell death in cancer cells, and the development of novel 
strategies through which to induce cell death in cancer cells resistant to apoptosis via 
conventional mechanisms.  
The aim of this study was to test the hypothesis that differences within the UPR exist 
between neural-crest-derived cancer types, resulting in the opposing prognostic 
outcomes observed for melanoma and neuroblastoma. In order to test this hypothesis 
experiments were designed to quantify the cellular expression of GRP78 and the UPR 
activators PERK, IRE1 or ATF6. This would allow for a direct comparison of cellular 
concentrations that exist not only between proteins, but also across cancer types. To 
confirm that the cellular localisation of GRP78 may affect a cancers response to stress, 
co-localisation experiments looking at GRP78 in comparison to the ER marker calnexin 
were also carried out. To determine cellular localisation, samples were assessed under 
both normal and pharmacologically-induced stressed conditions allowing for 
interpretation of any changes within expression and protein localisations as a direct 
result of stress. To generate a detailed understanding of the UPR, experiments were also 
undertaken to map the effect of ER stress on the activation of all three arms (through 
both time and dose response studies) of the UPR for; ATF4 induction, XBP-1 splicing 
and ATF6 cleavage in the different cancer cell types. 
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3.2: Results. 
3.2.1: Stoichiometry of UPR sensor components. 
To test the hypothesis that differences exist within the expression levels of GRP78 and 
the UPR activators across neural-crest-derived cancer cells, experiments were carried 
out to quantify the cellular concentration of GRP78 in a panel of neural-crest-derived 
cancer cells, consisting of metastatic melanoma, glioblastoma and neuroblastoma 
(Figure 3.2). Western blot analyses for the quantification of GRP78 concentration in 
CHL-1 and WM266-4 metastatic melanoma or MO59J and U251 glioblastoma or NGP 
and SH-SY5Y neuroblastoma cell lines against a standard curve of purified full length 
GRP78 standard (Figure 3.2. i - iii) were carried out with 100 000 cells and expression 
per cell calculated by measurement from a specific standard curve and adjusted by cell 
volumes to determine cellular concentrations.  
These data showed that for melanoma, glioblastoma and neuroblastoma there was no 
significant difference in GRP78 concentration between cell lines of the same cancer 
type (P > 0.05). When concentrations of GRP78 were compared between differing 
cancer types, there was, however, a significant difference in GRP78 concentration 
(Figure 3.2.B). The expression of GRP78 in metastatic melanoma cells was increased in 
comparison to normal primary melanocytes (Figure 3.2 C, Two-Way ANOVA, F3, 8 = 
87.6, P < 0.0001) and melanoma cells demonstrated significantly greater expression 
than that observed in either glioblastoma or neuroblastoma (Figure 3.2.B, for the 
comparison of metastatic melanoma to glioblastoma, One Way ANOVA with contrast 
coefficients F1, 29 = 19.3 P < 0.005, or neuroblastoma F1, 29 = 38.6, P < 0.001). Data also 
showed a significant difference in the concentration of GRP78 between glioblastoma 
and neuroblastoma (Figure 3.2.B, for the comparison of glioblastoma to neuroblastoma 
F1, 29 = 38.7, P < 0.005). These data thus highlight a significant difference in GRP78 
concentration between cancer types. 
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Figure 3.2: Cellular concentrations of GRP78. (A) Western blot analysis of CHL-1, 
WM266-4 (metastatic melanoma cells), MO59J, U251 (glioblastoma cells), NGP and 
SH-SY5Y (neuroblastoma cells) were carried out to determine the cellular 
concentration of GRP78. Concentration of each cell line were determined per 100 000 
cells in comparison to a standard curve of full length purified GRP78 standard, ranging 
from 10 µM – 1 nM. (B) Comparison of cellular concentrations of GRP78, determined 
for densitometry analysis of western blots and cell line expression measured from a 
specific standard curves and the resulting data adjusted for per cell. Cell volumes were 
derived from confocal images of detached DAPI stained spherical cells, to allow for the 
volume of the nucleus to be subtracted, and compared to a µm gauge slide. (C) Western 
blot analysis comparing the expression of GRP78 in metastatic melanoma cell lines to 
that of primary melanocytes. Western blot data were expressed as the mean ± 95% CI of 
three independent experiments. 
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Since GRP78 is thought to bind PERK, IRE1 and ATF6, experiments were carried out 
to quantify the cellular concentration of the UPR activators to assess their stoichiometry 
in relation to GRP78. Western blot analysis for the quantification of PERK, IRE1 and 
ATF6 expression in CHL-1 and WM266-4 metastatic melanoma or MO59J and U251 
glioblastoma or NGP and SH-SY5Y neuroblastoma cell lines against standard curves of 
purified fragments of each specific protein standard (Figure 3.3) were carried out with 
100 000 cells and expression per cell calculated by measurement from protein specific 
standard curves and adjusted by cell volume for their cellular concentrations.  
To determine, if like GRP78, differences in the expression levels of the UPR activators; 
PERK IRE1 and ATF6 also existed between differing neural-crest-derived cancer types 
that may alter the UPR capacity to react to stress, stoichiometric analysis were 
performed to quantify cellular concentrations. Data demonstrated that there was no 
significant difference in the cellular concentrations of PERK or ATF6 between cell lines 
of the same cancer type, or between differing cancer cell types (P > 0.05). However, for 
the cellular concentration of IRE1 there was a significant difference between cell lines 
within melanoma and neuroblastoma (Figure 3.3, analysis by One Way ANOVA for the 
concentration of IRE1 between metastatic melanoma F1, 18 = 7.6, P < 0.01 and between 
glioblastoma cell lines F1, 18 = 4.5, P < 0.05), and also between glioblastoma and 
neuroblastoma (analysis by One Way ANOVA F1, 18 = 5.6, P < 0.01). In summary, these 
data demonstrate that although there were differences between cell lines in the cellular 
concentrations of UPR activators, these did not correlate with the differences observed 
for the cellular concentrations of GRP78. Furthermore, when comparing the cellular 
expressions of PERK, IRE1 and ATF6 to each other or between cell lines, there was a 
significant difference in IRE1 expression compared with both PERK and ATF6 across 
all cell lines (Figure 3.3, comparing the expression of IRE1 to PERK F3, 47 = 67.3 or 
ATF6 F3, 47 = 94.2, P < 0.001 for either). 
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Figure 
3.3: Cellular concentration of GRP78 and the UPR activators.   (A)  Western blot 
analysis of CHL-1, WM266-4 (melanoma cells), MO59J, U251 (glioblastoma cells), 
NGP and SH-SY5Y (neuroblastoma cells) were carried out to determine the cellular 
expression of GRP78, PERK, IRE1 and ATF6. Expression of each protein, within each 
cell line, was determined per 100 000 cells in comparison to a standard curve of either; 
full length purified GRP78 or fragments of each individual UPR activator, ranging from 
500 nM – 1 nM. Cellular concentrations were determined as described previously 
Western blot data were expressed as the mean ± 95% CI of three independent 
experiments. (B) To illustrate the relationship between GRP78 and the UPR activators, 
scatter plots analysis for the mean GRP78 and total UPR activator concentrations are 
shown. Representative western blot images for the detection of PERK, IRE1 and ATF6 
are demonstrated in Figure 5.10 (Chapter 5, page 170). 
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Comparing the expression levels of PERK, IRE1 or ATF6, within cell lines of the same 
cancer type, showed that for PERK and ATF6 there was no significant difference in 
expression between cell lines (P > 0.05). However, for the expression of IRE1, there 
was a significant difference between cell lines (Analysis by One Way ANOVA F1, 23 = 
13.6, P < 0.005).  The expression of IRE1 between metastatic melanoma and 
neuroblastoma cells showed a significant difference in expression (comparing 
metastatic melanoma cells, One Way ANOVA; CHL-1 to WM266-4 F1, 21 = 8.9, P < 
0.05 and neuroblastoma cells NGP and SH-SY5Y F1, 21 = 17.3 P < 0.01); however no 
significant differences between glioblastoma cell lines were evident (P > 0.05). 
Interestingly, the expression of IRE1 did not correlate with GRP78 expression, and 
demonstrated that SH-SY5Y cells have significantly higher expression compared to all 
other cells lines (comparing SH-SY5Y expression of IRE1 by One Way ANOVA with 
Dunnett’s post hoc corrections to; CHL-1 = P < 0.001, WM266-4 = P < 0.05, MO59J =  
P < 0.005, U251 = P < 0.0001 and NGP = P < 0.01).  
Although there was no correlation between GRP78 and the UPR activator 
concentrations, data were analysed to investigate the relative relationship between 
GRP78 and the total UPR activator concentration (the sum of PERK, IRE1 and ATF6 
concentrations within a given cell line) as a more representative predictor of UPR 
capacity. Comparing the mean GRP78 expression against the accumulative means of 
PERK, IRE1 and ATF6 for metastatic melanoma and glioblastoma indicated a 
significant difference in favour of GRP78 (Comparing GRP78 to UPR activators by 
One Way ANOVA with Dunnett’s post hoc corrections within CHL-1 = P < 0.0001, 
WM266-4 =  P < 0.001, MO59J = P < 0.005 and U251 = P < 0.001). In the case of 
neuroblastoma cell lines, data also demonstrated a significant difference between 
GRP78 and total UPR activator expression, however for neuroblastoma cell lines the 
stoichiometry was in favour of UPR activators (Comparing GRP78 to UPR activators, 
by One way ANOVA with Dunnett’s post hoc correction, within neuroblastoma cell 
lines as for melanoma and glioblastoma, data demonstrated for NGP = P < 0.05 and SH-
SY5Y = P < 0.0001 in favour of excess UPR activators). 
In summary this study highlighted a significant difference between cancer types in the 
stoichiometry of the UPR sensor mechanism. The difference in ratio between GRP78 
and UPR activators present for metastatic melanoma and glioblastoma, to that of 
neuroblastoma demonstrates a difference in UPR activity across cancer types. These 
results suggest that differences in the dynamic equilibrium across cancer types. The 
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expression of GRP78 to that of the UPR activators and therefore the ability of GRP78 to 
negatively regulate the UPR, which in metastatic melanoma and glioblastoma results in 
the inactivation of the UPR due to an excess in GRP78. Conversely, in neuroblastoma 
the system may become primed towards an active UPR, due to the high expression of 
UPR activators to GRP78. 
3.2.2: Subcellular localisation of GRP78. 
To compare the localisation and distribution of GRP78 in different cell lines, methanol-
fixed cells were stained with antibodies to GRP78 and calnexin as an ER-resident 
marker. Cells were then analysed for their co-localisation coefficient to determine if 
there were any differences in cellular localisation between cell lines (Figure 3.4) and to 
determine if treatment of differing cancer cells lines with ER stress-inducing agents 
altered the distribution (Figure 3.5).  
For metastatic melanoma there was a significant difference in co-localisation 
coefficients between CHL-1 and WM266-4 cells (Analysis by ONE Way ANOVA, F1, 
18 = 14.9 P < 0.05), but no difference was observed between glioblastoma or 
neuroblastoma cell lines (P > 0.05). There was also a significant difference in the 
localisation of GRP78 in relation to calnexin across the differing cancer types 
(Investigation GRP78 to calnexin localisation by One Way ANOVA F5, 18 = 29.7 P < 
0.0001: One Way ANOVA with Dunnetts post hoc correction for the comparison of 
metastatic melanoma to glioblastoma or neuroblastoma P < 0 001 and P < 0.05 
respectively or for glioblastoma to neuroblastoma P < 0.001).   
To investigate the effect of ER stress on the co-localisation of GRP78 and calnexin 
(Figure 3.5 and Figure 3.6), cells were treated with either fenretinide or bortezomib for 
24 h and fixed in 100% ice cold methanol prior to staining for GRP78 and calnexin.  
The co-localisation coefficients for the effect of treatment on distribution were not 
statistically significant (Figure 3.6). Nevertheless, there was an apparent trend for an 
increase in localisation of GRP78 to calnexin when cells were treated with either ER 
stress-inducing agent. When assessing the effect of fenretinide or bortezomib, 
irrespective of cell, data demonstrated a significant increase in co-localisation with 
either ER stress-inducing agent (One Way ANOVA with Dunnett’s post hoc corrections, 
for fenretinide P < 0.05 or bortezomib P < 0.01). These data indicate that cellular 
distribution of GRP78 is influenced by stress and that GRP78 is extensively 
cytoplasmic in all cancer types tested. 
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Figure 3.4: Cellular distribution of GRP78. Cancer cell lines; CHL-1, WM266-4 
(melanoma cells), MO59J, U251 (glioblastoma cells), NGP and SH-SY5Y 
(neuroblastoma cells) were fixed in 100% ice cold methanol and stained for GRP78 in 
comparison to the ER resident chaperone Calnexin.  Images are representation of 3 
independent experiments, each experiment a minimum of 4 images were acquired to 
allow for the collection of co-localisation coefficients for a minimum of  30 cells per 
condition. Scale bar = 20 µm. 
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Figure 3.5: The effect of ER stress on GRP78 distribution.  Cancer cell lines; CHL-1, 
WM266-4 (melanoma), MO59J, U251 (glioblastoma), NGP and SH-SY5Y 
(neuroblastoma) cell lines were treated with fenretinide (FenR, 10 µM for melanoma or 
glioblastoma or 5 µM for Neuroblastoma) or bortezomib (Bort, 200 nM for melanoma 
or glioblastoma or 20 nM for Neuroblastoma) for 24 h prior to being fixed in 100% ice 
cold methanol and stained for GRP78 in comparison to the ER resident chaperone 
Calnexin. Images are representation of 3 independent experiments, each experiment a 
minimum of 4 images were acquired to allow for the collection of co-localisation 
coefficients for a minimum of  30 cells per condition. Scale bar = 20 µm. 
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Figure 3.6: The effect of ER stress on GRP78 cellular distribution. A comparison of 
coefficients. Coefficients for the effect of fenretinide or bortezomib treatment of GRP78 
co-localisation with Calnexin were generated from confocal microscopy data 
(experimental setup as for Figure 3.5). Data are the average of 3 replicate experiments 
containing a minimum of 4 images per experiment ± 95% CI. 
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3.2.3: Induction of the UPR in response to ER stress. 
To investigate the induction of the UPR in metastatic melanoma and glioblastoma in 
comparison to neuroblastoma, cells were treated with increasing doses of fenretinide 
and bortezomib (1 – 15 µM fenretinide and 10 – 300 nM bortezomib for melanoma and 
glioblastoma or 0.5 – 10 µM and 1 – 30 nM bortezomib for neuroblastoma) for 4 h prior 
to the analysis of ATF4 induction by western blotting. Concentrations of either 
fenrretinide or botezomib used to treat neuroblastoma cell lines were lower than those 
used for melanoma and glioblastoma, since neuroblastoma cells are more sensitive to 
cell death [112], but each agent was employed up to and including the maximum 
clinically-achievable dose.  Western blots were carried out as for GRP78 and the UPR 
activators to allow for cellular concentrations of ATF4 to be determined. 
Results demonstrated that both ER stress-inducing agents activated the UPR in a dose 
dependent manner. For fenretinide  CHL-1, MO59J, U251, NGP amd SH-SY5Y cells; a 
minimum of 5 µM fenretinide was sufficient to induce the expression of ATF4 ((Figure 
3.7 A, C & E) analysis by One Way ANOVA with Dunnetts post hoc corrections for 
CHL-1, MO59J, U251 cells treated with 5 – 15 µM fenretinide P < 0.0001 and for 
neuroblastoma cell lines NGP and SH-SY5Y 5 - 10 µM fenretinide P < 0.001- 0.0001 
respecively). WM266-4 cells treatment with fenretinide resulted in a significant 
induction of ATF4 but required concentrations of 10 µM ((Figure 3.7 A) analysis by 
One Way ANOVA with Dunnetts post hoc corrections for treatment with 10 µM P < 
0.001 and 15 µM P < 0.0001 fenretinide respectively).  Treatment with bortezomib, in 
all cell lines, resulted in a significant induction of ATF4 (Figure 3.7 B, D & F). In 
metastatic melanoma and glioblastoma cells ATF4 was significantly induced by 
concentrations of 100 nM bortezomib (Analysis by One way ANOVA with Dunnetts 
post hoc corrections, for CHL-1 and WM266-4 metastatic melanoma or MO59J and 
U251 glioblastoma cell lines treated with bortezomib  doses of 100 – 300 nM P < 
0.0001), while  in WM266-4 cells, significant induction was demonstrated in response 
to 10 nM concentrations (P < 0.001).  
Bortezomib also significantly induced ATF4 expression in neuroblastoma cell lines, 
where a significant induction was evident in resposne to a lower dose of 10 nM 
(Analysis by One way ANOVA with Dunnett’s post hoc corrections for NGP and SH-
SY5Y cells treated with 10 nM – 30 nM bortezomib P < 0.0001, except for NGP with 
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10 nM bortezomib P < 0.001) indicating that both fenretinide and bortezomib are potent 
inducers of the UPR.  
These data indicate a difference in UPR activation strength between melanoma and 
neuroblastoma cell lines, demonstrating a significant difference between cancer cell 
type  (Comparing cancer types for the effect of fenretinide by One way ANOVA with 
Dunnetts post hoc corrections P < 0.01 and Bortezomib P < 0.001).  Furthermore these 
data also highlighted a difference between fenretinide and bortezomib induction of 
ATF4 within all cell lines except U251 glioblastoma cells (Comparing the effect of 
fenretinide and bortezomib for CHl-1 F4, 72 = 3.164, 2229.8, P < 0.0001 and WM266-4 
154.6 and 2991.2, P < 0.0001 respecitvely. For MO59J cells F4, 72 = 226.5, 612.1, P < 
0.05, neuroblastoma cell lines NGP F4, 72 = 33.7, 52.3, P < 0.001 and SH-SY5Y F4, 72 = 
19.7 or 106.2, P < 0.01 respectively). 
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Figure 3.7: The effect of fenretinide and bortezomib dose on the induction of ATF4 as 
an indicator of UPR activation.. Assessing ATF4. CHL-1, WM266-4 (melanoma), 
MO59J, U251 (glioblastoma), NGP and SH-SY5Y (neuroblastoma) cell lines were 
treated with fenretinide (FenR, 1 - 15 µM for melanoma or glioblastoma or 0.1 - 10 µM 
for Neuroblastoma) or bortezomib (Bort, 10 - 300 nM for melanoma or glioblastoma or 
1 - 30 nM for Neuroblastoma) for 4 h prior to harvesting. Cells were then counted and 
western blots used to determine cellular concentration (as described for GRP78). 
Western blot data were expressed as the mean ± 95% CI of three independent 
experiments. 
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To determine the effect of each ER stress-inducing agents over time, cells were treated 
with fenretinide or bortezomib (10 µM fenretinide and 200 nM bortezomib for 
metastatic melanoma and glioblastoma cell lines or 5 µM fenretinide and 20 nM 
bortezomib for neuroblastoma cell lines) and cellular concentrations of ATF4 
determined at 0, 1, 2, 4, 8 and 24 h (Figure 3.8). Results showed that fenretinide 
significantly induced the expression of ATF4; however this effect was not time 
dependant (Figure 3.8 A, C & E). 
Fenretinide induced UPR activation over variable times, with the most significant effect 
occuring at 4 – 8 h, while ATF4 expression in all cell lines decreased in expression by 
24 h. CHL-1, MO59J , U251 and NGP demonstrated a significant induction of ATF4 by 
2 h (One way ANOVA with Dunnett’s post hoc corrections for CHL-1, U251 and NGP 
cell lines P < 0.05 or MO59J = P < 0.0001), where WM266-4 and SH-SY5Y cells 
showed significant induction by 4 h (One way ANOVA with Dunnett’s post hoc 
corrections for WM266-4 and SH-SY5Y cell lines = P < 0.0001 or  P < 0.01 
respectively). Metastatic melanoma and neuroblastoma cells showed maximum 
induction of ATF4 by 4 h fenretinide treatment (One way ANOVA with Dunnett’s post 
hoc corrections for or CHL-1, WM266-4 and NGP cell lines = P < 0.0001 or SH-SY5Y 
cells = P < 0.01) however, glioblastoma showed a slower induction, reaching maximum 
induction at 8 h (One way ANOVA with Dunnett’s post hoc corrections for or both 
MO59J and U251 = P < 0.0001). 
ATF4 induction by bortezomib in metastatic melanoma and neuroblastoma cancer types 
increased in a time dependent manner (Figure 3.8 B, D & F), with a significant response 
detectable by 2 h for melanoma and 4 or 8 h for NGP and SH-SY5Y neuroblastoma cell 
lines respectively (One way ANOVA with Dunnett’s post hoc corrections for or CHL-1 
and WM266-4 = P < 0.0001, NGP = P < 0.05 and SH-SY5Y = P < 0.01) which 
achieved maximum effect by 24 h. 
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Figure 3.8: Assessing ATF4 induction over time for the effect of ER stress-inducing 
agents fenretinide and bortezomib on UPR activation.  CHL-1, WM266-4 (melanoma), 
MO59J, U251 (glioblastoma), NGP and SH-SY5Y (neuroblastoma) cell lines were 
treated with fenretinide (FenR, 10 µM for melanoma or glioblastoma or 5 µM for 
Neuroblastoma) or bortezomib (Bort, 200 nM for melanoma or glioblastoma or 20 nM 
for Neuroblastoma) for 0, 1, 2, 4, 8 and 24 h prior to harvesting. Cells were then 
counted and western blots ran to determine cellular concentration (as described for 
GRP78). Western blot data were expressed as the mean ± 95% CI of three independent 
experiments. 
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Glioblastoma cells treated with bortezomib demonstrated a similar trend of ATF4 
induction over time to that seen with fenretinide, with cell lines demonstrating reaching 
a maximal response by 8 h treatment, and with induction detectable by 2 h (One way 
ANOVA with Dunnett’s post hoc corrections for MO59J = P < 0.0001 and U251 = P < 
0.05), reaching maximum response at 8 h (P < 0.0001) followed by a reduction in 
expression by 24 h. 
Collectively, these data show a difference between individual cell line response to either 
fenretinide or bortezomib, demonstrating that UPR activation can differ depending on 
the type of ER stress (Two-way ANOVA, Comparing the effect of fenretinide over cell 
lines F6, 108 = 6.2, P < 0.01 or Bortezomib F6, 108 =35.6, P < 0.0001). These data also 
confirmed the findings for the effect of dose of ER stress-inducing agent on ATF4 
induction, showing both agents are capable of inducing the UPR. However, bortezomib 
demonstrated a greater effect on inducing the UPR (Two-way ANOVA, Comparing the 
effect of fenretinide and bortezomib, per cell line induction of ATF4 over time; CHL-1 
and WM266-4 melanoma and MO59J or U251 glioblastoma cells F2, 36 = 36.2, F2, 36 = 
37.6, F2, 36 = 36 and F2, 36 = 27.2, P < 0.0001 respectively or NGP neuroblastoma cells F2, 
36 = 9.4, P < 0.01), as well as activating the UPR for longer.  
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Figure 3.9: The effect of fenretinide and bortezomib dose on ER stress-induced ATF6 
cleavage. CHL-1, WM266-4 (melanoma), MO59J, U251 (glioblastoma), NGP and SH-
SY5Y (neuroblastoma) cell lines were treated with fenretinide (FenR, 1 - 15 µM for 
melanoma or glioblastoma or 0.1 - 10 µM for Neuroblastoma) or bortezomib (Bort, 10 - 
300 nM for melanoma or glioblastoma or 1 - 30 nM for Neuroblastoma) for 4 h prior to 
harvesting. Cells were then counted and western blots used to determine cellular 
concentration (as described for GRP78). Western blot data were expressed as the mean 
± 95% CI of three independent experiments. 
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The effect of ER stress on the activation of the ATF6 arm of the UPR in melanoma, 
glioblastoma and neuroblastoma neural-crest-derived cancer types was also determined 
in response to fenretinide and bortezomib. Antibodies that would reliably detect the 
cleaved form of ATF6 were not commercially available; therefore an antibody that 
detected full length ATF6 was used. The activation of the UPR results in the processing 
of ATF6 by cleavage, resulting in a decrease in full length products and increase in an 
active component that was undetectable using the ATF6 antibody employed.  
As in previous experiments, cells were treated with increasing doses of fenretinide and 
bortezomib (1 – 15 µM fenretinide and 10 – 300 nM bortezomib for melanoma and 
glioblastoma or 0.5 – 10 µM and 1 – 30 nM bortezomib for neuroblastoma) for 4 h prior 
to western blot analysis for the expression of ATF6 in comparison to a standard curve of 
purified ATF6 fragment (Figure 3.9). Dose response curves for fenretinide or 
bortezomib showed that the cellular concentration of ATF6 was reduced in a dose 
dependant manner. All cancer types demonstrated significant reduction of full length 
ATF6 when cells were treated with a minimum of  5 µM fenretinide (Figure 3.9 A, C & 
E,  One-way Anova with Dunnett’s post hoc corrections for melanoma = P < 0.05, 
glioblastoma = P < 0.01 and neuroblastoma = P < 0.0001). For all cells, the significance 
in response (with regards to ATF6 cleavage) increased with the dose of fenretinide 
(reaching = P < 0.0001 in all cell lines by 10 µM). Also for NGP neuroblastoma cells a 
significant response was detectable at 2.5 µM (One-way Anova with Dunnett’s post hoc 
corrections = P < 0.05). 
With respect to bortezomib treatment (figure 3.9 B, D & F), except CHL-1 cells, data 
showed no significant difference to that for fenretinide (One-way Anova with Dunnett’s 
post hoc corrections for CHL-1 = P < 0.0001).  Analysing the effect of bortezomib dose 
on ATF6 expression showed a significant effect  for melanoma and glioblastoma cells 
from concentrations of 100 nM (One-way Anova with Dunnett’s post hoc corrections, 
for the effect of bortezomib on ATF6 expression; CHL-1 and WM266-4 cells P < 
0.0001 or MO59J = P < 0.01 and U251 = P < 0.05) and expression significantly 
decreased further with dose (with melanoma and glioblastoma reaching = P < 0.0001). 
For neuroblastoma cell lines a significant effect of bortezomib on ATF6 was achieved 
by 20 nM (One-way Anova with Dunnett’s post hoc corrections, for NGP = P < 0.05 
and SH-SY5Y = P < 0.0001) increasing further with dose (P < 0.0001 for both cell 
lines).  
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Although there was only a significant difference between CHL-1 response to fenretinide 
or bortezomib-induced reduction in ATF6 expression, data demonstrated that the effect 
of both fenretinide and bortezomib did significantly differ between cancer types (For 
fenretinide and bortezomib F2, 72 = 49.2 or 51.5, P < 0.0001 respectively).  The data for 
the ability of ER stress-inducing agents fenretinide and bortezomib to activate the 
induction of ATF4 or processing of ATF6 (reduction in expression) differed, with 
respect, that fenretinide is a more potent activator of ATF6 cleavage. This may 
represent a stressor-specific outcome of the UPR as described by DuRose et al [227]. 
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Figure 3.10: The effect of ER stress-inducing agents fenretinide and bortezomib on 
ATF6 cleavage over time. CHL-1, WM266-4 (melanoma), MO59J, U251 (glioblastoma), 
NGP and SH-SY5Y (neuroblastoma) cell lines were treated with fenretinide (FenR, 10 
µM for melanoma or glioblastoma or 5 µM for Neuroblastoma) or bortezomib (Bort, 
200 nM for melanoma or glioblastoma or 20 nM for Neuroblastoma) for 0, 1, 2, 4, 8 
and 24 h prior to harvesting. Cells were then counted and western blots ran to 
determine cellular concentration (as described for GRP78). Western blot data were 
expressed as the mean ± 95% CI of three independent experiments. 
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To characterise the time course of the UPR, with respect to ATF6, cells were treated 
with either fenretinide or bortezomib (10 µM fenretinide and 200 nM bortezomib for 
metastatic melanoma and glioblastoma cell lines or 5 µM fenretinide and 20 nM 
bortezomib for neuroblastoma cell lines) for 0, 1, 2, 4, 8 and 24 h prior to analysis for 
ATF6 cellular expression as described previously (Figure 3.10). 
Measurements of ATF6 cellular concentration over time allows for the detection of both 
UPR activation (a decrease in ATF6 concentration) and the eventual downstream 
induction of ATF6 (an eventual increase in ATF6 concentration), as the system returns 
to equilibrium. Data for the effect of fenretinide on ATF6 cellular concentration (Figure 
3.10 A, C & E) demonstrated a significant reduction in ATF6 concentration within all 
cell lines. For glioblastoma and NGP neuroblastoma cells, a significant effect was 
detectable by 1 h exposure to fenretinide (One-way Anova with Dunnett’s post hoc 
corrections = P < 0.05 for all), with melanoma and SH-SY5Y neuroblastoma cells 
showing a significant response by 2 h (One-way Anova with Dunnett’s post hoc 
corrections, P < 0.0001).  Bortezomib showed a significant effect on WM266-4, MO59J, 
U251 and SH-SY5Y cells by 1 h (One-way Anova with Dunnett’s post hoc corrections, 
for WM266-4 and MO59J P < 0.05, U251 = P < 0.01 and SH-SY5Y =  P < 0.0001) with 
CHL-1 and NGP cells showing a response at the 2 h time point (For CHl-1 =  P < 0.005 
and NGP = P < 0.0001). 
All cell lines showed maximum response to either ER stress-inducing agent between 2 
and 4 h (all cell lines reaching = P < 0.0001 in comparison to control). Although data 
indicated that the maximum response for bortezomib-treated cells occurred at 4 h, 
where fenretinide demonstrated maximum responses from 2 h, there were no significant 
difference between cellular responses within the ATF6 arm of the UPR (Figure 3.10, 
P > 0.05). These data also demonstrated there were no significant differences within the 
response of individual cell lines to ER stress (P > 0.05); although there was a significant 
detectable difference across cancer type for both fenretinide and bortezomib (F6, 108 = 
10.1 or 4.8 with P < 0.0001 respectively).  
Collectively these data demonstrate the cellular response to stress via the ATF6 arm is 
detectable at early time points (2 h), with the expression of ATF6 beginning to recover 
by 8 h within all cell lines (indicating the translation of ATF6), and returning to basal 
levels by 24 h, indicating  a reproducible response across all cancer types. 
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Figure 3.11: The effect of fenretinide and bortezomib dose on ER stress-induced 
activation of XBP-1 splicing. CHL-1, WM266-4 (melanoma), MO59J, U251 
(glioblastoma), NGP and SH-SY5Y (neuroblastoma) cell lines were treated with 
fenretinide (FenR, 1 - 15 µM for melanoma or glioblastoma or 0.1 - 10 µM for 
Neuroblastoma) or bortezomib (Bort, 10 - 300 nM for melanoma or glioblastoma or 1 - 
30 nM for Neuroblastoma) for 4 h prior to harvesting. Cells were then counted and 
assessed by real time PCR for XBP-1 and XBP-1s expression over time, using actin as 
control.  Data were expressed as the mean of 3 independent experiments ± 95% CI. 
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To complete the characterisation of the activation of the UPR within neural-crest-
derived melanoma, glioblastoma and neuroblastoma cancer cells, the activation of the 
IRE1 arm of the UPR was assessed by measurement of the product of splicing of XBP-1, 
a downstream process of active IRE1. As in previous experiments, cells were treated 
with increasing doses of fenretinide or bortezomib (1 – 15 µM fenretinide and 10 – 300 
nM bortezomib for melanoma and glioblastoma or 0.5 – 10 µM and 1 – 30 nM 
bortezomib for neuroblastoma) for 4 h prior to real time PCR analysis for the expression 
of UPR components XBP-1 and XBP-1s in comparison to β-Actin (Figure 3.11).  
Data demonstrated a significant dose dependent induction of XBP-1s in all cell lines 
with increasing doses of fenretinide, coupled with a significant reduction in XBP-1 
(Figure 3.11 A, C & E). There was a significant induction of XBP-1s for all cell lines 
after treatment with 5 µM fenretinide (One-way Anova with Dunnett’s post hoc 
corrections, for WM266-4, U251 or SH-SY5Y cell lines = P < 0.05, and CHL-1 or NGP 
= P < 0.01 or MO59J = P < 0.0001), however only melanoma cells showed a significant 
depletion of XBP-1 at 5 µM concentrations (One-way Anova with Dunnett’s post hoc 
corrections, for CHL-1 and WM266-4 = P < 0.0001). All cell lines showed increasing 
significance of XBP-1s formation with dose (For melanoma and glioblastoma = P < 
0.0001 or for neuroblastoma = P < 0.005). For the depletion of XBP-1, fenretinide 
influenced expression in melanoma and neuroblastoma significantly (One-way Anova 
with Dunnett’s post hoc corrections, for CHL-1 and WM266-4, 5 & 10 µM = P < 
0.0001, 15 µM for WM266-4 = P < 0.01), but showed no significant reduction in XBP-
1 in glioblastoma cell lines (P > 0.05).  
With respect to bortezomib, there was a significant dose induction of splicing of XBP-1 
in all cell lines tested (Figure 3.11 B, D & F). For melanoma and glioblastoma cells a 
significant increase in XBP-1s occurred in response to 100 nM bortezomib (One way 
Anova with Dunnett’s post hoc corrections, for WM266-4 = P < 0.01, CHL-1 and U251 
= P < 0.001 or MO59J = P < 0.0001) while in neuroblastoma cell lines a significant 
increase in XBP-1s was detected by 10 nM concentrations (One-way Anova with 
Dunnett’s post hoc corrections, SH-SY5Y = P < 0.005,  NGP = P < 0.001). All cell lines 
demonstrated higher significance with dose (all cell lines reaching = P < 0.0001). The 
effect of bortezomib on expression of XBP-1 expression demonstrated a significant 
reduction (One-way Anova with Dunnett’s post hoc corrections, for melanoma 200 nM 
bortezomib = P < 0.01,  U251 cells treat with 100 nM = P < 0.05, glioblastoma treated 
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with 200 nM or above = P  < 0.001 or SH-SY5Y treat with 20 nM bortezomib = P  < 
0.01, neuroblastoma with = 30 nM bortezomib P  < 0.001). 
These data demostrate a significant  induction of splicing by fenretinide or bortezomib. 
Comparing individual cell lines, for glioblastoma cells there was a significant difference 
between XBP-1s formation (F4, 72 = 22.3, P < 0.0001), however for melanoma and  
neuroblastoma for both XBP-1s formation and XBP-1 depletion or glioblastoma for 
XBP-1 depletion, there was no significant difference in cellular response to either agent 
(P > 0.05). These data parallel the conclusions for the activation of the ATF6 arm of the 
UPR where a similar response was achieved.  Thus, with regards to XBP-1 splicing, 
these data demonstrate a significant difference between cancer types and their response 
to either fenretinide and bortezomib (analysis by 2 Way ANOVA F2, 24 = 38.2 or 64.5, P 
< 0.001 for both), highlighting a difference in the degree of UPR activity across 
melanoma, glioblastoma and neuroblastoma cancer models. 
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Figure 3.12: Assessing the effect of fenretinide and bortezomib induced XBP-1 splicing 
over time. CHL-1, WM266-4 (melanoma), MO59J, U251 (glioblastoma), NGP and SH-
SY5Y (neuroblastoma) cell lines were treated with fenretinide (FenR, 10 µM for 
melanoma or glioblastoma or 5 µM for Neuroblastoma) or bortezomib (Bort, 200 nM 
for melanoma or glioblastoma or 20 nM for Neuroblastoma) for 0, 1, 2, 4, 8 and 24 h 
prior to harvesting. Cells were then counted and assessed by real time PCR for XBP-1 
and XBP-1s expression over time, using actin as control.  Data were expressed as the 
mean of 3 independent experiments ± 95% CI. 
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Investigating the activity of the IRE1 branch of the UPR over time to stress, cells were 
treated with either fenretinide or bortezomib (10 µM fenretinide and 200 nM 
bortezomib for metastatic melanoma and glioblastoma cell lines or 5 µM fenretinide 
and 20 nM bortezomib for neuroblastoma cell lines for 0, 1, 2, 4, 8 and 24 h prior to 
analysis for the formation of XBP-1s in comparison to the expression of XBP-1, in 
relation to β-Actin (Figure 3.12). 
 For the effect of  fenretinide on the formation of XBP-1s, all cells showed a significant 
increase in XBP-1s by 2 h (Figure 3.12 A, C & E, One-way Anova with Dunnett’s post 
hoc corrections, for CHL-1 = P < 0.05, WM266-4 and both glioblastoma and 
neuroblastoma cell lines = P < 0.0001), however, only metastatic melanoma and NGP 
neuroblastoma cells demonstrated a significant depletion in endogenous XBP-1 at 2 h 
(One-way Anova with Dunnett’s post hoc corrections, for CHL-1 and WM266-4 
melanoma cells = P < 0.001 or NGP = P < 0.005), and showed a significant increase in 
XBP-1s up to the 4 h time point (One-way Anova with Dunnett’s post hoc corrections, 
for all cell lines = P < 0.0001) or a depletion up to the 8 h time point (One-way Anova 
with Dunnett’s post hoc corrections, for both melanoma and neuroblastoma cell lines = 
P < 0.0001) or up to the 4 h for glioblastoma (both cell lines = P < 0.005). Data 
demonstrated a normalisation in either XBP-1 or XBP-1s expression levels, as the 
system returned to equilibrium, at 24 h, except for neuroblastoma cells that still 
demonstrated a significant expression of XBP-1s (Both cell lines = P < 0.0001). 
The effect of bortezomib on XBP-1 splicing over time (Figure 3.12 B, D & F) showed a 
response similar to that of fenretinide (Figure 3.11 A, C & E). Data showed a significant 
induction of XBP-1s formation by 2 h in all cells (One-way Anova with Dunnett’s post 
hoc corrections, for NGP and SH-SY5Y = P < 0.05, CHL-1 = P < 0.005, WM266-4 and 
U251 = P < 0.001), except for MO59J that showed a significant induction by 4 h (P < 
0.05).   
Bortezomib, for all cell lines, demonstrated maximal induction of XBP-1s formation 
(One-way Anova with Dunnett’s post hoc corrections, for MO59J cells = P < 0.05 and 
for all other cell lines = P < 0.0001) and XBP-1 depletion (For metastatic melanoma and 
neuroblastoma cell lines = P < 0.0001 or both glioblastoma cell lines) by 4 h, followed 
by a gradual normalisation of expression to basal by 24 h. XBP-1 expression, like that 
of ATF6 is induced by the UPR to recover the system and allow for a prolonged 
activation of the UPR and therefore recovery is required to reset the system. 
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These data thus indicate the basic characteristics of both the IRE1 and ATF6 arm of the 
UPR respond to stress over a similar period of time, with no discrimination between the 
types of stress. Further investigation demonstrated no significant difference between the 
responses to fenretinide across cancer types (P > 0.05), with regard to XBP-1s 
formation. However, data demonstrated a significant difference between cancer cell 
types in their response to bortezomib induced ER stress (F6, 108 = 62.9, P < 0.01).  
Therefore this work demonstrated a cancer types capacity to activate UPR can vary 
within each arm of the UPR. Melanoma demonstrated significantly higher induction of 
ATF4 than glioblastoma or neuroblastoma, yet activated XBP-1 splicing and ATF6 
cleavage to a similar magnitude. This study also demonstrated that XBP1 splicing 
occurred for significantly longer in neuroblastoma.  
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3.2.4: Results Summary. 
 Cellular concentrations of GRP78 differed across neural-crest-derived cancer 
types with human metastatic melanoma cells demonstrating significantly higher 
expression. 
 Cell lines within a certain cancer types expressed GRP78 to the same extent, 
demonstrating a cell type-specific requirement. 
 In neural-crest-derived cancer models, expression of the UPR activators did not 
correlate with GRP78 expression, with IRE1 showing a significantly higher 
expression than either PERK or ATF6. 
 Co-localisation analysis of GRP78 to calnexin demonstrated differences in 
GRP78 distribution between cancer types. However, GRP78 was predominantly 
cytoplasmic within all cancer types. 
 Induction of stress by either fenretinide or bortezomib increased co-localisation, 
suggesting a stress triggered migration of GRP78.  
 Exposure to fenretinide or bortezomib induced UPR, demonstrated by induction 
of ATF4, splicing of XBP-1 or cleavage of ATF6. 
 Cancer types demonstrated differences in the magnitude of response to ER stress 
stimulated ATF4 induction, with melanoma cells showing greater response to 
that of glioblastoma or neuroblastoma. 
 Neural-crest-derived cancer cells showed similar levels of induction of XBP-1s, 
however neuroblastoma demonstrated activation for significantly longer than 
either glioblastoma and neuroblastoma cells. 
 ER stress-induced ATF6 cleavage by fenretinide and bortezomib, as for XBP-1 
splicing, was observed to a similar extent across cancer types. 
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3.3: Discussion. 
Investigating the UPR across differing neural-crest-derived cancer cells demonstrated 
differences in cellular concentrations of GRP78. Furthermore, the cellular 
concentrations of UPR activators did not correlate with GRP78 expression, 
demonstrating a cell line-dependent concentration of PERK, IRE1 or ATF6. The 
expression of the UPR activators also showed a significant difference in cellular 
concentrations within all cancer types, with IRE1 demonstrating the highest expression. 
Furthermore, comparing GRP78 to the cellular concentration of total UPR activators, 
melanoma and glioblastoma cancer types demonstrated higher expressions of GRP78, 
compared to neuroblastoma cells, however, neuroblastoma cells displayed higher 
concentrations of UPR activators compared to levels of GRP78.  
Differences in GRP78 cellular concentrations between cancer types suggested the 
existence of a cell type specific requirement. Although these cells have all originated 
from the neural-crest, significant differentiation occurs to generate cells designed for 
specialized jobs. The significantly higher expression of GRP78 in melanoma in 
comparison to melanocytes suggests a disease-related increase. These findings confirm 
that of Zhuang et al., which demonstrated an increase in GRP78 expression with 
melanoma disease state [115].  In addition, melanoma and glioblastoma may display 
significantly higher expression of GRP78 as a consequence of an increase in protein 
synthesis, which in turn has influenced ER capacity and chaperone expression [228].  
Depending on cancer type, chaperones may be expressed at different cellular 
concentrations and although GRP78 expression was lower in neuroblastoma cells, other 
members of the heat shock protein family may be more highly expressed. Studies have 
shown that total chaperone expression counters any changes in overall expression by up 
or down regulating family members to maintain equilibrium [229]. Although GRP78 
expression levels in the present study were significantly higher in melanoma, compared 
to neuroblastoma, GRP94 has been shown to be over-expressed in neuroblastoma and 
hence GRP78 was observed to be expressed to a lesser extent [230]. Nevertheless, these 
findings do not necessarily confirm a cancer type specific difference in total chaperone 
expression. However, results derived from the present study may suggest a difference 
between cancer types in their dependence on GRP78 and the UPR as a mechanism to 
buffer cellular insults or for protein turn-over in general.   
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Quantification of UPR activator expression highlighted the importance of IRE1. The 
evolutionary conserved component of the UPR [231] showed a significantly higher 
cellular concentration than either of the other two UPR activators, suggesting that IRE1 
may still function as the primary UPR activator in the cellular response to stress and 
although the mammalian UPR has developed a complex and diverse set of cascades 
[226], IRE1 signalling is still essential.  
Stoichiometric analysis also showed that melanoma and glioblastoma cell lines 
exhibited significantly higher cellular concentrations of  GRP78  compared to the 
combined concentrations of PERK, IRE1 and ATF6; however, in neuroblastoma the 
opposite was observed (For melanoma 1 : 0.65 , Glioblastoma 1 : 0.7 and 
neuroblastoma 1 : 1.5, averaged between cell lines of the same cancer type). These data 
suggest differences between GRP78 and the UPR activators with regard to the dynamic 
equilibrium of the UPR. It is well established that GRP78 acts as a central inhibitory 
hub of the UPR, binding to PERK, IRE1 and ATF6 under periods of normal physiology 
[209]. These data suggest that for melanoma and glioblastoma a large reservoir of free 
GRP78 exists which may interact with unfolded of mis-folded protein substrates, 
reducing the probability that a GRP78 molecule, that is inhibiting a PERK, IRE1 or 
ATF6, will come into contact with a substrate. However for neuroblastoma this 
relationship was reversed, indicating a population of cells with free UPR activators 
under periods of normal physiology, suggesting that these cells have the capability to 
present an active UPR at any time. 
The observed differences in cell line co-localisation of GRP78 and ER resident calnexin 
suggests differences in ER capacity. As GRP78 has been shown to exist in the nucleus, 
peri-nucleus, cytoplasm and cell membranes of a number of different cell type, 
differences in co-localisation suggests cell types exert differing ER capacity, and 
demonstrating lower co-localisation to calnexin. When melanoma and glioblastoma 
cells were stressed by either fenretinide or bortezomib, a significant increase in co-
localisation was observed, suggesting ER stress related recruitment of GRP78 to the ER. 
This would result in an increase in the concentration of GRP78 within the ER and allow 
a cell to buffer higher levels of stress, prior to the activation of the UPR, increasing the 
probability of cell survival, by increasing the ER chaperone activity. 
Mapping the activation of the UPR over time using fenretinide and bortezomib as 
inducers of ER stress demonstrated cancer types respond differently, depending on the 
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type of stress present. Research by Lin et al., showed that time of activation of each arm 
of the UPR is critical in determining a cells fate to stress and requires prolonged 
activation of PERK after other UPR activators had been attenuated [225]. The present 
study demonstrated that all three cancer types respond differently to ER stress, with 
bortezomib showing a greater ability to activate the UPR than fenretinide. These 
observations suggest differences in the mechanism of action and ultimately the manner 
to which either agent perturbs the ER, can affect the response outcome. Bortezomib 
induces inhibition of the 26S proteasome exerting a more ER specific stress, rather than 
the accumulation of ROS by fenretinide [82, 201, 203, 232-240]. Interestingly, although 
fenretinide has been shown to induce cell death via ER stress, the activation of the 
PERK arm never exceeded that of the IRE1 arm, suggesting that time difference 
between UPR branches is not the determining factor for life or death, with regards to 
ROS induced ER stress [225]. Data demonstrated a significantly greater induction of 
ATF4 in melanoma than glioblastoma and neuroblastoma, yet there was no significant 
difference between PERK expression. This suggests that differences may exist in ATF4 
mRNA transcription and/or translation. 
The effect of ER stress on UPR within neuroblastoma highlighted a prolonged 
activation of IRE1, showing a significantly different response to that of melanoma and 
glioblastoma. This difference was present when neuroblastoma cells were treated with 
either fenretinide or bortezomib and may suggest that there is an imbalance of GRP78 
to UPR activator expression within this cancer type. Studies have indicated the 
importance of the PERK arm of the UPR for the induction of the pro-apoptotic 
transcription factor Gadd153 [112, 220, 241], however it has also been shown that IRE1 
is capable of promoting cell death, either by the induction of Gadd153 transcription  or 
via JNK activation [213]. These data suggest that although the PERK cascade 
demonstrates activity under ER stress-induced by either fenretinide or bortezomib, IRE1 
maybe essential within the response of the UPR.  
However, the differences in the activation of IRE1 over time observed in neuroblastoma 
cells would also imply the presence of another regulatory body for IRE1 activation, as 
the formation of XBP-1s was only present after stimulation by ER stress-inducing 
agents. Research into the activation of IRE1 in yeast has demonstrated the requirement 
of IRE1 to interact with an unfolded protein after dissociation from GRP78 to become 
active. This work did not correlate with human IRE1, but does suggest that IRE1 may 
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undergo a more complex activation, requiring release from GRP78 and a secondary 
trigger prior to becoming capable of signalling to the nucleus [242]. 
The activity of the ATF6 element of the UPR demonstrated a significant response from 
2 h until the UPR induction of ATF6 and IRE1 replenished the system after 8 h [243]. 
The present study however, could only demonstrate significant activation of the ATF6 
arm of the UPR (and therefore loss of full length protein) from 2 h and was unable to 
demonstrate the presence of the activated cleaved ATF6 fragment, which would allow 
for a conclusive assessment of the total activity of this arm of the UPR. 
For the effect of ER stress on the activation of the UPR, neuroblastoma cells were 
treated with significantly lower doses of either fenretinide or bortezomib, compared to 
melanoma and glioblastoma due to their increased sensitivity to death by either agent. 
Although neuroblastoma cells were more sensitive to fenretinide/bortezomib-induced 
cell death compared to the utilised melanoma cells, induction of ATF4 was markedly 
decreased. Induction of XBP-1 splicing and ATF6 cleavage however was similar across 
all cancer cell types. These data thus suggest ATF4 mediated Gadd153-induced cell 
death is not crucial for neuroblastoma cells in response to either fenretinide or 
bortezomib.  
Due to the differences observed within the UPRs response to ER stress, further research 
into the effect of the dynamic equilibrium between GRP78 and UPR activators across 
cancer types and their response to cellular stress is required. Developing a more 
comprehensive understanding of the UPR and the role that it plays in cancer cell 
resistance, aggression and overall survival to either natural or pharmaceutical stimuli is 
warranted and may allow for a more specific targeting strategy and overall improvement 
in prognosis for cancer patients. Previous studies have correlated GRP78 expression 
with tumour stage and progression, as well as chemo-resistance. In a vast number of 
solid tumours including the neural-crest-derived melanoma and glioblastoma cancer 
types [113, 115], increased GRP78 expression correlated with a poor prognosis, 
however in studies of acute myeloid leukaemia and neuroblastoma, increased GRP78 
correlated with a favourable outcome [116]. Further studies were therefore required to 
establish the role of GRP78 and the relationship with UPR activation and to test the 
hypothesis that GRP78 expression influences cellular UPR signalling and downstream 
activation of death stimuli, ultimately affecting cellular survival.  
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3.4: Conclusion. 
This study highlights a cancer type specific expression of GRP78, which does not 
correlate to the individual expressions of the UPR activators. Comparing GRP78 and 
the UPR activators showed that unlike melanoma or glioblastoma, neuroblastoma 
contained a higher concentration of UPR activators than GRP78 to inhibit them. ER 
stress-induced ATF4 expression highlighted that cancer types respond differently to 
stressors, as well as possess different capacity to induce ATF4 expression, with 
melanoma capable of inducing greater levels. Although differences were observed 
between ATF4 induction, the magnitude of response for both XBP-1 splicing and ATF6 
cleavage were similar across cancer types, with neuroblastoma showing detectable 
levels of XBP-1s longer than melanoma and glioblastoma. 
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Chapter 4: 
 
Reduction in GRP78 expression affects 
the response of cancer cells to ER 
stress-induced cell death. 
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4.1: Introduction. 
In eukaryotic cells, proteins (both membrane and secretory) are folded and assembled 
within the ER before transport to the cell surface or destination organelle [206].  Newly-
synthesised proteins enter the lumen of the ER where they often undergo glycosylation 
[206]. For a protein to reach its functional tertiary or quaternary structural state, it must 
undergo physical processing, where bonds are actively added to maintain the complex 
structures required for a functional state. This is often achieved by the addition of 
disulphide bonds [206]. Cellular insults can hinder these processes by altering 
environmental conditions within the lumen of the ER, achieving a state that no longer 
promotes correct secondary structure formation or affects the ability of bond formation, 
as a direct consequence of changes to the ER redox state [206]. As a consequence, cells 
activate intracellular signalling pathways which regulate protein folding capacity of the 
cell [91, 111].  The UPR consists of 3 individual signalling cascades initiated by IRE1, 
PERK and ATF6 [91, 111]. Upon activation of these three UPR signalling proteins, the 
outcome is initially a pro-survival response to any cellular insult that has perturbed the 
functioning of the ER followed by the activation of cell death pathways if the stress is 
too severe or persistent. To regulate this homeostatic response, each UPR activator 
binds to and is inhibited by the central stress regulator GRP78 [168, 209, 244-246]. 
Studies by Kohmo, Shen and Bertolotti et al., have demonstrated a direct interaction 
between PERK, IRE1 and ATF6 [168, 209, 210, 247]. Using pull down experiments, 
Kohmo and Bertolotti et al., demonstrated a dynamic interaction between GRP78 and 
either IRE1 or PERK. This interaction results in the prevention of self-association of 
PERK and IRE1, as the interaction with GRP78 masks the required luminal domain 
sequences, preventing homo-dimerization to the active complex (Figure 4.1) [209, 247-
249]. Kohno et al., demonstrated that upon ER stress, IRE1 dissociates from the 
substrate binding domain of GRP78 [248], allowing IRE1 to homodimerise and activate 
a signalling cascade to the nucleus with a consequent up-regulation of chaperone 
mRNA, including GRP78 [249]. 
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Figure 4.1: The primary structure of the ER stress sensors: inositol requiring kinase 
1(IRE1), protein kinase-like endoplasmic reticulum kinase (PERK), and activating 
transcription factor 6 (ATF6).  Red lines represent regions interacting with BiP. The 
black boxes represent the signal peptides, and the blue lined boxes depict the region of 
limited homology between IRE1 and PERK as well as regions sufficient for signal 
transduction or oligomerization. Purple lines full and dotted represent the sites for site 
1 protease and site 2 protease respectively. The other abbreviations are bZIP, basic 
leucine zipper; GLS1 and GLS2, Golgi localization sequences 1 and 2; TAD, 
transcriptional activation domain; and TM, trans-membrane domain. Picture modified 
from Schröder et al [91].  
Using a similar approach, Prywes et al, demonstrated a dynamic relationship between 
ATF6 and GRP78 in which dissociation occurred under periods of stress induced by 
DTT treatment [244-246]. These studies [244-246] demonstrated the presence of Golgi 
localization sequences within the luminal domain of ATF6 [168, 210] and also showed 
the requirement of Golgi localisation sequences for ATF6 activation. Furthermore, Shen 
et al., also demonstrated over expression of GRP78 can prevent ATF6 activation under 
periods of stress by masking the Golgi localisation sequences, thus retaining ATF6 
within the ER [246]. 
Collectively these studies clearly show an inhibitory role of GRP78, acting as a stress 
sensor for the activation of the UPR within mammalian cells. However, there have been 
106 
 
numerous studies demonstrating a correlation between GRP78 expression and UPR 
activation [250, 251]. These findings suggest the presence of a dynamic equilibrium 
between GRP78 and the UPR activators that if altered can influence the outcome of the 
UPR.  
The fact that increased expression of GRP78 prevents the activation of ATF6 [210] 
suggests that the up-regulation of GRP78 as a downstream consequence of the UPR 
may not only function to aid ER recovery, but may also act to negatively regulate the 
UPR [168, 210]. Studies in melanoma, breast, colon, liver, lung and many other solid 
tumour types, have demonstrated increased expression of GRP78 relative to non-tumour 
tissue [115, 252-255], particularly in metastatic tumour cells [256]. Experiments to 
understand the consequence of GRP78 expression have demonstrated that, in certain 
cancer types such as melanoma, increased levels of GRP78 results in a more malignant 
and chemo-resistant phenotype. The association of UPR activators with GRP78 
therefore prevents activation of death induction in the absence of stress. However, in 
cancerous cells, adaptations in cellular mechanisms to evade cell death and altered 
cellular proliferation result in a harsh environmental condition: these cells demonstrate 
changes in GRP78 and UPR activity. Conditioning of a cancer cell to such stress results 
in a favourable up-regulation of GRP78 expression, as well as the negative regulation of 
the UPR, that maybe suppressing the activation of UPR and the ability to induce cell 
death.  
Suzuki et al, Sun et al., and Lee et al., demonstrated that knockdown of GRP78 
expression increased cell sensitivity to apoptosis [251, 257, 258]. Using a Hela cell 
model, Suzuki et al., demonstrated the activation of UPR signalling in cells with 
reduced GRP78, confirming the presence of a dynamic equilibrium (Figure 4.2) [251]. 
These data, using a p5 x ATF6-GL3 or pGL3-GRP78 luciferase assay, showed 
significant induction of UPR-related promoters in cells with reduced GRP78, in 
comparison to control. Moreover, these studies indicated the activation of XBP-1 
splicing in knockdown cells and importantly demonstrated a significant induction of 
GADD153 [251]. Sun et al., and Lee et al., showed that a decrease in GRP78 
significantly decreased cell proliferation and highlighted GRP78 as crucial mediator of 
angiogenesis, by regulating cell proliferation, survival and migration [257, 258]. Sun et 
al., also demonstrated, in an RKO cell model, an increase in spontaneous apoptosis in 
cells with reduced GRP78 expression [257].  
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Figure 4.2: The dynamic equilibrium of GRP78 and the activation of the UPR.  The 
relationship that exists between GRP78 and the UPR activators PERK, IRE1 and ATF6 
is crucial for life. GRP78 binds to and inactivates PERK, IRE1 and ATF6 (diagram 
uses IRE1 as an example). However, GRP78 has a higher affinity for unfolded or mis-
folded substrates and therefore on exposure to a substrate dissociates from the UPR 
activator to function as a chaperone, aiding protein synthesis and ER recovery. GRP78 
interaction with a substrate is dependent on the presence of either ATP/ADP. When 
bound to ADP, GRP78 demonstrates a stronger affinity for unfolded substrates. On 
replacement of ADP with ATP a much weaker attraction is present and GRP78 
dissociates. The now free GRP78 is capable of binding to another protein substrate or 
to a UPR activator depending on proximity and substrate concentration. Therefore the 
expression levels of GRP78, UPR activators and unfolded protein substrates all affect 
the dynamic relationship present within the UPR [259]. 
Studies into the effect of GRP78 expression on patient prognosis reveal a significant 
difference in outcome, depending on cancer type. Research specifically investigating the 
role of GRP78 within neural-crest-derived tumours demonstrated in melanoma and 
glioblastoma, an increase in GRP78 expression directly correlated with disease 
progression and resistance [113, 114, 224], however in the case of neuroblastoma a 
more favourable prognosis was associated with increased GRP78 [116]. Therefore, the 
aim of this study was to investigate the effect of GRP78 expression on neural-crest-
derived cancer cell sensitivity to ER stress. Studies into the effect of fenretinide or 
bortezomib have been carried out previously, demonstrating both agents act as potent 
inducers of ER stress and cell death in neural-crest-derived cancer types, however to 
date no direct comparison has been made between differing cancer types and sensitivity 
to ER stress or the underlying differences in the mechanism of UPR in relation to 
patient prognosis [82, 203, 235, 240, 260-262]. 
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4.2: Results. 
4.2.1: Fenretinide and Bortezomib induced ER stress. 
To test the hypothesis that the cellular expression of GRP78 can affect the outcome of 
ER stress, with regards to triggering cell death, experiments were designed to test the 
effect of reducing GRP78 expression on neural-crest-derived cancer cell sensitivity to 
ER stress-induced cell death in response to fenretinide or bortezomib. Previous studies 
within the group have demonstrated that fenretinide and bortezomib both potently 
induce cell death in melanoma and neuroblastoma cancer cell lines in vitro [82, 112, 
203]. However, to confirm the activity of ER stress-inducing agents within this study 
and to determine the effect of fenretinide and bortezomib as well as the ability of either 
agent to induce cell death of glioblastoma cells, CHL-1 and WM266-4 (metastatic 
melanoma), NGP and SH-SY5Y (neuroblastoma) as well as MO59J and U251 
glioblastoma cells were therefore treated with a dose range of both drugs  
Using previous reports as a guide, melanoma and glioblastoma cells were treated with 
2-fold or 10-fold higher concentrations of fenretinide or bortezomib respectively [82, 
112], compared to concentrations of either agent used to treat neuroblastoma cells. To 
determine a standardised dose of both fenretinide and bortezomib for further studies, 
and to allow for a comparison of the UPR across cancer types as well as investigate the 
effect of manipulating the UPR on stress induced cell death, cells were compared for the 
induction of death or inhibition of cell viability for a drug dose that: 
1. Gave a measurable effect for both death and viability 
2. Was biologically significant in response, in comparison to control 
3. Was less than the maximally inducible level for each drug (upper asymptote of dose 
response curves) 
4. Was within the clinically-achievable dose range (below 15 µM for fenretinide or 300 
nM for bortezomib) 
5. Gave a significant biological and statistical affect for both cell lines of the same 
cancer type. 
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Figure 4.3: Fenretinide- or Bortezomib-induced cell death in a panel of neural-crest-
derived cancer cells.  Melanoma (A & B), glioblastoma (C & D) and neuroblastoma (E 
& F) cells were treated with increasing doses of either fenretinide (0 – 50 µM for 
melanoma and glioblastoma or 0 – 20 µM for neuroblastoma cell lines) or bortezomib 
(0 – 400 nM for melanoma and glioblastoma or 0 – 100 nM for neuroblastoma cell 
lines) for 24 h prior to harvesting, and samples analysed for cell death by propidium 
iodide staining and flow cytometry to quantify the proportion of cells with SubG1 DNA 
content. Data are the mean of 3 repeat experiments ± 95% CI.  
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Dose response experiments of fenretinide- or bortezomib- induced cell death of 
metastatic melanoma, glioblastoma and neuroblastoma cancer cells were carried out in 
order to determine optimal doses for subsequent experiments for the effect of GRP78 
expression on cell line sensitivity. Cells were treated with increasing doses of 
fenretinide (0 – 50 µM for both melanoma and glioblastoma or 0 – 20 µM for 
neuroblastoma) or bortezomib (0 – 400 nM for melanoma and glioblastoma or 0 – 100 
nM for neuroblastoma) and apoptosis assessed by flow cytometry (Figure 4.3). Data 
demonstrated a dose-dependent increase in cell death in response to either fenretinide or 
bortezomib but with no significant difference in EC50 values between individual cell 
lines (P > 0.05) across a single tumour type. However, significant differences in the 
maximum achievable level of cell death (in the achieved upper asymptote) were evident 
between differing tumour types. 
Metastatic melanoma and neuroblastoma cells showed a significant difference in 
response to either fenretinide or bortezomib (Figure 4.3 A & E, One-way ANOVA 
comparing melanoma cells; F4, 34 = 27 or 12.8, P < 0.0001 for either agent, respectively, 
or for neuroblastoma; F4, 28 = 104.9, P < 0.0001 with fenretinide and F4, 28 = 49.3, P < 
0.01 with bortezomib), with CHL-1 and SH-SY5Y suffering higher levels of cell death. 
The data also demonstrated differences between cell lines in the level of cell death 
induced by each ER stress-inducing agent. For glioblastoma cells, there was a 
significant difference between cell lines treated with bortezomib (Figure 4.3 D, One-
way ANOVA comparing glioblastoma cell lines; F4, 34 = 113.4, P < 0.0001), with 
MO59J being the most sensitive. When treated with fenretinide, both glioblastoma cell 
lines responded in a similar way (Figure 4.3 C). These data showed that the 
susceptibility of glioblastoma to death differed depending on the ER stress-inducing 
agent used. Thus, cells differed in their sensitivity to death in a drug-dependant manner. 
Based on the data derived in figure 4.3, optimal doses of fenretinide or bortezomib were 
determined; for melanoma or glioblastoma cell lines, 10 µM fenretinide or 200 nM 
bortezomib or for neuroblastoma, 5 µM fenretinide or 20 nM bortezomib, were 
subsequently used as single agent concentrations and importantly at doses which induce 
biologically-reproducible effects below the maximum-tolerated dose. 
The effects of fenretinide or bortezomib-induced cell death as determined by FACS 
analysis of SubG1 were confirmed by the analysis of cell viability (Figure 4.4). Data 
indicated a dose-dependent increase in fenretinide or bortezomib- induced inhibition of 
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cell viability for all cell lines (One-way ANOVA with Dunnett’s post hoc corrections, P 
≤ 0.001 for all cell lines, with either agent).  Melanoma cells demonstrated differences 
in responses to both fenretinide and bortezomib (Figure 4.4 A & B) with regards to the 
maximally achievable levels of inhibition of cell viability (Figure 4.4 A, Two-way 
ANOVA comparing drug, F4, 95 = 42.4 or 12.3, P < 0.01). For glioblastoma and 
neuroblastoma, differences in cell line response to bortezomib were also observed, 
showing U251 and SH-SY5Y cells as the most sensitive (Figure 4.4 D & F, Two-way 
ANOVA, F4, 95 = 12.6 or 9.4, respectively, P ≤ 0.01). However, in response to 
fenretinide, both cancer types responded in the same way (Figure 4.4 C & E, P > 0.05). 
Comparing cancer cell types, there was a significant difference in the Ec50 for 
fenretinide and the maximum achievable effect (Nested ANOVA, For Ec50 F2, 12 = 16.4, 
P < 0.001 and asymptote F2, 12 = 121.4, P < 0.01), with no significant differences in 
bortezomib response (P > 0.05).  
Comparing the data for death and inhibition of cell viability showed that although a 
given cell line maybe more sensitive to death, this does not necessarily correlate with 
inhibition of cell viability. These data thus confirmed the single-drug dose 
concentrations of ER stress-inducing agents selected for use in subsequent knockdown 
experiments. 
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Figure 4.4: Fenretinide and Bortezomib induced inhibition of cell viability in a panel of 
neural-crest-derived cancer cells.  Melanoma (A & B), glioblastoma (C & D) and 
neuroblastoma (E & F) cells were treated with a dose response curve of either 
fenretinide (0 – 50 µM for melanoma and glioblastoma or 0 – 20 µM for neuroblastoma 
cell lines) or bortezomib (0 – 400 nM for melanoma and glioblastoma or 0 – 100 nM for 
neuroblastoma cell lines) for 24 h prior to harvesting and samples analysed for their 
effect on cell viability using the commercially available colorimetric based (MTS) 
metabolic assay. Experiments are the mean of 3 replicate experiments, each containing 
3 replicates, ± 95% CI.  
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To determine if fenretinide induces ROS accumulation and to compare the level of ER 
stress achieved between neural-crest-derived cancer types, cells were treated with 
fenretinide (10 µM for melanoma or glioblastoma and 5 µM for neuroblastoma) for 0 – 
6 h prior to the assessment of ROS induction by flow cytometry of DCDHF stained 
cells (Figure 4.5). Cells were also treated with bortezomib (200 nM for melanoma or 
glioblastoma and 20 nM for neuroblastoma) for 0 – 24 h to determine if bortezomib-
induced inhibition of the 26S proteasome results in protein accumulation, as measured 
by western blot analysis for ubiquitin and ubiquitin smears, in comparison to β-Actin as 
loading control (Figure 4.6). 
Data (Figure 4.5) demonstrated a time dependant induction in ROS in all cell lines 
(One-way ANOVA with Dunnett’s post hoc corrections, for all cell lines P < 0.0001) 
from a minimum of 30 minutes exposure to fenretinide (For WM266-4 melanoma cells, 
either neuroblastoma or glioblastoma cell line P < 0.05. For CHL-1 melanoma cells P < 
0.001). Comparing cell lines of the same cancer type revealed no significant difference 
in response of glioblastoma or neuroblastoma (P > 0.05), however CHL-1 melanoma 
cells showed significantly higher induction of fenretinide-induced ROS, in comparison 
to WM266-4 cells (Two-way ANOVA, F24, 47 = 59.2, P < 0.001). Data for melanoma or 
glioblastoma demonstrated a significantly greater expression of ROS at 0 h, compared 
to neuroblastoma (Two-way ANOVA, F6, 17 = 88.3, P < 0.0001). However, over time 
there were no significant differences between cancer types for the induction of ROS 
(P > 0.05). 
Investigating the effect of bortezomib on the accumulation of ubiquitin-tagged proteins 
(Figure 4.6, ubiquitin smears) demonstrated a significant increase in ubiquitin smears 
over time in all cell lines (One-way ANOVA with Dunnett’s post hoc corrections, P ≤ 
0.01 for all cell lines). Ubiquitin was significantly induced in melanoma and 
glioblastoma cells by 4 h (P ≤ 0.05), whereas induction was not significantly increased 
in neuroblastoma cells until 6 h (P ≤ 0.01). 
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Figure 4.5: The induction of ROS over time by fenretinide treatment.  Melanoma (A), 
glioblastoma (B) or neuroblastoma (C) cells were treated with either 5 µM 
(neuroblastoma) or 10 µM (melanoma and glioblastoma) fenretinide and the induction 
of ROS assessed over a 6 hour time course by DCDHF staining and subsequent flow 
cytometry for FL-1 positivity. Data are the mean of 3 individual experiments for the FL-
1 peak area ± 95% CI. 
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Figure 4.6: The effect of Bortezomib treatment on 26S proteasome inhibition in neural-
crest-derived-cancer cells.  (A) Melanoma (i), glioblastoma (ii) or neuroblastoma (iii) 
cells were treated with either 20 nM (neuroblastoma) or 200 nM (melanoma and 
glioblastoma) bortezomib and samples harvested over a 24 hour time course and 
processed for ubiquitin smears in comparison to free ubiquitin, using β-actin as a 
loading control. (B) Densitometry analysis for the induction of ubiquitin smears by 
bortezomib treatment. Data are the mean of 3 individual experiments ± 95% CI. 
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Data also demonstrated that ubiquitin smears were significantly increased in CHL-1 and 
MO59J cell lines compared to their partner cell lines, WM266-4 and U251 respectively 
(Two-way ANOVA, F21, 41 = 94.6 for melanoma and 129.3 for glioblastoma, P < 
0.0001) On the other hand, data for neuroblastoma demonstrated no significant 
differences in effect between cell lines (P < 0.05).  
Analysing the magnitude of response over cancer types demonstrated a significant 
difference in the accumulation of ubiquitin tagged proteins between melanoma or 
glioblastoma, compared to neuroblastoma (Two-way ANOVA, F42, 125 = 45.3 for 
melanoma or 94.9 for glioblastoma, P < 0.0001), with no significant difference 
observed between melanoma and glioblastoma (P > 0.05). Collectively these data 
therefore demonstrate that fenretinide and bortezomib increase ER stress, fenretinide via 
induction of ROS and bortezomib via the inhibition of the 26S proteasome.   
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Figure 4.7:  The effect of fenretinide and bortezomib on ER stress-induced cancer cell 
death.  (A) Cell lines were treated with single dose of either fenretinide (10 µM for 
melanoma and glioblastoma cell lines or 5 µM for neuroblastoma cell lines) or 
Bortezomib (200 nM for melanoma and glioblastoma cell lines or 20 nM for 
neuroblastoma cell lines) and incubated for 8 h prior to harvesting. Samples were than 
assessed by western blot for GRP78, peIF2α, Noxa, Gadd153 and β-Actin as loading 
control. Experimental design allows for the interpretation of UPR activation (peIF2α), 
induction of pro-survival chaperones (GRP78), pro-death stimuli (Gadd153) and ER to 
mitochondria cross talk (Noxa). (B) Densitometry data (data on next page) for the 
activation of the UPR in melanoma (i + ii), glioblastoma (iii + iv) or neuroblastoma (v 
+ vi) by either fenretinide (grey bars) or bortezomib (black bars) were carried out on 
blots of 3 independent experiments in comparison to control (white bars). Data were 
expressed relative to β-Actin and relative to control samples (no treatment) ± 95% CI. 
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To test the hypothesis that the induction of cell death in all neural-crest-derived cell 
lines was stimulated through ER stress activation of the UPR (Figure 4.7), cells were 
treated with fenretinide (10 µM for both melanoma and glioblastoma or 5 µM for 
neuroblastoma) or bortezomib (200 nM for both melanoma and glioblastoma or 20 nM 
for neuroblastoma) for 8 h prior to assessment of GRP78 and ATF4 expression by 
western blotting as a measure of UPR activation, GADD153 as a pro-death stimulus of 
the UPR and Noxa as a marker of ER-mitochondrial cross talk [184, 263].  
Data demonstrated that both fenretinide and bortezomib induced a significant increase 
in GRP78 expression in melanoma (Figure 4.7 B; One-way ANOVA with Dunnett’s 
post hoc correction for the effect of fenretinide in CHL-1 P < 0.0001 and WM266-4 P < 
0.01 or bortezomib; CHL-1 P < 0.0001 and WM266-4 P < 0.01) and glioblastoma cells 
(One-way ANOVA with Dunnett’s post hoc correction for the effect of fenretinide in 
MO59J P < 0.01 or bortezomib; MO59J P < 0.0001 and U251 P < 0.05). Fenretinide, 
however had no significant effect on GRP78 induction in U251 cells, and only 
fenretinide induced a significant effect in SH-SY5Y neuroblastoma cells (Figure 4.7 B; 
One-way ANOVA with Dunnett’s post hoc correction, P < 0.01). There was also a 
significant difference between the ability of fenretinide or bortezomib to induce GRP78 
expression in melanoma and glioblastoma (One-way ANOVA for treatment with either 
fenretinide or bortezomib for melanoma F11, 25 = 438 or 1058 and glioblastoma F11, 25 = 
68.2 or 131.3 with P < 0.0001 respectively), with no significant difference observed in 
neuroblastoma. When comparing either fenretinide or bortezomib -induced GRP78 
expression between cancer types, significant differences in effect between each agent 
were observed (Figure 4.7 B; One-way ANOVA for either fenretinide or bortezomib; F5, 
8 = 277.7 or F5, 8 = 1938, P < 0.0001, respectively).  
GRP78 induction is a consequence of UPR activation and indicative of a UPR response; 
however, phosphorylation of eIF2α was also assessed as an indicator of UPR activation 
(Figure 4.7 B); the phosphorylation of eIF2α at serine 51 is the critical step in global 
protein synthesis [264]. Phosphorylation results in promotion of a more specialized 
protein synthesis via an alternative internal ribosomal entry site (IRES), allowing for the 
up-regulation of key chaperones and folding machinery capable of aiding ER folding 
capacity during stress [264].  
As for GRP78, there was a significant induction of eIF2α phosphorylation after 
fenretinide or bortezomib treatment in melanoma (One-way ANOVA with Dunnett’s 
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post hoc correction, for fenretinide and bortezomib in CHL-1 P < 0.0001 or WM266-4 
P < 0.05 for either agent) and glioblastoma (One-way ANOVA with Dunnett’s post hoc 
correction for fenretinide and bortezomib in MO59J P < 0.05 or U251 P < 0.05 and P < 
0.01, respectively), with no significant induction seen in neuroblastoma cells. 
Comparing fenretinide and bortezomib-induced eIF2α phosphorylation across cell lines 
of the same cancer type, results demonstrated a significant difference between 
melanoma cell lines in response to either ER stress-inducing agent, but not between 
glioblastoma and neuroblastoma cell types (Comparing CHL-1 F2, 8 = 340.8,  and 
WM266-4 F2, 8 = 39, P < 0.0001). Induction of GRP78 also differed across cancer types 
(One-way ANOVA with Bonferroni post hoc correction to compare melanoma with 
either glioblastoma or neuroblastoma P < 0.0001 for both, respectively, and 
glioblastoma with neuroblastoma P < 0.01).  
The induction of GADD153 (Figure 4.7 B) was compared between differing cell lines 
to correlate UPR activation with cell death stimulation.  Results showed both fenretinide 
and bortezomib induced a significant induction of GADD153 in melanoma (One-way 
ANOVA with Dunnett’s post hoc correction, for CHL-1 and WM266-4 cells with either 
agent P < 0.0001), glioblastoma (MO59J cells treated with fenretinide P < 0.005 or 
MO59J and U251 treated with bortezomib, P < 0.01) and neuroblastoma (Fenretinide in 
which fenretinide P < 0.001 or bortezomib P < 0.001 for either cell lines), except for 
U251 cells in which there was no significant effect. With respect to the effect of either 
fenretinide or bortezomib on GADD153 induction between differing cell lines, there 
was no difference in effect amongst cell lines of the same cancer type, but significant 
differences were observed between melanoma and the other cancer types (One-way 
ANOVA with Bonferroni post hoc correction, P < 0.0001).   
Noxa, a member of the BCL-2 family, is a key mediator of ER stress [265] and is 
important for the downstream events of ER stress-induced cell death in response to 
fenretinide and bortezomib [184]. Results demonstrated Noxa was significantly induced 
by either fenretinide or bortezomib in melanoma, glioblastoma and neuroblastoma cell 
lines (One-way ANOVA with Dunnett’s post hoc correction, for CHL-1 and WM266-4, 
with either fenretinide or bortezomib P < 0.0001, NGP and SH-SY5Y with either 
fenretinide or bortezomib P < 0.001 or MO59J and U251 with bortezomib P < 0.01), 
except for each glioblastoma cell line treated with fenretinide in which there was no 
significant effect. As for all other proteins tested, bortezomib was a more potent inducer 
of Noxa compared to fenretinide. There was a significant difference in fenretinide and 
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bortezomib- induced Noxa expression levels between CHL-1 and WM266-4 melanoma 
cells (One-way ANOVA with Bonferroni post hoc correction, for fenretinide P < 0.005 
or bortezomib P < 0.0001). Except for a higher induction of Noxa in CHL-1 cells, all 
other cell lines demonstrated similar changes in expression, although no response was 
observed in glioblastoma cells treated with fenretinide (Figure 4.7 B). 
Collectively these results show that fenretinide and bortezomib induced ER stress in all 
three cancer types, but with some variability. Melanoma cells demonstrated the greatest 
sensitivity to either ER stress-inducing agent with respect to inhibition of cell viability 
but were less sensitive to ER stress-induced cell death (Figure 4.3) compared to 
glioblastoma cell lines, despite this, melanoma demonstrated the most UPR activity. 
These data suggest the possibility of more than one pathway conferring cellular 
resistance to ER stress. To further evaluate the ability of fenretinide or bortezomib to 
induce cell death and confirm that both agents induce apoptosis, the activation of pro-
caspase-3 was measured as an additional marker. 
All cells lines were treated for 24 h with increasing doses of fenretinide (1 – 20 µM for 
melanoma and glioblastoma or 1 – 10 µM for neuroblastoma) or bortezomib (10 – 300 
nM for melanoma and glioblastoma or 1 – 30 nM for neuroblastoma) within clinically-
achievable dose ranges prior to analysis of caspase 3 cleavage by western blotting 
(Figure 4.8). Results revealed a significant difference between fenretinide and 
bortezomib-induced caspase-3 cleavage (One-way ANOVA, F1, 23 = 15.4, P < 0.001) 
across all cell lines. Treatment with fenretinide resulted in  a dose dependent and a 
significant increase of caspase-3 cleavage in melanoma  (Figure 4.8 A, One-way 
ANOVA with Dunnett’s post hoc correction, for CHL-1 cells 10 µM & 20 µM P < 0.01 
and WM266-4 10 µM & 20 µM P < 0.05 or P < 0.01 respectively), glioblastoma (Figure 
4.8 C, for MO59J cells 10 µM & 20 µM P < 0.05 and P < 0.01 respectively and U251 
cells 20 µM P < 0.001) and neuroblastoma cells (Figure 4.8 E, for NGP and SH-SY5Y 
cells 5 µM & 10 µM P < 0.005 and NGP cells treated with 2.5 µM P < 0.05) and these 
data showed no significant difference in effect between cell lines of the same cancer 
type and hence demonstrated a similar drug-dependent sensitivity (in terms of signal 
intensity) to caspase-dependent cell death. 
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Figure 4.8 continued on next page. 
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Figure 4.8 continued. 
 
 
Figure 4.8 legend on next page. 
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Figure 4.8:  The effect of fenretinide and bortezomib on inducing Caspase 3 cleavage 
as a marker of apoptosis. (A) Neural-crest-derived cancer cells were treated with 
increasing doses for both fenretinide (0 – 50 µM for melanoma and glioblastoma or 0 – 
20 µM for neuroblastoma cell lines) or bortezomib (0 – 400 nM for melanoma and 
glioblastoma or 0 – 100 nM for neuroblastoma cell lines) and incubated for 24 h prior 
to harvesting. Cell lysates were analysed by western blotting for the formation of the 
two cleaved products of pro-caspase 3, indicative of active caspase 3 (17 kDa and 19 
kDa active Caspase-3 fragments). Figure 4.8 is a representative blot of 3 individually 
replicated experiments. (B) Densitometry data (data on next page) for the caspase 3 
cleavage in melanoma (i + ii), glioblastoma (iii + iv) or neuroblastoma (v + vi) cells by 
increasing doses of either fenretinide (grey bars) or bortezomib (black bars) were 
carried out in comparison to control (white bars). Data were expressed relative to β-
Actin and relative to control samples (no treatment) ± 95% CI. 
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Data for the effect of bortezomib indicated a significant increase in the expression of 
cleaved Caspase 3 in melanoma (Figure 4.8 B, One-way ANOVA with Dunnett’s post 
hoc correction, for CHL-1 cells 100 nM – 300 nM P < 0.0001 and WM266-4 100 nM – 
300 nM P < 0.05, P < 0.001 or P < 0.001 respectively), glioblastoma (Figure 4.8 D, for 
MO59J and U251 cells treated with 100 nM – 300 nM P < 0.0001) and neuroblastoma 
(Figure 4.8 F, for NGP and SH-SY5Y cells treated with 20 nM & 30 nM P < 0.0001 and 
NGP cells with 10 nM P < 0.001).  Furthermore, bortezomib-induced Caspase 3 
cleavage was significantly higher in CHL-1 compared to WM266-4 cells (Two-way 
ANOVA, F1, 23 = 12.1, P < 0.001), although there was no significant difference in 
response amongst glioblastoma or neuroblastoma cell lines (P > 0.05). However, 
differences in response were observed with respect to bortezomib dose; WM266-4 cells 
showed bortezomib induced a dose-dependent increase in cleaved caspase 3, but for 
CHL-1, MO59J and U251 cells concentrations of 100 nM or above induced caspase 3 
cleavage to the same extent. These data suggest therefore, that CHL-1 and glioblastoma 
cells were more sensitive to bortezomib-induced apoptosis compared to WM266-4 cells. 
Comparing the responses to 100 nM demonstrated significant differences in expression 
between cell lines (One-way ANOVA with Dunnett’s post hoc corrections, WM266-4, 
P < 0.0001). With respect to the sensitivity of neuroblastoma cells to fenretinide or 
bortezomib, these cell lines were significantly more sensitive to either agent compared 
to melanoma and glioblastoma cells. 
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Figure 4.9:  Immunofluorescent analysis of fenretinide and bortezomib induced caspase 
3 cleavage, as a marker of cancer cell apoptosis.    Neural-crest-derived cancer cells 
were treated with increasing doses for both fenretinide (10 µM for melanoma and 
glioblastoma cell lines or 5 µM for neuroblastoma cell lines) or Bortezomib (200 nM 
for melanoma and glioblastoma cell lines or 20 nM for neuroblastoma cell lines) and 
incubated for 24 h prior to fixation in 4% PFA.  Samples were then stained for active 
caspase-3, using DAPI as a marker of the cell nucleus. Immunofluorescence images are 
representative of 3 individual experiments. Scale bar on SH-SY5Y control = 20 µm. 
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Caspase 3 cleavage in response to fenretinide or bortezomib was also assessed by 
immunofluorescence (figure 4.9). While Western blot data demonstrated a significant 
induction of cleaved caspase-3 by either fenretinide or bortezomib (One-way ANOVA 
with Dunnett’s post hoc correction, for fenretinide P < 0.05 for all cell lines, and for 
bortezomib, CHL-1 and WM266-4 P < 0.001, MO59J and U251 cells P < 0.0001 or for 
NGP and SH-SY5Y neuroblastoma cells P < 0.001 or P < 0.0001 respectively), as well 
as a significant difference between fenretinide and bortezomib treatment (Figure 4.9; 
CHL-1 and WM266-4 cells F2, 17 = 1.3, F2, 17 = 2.7,  P < 0.01, NGP cells F2, 17 = 5.8,  P < 
0.001 or for MO59J, U251 and SH-SY5Y cells F2, 17 = 15.6, F2, 17 = 11.9, F2, 17 = 15.9, P 
< 0.0001 respectively), immunofluorescence studies demonstrated a non-homogenous 
response to either fenretinide or bortezomib within a population of each individual cell 
line. Instead of an increase in the basal expression a significant increase in cleaved 
caspase 3 expression was only evident in a subset of cells within each population. For 
melanoma cells, CHL-1 18% and 21%, WM266-4 16% and 19% or glioblastoma cells 
MO59J 22% and 26%, U251 18% and 21 % or neuroblastoma cell lines NGP 26% and 
32%, SH-SH5Y 20% and 29% were positive (demonstrating higher staining intensity 
than control cells) for cleaved caspase 3 after treatment with either fenretinide (10 µM 
for melanoma and glioblastoma or 5 µM for neuroblastoma) or bortezomib (200 nM for 
melanoma and glioblastoma or 20 nM for neuroblastoma), respectively. 
These data demonstrate that fenretinide and bortezomib induce ER stress-induced cell 
death in all cell lines representing three neuronal or neuro-ectodermally-derived cancers. 
To gain a better understanding for the role that GRP78 plays in cellular sensitivity to ER 
stress and gain a better understanding of how changes in GRP78 expression can affect 
the outcome of ER stress, subsequent experiments were designed to reduce GRP78 
expression and therefore alter the dynamic equilibrium of the UPR. Cellular sensitivity 
to ER stress-induced by fenretinide and bortezomib was then evaluated by propidium 
iodide stained flow cytometry for the induction of cell death or the inhibition of 
viability by MTS assay. 
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4.2.2: The role of GRP78 in UPR  
To test the hypothesis that the UPR in relation to ER stress is regulated by a dynamic 
equilibrium between GRP78 and the UPR activators PERK, IRE1 and ATF6, the 
expression of GRP78 was reduced by RNA interference. SiRNA mediated knock-down 
of GRP78 was optimised in comparison to a scrambled control (Figure 4.10) and 
required double transfection in order to achieve a significant reduction in GRP78 
expression. For all cell lines, GRP78 expression was significantly reduced by more than 
50% (One-way ANOVA with Dunnett’s post hoc correction P < 0.0001 for all cell 
lines). The mean reduction of GRP78 levels, compared to control SiRNA, was 56.3% 
for CHL-1, or 58.9% in WM266-4 melanoma, and 62.8% in MO59J and 82.3% in U251 
glioblastoma cells, and 63.8% in NGP and 60.3% in SH-SY5Y neuroblastoma cells. 
Following RNAi mediated knock-down of GRP78, cells were also treated with 
fenretinide or bortezomib to determine if GRP78 knock-down resulted in ER stress-
induced GRP78 which demonstrated GRP78 expression was in fact increased by both 
agents in all three neural-crest-derived cancer types (Figure 4.10 A – C).  
The effect of GRP78 specific knock-down resulted in a significant reduction in the 
ability of either fenretinide or bortezomib to induce the expression of GRP78 in either 
melanoma (Figure 4.10 A, analysis by One-way ANOVA with Dunnett’s post hoc 
correction for CHL-1 cells treated with fenretinide P < 0.05 or both CHL-1 and 
WM266-4 cells with bortezomib P < 0.01), glioblastoma (Figure 4.10 B, for MO59J 
cells treated with fenretinide P < 0.001 or bortezomib P < 0.0001 and U251 treated with 
either fenretinide or bortezomib P < 0.01 respectively) or neuroblastoma cells (Figure 
4.10 C, for NGP with either fenretinide or bortezomib P < 0.01 or SH-SY5Y with 
fenretinide P < 0.01 or bortezomib P < 0.05) in comparison to cells transfected with the 
scrambled control, except for WM266-4 melanoma cells that were treated with 
fenretinide.  
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Figure 4.10:  The effect of GRP78 siRNA on neural-crest-derived cancer cell line 
expression of GRP78. The effect of GRP78 specific SiRNA, in comparison to control 
scrambled, on GRP78 expression in a panel of neural-crest-derived cancer cell lines.  
CHL-1 and WM266-4 metastatic melanoma (A), MO59J and U251 glioblastoma (B) or 
NGP and SH-SY5Y neuroblastoma cell lines (C) were transfected with 40 nM GRP78-
specific siRNA in comparison to a scrambled control and incubated for 2 x 24 h prior to 
treatment with either fenretinide (grey bars, 10 µM for melanoma and glioblastoma cell 
lines or 5 µM for neuroblastoma cell lines) or Bortezomib (black bars, 200 nM for 
melanoma and glioblastoma cell lines or 20 nM for neuroblastoma cell lines) for a 
further 24 h. Samples were then harvested and analysed for GRP78 protein expression 
in comparison to β-Actin as a loading control. Densitometry is expressed as a 
percentage of control, relative to β-Actin as a mean of 3 replicate experiments ± 95 % 
CI. Data for the effect of siRNA on GRP78 expression in melanoma cells were 
previously published [266]. 
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The effect of GRP78 specific siRNA between cell lines, of the same cancer type, 
indicated a significant difference between the responses of either glioblastoma cell line 
(F1, 17 = 65.2, P < 0.01). Knock-down of GRP78 also resulted in a significant difference 
in sensitivity to ER stress-induced UPR induction of GRP78 observed between differing 
cancer types (Comparing melanoma to glioblastoma F2, 53 = 11.1, P < 0.05 or 
neuroblastoma F2, 53 = 22.8, P < 0.01 and glioblastoma to neuroblastoma F2, 53 = 36.3, P 
< 0.01). 
These data demonstrate a significant reduction in GRP78 expression as well as a 
reduction in UPR-mediated up-regulation of GRP78. This potentially creates an UPR 
system where the dynamic equilibrium has been shifted towards an active or free UPR 
activator state.  
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Figure 4.11:  The effect of GRP78 expression of neural-crest-derived cancer cell 
sensitivity to fenretinide and bortezomib induced cell death.  CHL-1 and WM266-4 
metastatic melanoma (A & B), MO59J and U251 glioblastoma (C & D) or NGP and 
SH-SY5Y neuroblastoma cell lines (E & F) were transfected with 40 nM GRP78 specific 
siRNA in comparison to a scrambled control and incubated for 2 x 24 h prior to 
treatment of the samples with either fenretinide (grey bars, 10 µM for melanoma and 
glioblastoma cell lines or 5 µM for neuroblastoma cell lines) or bortezomib (black bars, 
200 nM for melanoma and glioblastoma cell lines or 20 nM for neuroblastoma cell 
lines) for a further 24 h. Samples were then assessed for changes in sensitivity to cell 
death by propidium iodide stained flow cytometry for the increase in the SubG1 
population. Data are expressed as relative to control (no treatment) scrambles siRNA-
treated cells and bars are the mean of 3 replicate experiments ± 95 % CI. Data for the 
effect of reduced GRP78 expression on ER stress-induced melanoma cell death were 
previously published [266]. 
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To determine if the shift in the dynamic equilibrium sensitizes neural-crest-derived 
cancer cells to ER stress-induced cell death, cells were transfected with scrambled or 
GRP78 siRNA, and subsequently treated with control vehicle, fenretinide or bortezomib 
for 24 h prior to the assessment of cell death and cell viability. Data demonstrated 
GRP78 knock-down resulted in a cancer type specific sensitivity to either fenretinide or 
bortezomib (Figure 4.11, comparing the effect of GRP78 SiRNA on fenretinide and 
bortezomib induced cell death over cancer types, F3, 36 = 57.1, P < 0.001). In melanoma 
cell lines (Figure 4.11 A & B) reduction in GRP78 expression resulted in significantly 
enhanced cell death in response to either fenretinide or bortezomib (One-way ANOVA 
with Dunnett’s post hoc correction, to compare the effect of fenretinide or bortezomib 
across siRNA treatments P < 0.0001 respectively). Knock-down of GRP78 also 
significantly increased cell death in CHL-1 in absence of drug treatment, although this 
effect was not observed in WM266-4 cells. 
The effect of GRP78 knock-down on fenretinide and bortezomib-induced cell death in 
glioblastoma (Figure 4.11 C & D) resulted in a significant increase in cell death, 
induced by either ER stress-inducing agent (Comparing fenretinide or bortezomib 
across siRNA treatments by One Way ANOVA with Dunnett’s post hoc correction 
within MO59J P < 0.0001 or U251 P < 0.001 respectively). Furthermore, transfection of 
GRP78 siRNA in both melanoma and glioblastoma cells resulted in an increase in 
fenretinide and bortezomib- induced cell death. Significant differences between the 
responses of melanoma and glioblastoma were also observed, with melanoma cells 
being more susceptible to both ER stress-inducing agents compared to glioblastoma 
cells (One-way ANOVA with Dunnett’s post hoc correction, P < 0.001 for either 
fenretinide or bortezomib). In neuroblastoma cells however, (Figure 4.11 E & F) in 
general there was no significant increase in ER stress-induced cell death in either cell 
line following GRP78 knock-down in comparison to basal levels of GRP78 expression 
(P > 0.05), although in SH-SY5Y cells treated with fenretinide there was a small but 
significant decrease in cell death (One-way ANOVA with Dunnett’s post hoc correction, 
P < 0.05) 
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Figure 4.12:  The effect of GRP78 expression of neural-crest-derived cancer cell 
sensitivity to fenretinide and bortezomib induced inhibition of cell viability. CHL-1 and 
WM266-4 metastatic melanoma (A & B), MO59J and U251 glioblastoma (C & D) or 
NGP and SH-SY5Y neuroblastoma cell lines (E & F) were transfected with 40 nM 
GRP78 specific SiRNA in comparison to a scrambled control and incubated for 2 x 24 h 
prior to treating the samples with either fenretinide (grey bars, 10 µM for melanoma 
and glioblastoma cell lines or 5 µM for neuroblastoma cell lines) or bortezomib (black 
bars, 200 nM for melanoma and glioblastoma cell lines or 20 nM for neuroblastoma 
cell lines) for a further 24 h. Samples were then assessed for changes in cell viability 
using the MTS colorimetric based metabolic assay. Data are expressed as the mean of 3 
replicate experiments ± 95 % CI. Data for the effect of reduced GRP78 expression on 
ER stress-induced inhibition of melanoma cell viability were previously published 
[266]. 
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Similar results were obtained for the effect of GRP78 knock-down on ER stress-induced 
inhibition of cell viability (Figure 4.12). In melanoma and glioblastoma cells (Figure 
4.12 A & B for melanoma or C & D for glioblastoma), GRP78 knock-down resulted in 
a significant increase in either fenretinide or bortezomib-induced inhibition of cell 
viability (One-way ANOVA with Dunnett’s post hoc correction for CHL-1 melanoma 
cells and either glioblastoma cell line treated with fenretinide P < 0.001 or WM266-4 
with fenretinide and bortezomib or CHL-1, MO59J and U251 treated with bortezomib P 
< 0.0001, respectively). Although there was an apparent reduction in cell viability in 
untreated cells in response to a decrease in GRP78 expression, this was not significant 
(P > 0.05). CHL-1 and WM266-4 metastatic melanoma cells also demonstrated 
significant differences in response (F1, 47 = 10.3, P < 0.01), with WM266-4 cells being 
less affected by GRP78 knock-down. Data for the effect of GRP78 knock-down on ER 
stress-induced inhibition of neuroblastoma cell viability also demonstrated no 
significant differences between cells transfected with control or GRP78 specific siRNA 
(P > 0.05).  
These results therefore demonstrate the importance of the UPR in cancer cell survival 
but the differing effects on reduction of cell viability and induction of cell death 
between cancer types (One-way ANOVA comparing melanoma and glioblastoma to 
neuroblastoma F3, 96 = 68.1 or F3,96 = 138.5 with P < 0.001 for both). Although GRP78 
knock-down in melanoma cells resulted in a significantly higher level of cell death 
compared to the effects on glioblastoma-induced cell death (P > 0.05), cell viability data 
did not demonstrate any significant differences between cancer types. (Figure 4.12 A & 
B vs. C & D, F3, 36 = 57.1, P < 0.001). 
This study shows that sensitivity to ER stress can be enhanced by a reduction in GRP78 
expression and is cancer type dependent, with cancer expressing high levels of GRP78 
being more susceptible to ER stress in the absence of GRP78. This demonstrates a 
cancer type-specific reliance on GRP78. 
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4.2.3: Results Summary. 
 Fenretinide and bortezomib induced cell death and inhibit cell viability of neural-
crest-derived cancer cells. 
 
 There were differences in cell line sensitivity to ER stress-induced death or 
inhibition of cell viability between melanoma, glioblastoma and neuroblastoma. 
 
 Fenretinide and Bortezomib significantly induced the UPR pro-death transcription 
factor Gadd153 in all cancer types, however a significant difference in the level of 
induction was observed (Melanoma > Glioblastoma > Neuroblastoma). 
 
 Both fenretinide and bortezomib induced significant induction of Noxa in all cell 
types, a pro-apoptotic member of the BCL-2 family.  
 
 Knockdown in GRP78 expression resulted in a more than 50% reduction in GRP78 
expression within all neural-crest-derived cancer types. 
 
 GRP78 siRNA decreased fenretinide and bortezomib-induced GRP78  in all cancer 
types, demonstrating the presence of on-going SiRNA mediated knockdown after 
transfection. 
 
 Reduction in GRP78 expression increased the sensitivity of melanoma and 
glioblastoma cell lines to both fenretinide and bortezomib-induced death or 
inhibition of cell viability. 
 
 GRP78 knock down had no significant effect on ER stress-induced cell death or 
inhibition of neuroblastoma cell viability. 
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4.3: Discussion. 
The results from this study demonstrate that ER stress-inducing agents fenretinide or 
bortezomib induced cell death and inhibited cell viability of melanoma, glioblastoma 
and neuroblastoma cells. Fenretinide or bortezomib showed a significant induction of 
pro-death stimuli including Gadd153, as well as the BCL-2 family member Noxa in all 
cancer types, as a consequence of both ROS induction and ubiquitin-tagged protein 
accumulation, respectively [112, 184]. SiRNA mediated knock-down of GRP78 
resulted in over 50% reduction in cellular expression in all cell lines with data 
demonstrating a cancer type specific effect on sensitivity to ER stress-induced cell death. 
Melanoma and glioblastoma cancer types demonstrated a significant increase in 
sensitivity to ER stress-induced cell death; however neuroblastoma showed no 
significant difference to control. 
Dose response studies of fenretinide and bortezomib-induced cell death confirmed that 
both agents are potent inducers of cell death of neural-crest-derived cancer models [82, 
83, 112, 201, 203, 240, 267]. Assessing fenretinide and bortezomib for their mechanism 
to induce ER stress, by monitoring ROS and ubiquitin tagged protein accumulation, 
respectively, showed that fenretinide induced a similar response in all cancer types. 
Interestingly, neuroblastoma showed the lowest basal level of ROS of all three cancer 
types tested, coupled with similar levels of ROS induction with half the concentration of 
fenretinide (5 µM). These findings highlight the sensitivity of neuroblastoma to ROS 
accumulation, in comparison to other neuro-ecto-dermal derived cancers. Bortezomib 
had a cell line dependant effect, with neuroblastoma cells demonstrating significantly 
lower levels of protein accumulation.  
Interestingly, the sensitivity of neuroblastoma cells to bortezomib-induced cell death 
was comparable to the sensitivity of melanoma cells, even though they do not receive 
the same magnitude of protein build-up (ER stress). The differences in protein 
accumulation may therefore be a direct consequence of the lower dose of bortezomib 
used to treat neuroblastoma, cells, further emphasising the sensitivity of these cells to 
ER stress-induced death [268, 269]. 
In all cell lines fenretinide and bortezomib treatment induced Gadd153, the down-
stream inducible transcription factor of the UPR, that triggers cell death via ER stress 
[204]. A significant induction of the pro-apoptotic BCL-2 family member Noxa was 
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also observed, highlighting the cross talk required between the ER and mitochondria to 
successfully induce cell death [184]. Variation between cancer models was observed for 
the induction of GRP78 and peIF2α (markers of UPR induction) in response to 
fenretinide and bortezomib with glioblastoma and neuroblastoma showing minimal 
activation.  
Previous data, for the activation of the UPR over time (Chapter 3, Figure 3.8) 
highlighted ATF4 was detectable at 4 h but lost by 8 h. Therefore, the lack of detectable 
induction of peIF2α and GRP78 in glioblastoma and neuroblastoma cells may have 
been a time-dependent consequence. Mapping the induction of ATF4 over time 
(Chapter 3, figure 3.8) also indicated that for neuroblastoma, the response was 
significantly smaller than that of melanoma or glioblastoma, which is confirmed by the 
minimal induction of eIF2α phosphorylation detected in these experiments. Differences 
within the extent of GRP78 induction across cancer types, conforms to the data 
generated for the induction of ATF4 (Figure 3.6), were a greater response was observed 
in melanoma cells, than in glioblastoma or neuroblastoma, suggesting the presence of a 
more active or greater UPR capacity within these cancers. 
Comparing the induction levels of pro-apoptotic stimuli Gadd153 and Noxa (Figure 4.7 
A & B) to the levels of cell death achieved within differing cell lines (propidium iodide 
stained flow cytometry data), indicated that for CHL-1 cells ER stress-induced Noxa 
and Gadd153 were significantly higher compared to induction in WM266-4 cells, which 
also directly correlated with the levels of achievable cell death or inhibition of cell 
viability. Melanoma cells have been shown to have significant up-regulation of anti-
apoptotic BCL-2 family members, such as BCL-XL, resulting in an increase resistance 
to cell death [270]. However, this explanation is down-stream of these experimental 
observations. Moreover, WM266-4 cells harbour a BRAF
V600E
 mutation [271], which is 
well documented to increase cellular resistance to death and may therefore influence the 
outcome of ER stress due to the activation of other pro-survival pathways. 
The effects of either fenretinide or bortezomib on neuroblastoma or glioblastoma-
induced cell death or inhibition of cell viability also differed to the effects on induction 
of either Gadd153 or Noxa, suggesting the involvement of another mechanism that may 
also contribute to glioblastoma and neuroblastoma cell line sensitivity to bortezomib. 
For example, NGP and SH-SY5Y cells differ in MYCN status, with NGP cells 
demonstrating amplification of MYCN expression compared to SH-SY5Y [272]. 
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MYCN amplification status has been demonstrated to alter cell line sensitivity to death 
and therefore could hinder the outcome of ER stress-inducing agents [272]. 
The significant difference between fenretinide and bortezomib induced caspase 3 
cleavage, with bortezomib showing greater induction, highlights bortezomib as a 
stronger inducer of ER stress stimulated cell death and a better candidate agent for 
future trials. Immunofluorescence studies showed high induction of cleaved caspase 3, 
in a sub-population of cells, rather than within all cells. This observation may relate to 
the probability of inducing cell death within any given population. Factors such as cell 
cycle, BCL-2 family expression and even cell-cell contact can alter a cells susceptibility 
to death, by priming a cell to a given stress, and therefore making that cell less resistant 
to death induced by fenretinide or bortezomib. Due to cells existing at different phases 
of the cell cycle, coupled with protein half-life suggests that within a given population, 
cells at any one time point can be more susceptible or resistant to death stimuli. 
After GRP78 knock-down, metastatic melanoma and glioblastoma cells became more 
susceptible to ER stress-induced cell death, suggesting that GRP78 plays an important 
inhibitory role in the UPR and shift in the dynamic equilibrium of the UPR towards a 
free and active cascade. This shift towards an active response pre-primes the UPR; and 
therefore less stress is required to push a cell over the threshold of activation, and 
towards death. These data support the findings of Suzuki et al, where reduction of 
GRP78 expression increased basal UPR signalling, as measured by ATF4 induction and 
XBP-1 splicing. This increase in signalling prior to the induction of stress, primes 
melanoma and glioblastoma cells, shifting them closer to the threshold of death, before 
treatment with either fenretinide or bortezomib. Initial theories focused on the reduction 
in chaperone activity as the primary factor that enhances cell line susceptibility to stress, 
however, subsequent research has demonstrated that GRP78 reduction results in the up 
regulation of other chaperones to counter act its loss [251].  
In neuroblastoma there was no significant increase in sensitivity to ER stress, despite 
more than a 60% reduction in GRP78 expression. Following on from the data (in Figure 
3.3) that demonstrated that the expression of total UPR activators is greater than that of 
GRP78 within neuroblastoma, this may describe the evolution of a cell type that 
requires high UPR activity. Therefore, a further shift towards free UPR activators, 
induced by knocking-down GRP78, may not induce the same consequence as 
demonstrated in melanoma and glioblastoma. These findings therefore suggest a more 
complex network within the UPR where downstream induction of pro- and anti-
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apoptotic stimuli is different not only depending on the type of stress [273], but also the 
cell type the stress occurs in.  
When comparing the increase in cell line sensitivity, to samples with control basal 
expression of GRP78, data demonstrated higher basal expression (Figure 3.2) of GRP78 
correlates with the greater influence it has on the outcome of the UPR (i.e. melanoma 
cell lines showed the highest cellular concentration of GRP78 and became the most 
sensitive to fenretinide or bortezomib induced death when GRP78 is reduced). 
Melanoma cells demonstrated a greater response to GRP78 knock-down compared to 
either glioblastoma or neuroblastoma, while glioblastoma showed a significant 
difference in response compared to neuroblastoma. GRP78 knock-down also resulted in 
a decrease in GRP78 induction in response to either fenretinide or bortezomib, 
suggesting that there was an on-going effect of the siRNA, within all cancer types, up to 
48 h post transfection.  
Studies by Chen et al., have correlated an increase in GRP78 expression with a 
favourable prognosis within neuroblastoma [116]. Findings from the present study 
indicate that reduction in GRP78 expression does not sensitize neuroblastoma cells to 
ER stress-induced cell death, as for melanoma or glioblastoma. Therefore, to confirm 
the outcome of these data, experiments were designed to test the hypothesis that 
increasing the expression of GRP78 decreases melanoma and glioblastoma cell line 
sensitivity to death, but increases the sensitivity of neuroblastoma cell lines by altering 
the activity of the UPR as a result of changes in the dynamic equilibrium. These 
experiments form the basis of chapter 5. 
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4.4: Conclusion 
This study showed that there was a difference in cancer type sensitivity to ER stress, 
with neuroblastoma cells being significantly more sensitive to ER stress-induced cell 
death than melanoma or glioblastoma; even though they demonstrate lower levels of ER 
stress (ROS or ubiquitin build-up). There was a cancer type specific outcome for the 
effect of reduced GRP78 on ER stress-induced cell death, with melanoma cells showing 
enhanced sensitivity. 
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Chapter 5: 
 
Over-expression of GRP78 affects the 
response of cancer cells to ER stress in 
vitro. 
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5.1: Introduction. 
Solid tumours could be classified as organs, consisting of both cancerous and non-
cancerous cells. The non-cancerous cells include: myofibroblasts, endothelial cells, 
pericytes, cancer-associated fibroblasts, mesenchyme stem cells and immune 
inflammatory cells [274-277]. These non-cancerous cells are important within the 
tumour and provide support for cancer cell growth, angiogenesis and metastasis [276, 
278-280]. Tumour growth often occurs faster than the stimulation of blood vessel 
production, resulting in a hypoxic, glucose-deprived and acidic (lactic acid) 
environment. The interaction of cancer cells with and the severity of the tumour 
microenvironment plays a critical role in modulation of tumour growth, metabolism and 
metastasis [276, 280, 281]. 
These extracellular noxae of the tumour microenvironment are intrinsic stressors, 
affecting the biosynthesis of larger macro-molecules, glycoproteins and lipids by cancer 
cells. Errors in protein synthesis induce the UPR. Mounting evidence for solid tumours 
has documented the importance of UPR activation for cancer-cell growth and disease 
progression. Studies in breast, liver, colon and brain cancers have described UPR-
induced GRP78 and ATF6 expression, as well as XBP-1 splicing in cancer cells. 
However, no induction of the UPR was observed in the non-cancerous peritumoral areas 
[282]. 
Lee et al., demonstrated a critical role of GRP78 in tumour proliferation, survival and 
tumour angiogenesis. Mice heterozygous for GRP78 (+/-) were crossed with 
MMTVPyVT mice (expressing the polyoma middle T oncogene (PyT) and therefore 
genetically susceptible to mammary tumours) and offspring monitored for changes in 
tumour progression, with results demonstrating no significant differences in animal 
growth and development in comparison to wild type (wt) siblings [283]. Yet, with 
regard to tumour progression, mice heterozygous for GRP78 demonstrated an increased 
latency period before cancer was detectable. These mice also demonstrated a decreased 
proliferative capacity, coupled with an increased propensity to apoptosis. Further 
analysis identified a significant increase in Gadd153 and downstream caspase activity, 
suggesting a decrease in GRP78 expression may reduce the inhibitory role it plays upon 
the UPR and result in a shift within the dynamic equilibrium to an active state. 
Therefore, the priming of the UPR within these heterozygous tumour cells results in an 
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increase in the achievable levels of death induced by the tumour microenvironment 
[283]. Assessing tumour samples for differences in angiogenesis using the endothelial 
cell marker CD31 highlighted a reduction in heterozygous mice, compared to wt control 
[283]. 
Denko et al., and Koong et al., also demonstrated the importance of UPR signalling in 
tumour growth. Transformed mouse fibroblasts deficient in XBP-1 or fibroblasts with 
reduced XBP-1 expression, showed decreased ability to buffer hypoxic conditions as 
well as reduced growth and capacity to stimulate angiogenesis in comparison to control 
cells. These finding were consistent with data for human fibrosarcoma, where xenograft 
tumours with reduced XBP-1 expression also showed growth inhibition [284, 285]. 
Conversely, over-expression of XBP-1 in human fibrosarcoma cells expressing 
dominant-negative IRE1 resulted in the rescue of angiogenesis [284, 285]. PERK 
signalling has also been documented to support tumour cell growth. Inactivation of 
PERK or introduction of a dominant-negative form of PERK resulted in the formation 
of smaller tumours, with decreased growth capacity and angiogenic activity, when 
engrafted into immune-compromised mice models [286, 287]. 
Collectively, these studies highlight the importance of the UPR signalling cascade for 
tumour cell progression. However, increases in GRP78 expression have been 
documented in numerous cancer types. Enhanced GRP78 expression may be detectable 
as a downstream consequence of an increase in UPR signalling, rather than a change in 
the basal expression of GRP78 within the cancer cell. Lee et al., demonstrated that 
although malignant glioma samples (TuBEC) demonstrated an increase in GRP78 
expression, activation of other downstream UPR targets, including ATF4 and XBP-1s 
were not evident [288]. Kaufman et al., also demonstrated in CHO cells stably over-
expressing GRP78, a decrease in GRP78 and GRP94 mRNA translation when treated 
with tunicamycin [289]. These findings suggest that GRP78 may play a key role in 
stress-induced chaperone induction or that an increase in GRP78 expression buffers 
stress and therefore reduces UPR-induced chaperone induction [289]. 
The role of GRP78 in cancer is still not fully understood; however, there is growing 
evidence that GRP78 functions in a more diverse manner to that of normal cells. In 
normal cells, GRP78 is localised to the ER, due to the presence of ER localisation and 
KDEL sequences. Conversely, in cancer cells GRP78 is detectable in the cytosol, 
mitochondria, nucleus and at the cell surface [290, 291]. Global profiling of cell surface 
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proteome of tumour cells demonstrated a relative abundance of heat shock and glucose 
regulated proteins, including GRP78 [292]. Cell surface GRP78 has been implicated in 
tumour-specific targeting by circulating ligands and mediates the anti-angiogenic and 
pro-apoptotic activity of Kringle 5 in hypoxic and cytotoxic stressed tumours [293, 294].  
Studies by Lee et al., and Brodie et al., demonstrated that in GRP78 over-expression 
models, stress-induced apoptosis is significantly decreased with a marked increase in 
cell growth was also observed. Lee et al., also demonstrated higher expression of 
GRP78 in the vascular of human derived glioma, both  in situ and in vitro cultures of 
TuBEC cells, than in surrounding non-malignant brain tissues (BEC) [288], correlating 
GRP78 expression directly to cellular resistance to apoptosis induced via ER stress.  
Lee et al., and Brodie et al., also highlighted an interaction between GRP78 and caspase 
7. Co-immunoprecipitation studies demonstrated GRP78 constitutively associates with 
caspase 7 and over-expression of GRP78 suppressed the activation of caspase 7 in 
response to etoposide and cisplatin treatment both in vitro and in vivo [113, 295]. The 
association of GRP78 with caspase 7 could be reversed by the addition of dATP, 
suggesting that the ATP binding domain of GRP78 was important for caspase 7 
interaction. Further to this, using a mutant version of GRP78, which possessed a 
mutation within the ATP binding domain, studies demonstrated significant loss of 
caspase 7 binding capacity, as well as a reduction in resistance to etoposide treatment 
[113, 295].   
In hepatocellular carcinoma, a positive correlation of GRP78 with both portal and intra-
hepatic invasion has been demonstrated [296]. Over-expression of GRP78 in 
SMMC7721 cells promoted invasion both in vitro and in vivo. Mechanistic studies 
showed that GRP78 over-expression enhanced focal adhesion kinase (FAK). FAK plays 
an important role in tumour invasion and metastasis, by negatively regulating rock 
kinase activity, which although required at a basal expression, over activation of rock 
kinase prevents invasion [296]. 
Although the majority of cancer types demonstrate a correlation between GRP78 
expression and poor patient prognosis, due to changes in cellular resistance and capacity 
to buffer ER stress, neuroblastoma demonstrates the converse [116]. Therefore, using 
neural-crest-derived cancer types, the aim of the present study was to test the hypothesis 
that over-expression of GRP78 increases resistance in melanoma and glioblastoma and 
decreases the resistance of neuroblastoma, to ER stress-induced cell death in response to 
either fenretinide or bortezomib.  
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5.2: Results. 
5.2.1: Over-expression of GRP78 
To test the effect of GRP78 over-expression on neural-crest-derived cancer types, one 
cell line of melanoma, glioblastoma and neuroblastoma was stably transfected with 4 µg 
pcDNA3.1 (+) GRP78  or vector control  (pcDNA3.0) by selection with 1.5 mg/ml 
G418 for 10 passages as mixed populations of stably transfected cells. GRP78 
expression was verified by western blotting, relative to β-Actin as loading control 
(Figure 5.1). Although it was preferable to do this work with all six cell lines, despite 
much effort, stable transfection of SH-SY5Y cells could not be achieved, therefore only 
one cell line of each cancer type was used to ensure a balanced approach. 
Results confirmed a significant increase in GRP78 expression in WM266-4 melanoma, 
MO59J glioblastoma and NGP neuroblastoma cells (Figure 5.1 B, One-way ANOVA, 
F2, 54 = 65.054, P < 0.0001) after transfection with GRP78 plasmid compared to either 
wild-type cells or cells stably transfected with control plasmid. These data also 
demonstrate no significant effect of the antibiotic selection (1500 µg/ml G418) on 
GRP78 expression (P > 0.05). The increase in GRP78 expression was 1.7-fold for 
melanoma (One-way ANOVA with Bonferroni post hoc correction, P < 0.0001), 1.96-
fold for glioblastoma of (P < 0.0001) and 1.5-fold for neuroblastoma of (P < 0.01). 
Comparing cells lines individually demonstrated a significant difference between 
glioblastoma and neuroblastoma (One-way ANOVA with Bonferroni post hoc 
correction, P < 0.001). 
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Figure 5.1: Over-expression of GRP78 in neural-crest-derived cancer cells. WM266-4 
metastatic melanoma, MO59J glioblastoma and NGP neuroblastoma cells were stably 
transfected with pcDNA3.0 or pcDNA3.1 (+) GRP78 and western blot analysis carried 
out to confirm GRP78 expression (A). Densitometry was performed on a minimum of 4 
individual experiments for the expression of GRP78 in comparison to β-Actin loading 
control (B). Experimental data are expressed as mean values ± 95% CI. 
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To confirm the western blot data for the over-expression of GRP78 protein, Real time 
PCR analysis also revealed a significant increase in GRP78 mRNA in all cell types, 
again using β-Actin mRNA as loading control (Figure 5.2). Data demonstrated 
significant difference between plasmid-transfected cell types with pcDNA3.1 (+) 
GRP78 significantly increasing GRP78 mRNA (One-way ANOVA, F2, 54 = 187.6, P < 
0.0001) by 1.8-fold for melanoma cells (One-way ANOVA with Bonferroni post hoc 
corrections, P < 0.0001), 1.75-fold for glioblastoma (P < 0.0001) and 1.45-fold for 
neuroblastoma (P < 0.0001),  compared to pcDNA3.0 control vector and wild-type cell 
lines.  
With respect to GRP78 mRNA over-expression between cancer types, there was no 
difference between melanoma and glioblastoma (P > 0.05) but a significant difference 
between either melanoma or glioblastoma compared to neuroblastoma (Figure 5.2, One-
way ANOVA with Bonferroni post hoc corrections, comparing neuroblastoma to 
melanoma P < 0.001 and glioblastoma P < 0.01). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
150 
 
 
 
Figure 5.2: The effect of pcDNA3.1 (+) GRP78 on GRP78 mRNA expression. WM266-4 
melanoma, MO59J glioblastoma and NGP neuroblastoma neural-crest-derived cancer 
cells were stably transfected with control pcDNA3.0 or pcDNA3.1 (+) GRP78 (as 
described in methods) and the expression of GRP78 and β-Actin mRNA were analysed 
by real time PCR in comparison to wild type cell lines. Data are the mean of 3 
individual experiments and expressed as relative to loading control ± 95% CI. 
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Immunofluorescence staining was also used to determine the effect of transfection on 
GRP78 expression and cellular localisation. Confocal microscopy images (Figure 5.3 A) 
showed that although GRP78 intensity was significantly different between cell types 
(One-way ANOVA F8, 89 = 45.4, P < 0.0001), the effects of transfection resulted in 
similar GRP78 distribution. Data revealed that GRP78 cellular expression was 
cytoplasmic in localisation with an increased staining surrounding the peri-nuclear zone. 
A comparison of staining intensities for cells stably over-expressing GRP78 or control 
plasmid demonstrated a significant increase for melanoma (Figure 5.3 B, One-way 
ANOVA with Bonferoni post hoc correction, P < 0.0001), glioblastoma (P < 0.0001) 
and neuroblastoma (P < 0.01); and there was no significant difference between the wild-
type cell lines and control vector-transfected cells (P > 0.05). Furthermore, comparing 
neural-crest-derived cancer types, over-expressing GRP78, data also demonstrated 
significant differences between the relative mRNA expression of melanoma or 
glioblastoma and neuroblastoma (Figure 5.2, One-way ANOVA with Bonferroni post 
hoc corrections, for the comparison of neuroblastoma to melanoma or glioblastoma P < 
0.0001).  
Light microscopy (Figure 5.4) analysis also demonstrated that over-expression of 
GRP78 resulted in a morphological change in NGP neuroblastoma cells (Figure 5.4). 
Photomicrographs also revealed a swelling of the cells with a decrease in dendrites, 
representing a significant increase in NGP cell size (Figure 5.4 B, One-way ANOVA, 
F2, 29 = 62.4, P < 0.0001). Melanoma and glioblastoma cells however, showed no 
apparent change in cell morphology. 
These data indicate a significant increase in GRP78 mRNA and protein expression, that 
has not altered cellular distribution, however has induced a morphological change in 
neuroblastoma. 
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Figure 5.3: The effect of pcDNA3.1 (+) GRP78 on GRP78 expression and localisation. 
(A) WM266-4 melanoma, MO59J glioblastoma and NGP neuroblastoma neural-crest-
derived cancer cells were stably transfected with control pcDNA3.0 or pcDNA3.1 (+) 
GRP78 and the expression of GRP78 assessed by immunofluorescence. Cells were fixed 
in 100% ice cold methanol for 30 min, prior to staining for GRP78, using DAPI as 
control dye for the nucleus. Data are representative images of 3 individual experiments. 
Scale bar on NGP wt = 20 µm. (B) Cellular fluorescent intensities for the effect of 
GRP78 over-expression (black) in comparison to vector (grey) on GRP78 staining are 
the average of 30 cells per condition and data expressed as relative to control wild type 
(white) ± 95% CI.  
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Figure 5.4: The effect of GRP78 expression on cell line morphology. (A) Neural-crest-
derived melanoma, glioblastoma and neuroblastoma cancer cells that were stably over-
expressing GRP78 in comparison to control empty vector were assessed by light 
microscopy for the effect of transfection and GRP78 over-expression on morphology, in 
comparison to control wild-type cell lines. (B) Cell area for NGP neuroblastoma cell 
lines were calculated and data expressed as mean area of 30 cells over 3 individual 
experiments ± 95% CI. 
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Figure 5.5: The effect of GRP78 over-expression on neuroblastoma. (A) NGP 
neuroblastoma cells were transiently transfected with increasing concentrations of 
pcDNA3.1 (+) GRP78 to a maximum of 4 µg. Each individual transfection contained 
the same amount of total plasmid DNA by supplementing with pcDNA3.0 control vector 
and the effect of GRP78 on cell death assessed by propidium iodide stained flow 
cytometry. Flow cytometry data are the means of 3 individual experiments ± 95%. (B) 
Light microscopy images were acquired prior to flow cytometry to highlight the effect of 
GRP78 expression.  
Experiment 1 
 
Experiment 2 
 
Experiment 3 
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Over-expression of GRP78 also resulted in a noticeable induction of cell detachment in 
neuroblastoma, but not in melanoma or glioblastoma cells. To check that the 
consequence of GRP78 over-expression were dose-dependent, NGP cells were 
transiently transfected with increasing amounts of pcDNA3.1 (+) GRP78. The final 
amount of plasmid DNA was kept at 4 µg/ml by the addition of pcDNA3.0. After 
transfection (24 h), cells were imaged prior to the analysis of cell death by flow 
cytometry of propidium iodide stained cells (Figure 5.5). Results demonstrated a 
significant increase in cell death of NGP cells with increasing amounts of transfected 
GRP78 (Figure 5.5 A, One-way ANOVA, F5, 17 = 138.1, P < 0.0001). Light microscopy 
images (Figure 5.5 B) also showed increasing concentrations of GRP78 transfection 
resulted in an increase in detached cells and a decrease in attached, flat cells. This 
suggests that an increase in GRP78 expression impacts on neuroblastoma cellular stress 
and survival.  
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5.2.2: The effect of GRP78 over-expression on cellular resistance to death. 
The effect of stable GRP78 over-expression in neural-crest-derived cell models on ER 
stress-induced cell death was also evaluated by flow cytometry of propidium iodide 
stained cells after treatment with either fenretinide (10 µM for melanoma and 
glioblastoma or 5 µM for neuroblastoma) or bortezomib (200 nM for melanoma and 
glioblastoma or 20 nM for neuroblastoma) (Figure 5.6). Results clearly demonstrated 
over-expression of GRP78 affected the sensitivity of all neural-crest-derived cancer 
types.  Comparing the effect of control transfection to transfection with GRP78, data 
revealed that there were no significant differences due the contrasting outcomes 
observed between melanoma or glioblastoma, to that of neuroblastoma (P > 0.05). 
However, results comparing the effect of GRP78 transfection across cancer type showed 
significant differences (Two-way ANOVA, F 2, 26 = 193.7, P < 0.0001).  
In melanoma or glioblastoma cells, over-expression of GRP78, resulted in a significant 
decrease in fenretinide- or bortezomib-induced cell death compared to either wild-type 
cells or cells stably transfected with vector control (Figure 5.6 A & B, One-way 
ANOVA with Bonferroni post hoc corrections, P < 0.0001 for either agent in both 
cancer types). Conversely, in neuroblastoma cells over-expressing GRP78 resulted in a 
significant increase in sensitivity to fenretinide- and bortezomib-stimulated ER stress-
induced death (Figure 5.6 C, One-way ANOVA with Bonferroni post hoc corrections, P 
< 0.01 or P < 0.0001 for either fenretinide or bortezomib, respectively).  Although 
stable transfection of GRP78 affected the response of cells to both fenretinide and 
bortezomib, a significantly greater inhibition of response was observed in melanoma 
cells treated with bortezomib (Figure 5.6 A, One-way ANOVA with Bonferroni post 
hoc corrections, P < 0.0001). In glioblastoma and neuroblastoma cells, however, there 
was no significant difference between responses to either fenretinide or bortezomib, 
with regards to the capacity of either agent to induce cell death in the presence of 
GRP78 over-expression (P > 0.05). 
Investigating the effect of GRP78 over-expression on the ability of fenretinide or 
bortezomib to induce inhibition of cell viability, data demonstrated a significant effect 
on melanoma, glioblastoma and neuroblastoma cancer types (Figure 5.7). These data 
showed significant differences in response between both plasmid and cell type (Two-
way ANOVA, F2, 27 = 406.6, P < 0.001 for cell and F2, 27 = 12.3, P < 0.0001 for plasmid). 
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These data highlight a significant influence of GRP78 on fenretinide and bortezomib 
induced cell death, as well as a significant difference in response type within 
neuroblastoma. 
Data for melanoma and glioblastoma demonstrated a significant reduction of fenretinide 
and bortezomib induced inhibition of cell viability, in comparison to controls (Figure 
5.7 A & B, One-way ANOVA with Bonferroni post hoc corrections, P < 0.0001 for 
either agent, in both cancer types). Neuroblastoma cells overexpressing GRP78 showed 
an increase in sensitivity to ER stress (Figure 5.7 C, One-way ANOVA with Bonferroni 
post hoc corrections P < 0.001 for fenretinide and P < 0.0001 for bortezomib). 
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Figure 5.6: The effect of GRP78 over-expression on neural-crest-derived cancer cell 
sensitivity to ER stress-induced cell death. Melanoma (A), glioblastoma (B) and 
neuroblastoma (C) cells stably over-expressing GRP78 were assessed for any changes 
in cellular resistance to death induced by either fenretinide (F, 10 µM for melanoma 
and glioblastoma or 5 µM for neuroblastoma) or bortezomib (B, 200 nM for melanoma 
and glioblastoma or 20 nM for neuroblastoma) compared to control (C, vehicle treated) 
for 24 h, in comparison to control transfected and wild type cells. Cell death was 
compared by propidium iodide stained flow cytometry on 70% ethanol fixed cells. Data 
were expressed as mean values of 3 independent experiments ± 95% CI. 
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Figure 5.7: The effect of GRP78 over-expression on cancer cell sensitivity to ER stress 
-induced inhibition of cell viability. Melanoma (A), glioblastoma (B) and 
neuroblastoma (C) cells that were stably over-expressing GRP78 were assessed for any 
changes in cellular resistance to inhibition of cell viability in comparison to control 
vector transfected or wild type cell lines, induced by either fenretinide (F, 10 µM for 
melanoma and glioblastoma or 5 µM for neuroblastoma) or bortezomib (B, 200 nM for 
melanoma and glioblastoma or 20 nM for neuroblastoma) in comparison to control (C, 
vehicle treated) for 24 h. Cell viability was assessed by the commercially available MTS 
assay. Data were expressed as the mean values of 3 independent experiments of 8 
individual replicates ± 95% CI. 
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To test the hypothesis that neural-crest-derived cancer cell sensitivity to ER stress is 
altered by GRP78 expression, due to changes in UPR activation as a consequence of 
manipulating the dynamic equilibrium between GRP78 and the UPR activators PERK, 
IRE1 and ATF6, the induction of ATF4 was investigated. Melanoma, glioblastoma and 
neuroblastoma stably expressing GRP78 were treated with fenretinide or bortezomib for 
4 h in comparison to control pcDNA3.0 vector transfected cells, prior to analysis of 
ATF4 induction (Figure 5.8). Results demonstrated a significant effect on UPR 
induction in cells over-expressing GRP78 (Two-way ANOVA comparing the response 
across plasmid type or cancer type, F1, 28 = 12.5 P < 0.001 for plasmid and F2, 28 = 406.9, 
P < 0.0001 for cell line), with decreased ATF4 induction observed in response to 
fenretinide or bortezomib in melanoma and glioblastoma cells over-expressing GRP78 
(Figure 5.8, One-way ANOVA with Bonferroni post hoc corrections, for melanoma 
treated with fenretinide P < 0.0001 or bortezomib P < 0.001 and for glioblastoma 
treated with fenretinide P < 0.001 or bortezomib P < 0.0001).  
These data indicated an increased induction in response to ER stress in neuroblastoma 
cells over-expressing GRP78 and, therefore, highlighted a difference in mechanistic 
outcome in neuroblastoma, compared to either melanoma or glioblastoma. In this 
context, GRP78 over-expression in neuroblastoma cells resulted in significantly reduced 
induction of ATF4 in both control and fenretinide treated (Figure 5.8 A & B iii, One-
way ANOVA with Bonferroni post hoc corrections, P < 0.0001 for either condition). 
Conversely, when treated with bortezomib, neuroblastoma cells demonstrated an 
increase in UPR activity, as shown by increased ATF4 induction (P < 0.0001). 
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Figure 5.8 continued on next page 
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Figure 5.8 continued  
 
 
Figure 5.8 legend on next page 
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Figure 5.8: The effect of GRP78 over-expression on UPR activity. (A) WM266-4 
melanoma, MO59J glioblastoma and NGP neuroblastoma neural-crest-derived cancer 
cells stably over-expressing GRP78 in comparison to control vector were treated with 
fenretinide (10 µM for melanoma and glioblastoma or 5 µM for neuroblastoma) or 
bortezomib (200 nM for melanoma and glioblastoma or 20 nM for neuroblastoma) for 4 
h. Western blot analysis for the induction of ATF4 were carried out in comparison to β-
Actin as a loading control. Western blot data are representative blots of 3 repeat 
experiments. Figure 5.8 A; Cells treated with control = C, Fenretinide = F and 
Bortezomib = B. (B) Densitometry data for the effect of GRP78 expression on 
fenretinide (FenR, grey bars) or bortezomib (Bort, black bars) (graphs on next page) 
capacity to induce ATF4 in comparison to control (Con, white bars) are the average of 
triplicate experiments and bars are expressed as mean data relative to control (white 
bars, no treatment) ± 95% CI.  
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To investigate if GRP78 modulation and the effects on ER stress-induced cell death 
resulted in downstream caspase activation, melanoma, glioblastoma and neuroblastoma 
cells over-expressing GRP78 were treated with fenretinide or bortezomib for 24 h and 
the effects on caspase 3 cleavage determined by western blotting (Figure 5.9). Data 
demonstrated GRP78 over-expression resulted in the inhibition of both fenretinide and 
bortezomib-induced caspase 3 cleavage in all neural-crest-derived cancer types (Figure 
5.9, One-way ANOVA with Bonferroni post hoc corrections, for melanoma treated with 
fenretinide P < 0.001 or bortezomib P < 0.0001 and glioblastoma or neuroblastoma 
treated with either ER stress-inducing agent P < 0.0001). Investigating these effects 
between cancer types also demonstrated a significant difference between melanoma and 
either glioblastoma or neuroblastoma (Figure 5.9, One-way ANOVA with Dunnett’s 
post hoc correction, P < 0.001 or P < 0.0001 respectively). 
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Figure 5.9 continued on the next page 
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Figure 5.9 continued 
 
 
Figure 5.9 legend on next page 
167 
 
Figure 5.9: The effect of GRP78 over-expression on the induction of caspase dependant 
cell death. (A) WM266-4 melanoma, MO59J glioblastoma and NGP neuroblastoma 
neural-crest-derived cancer cells stably over-expressing GRP78 in comparison to 
control vector were treated with fenretinide (10 µM for melanoma and glioblastoma or 
5 µM for neuroblastoma) or bortezomib (200 nM for melanoma and glioblastoma or 20 
nM for neuroblastoma) for 24 h. Western blot analysis for the induction of caspase 3 
cleavage were carried out in comparison to β-Actin as a loading control. Western blot 
data are a representative blot of 3 repeat experiments. Figure 5.9 A; Cells treated with 
control = C, Fenretinide = F and Bortezomib = B. (B) Densitometry data for the effect 
of GRP78 expression on fenretinide (FenR, grey bars) or bortezomib (Bort, black bars) 
on caspase 3 cleavage, in comparison to control (Con, white bars, vehicle treated) are 
the average of triplicate experiments and bars are expressed as mean data relative to 
control (white bars, no treatment) ± 95% CI. For caspase 3 cleavage the accumulative 
intensity of the 17 and 19 kDa bands were used. 
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To test the hypothesis that GRP78 over-expression alters its dynamic equilibrium with 
PERK, IRE1 and ATF6, the expression of each protein was evaluated in all neural-
crest-derived cells over-expressing GRP78 compared to vector control or wild type cell 
lines (Figure 5.10). Results revealed a significant effect of GRP78 over-expression on 
the expression levels of each UPR activator, as well as significant differences between 
cancer types and the relative change in expression of each UPR activator (Figure 5.10, 
Two-way ANOVA, comparing plasmid and cell line expression, F11, 107 = 77.1, P < 
0.0001 or P < 0.005 respectively).  
Analyses highlighted that changes in UPR activator expression, with regard to the 
magnitude of protein expression, was altered by GRP78 over-expression and was also 
significantly different for all cancer types (Figure 5.10, One-way ANOVA, comparing 
UPR activators, F11, 35 = 77.1 for melanoma, 20.1 for glioblastoma and 67.8 for 
neuroblastoma, P < 0.001 for all cancer types). 
With respect to PERK, IRE1 or ATF6 expression, there were no significant differences 
between wild type and control vector-transfected cell lines for each tumour type. 
Melanoma cells over-expressing GRP78 showed a significant increase in IRE1 and a 
significant decrease in ATF6 expression (Figure 5.10, One-Way ANOVA with 
Dunnett’s post hoc correction, comparing stable transfected cells to wild type, P < 
0.0001 for IRE1 and P < 0.01 for ATF6) while glioblastoma cells stably over-
expressing GRP78 demonstrated a significant reduction in PERK expression (P < 
0.001). Over-expression of GRP78 in neuroblastoma cells on the other hand resulted in 
a significant increase in all three UPR activators (Figure 5.10, comparing the expression 
of control wild type cells to GRP78 over-expressing for the expression of PERK P < 
0.05, IRE1 or ATF6 P < 0.0001 for both). 
Overall, changes in UPR activator concentration (fold increases in comparison to 
control) were significantly greater in neuroblastoma compared to either melanoma or 
glioblastoma (Figure 5.10, One-way ANOVA with Dunnett’s post hoc correction, P < 
0.001 for PERK and IRE1, or P < 0.0001 for ATF6). 
Further analysis of relative changes in GRP78 and the UPR activator expression in 
neural-crest-derived cell lines stably over-expressing GRP78, in comparison to control 
vector were carried out to determine if over-expression of GRP78 altered the existing 
dynamic equilibrium with the UPR activators PERK, IRE1 and ATF6. Data 
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demonstrated a significant effect of GRP78 over-expression on the dynamic equilibrium 
that GRP78 exists in with the UPR activators (Figure 5.11).  
There were also significant differences between cancer types (Figure 5.11, Two-way 
ANOVA, F9, 35 = 72.4, P < 0.0001). Melanoma and glioblastoma cells exhibited a 
significantly greater fold increase in GRP78 expression, compared with the changes to 
the UPR activators (One-way ANOVA with Bonferroni post hoc corrections, P < 
0.0001 for both cancer types). Conversely, over-expression of GRP78 in neuroblastoma 
cells resulted in a greater fold induction of UPR activators compared to the fold increase 
in GRP78 itself (One-way ANOVA with Bonferroni post hoc corrections, P < 0.0001). 
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Figure 5.10: The effect of GRP78 on UPR activator expression. (A) WM266-4 
melanoma, MO59J glioblastoma and NGP neuroblastoma neural-crest-derived cancer 
cells stably over-expressing GRP78 in comparison to control vector or wild type cell 
line were assessed for changes in the expression of PERK, IRE1 and ATF6 in 
comparison to β-Actin as a loading control. (B) Densitometry analyses were performed 
for melanoma (i), glioblastoma (ii) and neuroblastoma (iii) western blotting data and 
were expressed as relative to control. Data on next page) and each bar is the mean of 3 
replicate experiments ± 95% CI. 
 
 
 
 
Figure 5.10 continued on next page 
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Figure 5.10 continued  
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Figure 5.11: The effect of GRP78 over-expression on relative expression of the UPR 
activators. Melanoma, glioblastoma and neuroblastoma cells stably over-expressing 
GRP78 (black bars) in comparison to control pcDNA3.0 (white bars) were analysed for 
the changes in GRP78 and UPR activator proteins expression and data expressed as 
relative fold changes of either GRP78 or combined UPR activator expression. Data 
expressed as relative to β-Actin prior to control vector compensation. Data were the 
mean of 3 independent experiments ± 95% CI. 
173 
 
To check that the decrease in fenretinide or bortezomib-induced cell death resulting 
from GRP78 over-expression was a result of changes to signalling downstream of 
GRP78 and not the amount of stress resulting from drug treatment, the amount of ROS 
or ubiquitin tagged proteins was measured under control and over-expression conditions. 
Cells were treated with either fenretinide (Figure 5.12) for 6 h or bortezomib (Figure 
5.13) for 8 h or 24 h. Subsequent analysis demonstrated GRP78 over-expression in 
melanoma and glioblastoma cells resulted in significant inhibition of fenretinide 
induced ROS (Figure 5.12, One-way ANOVA with Bonferroni post hoc corrections, P < 
0.0001 for both cancer types). Conversely, GRP78 over-expression had no significant 
effect on ROS accumulation in neuroblastoma cells (One-way ANOVA with Bonferroni 
post hoc corrections, P < 0.05). 
Treatment of cells with bortezomib resulted in a build-up of ubiquitin-tagged proteins 
and this was significantly reduced by GRP78 over-expression in melanoma and 
glioblastoma cells compared to control-transfected and wild-type cell lines, following 
treatment with bortezomib for either 8 or 24 h (Figure 5.13 B, One-way ANOVA with 
Bonferroni post hoc corrections, for melanoma P < 0.005 and P < 0.01 or glioblastoma 
P < 0.05 and P < 0.01 at 8 h and 24 h, respectively). Conversely, neuroblastoma cells 
over-expressing GRP78 showed an increase in ubiquitin-tagged proteins (P < 0.001 for 
both time points) in response to bortezomib. Comparisons across cancer types showed a 
significant difference between melanoma and glioblastoma, to neuroblastoma (Figure 
5.13, One-way ANOVA with Bonferroni post hoc corrections comparing neuroblastoma 
to either melanoma or glioblastoma at either 8 h or 24 h, P < 0.0001). Comparing the 8 
h and 24 h time points, results demonstrated that there was no significant difference for 
ubiquitin build-up across cancer type. 
Data demonstrate a difference in response outcome to ER stress between cancer types 
with melanoma and glioblastoma showing increased resistance. This study also showed 
that an increase in GRP78 expression alters UPR activator expression in a cancer type-
specific manner resulting in a significant increase in UPR activators in neuroblastoma, 
which may prime this cancer type to ER stress induced death. 
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Figure 5.12: The effect of GRP78 over-expression on ROS production. WM266-4 
melanoma, MO59J glioblastoma and NGP neuroblastoma neural-crest-derived cancer 
cells stably over-expressing GRP78 (black bars) in comparison to control vector (grey 
bars) and wild type cell lines (white bars) were treated with fenretinide (10 µM 
fenretinide for melanoma and glioblastoma or 5µM for neuroblastoma) for 6 h, prior to 
staining with H2DCFDA for 20 min (as described in methods) and assessed for 
fluorescent induction by flow cytometry (FL-1). Data were expressed as mean values of 
3 experiments ± 95% CI. 
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Figure 5.13 legend is on the next page  
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Figure 5.13: The effect of GRP78 over-expression on ER stress-induced protein 
degradation.  (A) Neural-crest-derived melanoma (WM266-4), glioblastoma (MO59J) 
and neuroblastoma (NGP) cancer cell lines that were stably over-expressing pcDNA3.0 
(grey bars) or pcDNA3.1 (+) GRP78 (black bars), in comparison to wild type cells 
(white bars), were treated with bortezomib (200 nM for melanoma and glioblastoma or 
20 nM for neuroblastoma) for 8 (i) and 24 (ii) h, prior to harvesting. Cell lysates were 
assessed by western blot analysis for ubiquitin smears (indicative of proteins tagged for 
degradation) in comparison to β-Actin as a loading control. (B) Densitometry was 
carried out for Ubiquitin smears and data expressed as relative to control. Each bar is 
the mean of 3 individual experiments ± 95& CI. 
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5.2.3: Results Summary. 
 Neural-crest-derived cancer types demonstrated significant differences in the ability 
to over-express GRP78. Glioblastoma cells showed the greatest increase in GRP78 
expression. 
 
 The ability to increase the expression of GRP78 did not correlate with basal 
expression, as neuroblastoma cell lines demonstrated the lowest cellular 
concentration and the smallest increase when transfected with pcDNA3.1(+) 
GRP78 
 
 Over-expression of GRP78 significantly reduced melanoma and glioblastoma cell 
line sensitivity to ER stress-induced cell death. However, neuroblastoma cells 
showed an increase in cellular sensitivity to either fenretinide or bortezomib 
induced cell death. 
 
 Melanoma and glioblastoma cells with increased GRP78 expression demonstrated a 
decrease in fenretinide and bortezomib induced inhibition of cell viability. 
Neuroblastoma cells, over-expressing GRP78, were significantly more sensitive to 
ER stress-induced inhibition of cell viability. 
 
 The induction of caspase-3 cleavage by fenretinide or bortezomib was significantly 
reduced in neural-crest-derived cancer types that demonstrated a significant 
increase in GRP78 expression.  
 
 Investigating the effect of GRP78 over-expression on UPR activation, 
demonstrated a significant reduction in induction of ATF4 in melanoma and 
glioblastoma cells in response to ER stress, but neuroblastoma cells showed a 
significant increase in ATF4 expression in response to fenretinide and bortezomib.   
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 Stable over-expression of GRP78 resulted in changes to the expression levels of the 
UPR activators PERK, IRE1 and ATF6. Neuroblastoma showed the greatest 
alteration in UPR activator expression, with an increase overall. 
 
  Melanoma and glioblastoma cells with increased expression of GRP78 
demonstrated a significant reduction in fenretinide or bortezomib ROS or Ubiquitin 
tagged protein accumulation, respectively. Neuroblastoma cells demonstrated no 
changes in ROS accumulation, however demonstrated a significant increase in 
ubiquitin tagged proteins in response to bortezomib treatment. 
 
 Transient increase in GRP78 expression in neuroblastoma cells induced cell death. 
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5.3: Discussion. 
Data from the present chapter demonstrate that increased GRP78 expression altered the 
sensitivity of neural-crest-derived cancer cells to ER stress-induced cell death and 
inhibition of cell viability. As a consequence of GRP78 over-expression, ER stress-
induced UPR activation in melanoma and glioblastoma was reduced (as measured by 
ATF4 induction). However, neuroblastoma cells showed an increase in cellular 
sensitivity to ER stress-induced cell death, demonstrating the capacity to induce 
significantly higher levels of ATF4 during periods of ER stress. Unexpectedly, the data 
for neuroblastoma, in contrast to that of either melanoma or glioblastoma, demonstrated 
a marked decrease in caspase-3 activation. Over-expression of GRP78 also modulated 
the expression of the UPR activators PERK, IRE1 or ATF6 as well as the induction of 
spontaneous cell death in neuroblastoma cells. Furthermore, GRP78 over-expression 
altered the level of stress “seen” by the cells as measured by ROS and ubiquitin-tagged 
protein accumulation. 
Stable clones of all cancer types over-expressing GRP78 were generated and 
demonstrated a significant increase in cellular expression of GRP78 in comparison to 
cells transfected with pcDNA3.0 vector control or wild type cells. GRP78 expression 
increased at both the mRNA and protein level, with expression of mRNA correlating 
with achievable protein induction. Optimisation of over-expression generated cells with 
a 1.5 (neuroblastoma) to 2.0 (melanoma and glioblastoma)-fold increase in expression. 
Previous studies have evaluated the role of GRP78, by generating a range of cell types 
over-expressing GRP78: in these studies GRP78 over-expression was to a similar 
degree as in the present study, ranging from 1.5 to 3 fold [295-301]. These studies were 
carried out in a range of differing cell types and demonstrate the cell line models 
developed in this study are within the achievable range for GRP78 over-expression. The 
over-expression of GRP78 showed that the ability of a particular cell line to increase its 
expression of GRP78 is not related to the basal concentration. Neuroblastoma cells 
demonstrated the lowest cellular concentrations of GRP78 and the smallest amount of 
inducible GRP78 compared to glioblastoma and melanoma cells. These findings suggest 
differences between cell types and their capacity to allow protein concentrations to 
fluctuate. These data also highlight the differential importance of GRP78 in different 
cancer types and thereby allow a greater promotion of GRP78 translation. 
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Evaluation of the effect of GRP78 over-expression on the sensitivity of neural-crest-
derived cells to ER stress-induced cell death or inhibition of cell viability demonstrated 
increased resistance in melanoma and glioblastoma cells. This suggests that GRP78 aids 
melanoma and glioblastoma survival during periods of ER stress. These findings may 
be a direct consequence of changes to the dynamic equilibrium of the UPR. An increase 
in GRP78 may reduce UPR activation, as increased GRP78 would result in a decreased 
probability of a substrate binding to a GRP78 molecule, interacting with a UPR 
activator at such time. Confirming GRP78 over-expression reduces fenretinide or 
bortezomib-induced cell death, demonstrated a significant reduction in caspase-3 
cleavage. 
To test whether GRP78 over-expression resulted in a decrease in ER stress-induced 
UPR signalling, downstream ATF4 induction was analysed after treatment with either 
fenretinide or bortezomib. Results demonstrated a significant reduction in UPR 
activation with increased GRP78 expression. These findings suggest that GRP78 over-
expression results in an increased inhibition of the UPR, with cells becoming more 
resistant to cell death due to a reduction in the translation of pro-apoptotic stimuli. 
Previous studies of GRP78 have indicated that GRP78 expression correlates with 
chemo-resistance [288, 296], suggesting changes in cellular stress regulation.  
However, changes in UPR signalling are only part of the story an increase in GRP78 
expression significantly reduced both ROS and ubiquitin-tagged protein accumulation. 
An increase in GRP78 would result in an enhanced cellular chaperone activity and 
therefore a reduction in proteins tagged for degradation would be a direct consequence 
of increased folding capacity of the cells [293]. A decrease in UPR activity, as a result 
of an increase in GRP78 inhibition of the UPR activators may have decreased ER 
stress-induced ERAD activation. This reduction in ERAD may be the reason why 
GRP78 over-expression reduced bortezomib-induced ubiquitin-tagged protein 
accumulation. However, the decrease in ROS accumulation with increased GRP78 was 
an unexpected observation, indicating a role of GRP78 in buffering ROS, or in 
prevention of fenretinide interference within the ceramide synthesis pathway.  
Previously, it was reported that capsaicin, an ingredient of red pepper, induces apoptosis 
and also promotes cytoplasmic Gadd153 expression and nuclear translocation of GRP78 
in human hepatoma HepG2 cells [302]. These studies showed that capsaicin-induced 
apoptosis was mediated through elevation of intracellular production of ROS, and 
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regulation of the mitochondrial Bcl-2 family and caspase 3. In another example, 
knockdown of GRP78 sensitized cells to ROS-induced cell death, primarily due to an 
impaired DNA repair capacity [303]. Taken together, these observations suggest a 
nuclear form of GRP78 might play a role against DNA-damage-induced cell death 
through a distinct regulatory mechanism in the nucleus.   
To confirm that changes in the dynamic equilibrium of the UPR are important for 
melanoma and glioblastoma resistance to ER stress-induced cell death, the expression 
of the UPR activators; PERK, IRE1 and ATF6 were determined in cells over-expressing 
GRP78, in comparison to cells transfected with vector control or wild type cells. Data 
demonstrated that changes in expression of the UPR activators occurred as a direct 
consequence of GRP78 over-expression. IRE1 expression was increased in melanoma 
cells and PERK expression decreased in glioblastoma cells. These data suggest that 
interfering with the protein expression of GRP78, therefore results in changes to the 
UPR stoichiometry. However for glioblastoma, only a decrease in PERK expression 
was observed, which would further emphasise the shift within the dynamic equilibrium 
towards an inactive UPR. 
Comparing the expression of GRP78 to the combined expression of UPR activators, 
relative to pcDNA3.0 transfected cells allowed for a direct comparison of the 
relationship between GRP78 expression and cancer type. Data demonstrated a 
significantly greater fold increase in GRP78 in comparison to the combined UPR 
activators in melanoma and glioblastoma cells. This represents a shift in the dynamic 
equilibrium in favour of the UPR being inhibited; suggesting that a greater amount of 
stress would be required to activate this signalling cascade. However, neuroblastoma 
cells demonstrated a significantly greater fold induction of UPR activators, compared to 
the achievable fold increase in GRP78 expression. This outcome would result in a shift 
of the dynamic equilibrium within neuroblastoma to favour a system that is switched on 
to a greater extent. These findings are supported by studies demonstrating that 
melanoma and glioblastoma cells become more resistant to death with increased GRP78 
expression, in addition to studies in neuroblastoma showing the converse [113, 116, 
224]. 
Data for the effect of GRP78 expression on neuroblastoma cell sensitivity to death and 
inhibition of cell viability, demonstrated an increase in fenretinide or bortezomib 
induced cell death or inhibition of cell viability. These data correlate with previous 
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studies, where GRP78 expression was shown to improve patient prognosis [116]. 
Analysis of the UPR in neuroblastoma cells showed a significant increase in PERK, 
IRE1 and ATF6 expression in cells over-expressing GRP78. These data suggest that one 
consequence of GRP78 over-expression, in neuroblastoma, is to induce the expression 
of the UPR activators. However, data demonstrated that wild-type neuroblastoma cells, 
unlike melanoma and glioblastoma cells, exhibit more UPR activator molecules than 
GRP78 molecules, present to inhibit them. Therefore, an increase in the UPR activators 
PERK, IRE1 and ATF6 would further shift the dynamic equilibrium of the UPR toward 
an active cascade in neuroblastoma. To investigate the downstream effects of this 
significant increase in UPR activators, cells were treated with either fenretinide or 
bortezomib prior to the analysis of ATF4 induction. Data derived from studies in 
neuroblastoma cells showed GRP78 over-expression resulted in significant ATF4 
induction. However, when investigating downstream caspase activation, neuroblastoma 
cells showed a reduction in caspase 3 cleavage, suggesting that the increased UPR 
activity induced cell death in a caspase independent manner.  
Previous research in multiple myeloma has highlighted that when the expression of a 
single UPR activator was deregulated by siRNA, this resulted in the promotion of cell 
death via autophagy, but represses apoptosis of multiple myeloma cells [304]. Multiple 
myeloma, as for neuroblastoma, demonstrates a favourable prognosis with increased 
GRP78 expression [304]. Assuming that the UPR can simultaneously activate survival 
and apoptosis mediators, the fate of a stressed cell is predictable at both extremes of the 
ER stress spectrum. However, there may be a range of stress signals of intermediate 
intensity, where the balance between protective and cytotoxic pathways does not allow 
a clear-cut decision between survival and death. The ER stress generated, coupled with 
the deregulation of the UPR sensor expression, and thus may fall into this category.  
Neuroblastoma cells over-expressing GRP78 showed a significant increase in IRE1. 
Previous studies have proposed a link between IRE1 and JNK [305]. The JNK 
signalling pathway has been implicated in apoptosis-inducing factor (AIF)-dependent 
cell death and therefore an increase in IRE1 stimulated JNK activation may result in an 
increase in cell death in response to ER stress [306, 307].  
Optimisation of stable GRP78 over-expressing neuroblastoma cells showed an increase 
in cell death in response to GRP78 specific plasmid transfection, in comparison to 
experimental control. To test the hypothesis that GRP78 over-expression induces 
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spontaneous cell death in neuroblastoma cells, NGP cells were transfected within 
increasing doses of pcDNA3.1 (+) GRP78 normalised to a final 4 µg/ml by the addition 
of control pcDNA3.0 (Figure 5.5). Data showed that enhancing GRP78 expression 
significantly induced neuroblastoma cell death. Therefore the lower fold increase in 
neuroblastoma over-expressing clones may be a balance between sufficient plasmid to 
be resistant to antibiotic selection, but low enough induction of GRP78 expression to 
prevent cell death from being induced too much, with cells demonstrating extremes of 
either too much or too little plasmid dying. 
To date, the effect of GRP78 over-expression on neural-crest-derived cancer types UPR 
is poorly understood. These data demonstrate differences between cancer types with 
respect to the effect of GRP78 over-expression on UPR activator expression. Changes 
in neuroblastoma cells, whereby UPR activator expression significantly increased in 
comparison to GRP78, may tip the balance of the UPR. The resulting hyperactive UPR 
in this case may sensitize neuroblastoma cells to ER stress significantly more than the 
achieved 1.5 fold increase in GRP78 (enhanced chaperone activity and capacity to 
inhibit the UPR) can prevent it via its pro-survival mechanism. This concept is 
supported by data for neuroblastoma cells demonstrating that enhanced GRP78 
expression had no significant effect on ROS accumulation together with the observed 
increase in ubiquitin tagged proteins (ER stress) in response to bortezomib. These 
findings highlight that in neuroblastoma cells, although a significant increase in GRP78 
was achieved, no significant aid from GRP78 chaperone activity was observed. The 
increase in ubiquitin-tagged proteins may be a consequence of downstream ERAD 
activation as a consequence of the increase in UPR activators [308], which allows these 
neuroblastoma cells to induce UPR to a higher extent (determined by the increase in 
ATF4 induction). 
Collectively, these data highlight the importance of understanding the stoichiometry of 
UPR activators, as well as GRP78 in the response of cancer cells to ER stress. To 
further investigate the importance of GRP78 as a therapeutic target, neural-crest-derived 
cancer cells were treated with a panel of GRP78 inhibitors, alone and in combination 
with ER stress-inducing agents. 
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5.4: Conclusion 
This study, like that for the reduction of GRP78 expression, showed that increases in 
GRP78 altered sensitivity to ER stress in a cancer type-specific manner. Melanoma and 
glioblastoma observed increased resistance to ER stress-induced death, whereas 
neuroblastoma became more sensitive. Interpreting the effect of over-expression on 
UPR signalling showed that changes in resistance were linked with the activity of the 
UPR but not with caspase induction. Finally, this study demonstrated that over-
expression of GRP78 results in downstream changes to the UPR activator expressions, 
and the effect of this is cancer type specific. Neuroblastoma resulted in a further 
increase in UPR activators, further activating the cascade. For melanoma and 
glioblastoma, on the other hand, there was more GRP78 induction than UPR activators, 
increasing the negative regulation of the UPR. 
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Chapter 6: 
 
The effect of GRP78 inhibition on 
the survival of cancer cells 
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6.1: Introduction. 
Demonstrating that the expression of GRP78 is enhanced in metastasis and late-stage 
cancer have highlighted GRP78 as a protein of interest in cancer signalling [114, 115, 
258].  Research within this study has shown that reduction in GRP78 expression 
sensitizes only certain cancer types to ER stress-induced death; an outcome that was 
further confirmed when GRP78 over-expression models demonstrated opposing 
outcomes, with regards to the response to ER stress-inducing agents fenretinide or 
bortezomib across differing cancer types. However, to date studies using siRNA-
mediated knock-down have demonstrated the importance of GRP78 expression in 
cancer-cell survival in response to both environmental and chemical stress [309]. 
Although siRNA targeted knock-down of GRP78 has shown beneficial outcomes in 
vitro, difficulties arise in clinical application of this technique and therefore another 
approach to target GRP78 is required [288]. To date, GRP78 activity can be disrupted 
using nucleoside analogues, specific antibodies [11], as well as by natural inhibitors, 
such as epigallocatechin gallate (EGCG) [288] or inhibited by AB5 Subtilase cytotoxin 
(SubAB5) [198-200].  Recently, Jack Arbiser and colleagues have demonstrated an 
interaction between honokiol and GRP78 (unpublished data, personal communications). 
Honokiol may represent a novel inhibitor of GRP78. 
Like all large chaperones of the heat shock protein family, GRP78 is dependent on ATP 
for its chaperone activity; the processing of ATP to ADP alters the substrate binding 
domain and increases the affinity of GRP78 for unfolded or mis-folded proteins [310], 
and more recently Polizzi et al., demonstrated that GRP78 interaction with ATP is 
required for GRP78 interaction with either PERK or IRE1 [311]. Palleros et al., showed 
that on addition of Mg-ATP to HSP70-substrate complex, dissociation occurred [312]. 
However, when ATP-γS (a slowly metabolised ATP analogue) was used, there was no 
dissociation [312]. Therefore, these results suggest that the conversion of ATP to ADP 
is an important step for substrate release. This research also highlighted the importance 
of Mg-ATP binding, rather than hydrolysis as the essential step required for protein-
substrate dissociation and that without K
+ 
present within the reaction, substrate 
dissociation was again significantly reduced [312]. This study highlighted the 
importance of the ATPase domain of the HSP70 family in their ability to interact with 
substrates [312] and demonstrates that targeting ATPase activity is a viable route to 
inhibit the functioning of chaperones. 
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Rao et al., and Reddy et al., also demonstrated the importance of ATPase activity in 
GRP78 function. Using Jurkat cells over-expressing GRP78 or a mutant variant, 
deficient in the ATP binding domain, the importance of the ATPase domain was 
demonstrated in protection against etoposide cytotoxicity [295], and the treatment of 
HEK293T cells with dATP, resulted in the dissociation of GRP78 complexes from 
caspase-7 and -12 [313]. These studies suggest that nucleoside analogues which could 
bind to the ATPase domain and result in dissociation, could activate pro-death stimuli, 
as well as disrupt the ability of GRP78 to bind/release substrates (cycling reaction) and, 
along with directly competing with ATP for the GRP78 binding site, would decrease the 
ability of GRP78 to react to ER stress efficiently by hindering chaperone activity.  
Targeting the ATP binding domain was further evaluated between GRP78 and HSP70, 
demonstrating that designed quinolone (C9H7N) ligands potently bound to GRP78 and 
showed slow off-rates [314], However, dichlorophenyl ligands showed a greater 
inhibition of HCT116 cell proliferation [315]. Mapping the ATPase domain of GRP78 
in comparison to HSP70, by X-Ray crystallography, highlighted that although most 
residues were the same between proteins, GRP78 contains a non-polar Ile61 instead of a 
Thr37 seen in HSP70. This change results in GRP78 having a more hydrophobic 
binding site [316], capable of interacting with a more diverse group of substrates.  
EGCG, the most abundant catechin found in green tea, is reported to block the ATPase 
domain of GRP78, suppressing its anti-apoptotic property [317]. For example, TuBEC 
cells treated with EGCG in combination with temozolamide or etoposide demonstrated 
the induction of cell death, whereas single agents showed no significant cell death [301]. 
However, EGCG also has the ability to inhibit the 26S proteasome and NFκB signalling 
cascades and, therefore, is an ideal candidate as a drug to overcome chemoresistance in 
solid tumours [318]. Alastair Hawkins and Heather Lamb recently demonstrated that 
EGCG can bind to the unfolded form of the GRP78 ATPase domain (unpublished data). 
The SubAB5 cleaves GRP78 specifically at the di-leucine bridge between the ATPase 
and substrate binding domains; this specificity is due to the Sub A domain having an 
unusually deep active-site cleft [198]. AB5 toxins are key virulence factors of a range of 
bacteria, including shiga toxigenic Escherichia coli (E.coli), which is part of a diverse 
group of E.coli strains that are capable of producing shiga toxins [198]. This subtilase 
cytotoxin, named because the ‘A’ subunit shares sequence homology with a subtilase-
like serine protease of Bacillus anthracis, comprises a single A subunit and a pentamer 
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of substrate-targeting B subunits [319]. SubAB5 comprises of a single 35 kDa A subunit 
and a pentamer of 13 kDa B subunits [200]. Cell death is induced as a direct 
consequence of GRP78 cleavage [200], and treatment with SubAB5 at high doses results 
in the activation of the UPR, characterised by the induction of eIF2α phosphorylation 
and XBP-1 splicing [320], leading to the induction of Gadd153, characteristic changes 
in protein synthesis and EDEM. Thus, treatment with SubAB5 can induce ER stress 
signalling [320].  
Jack Arbiser and colleagues using biotinylated honokiol bound to strepdavadin beads 
demonstrated that GRP78 from SVR angiosarcoma cell lysates interacted with honokiol. 
Alastair Hawkins and Heather Lamb, as for EGCG, have demonstrated an interaction 
between GRP78 and honokiol. Again this work demonstrated interaction with the 
ATPase domain (Unpublished data). Honokiol is a lignan, a chemical component of 
plant cell walls, in this case present in the cones, bark, and leaves of Magnolia 
grandiflora and has been used in the traditional Japanese medicine Saiboku-to as an 
anxiolytic, antithrombotic, anti-depressant, anti-emetic, and anti-bacterial. While early 
research on the effective compounds in traditional remedies have simply used whole 
magnolia bark extracts, known as houpu magnolia, recent work has identified honokiol 
and its structural isomer magnolol as the active compounds in magnolia bark [323]. In 
the late 1990s, honokiol saw a revival in western countries as a potent and highly 
tolerable anti-tumorigenic and neurotrophic compound. More recently, honokiol has 
been shown to be anti-oxidant, anti-inflammatory and a bio-available, non-toxic 
inhibitor of angiogenesis [323].  
Honokiol induces apoptosis as a result of ER stress in chondrosarcoma cells with the 
concomitant up-regulation of GRP78, Bax and Bak and down-regulation of Bcl-xl [324].  
It is noteworthy that, in this model, a reduction in GRP78 expression resulted in a 
decrease in honokiol mediated cell death. In vivo treatment with honokiol saw a 53% 
reduction in tumour volume [324].  
The aim of this study was to test the effect of the known inhibitors of GRP78 SubAB5 
and EGCG on ER stress-induced cell death of neural-crest-derived cancer cells in 
response to either fenretinide or bortezomib. As honokiol demonstrated an interaction 
with GRP78, an additional aspect of this work was to determine if honokiol, like EGCG 
could inhibit GRP78. Inhibitors were tested alone or in combination with either ER 
stress-inducing agent. To assess the effect of drug combinations on death and viability, 
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fixed-dose-ratio experiments for inhibitors alone and in combination were carried out by 
propidium iodide-stained flow cytometry and MTS or SRB (for EGCG) -based cell 
viability assays, as well as western blot analysis for caspase-3 cleavage. A final aim of 
this study was to test the prediction from GRP78 over-expression and knockdown 
studies that neuroblastoma cells would show different responses to GRP78 inhibitors 
compared to melanoma and glioblastoma cells. 
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6.2: Results 
6.2.1: SubAB5 synergistically enhances ER stress-induced death of 
melanoma and glioblastoma, but not neuroblastoma. 
The effect of the GRP78 inhibitor SubAb5 (toxin) on death and viability of melanoma, 
glioblastoma and neuroblastoma cancer cell lines was tested in comparison to the 
inactive mutant SubAA272B5 (mutant toxin). The effect of SubAB5 on GRP78 protein 
levels was also investigated in parallel to confirm toxin activity by measuring the 
formation of the 28 kDa product resulting from toxin-specific cleavage of GRP78 
between the functional domains. Toxin-mediated cleavage of GRP78 was detected 
using a C-terminal-specific GRP78 antibody which detects the 28 kDa cleavage product. 
There was a significant dose-dependent increase in cell death (Figure 6.1)  and 
inhibition of cell viability (Figure 6.2) in all cancer types tested (One-Way ANOVA 
with Dunnett’s post hoc corrections, for cell death: all cell lines from 100 ng/ml P < 
0.0001, CHl-1 cells with 50 ng/ml P < 0.05, WM266-4, MO59J, NGP and SH-SY5Y 
cell lines with 20 and 50 ng/ml toxin P < 0.05 and 0.0001 respectively or U251 cells 20 
and 50 ng/ml toxin P < 0.0001; for inhibition of cell viability: melanoma and 
neuroblastoma cell lines from 5 ng/ml toxin upwards P < 0.001, or glioblastoma cells 
from 50 ng/ml toxin P < 0.0001). The mutant toxin had no significant effect on the 
induction of cell death (P > 0.05). Comparing the effect of the toxin to the mutant toxin 
to confirm that the toxin is different to the mutant control in all cell lines showed a 
significant difference in response within all cell lines (Two-way ANOVA, for cell death: 
CHL-1 F1, 41 = 36, WM266-4 F1, 41 = 8.6, MO59J F1, 41 = 52, U251 F1, 41 = 14.7 NGP F1, 
41 = 17.7 and SH-SY5Y F1, 41 = 18.6, P < 0.0001. For inhibition of cell viability: CHL-1 
F1, 111 = 111.9 , MO59J F1, 111 = 42.5, U251 F1,111 = 17.3 NGP F1, 111 = 16.3 and SH-
SY5Y F1, 111 = 19.4, P < 0.0001 or WM266-4 F1, 111 = 9.6, P < 0.01). Interestingly, high 
doses of mutant toxin had a small but significant effect on melanoma cell viability (P < 
0.001 for both melanoma cell lines). 
Comparing the effect of toxin between cell lines demonstrated a significant difference in 
all cancer types for cell death and a difference between melanoma and glioblastoma cell 
lines for inhibition of cell viability (Two-way ANOVA: Cell death data for: Melanoma 
F3, 83 = 36.8, glioblastoma F3, 83 = 54.8 or neuroblastoma F3, 83 = 33.8, P < 0.001. Cell 
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viability data for: Melanoma; F3, 223 = 83.5, glioblastoma; F3, 223 = 59.7, P < 0.001 or 
0.01 respectively).  
Western blot analyses for the effect of toxin on GRP78 protein (Figure 6.3) 
demonstrated a significant decrease in GRP78 levels with increasing toxin (One-way 
ANOVA with Dunnett’s post hoc correction, CHL-1, WM266-4 and from 50 ng/ml or 
MO59J and U251 from 20 ng/ml P 0.001. NGP cells from 10 ng/ml or SHSY-5Y cells 
from a dose of 2.5 ng/ml; P < 0.001). There was also a significant increase in GRP78 
cleaved product with dose (One-way ANOVA with Dunnett’s post hoc correction, 
CHL-1, WM266-4, U251 and SH-SY5Y cell lines treated with toxin from; 0.5 ng/ml P 
< 0.001. MO59J cells from 1 ng/ml P < 0.001 and NGP cells treated with toxin from; 20 
ng/ml P < 0.05). Comparing cell lines within the same cancer type demonstrated no 
significant difference (P > 0.05), however significant differences were observed 
between cancer types, with melanoma cells (Figure 6.3 A & B, i, ii) showing 
significantly greater induction of cleaved product than either glioblastoma (Figure 6.3 A 
& B, iii, iv) or neuroblastoma (Figure 6.3 A & B, v, vi,   Two Way ANOVA, F37, 371 = 
427.3, P < 0.0001). There were no significant differences between glioblastoma and 
neuroblastoma (P > 0.05) 
Comparing the effect of toxin to siRNA mediate knock-down in GRP78 expression 
demonstrated that for all cell lines where a more than 50%, reduction in GRP78 
expression by toxin cleavage resulted in higher levels of cell death than when GRP78 
was reduced by siRNA (One-way ANOVA, for CHL-1, WM266-4 and SH-SY5Y cells 
F1, 5 = 15.6, 11.1 or 21.6 respectively, P ≤ 0.01) 
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Figure 6.1: The effect of GRP78 specific SubAB5 on neural-crest-derived cancer cell 
death. CHL-1 and WM266-4 melanoma (A & B), MO59J glioblastoma (C & D) and 
neuroblastoma (E & F) cells were treated with increasing doses of subtilase cytotoxin 
(SubAB5, doses 0 – 200 ng/ml) in comparison to an inactive mutant (SubA272B5) for 24 h 
prior to cell death   analysis by flow cytometry for the percentage SubG1 peak of 
propidium iodide stained cells. Each point is the mean SubG1 peak percentage of 3 
individual experiments ± 95% CI. 
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Figure 6.2: The effect of GRP78 specific SubAB5 on the inhibition of neural-crest-
derived cancer cell viability. CHL-1 and WM266-4 melanoma (A & B), MO59J 
glioblastoma (C & D) and neuroblastoma (E & F) cells were treated with increasing 
doses of subtilase cytotoxin (SubAB5, doses 0 – 200 ng/ml) in comparison to an inactive 
mutant (SubA272B5) for 24 h prior to analysis for the effect of GRP78 inhibition on 
neural-crest-derived cancer cell viability by MTS assays. Each point is the mean of 8 
replicates over 3 individual experiments ± 95% CI. 
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Figure 6.3: The effect of SubAB5 on GRP78 expression and cleavage. (A) Melanoma (i 
& ii), glioblastoma (iii & iv) and neuroblastoma (v & vi) cell lines were treated with 
increasing doses of SubAB5 (Toxin, dose range = 0.1 – 200 ng/ml) for 24 h prior to 
western blot analysis for GRP78 and cleaved product, in comparison to β-Actin as 
loading control, which is the intermediate band. (B) Densitometry data for the effect of 
SubAB5 on the expression of GRP78 (grey bars) or cleaved product (black bars, data 
are on the next page) is the mean of 3 individual experiments ± 95% CI. Data are 
corrected for loading control β-Actin and relative to lowest dose (because lowest dose 
had no effect on GRP78 expression relative to control.  
A 
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To investigate the response to toxin with regards to activity over time and the exposure 
required to induce a biologically-significant response, time course studies were carried 
out in melanoma cells, either under constant exposure to toxin (Figure 6.4 A – F) or 
where samples were treated for 1 h with toxin in comparison to inactive mutant and then 
washed (Figure 6.4 G – J) and samples tested for the effect on induction of cell death in 
comparison to achieved cleavage of GRP78. 
In the continuous presence of 5 ng/ml of toxin, cell death increased with time in both 
melanoma cell lines, producing similar levels of apoptosis up to 24 h (Figure 6.4). There 
was a time-dependent increase in GRP78 cleavage in both cell lines detectable within 1 
h of exposure to toxin, and with a concomitant decrease in full length GRP78 (Figure 
6.4). The increase in GRP78 cleavage correlated with increased levels of cell death; the 
inactive SubAA272B mutant toxin had no effect on apoptosis and did not cleave GRP78.  
The length of exposure to toxin required to induce apoptosis was assessed by treating 
cells with wild-type or mutant toxin for 1, 2, 4, 8 and 24 h, then continuing incubation 
in the absence of toxin for the time remaining to 24 h after initial exposure. There was a 
significant difference in response to toxin between the two cell lines (2-Way ANOVA; 
effect of cell type F1, 20=13.8, P < 0.001). Using the 1 h exposure time as a reference for 
CHL-1 cells, cell death was only significantly increased after 24 h exposure (One-way 
ANOVA, Dunnett’s test, up to 8 h, P ≥ 0.2; 24 h, P < 0.001). Conversely, for the 
WM266-4 cells, cell death was significantly elevated after 4 h exposure (One-way 
ANOVA, Dunnett’s test, 4, 8 and 24 h, P ≤ 0.05). This difference between the cell lines 
was mirrored by higher levels of cleaved GRP78 in WM266-4 cells after even a short 1 
h exposure to toxin (Figure 6.4). 
 
197 
 
 
 
 
198 
 
Figure 6.4: Time-course of apoptosis in response to continuous (Time Course) or 
pulsed exposure (Wash Out) to SubAB5 treatment. CHL-1 and WM266-4 cells were 
treated with 5 ng/ml SubAB5 for 1, 2, 4, 8 and 24 h and harvested for flow cytometry (A 
& B) and to assess GRP78 cleavage by Western blotting (C & D); blots were probed 
simultaneously for GRP78 and β-actin and the β-actin band is intermediate in size 
between full length GRP78 and the cleavage product. Densitometry data for full length 
GRP78 (E) and the cleavage product (F), relative to the β-actin loading control from 
three independent experiments were combined and are shown in panels E & F. Error 
bars in E & F are ± ± 95% CI. To investigate the length of exposure to toxin required to 
induce apoptosis after 24 h, cells were treated with 5 ng/ml SubAB5 continuously for 24 
h, or for 1, 2, 4, or 8 h then washed and cultured in the absence of SubAB5 in the 
medium to the time remaining until 24 h after initial exposure; at 24 h the cells were 
harvested for measurement of apoptosis (G & H) or GRP78 cleavage as above (I & J). 
Flow cytometry data are means ± 95% confidence intervals. Data for the effect of 
SubAB5 compared to mutant over time on GRP78 cleavage and apoptosis of melanoma 
cells were previously published [266]. 
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In summary these data show that SubAB5 cleaved GRP78 in all cell lines, resulting in a 
decrease in GRP78 expression and increase in cleaved product. This cleavage resulted 
in the induction of apoptosis in all cell lines and when comparing the effect of SubAB5 
reduction in GRP78 on cell death (as single agent) to the level of cell death in cells with 
reduced GRP78 expression (by siRNA treatment), SubAB5 induced significantly higher 
levels of death.  
Fixed-dose-ratio experiments were performed for SubAB5 combined with either 
fenretinide (Melanoma and glioblastoma for fenretinide with SubAB5 2000:1 and 
neuroblastoma 1000:1) or bortezomib (Melanoma and glioblastoma for fenretinide with 
SubAB5 1:40 and neuroblastoma 1:4) to test the hypothesis that GRP78 cleavage 
enhanced ER stress -induced cell death, as well as to test the hypothesis that differences 
in response outcome would exist between melanoma and glioblastoma, to that of 
neuroblastoma cancer cells (Figure 6.5). When melanoma and glioblastoma cells were 
treated with SubAB5 and fenretinide or bortezomib there was increasing synergy with 
dose (Figure 6.5 A – P, combination indices listed in Table 6.1). For melanoma cells 
there were moderate levels of synergy (ci > 0.6), in comparison to mild synergy seen for 
glioblastoma (ci > 0.9 but < 0.6).  
Comparing the combination indices for melanoma cells with respect to death and 
viability (Figure 6.5: A – D vs. E – H) showed that CHL-1 cells treated with bortezomib 
responded more with regards to death than viability. Investigating the combination of 
SubAB5 with either fenretinide or bortezomib on cell death in neuroblastoma (Figure 
6.5 Q – T) demonstrated no correlation with dose. Combination index values showed 
that the combination of SubAB5 with either ER stress-inducing agent was inhibitory 
(ci > 1). For the effect of the combination on neuroblastoma cell viability (Figure 6.5 U 
– X) there was a decrease in favourable outcome with increased dose, represented by an 
increase in combination indices with dose (Table 6.1).  
Assessing the combination indices values generated for the effect of SubAB5 combined 
with either fenretinide or bortezomib (data summarised in graphs alongside table 6.5) 
demonstrated differences in response between cancer types. Comparing combination 
indices values to cell line demonstrated a significant difference in response to 
combination. When combining SubAB5 with fenretinide, a dose dependent effect was 
only observed in all cell lines (One-Way ANOVA with Tukeys post hoc analysis, P ≤ 
0.05), and for SubAB5 combined with Bortezomib, a dose dependent effect was 
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observed for U251 and NGP cell lines (P ≤ 0.05). Comparing the combination of either 
fenretinide or bortezomib with SubAB5 elicited a significant response between cancer 
types when treated with bortezomib (P ≤ 0.001 for both), however no significant 
difference was observed across cancer types for the fenretinide combinations (P > 0.05). 
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Figure 6.5: Effect of GRP78 specific SubAB5 on fenretinide and bortezomib induced 
apoptosis or inhibition of cell viability. CHL-1 (A & B, E & F) or WM266-4 (C & D, G 
& H) melanoma, MO59J (I & J, M & N) or U251 (K & L, O & P) glioblastoma and 
NGP (Q & R, U & V) or SH-SY5Y (S & T, W & X) neuroblastoma cells were treated 
with fenretinide (dose range = 1 – 20 µM for melanoma and glioblastoma or 1 – 10 µM 
for neuroblastoma), bortezomib (dose range = 10 – 400 nM for melanoma and 
glioblastoma or 1 – 40 nM for neuroblastoma) and SubAB5 (Toxin, dose range = 0.5 – 
10 ng/ml) alone and in combination for 24 h at fixed dose ratios of 2000:1 or 1000:1 
(nM fenretinide: ng/ml SubAB5) and 40:1 or 4:1 (nM bortezomib: ng/ml SubAB5) for 
melanoma and glioblastoma or neuroblastoma , respectively. Samples were analyzed 
for cell death (A – D, I – L, Q –T  for melanoma, glioblastoma and neuroblastoma cell 
lines treated with either fenretinide or bortezomib, respectively) or inhibition of cell 
viability (E – H, M – P, U - X. T  for melanoma, glioblastoma and neuroblastoma cell 
lines treated with either fenretinide or bortezomib, respectively). Note that fenretinide 
units are expressed in µM on the figure. Apoptosis data are the mean of 3 experiments 
for cell death or 8 individual replicates for inhibition on cell viability ± 95% confidence 
intervals. CalcuSyn was used to determine the outcome of drug combinations 
(Combination indices for the outcome of drug interactions are given in Table 6.1). Data 
for the effect of SubAB5 on fenretinide and bortezomib-induced cell death and inhibition 
of cell viability of melanoma cells was previously published [266]. 
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Table 6.1: Effect of GRP78 inhibition by SubAB5 treatment on ER stress-induced cell 
death or inhibition of melanoma cell viability. Drug interaction reviewed by fixed-dose-
ratio analysis for the effect of GRP78 specific SubAB5 (Tox) on fenretinide (FenR) or 
bortezomib (Bort) induced cell death or inhibition of cell viability of melanoma, 
glioblastoma and neuroblastoma cells. Combination indices (ci) values; < 1 = Synergy 
(green), ≤ 1 = Additive (black) and > 1 = inhibitory (red). Data are given in Figure 6.5. 
Alongside the combination indices data are graphs summarising the combination 
indices over dose range were obtained for the effect of combining SubAB5 with either 
fenretinide or bortezomib for all cell lines individually. 
Cell Line ER stress inducing 
agent 
GRP78 Inhibitor Cell Death 
(ci) 
Viability 
(ci) 
CHL-1 1. FenR (1 µM) 1. Tox (0.5 ng/ml) 1.281 0.476 
 2. FenR (5 µM) 2. Tox (2.5  ng/ml) 0.781 1.826 
 3. FenR (10 µM) 3. Tox (5 ng/ml) 0.755 1.835 
 4. FenR (15 µM) 4. Tox (7.5 ng/ml) 0.637 0.705 
 5. FenR (20 µM) 5. Tox (10  ng/ml) 0.7 0.755 
 1. Bort (10 nM) 1. Tox (0.25 ng/ml) 0.026 15.552 
 2. Bort (100 nM) 2. Tox (2.5  ng/ml) 0.073 17.402 
 3. Bort (200 nM) 3. Tox (5 ng/ml) 0.073 2.391 
 4. Bort (300 nM) 4. Tox (7.5 ng/ml) 0.051 0.838 
 5. Bort (400 nM) 5. Tox (10  ng/ml) 0.057 0.18 
WM266-4 1. FenR (1 µM) 1. Tox (0.5 ng/ml) 1.956 1.493 
 2. FenR (5 µM) 2. Tox (2.5  ng/ml) 0.995 1.375 
 3. FenR (10 µM) 3. Tox (5 ng/ml) 0.599 0.791 
 4. FenR (15 µM) 4. Tox (7.5 ng/ml) 0.648 0.787 
 5. FenR (20 µM) 5. Tox (10  ng/ml) 0.654 0.636 
 1. Bort (10 nM) 1. Tox (0.25 ng/ml) 0.221 27.733 
 2. Bort (100 nM) 2. Tox (2.5  ng/ml) 1.463 4.497 
 3. Bort (200 nM) 3. Tox (5 ng/ml) 0.6 2.256 
 4. Bort (300 nM) 4. Tox (7.5 ng/ml) 0.513 0.918 
 5. Bort (400 nM) 5. Tox (10  ng/ml) 0.572 0.652 
MO59J 1. FenR (1 µM) 1. Tox (0.5 ng/ml) 0.975 41.6 
 2. FenR (5 µM) 2. Tox (2.5  ng/ml) 0.883 0.981 
 3. FenR (10 µM) 3. Tox (5 ng/ml) 0.873 0.036 
 4. FenR (15 µM) 4. Tox (7.5 ng/ml) 0.882 0.13 
 5. FenR (20 µM) 5. Tox (10  ng/ml) 0.815 0.052 
 1. Bort (10 nM) 1. Tox (0.25 ng/ml) 1.993 0.041 
 2. Bort (100 nM) 2. Tox (2.5  ng/ml) 0.862 0.263 
 3. Bort (200 nM) 3. Tox (5 ng/ml) 0.893 0.862 
 4. Bort (300 nM) 4. Tox (7.5 ng/ml) 0.799 0.912 
 5. Bort (400 nM) 5. Tox (10  ng/ml) 0.763 0.986 
U251 1. FenR (1 µM) 1. Tox (0.5 ng/ml) 27.62 33.621 
 2. FenR (5 µM) 2. Tox (2.5  ng/ml) 4.839 7.632 
 3. FenR (10 µM) 3. Tox (5 ng/ml) 3.62 1.463 
 4. FenR (15 µM) 4. Tox (7.5 ng/ml) 0.844 0.886 
 5. FenR (20 µM) 5. Tox (10  ng/ml) 0.711 0.763 
 1. Bort (10 nM) 1. Tox (0.25 ng/ml) 43.4 29.83 
 2. Bort (100 nM) 2. Tox (2.5  ng/ml) 4.663 417.62 
 3. Bort (200 nM) 3. Tox (5 ng/ml) 1.431 22.63 
 4. Bort (300 nM) 4. Tox (7.5 ng/ml) 0.812 0.86 
 5. Bort (400 nM) 5. Tox (10  ng/ml) 0.786 0.73 
NGP 1. FenR (0.5 µM) 1. Tox (0.5 ng/ml) 16.83 0.843 
 2. FenR (2.5 µM) 2. Tox (2.5  ng/ml) 22.63 0.91 
 3. FenR (5 µM) 3. Tox (5 ng/ml) 8.621 0.93 
 4. FenR (7.5 µM) 4. Tox (7.5 ng/ml) 1.473 0.981 
 5. FenR (10 µM) 5. Tox (10  ng/ml) 9.62 1.124 
 1. Bort (1 nM) 1. Tox (0.25 ng/ml) 6.36 0.901 
 2. Bort (10 nM) 2. Tox (2.5  ng/ml) 11.6 0.973 
 3. Bort (20 nM) 3. Tox (5 ng/ml) 9.4 0.843 
 4. Bort (30 nM) 4. Tox (7.5 ng/ml) 11.1 0.916 
 5. Bort (40 nM) 5. Tox (10  ng/ml) 3.4 0.984 
SH-SY5Y 1. FenR (0.5 µM) 1. Tox (0.5 ng/ml) 17.6 0.791 
 2. FenR (2.5 µM) 2. Tox (2.5  ng/ml) 0.841 0.761 
 3. FenR (5 µM) 3. Tox (5 ng/ml) 1.013 0.684 
 4. FenR (7.5 µM) 4. Tox (7.5 ng/ml) 3.6 2.31 
 5. FenR (10 µM) 5. Tox (10  ng/ml) 5.8 1.610 
 1. Bort (1 nM) 1. Tox (0.25 ng/ml) 0.932 1.23 
 2. Bort (10 nM) 2. Tox (2.5  ng/ml) 0.916 0.94 
 3. Bort (20 nM) 3. Tox (5 ng/ml) 2.1 0.996 
 4. Bort (30 nM) 4. Tox (7.5 ng/ml) 0.994 1.433 
 5. Bort (40 nM) 5. Tox (10  ng/ml) 1.31 2.136 
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To determine if the increase in  cell death and inhibition of cell viability observed when 
GRP78 cleavage was combined with an ER stress-inducing agent was a consequence of 
changes in the UPR response, western blots for GRP78 expression, ATF4  induction 
and caspase 3 cleavage (Figure 6.6) were performed for the effect of fenretinide (For 
melanoma and glioblastoma: F1 = 5 µM and F2 = 10 µM or neuroblastoma F1 = 2.5 
µM and F2 = 5 µM), bortezomib  (B1 = 100 nM and B2 = 200 nM or neuroblastoma B1 
= 10 nM and B2 = 20 nM) or toxin (T1 = 5 ng/ml and T2 = 10 ng/ml) alone or in 
combination (FT1, FT2, BT1 and BT2) in melanoma, glioblastoma and neuroblastoma 
cell lines. In cells exposed to SubAB5, there was induction of cleaved product for all 
cancer types (Figure 6.6, One-way ANOVA with Bonferroni post hoc corrections, for 
all cell lines treated with T1 = P < 0.01, or T2 = P < 0.001). SubAB5 treatment in 
combination with ER stress-inducing agents resulted in a decrease in expression of 
GRP78 after exposure to BT1, BT2 or FT1, FT2 (One-way ANOVA with Bonferroni 
post hoc corrections, P < 0.01).  
Treatment of SubAB5 alone or in combination significantly induced the expression of 
cleaved GRP78 in all samples (One-way ANOVA with Bonferroni post hoc corrections, 
P < 0.01), except for SH-SY5Y cells treated with FT1 (P > 0.05). Combining an ER 
stress-inducing agent with the SubAB5 resulted in significant changes in the production 
of the cleaved product (Figure 6.6 A iii – F iii). Data showed that treatment with FT2 in 
comparison to SubAB5 alone significantly reduced GRP78 cleavage in all cell lines 
(One-way ANOVA with Bonferroni post hoc corrections, All cell line P ≤ 0.05), except 
in U251 cells, where treatment with FT1 demonstrated the capacity to hinder toxin 
induced GRP78 cleavage (P < 0.001). Treatment of CHL-1, WM266-4, MO59J and 
NGP cells with BT2 demonstrated a significant increase in cleaved product (One-way 
ANOVA with Bonferroni post hoc corrections, All cell line P ≤ 0.05). WM266-4, 
MO59J and NGP cells, as well as SH-SY5Y cells showed a significant increase in 
GRP78 cleavage when treated with BT1 (P ≤ 0.05).  
With respect to the induction of ATF4 or cleavage of caspase 3, the combination of 
fenretinide and SubAB5 showed a significant increase in ATF4 induction with either 
dose in both melanoma cell lines and MO59J cells (One-way ANOVA with Bonferroni 
post hoc corrections, for all cell lines with either concentration P ≤ 0.001), as well as 
showing a significant effect with high dose (FT2) in U251 glioblastoma and both 
neuroblastoma cell lines (P ≤ 0.001). For the combination of SubAB5 with bortezomib, a 
decrease in ATF4 induction was observed in melanoma cell lines and NGP 
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neuroblastoma cells with either dose (One-way ANOVA with Bonferroni post hoc 
corrections, for all cell lines with either concentration P ≤ 0.001), as well as MO59J 
cells with BT2 treatment (P ≤ 0.005). 
Combining SubAB5 with fenretinide demonstrated a reduction in caspase 3 cleavage for 
either FT1 or FT2 treatments in both melanoma cells lines, U251 glioblastoma and NGP 
neuroblastoma cell lines (One-way ANOVA with Bonferroni post hoc corrections, for 
all cell lines with either concentration P ≤ 0.001), and resulted in a decrease in FT2 
treatment in MO59J cells (P ≤ 0.01). For bortezomib, with SubAB5, data showed that 
the BT2 treatment for WM266-4 cells of either BT1 or BT2 for neuroblastoma cells 
showed a decrease in caspase 3 cleavage (One-way ANOVA with Bonferroni post hoc 
corrections, for all cell lines with either concentration P ≤ 0.001). Conversely, both 
glioblastoma cell lines demonstrated an increase in cleaved caspase 3 when treated with 
the BT2 combination (P ≤ 0.01). 
In summary, these data show that in melanoma and glioblastoma treatment of SubAB5 
with either ER stress-inducing agent fenretinide or bortezomib resulted in a synergistic 
enhancement of cell death and inhibition of cell viability. However, for neuroblastoma 
there was an inhibitory effect. Investigation into the effect of these combinations by 
western blotting for GRP78, ATF4 and cleaved caspase 3 demonstrated no clear effect 
on ER stress or apoptosis. 
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Figure 6.6: The effect of SubAB5 treatment on fenretinide or bortezomib induced ER 
stress and induction of apoptosis. Melanoma (A & B), glioblastoma (C & D) and 
neuroblastoma (E & F) cells were treated with fenretinide (light grey bars, For 
melanoma and glioblastoma, F1 = 5 µM and F2 = 10 µM or neuroblastoma F1 = 2.5 
µM and F2 = 5 µM), bortezomib (Dark grey bars, For melanoma and glioblastoma, B1 
= 100 nM and B2 = 200 nM or neuroblastoma B1 = 10 nM and B2 = 20 nM) and 
SubAB5 (Toxin, Dotted bars, T1 = 5 ng/ml and T2 = 10 ng/ml) alone or in combination 
(FT1, FT2, BT1and BT2) for 24 h. Western blot analysis (i) were performed for GRP78 
expression, induction of UPR inducible ATF4 and cleavage of caspase 3, using β-Actin 
as a loading control. Densitometry analysis were performed on GRP78 (ii), ATF4 (iii) 
and cleaved caspase 3 (iv) and data expressed as mean values, relative to β-Actin as a 
loading control, of 3 independent experiments ± 95%. Graphs are scaled across cancer 
types, differing depending on the protein of interest to allow for a visual comparison for 
the effect of drug combinations. 
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  Combination 
Cell Line Protein FT1 FT2 
  
BT1 BT2 
CHL-1 
GRP78 
        
WM266-4         
MO59J         
U251         
NGP         
SH-SY5Y         
  
CHL-1 
Cleaved GRP78 
    
  
    
WM266-4         
MO59J         
U251         
NGP         
SH-SY5Y         
  
CHL-1 
ATF4 
    
  
    
WM266-4         
MO59J         
U251         
NGP         
SH-SY5Y         
  
CHL-1 
Cleaved Caspase 3 
    
  
    
WM266-4         
MO59J         
U251         
NGP         
SH-SY5Y         
Table 6.2: The effect of SubAB5 treatment on ER stress and induction of cancer cell 
apoptosis.  A Summary table for the effect of drug combination in comparison to ER 
stress-inducing agents (fenretinide + F, Bortezomib + B) or SubAB5 treatment (Toxin = 
T). Data are the average of the response of 3 individual experiments and demonstrate 
an increase (green), decrease (red) or no significant difference (grey) in protein 
expression.  
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6.2.2: The effect of natural GRP78 inhibitor epigallocatechin gallate on ER 
stress-induced neural-crest-derived cancer cell survival. 
EGCG over a range of doses (0.1 – 200 µM) was used to investigate effects on cell 
death and viability of neural-crest-derived cancer cell lines (Figure 6.7). Cell viability 
was assessed by SRB assay, rather than MTS for all experiments including EGCG, due 
to auto-fluorescence affecting MTS readouts at high EGCG concentrations. There was a 
significant induction of cell death or inhibition of cell viability with increasing doses of 
EGCG in all cell lines tested (One-way ANOVA with Dunnett’s post hoc corrections, 
for cell death: MO59J, U251 and SH-SY5Y cells treated with 5 µM, WM266-4 or NGP 
with 7.5 µM or CHL-1 with 10 µM up wards P < 0.05. For viability: NGP with 0.5 µM, 
SH-SY5Y with 1 µM, WM266-4 and MO59J with 5 µM, U251 with 7.5 µM and CHL-
1 treated with 10 µM up wards P ≤ 0.05).  
There was a significant difference between melanoma cell lines, with regard to 
inhibition of cell viability (Two-way ANOVA, F19,59 = 86.3, P < 0.001), with no 
significant difference observed for glioblastoma and neuroblastoma (P > 0.05). 
Comparing cancer types for the induction of cell death showed melanoma cells 
responded significantly greater than either glioblastoma or neuroblastoma (Two-way 
ANOVA, for cell death melanoma vs. glioblastoma or neuroblastoma F19, 59 = 23.2 or 
27.9, P < 0.001, respectively). For cell viability there was no significant difference 
between cancer types (P > 0.05). 
The effect of EGCG on eliciting an ER stress response and activating apoptosis was 
carried out, looking at ATF4 and caspase 3 cleavage, this work demonstrated no 
significant induction in either proteins expression. This is represented in figure 6.9, as 
part of the fixed-dose-ratio work, where treatment with high and low dose of EGCG had 
no effect. 
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Figure 6.7: The effect of GRP78 inhibitor EGCG on neural-crest-derived cancer cells.  
Melanoma (A & B), glioblastoma (C & D) and neuroblastoma (E & F) cells were 
treated with increasing doses of epigallocatechin gallate (EGCG, dose range = 0.1 – 
200 µM) for 24 h. Cells were assessed for induction of cell death and inhibition of cell 
viability. Note; cell viability of cells treated with EGCG were performed by SRB assay 
due to the effect of auto-fluorescence. For cell death each point is the mean percentage 
SubG1 peak of 3 individual experiments or inhibition of cell viability 8 replicate 
experiments ± 95% CI. 
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Fixed-dose-ratio experiments were performed for EGCG combined with either 
fenretinide or bortezomib (melanoma and glioblastoma were used at ratios of 1:1 for 
fenretinide and 1:50 with bortezomib, Neuroblastoma were used at 1:2 with fenretinide 
and 1:500 with Bortezomib) to test the hypothesis that inhibition of GRP78 enhanced 
ER stress-induced cell death, and to test the hypothesis that differences in response 
outcome would exist between melanoma and glioblastoma to neuroblastoma cancer 
cells (Figure 6.8). There was an increase in synergy with dose for the combination of 
EGCG with fenretinide on melanoma cell death (Figure 6.8 A & C, reaching a ci < 0.4, 
combination indices values listed in Table 6.3). However, when EGCG was combined 
with bortezomib the interaction was inhibitory (ci > 1, Table 6.3). Cell viability data 
showed an increase in inhibition of cell viability when either ER stress-inducing agent 
was combined with EGCG (Figure 6.8 E – H). Combination indices for inhibition of 
cell viability demonstrated a lower level of synergy for cell death (ci < 0.7, Table 6.3). 
For glioblastoma cells combination indices for the combination of EGCG with either 
fenretinide or bortezomib were not dose dependent (Table 6.3), with an overall 
inhibitory effect (ci > 1), except for U251 cells treated with fenretinide and EGCG 
where at high doses a weak synergistic interaction was achieved (ci < 0.7, Table 6.3). 
NGP and SH-SY5Y neuroblastoma cells demonstrated a weak synergy for the induction 
of cell death cell death in EGCG/fenretinide combinations and for NGP cells treated 
with EGCG/bortezomib (ci < 0.5, Table 6.3). For the effect of EGCG on either 
fenretinide- or bortezomib-induced inhibition of cell viability (Figure 6.8 U – X), there 
was an inhibitory effect on fenretinide response and an additive effect on bortezomib 
responses (ci > 1, Table 6.3).  
Investigating the combination indices values generated for the effect of EGCG 
combined with either fenretinide or bortezomib (data summarised in graphs alongside 
table 6.3) demonstrated differences in response across cancer types. EGCG in 
combination with fenretinide- the cell type to cell line interaction was not significant 
(P > 0.05), so cell types were compared using Tukeys HSD where glioblastoma and 
melanoma differed significantly (P < 0.05) but there was no significant difference 
between neuroblastoma and glioblastoma (P > 0.05) or melanoma (P > 0.05).  EGCG in 
combination with bortezomib- cell type to cell line interaction was significant (P < 
0.0005) so the data were analysed by cell line.  The combination overall was inhibitory 
but particularly for SH-SY5Y neuroblastoma cells which was significantly different 
compared to the other cell lines (P < 0.05). 
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Figure 6.8: Effect of GRP78 inhibitor EGCG on fenretinide and bortezomib induced 
apoptosis or inhibition of cell viability. CHL-1 (A & B, E & F) or WM266-4 (C & D, G 
& H) melanoma, MO59J (I & J, M & N) or U251 (K & L, O & P) glioblastoma and 
NGP (Q & R, U & V) or SH-SY5Y (S & T, W & X) neuroblastoma cells were treated 
with fenretinide (dose range = 1 – 20 µM for melanoma and glioblastoma or 1 – 10 µM 
for neuroblastoma), bortezomib (dose range = 10 – 400 nM for melanoma and 
glioblastoma or 1 – 40 nM for neuroblastoma) and epigallocatechin gallate (EGCG, 
dose range = 1 – 20 µM) alone and in combination for 24 h at fixed-dose-ratios of 1:1 
or 2:1 (µM fenretinide: µM EGCG) and 1:50 or 1:500 (nM bortezomib: µM EGCG) for 
melanoma and glioblastoma or neuroblastoma , respectively. Samples were analyzed 
for cell death (A – D, I – L, Q –T  for melanoma, glioblastoma and neuroblastoma cell 
lines treated with either fenretinide or bortezomib respectively) or inhibition of cell 
viability (E – H, M – P, U - X. T  for melanoma, glioblastoma and neuroblastoma cell 
lines treated with either fenretinide or bortezomib, respectively). Apoptosis data are the 
mean of 3 experiments for cell death or 8 individual replicates for inhibition on cell 
viability ± 95% confidence intervals. CalcuSyn was used to determine the outcome of 
drug combinations (Combination indices for the outcome of drug interactions are given 
in Table 6.3). 
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Table 6.3: The effect of GRP78 
inhibition by EGCG treatment on ER 
stress-induced cell death or inhibition of cancer cell viability. Drug interaction review 
by fixed dose ratio analysis for the effect of GRP78 epigallocatechin gallate (EGCG) on 
fenretinide (FenR) or bortezomib (Bort) induced cell death or inhibition of cell viability 
of melanoma, glioblastoma and neuroblastoma cells. Combination indices (ci) values; 
< 1 = Synergy (Green), ≤ 1 = Additive (Black) and > 1 = inhibitory (red). Data are 
given in Figure 6.8. Alongside the combination indices data are graphs summarising 
the combination indices obtained for the effect of combining EGCG with either 
fenretinide or bortezomib. 
Cell Line ER stress 
inducing agent 
GRP78 
Inhibitor 
Cell Death 
(ci) 
Viability 
(ci) 
CHL-1 1. FenR (1 µM) 1. EGCG (1 µM) 1.062 1.986 
 2. FenR (5 µM) 2. EGCG (5 µM) 1.019 2.34 
 3. FenR (10 µM) 3. EGCG (10 µM) 0.376 0.68 
 4. FenR (15 µM) 4. EGCG (15 µM) 0.412 0.761 
 5. FenR (20 µM) 5. EGCG (20 µM) 0.316 0.68 
 1. Bort (10 nM) 1. EGCG (0.5 µM) 2.63 1.94 
 2. Bort (100 nM) 2. EGCG (5 µM) 3.14 0.74 
 3. Bort (200 nM) 3. EGCG (10 µM) 2.62 0.83 
 4. Bort (300 nM) 4. EGCG (15 µM) 1.93 0.79 
 5. Bort (400 nM) 5. EGCG (20 µM) 2.014 0.69 
WM266-4 1. FenR (1 µM) 1. EGCG (1 µM) 0.331 1.662 
 2. FenR (5 µM) 2. EGCG (5 µM) 1.62 0.991 
 3. FenR (10 µM) 3. EGCG (10 µM) 0.231 0.892 
 4. FenR (15 µM) 4. EGCG (15 µM) 0.376 0.73 
 5. FenR (20 µM) 5. EGCG (20 µM) 0.344 0.78 
 1. Bort (10 nM) 1. EGCG (0.5 µM) 1.016 1.919 
 2. Bort (100 nM) 2. EGCG (5 µM) 1.14 2.42 
 3. Bort (200 nM) 3. EGCG (10 µM) 1.63 0.96 
 4. Bort (300 nM) 4. EGCG (15 µM) 2.64 0.98 
 5. Bort (400 nM) 5. EGCG (20 µM) 2.81 0.91 
MO59J 1. FenR (1 µM) 1. EGCG (1 µM) 6.41 2.62 
 2. FenR (5 µM) 2. EGCG (5 µM) 4.86 0.53 
 3. FenR (10 µM) 3. EGCG (10 µM) 0.94 2.97 
 4. FenR (15 µM) 4. EGCG (15 µM) 0.79 6.37 
 5. FenR (20 µM) 5. EGCG (20 µM) 1.93 6.4 
 1. Bort (10 nM) 1. EGCG (0.5 µM) 2.62 0.36 
 2. Bort (100 nM) 2. EGCG (5 µM) 1.83 0.76 
 3. Bort (200 nM) 3. EGCG (10 µM) 1.99 2.62 
 4. Bort (300 nM) 4. EGCG (15 µM) 0.96 6.94 
 5. Bort (400 nM) 5. EGCG (20 µM) 1.18 6.39 
U251 1. FenR (1 µM) 1. EGCG (1 µM) 2.93 1.43 
 2. FenR (5 µM) 2. EGCG (5 µM) 0.63 0.97 
 3. FenR (10 µM) 3. EGCG (10 µM) 0.78 0.76 
 4. FenR (15 µM) 4. EGCG (15 µM) 0.97 1.09 
 5. FenR (20 µM) 5. EGCG (20 µM) 1.43 0.84 
 1. Bort (10 nM) 1. EGCG (0.5 µM) 2.4 3.4 
 2. Bort (100 nM) 2. EGCG (5 µM) 0.95 18.6 
 3. Bort (200 nM) 3. EGCG (10 µM) 1.4 19.9 
 4. Bort (300 nM) 4. EGCG (15 µM) 1.016 22.8 
 5. Bort (400 nM) 5. EGCG (20 µM) 1.005 17.6 
NGP 1. FenR (1 µM) 1. EGCG (2 µM) 4.99 1.01 
 2. FenR (2.5 µM) 2. EGCG (5 µM) 2.063 0.87 
 3. FenR (5 µM) 3. EGCG (10 µM) 2.011 0.93 
 4. FenR (7.5 µM) 4. EGCG (15 µM) 0.83 1.83 
 5. FenR (10 µM) 5. EGCG (20 µM) 0.48 3.7 
 1. Bort (1 nM) 1. EGCG (0.5 µM) 8.6 0.62 
 2. Bort (10 nM) 2. EGCG (5 µM) 0.93 1.1 
 3. Bort (20 nM) 3. EGCG (10 µM) 0.89 0.96 
 4. Bort (30 nM) 4. EGCG (15 µM) 0.84 0.99 
 5. Bort (40 nM) 5. EGCG (20 µM) 0.87 0.98 
SH-SY5Y 1. FenR (1 µM) 1. EGCG (2 µM) 0.036 0.96 
 2. FenR (2.5 µM) 2. EGCG (5 µM) 0.29 0.89 
 3. FenR (5 µM) 3. EGCG (10 µM) 0.48 0.94 
 4. FenR (7.5 µM) 4. EGCG (15 µM) 0.79 4.3 
 5. FenR (10 µM) 5. EGCG (20 µM) 0.83 3.3 
 1. Bort (1 nM) 1. EGCG (0.5 µM) 6.23 1.42 
 2. Bort (10 nM) 2. EGCG (5 µM) 24.6 0.91 
 3. Bort (20 nM) 3. EGCG (10 µM) 29.3 0.81 
 4. Bort (30 nM) 4. EGCG (15 µM) 27.6 0.83 
 5. Bort (40 nM) 5. EGCG (20 µM) 28.1 0.91 
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To investigate the effect of combining EGCG with an ER stress-inducing agent on 
biochemical markers of ER stress and apoptosis cell lines were treated with fenretinide 
(For melanoma and glioblastoma: F1 = 5 µM and F2 = 10 µM or neuroblastoma F1 = 
2.5 µM and F2 = 5 µM), bortezomib  (B1 = 100 nM and B2 = 200 nM or neuroblastoma 
B1 = 10 nM and B2 = 20 nM) or EGCG (E1 = 5 µM and E2 = 10 µM) alone or in 
combination (FE1, FE2, BE1 and BE2, Figure 6.9). 
Melanoma and glioblastoma cell lines demonstrated a reduction in GRP78 expression 
when treated with combinations of fenretinide or bortezomib with EGCG (Figure 6.9 A-
D ii, One-way ANOVA with Bonferroni post hoc corrections, For all samples P ≤ 0.01), 
except for CHL-1 and MO59J, where there was an increase in GRP78 expression in 
cells treated with the FE1 combination (P < 0.0001 for both).  
For ATF4 there was a significant reduction in expression in CHL-1 and WM266-4 cells 
treated with FE2, BE1 and BE2 combinations (Figure 6.9 A-D iii, One-way ANOVA 
with Bonferroni post hoc corrections, for all samples P ≤ 0.01). Significant increases in 
expression were demonstrated in the remaining combinations (P < 0.0001 for 
melanoma). MO59J and U251 glioblastoma cell lines for ATF4 expression, 
demonstrated no consistent change in response outcome for the combinations, 
respectively (P < 0.0001 for all). Where an increase in ATF4 expression was observed 
for MO59J with either bortezomib combination (P ≤ 0.01) and a decrease in expression 
in U251 cells treated with FE1, FE2 and BE2 (P ≤ 0.01) 
For caspase 3 cleavage there was a significant reduction in melanoma and glioblastoma 
cell lines with either fenretinide or bortezomib combinations with EGCG (Figure 6.9 A-
D iv, One-way ANOVA with Bonferroni post hoc corrections, For all samples P ≤ 0.01), 
except for CHL-1 treated with the FE1 combination, were an increase in caspase 3 
cleavage was observed (P ≤ 0.01). 
For the effect of EGCG combination with either fenretinide or bortezomib in 
neuroblastoma cell lines, data demonstrated a significant decrease in GRP78 expression, 
in NGP FE1, BE1 and BE2 combinations (Figure 6.9 E & F ii, One-way ANOVA with 
Bonferroni post hoc corrections, For all samples P ≤ 0.01), and an increase in NGP cells 
treated with the FE2 combination or all SH-SY5Y combinations (P < 0.05). The effect 
of EGCG combination with fenretinide or bortezomib on ATF4 induction in 
neuroblastoma cell lines demonstrated significant increase in expression in NGP cells 
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with the FE1 combination (Figure 6.9 E & F ii, One-way ANOVA with Bonferroni post 
hoc corrections, for all samples P ≤ 0.01). All other combinations demonstrated a 
significant reduction in ATF4 expression (For all samples P ≤ 0.01), except NGP cells 
treated with FE2 (P > 0.05). Caspase 3 data showed an increase in cleavage for NGP 
cells treated with FE2 and BE1 combinations (Figure 6.9 E & Fiv, One-way ANOVA 
with Bonferroni post hoc corrections, for all samples P ≤ 0.01) and a decrease for NGP 
cells treated with BE2 or all SH-SY5Y combinations (P ≤ 0.01).  
In summary, EGCG induced cell death and inhibition of cell viability in a dose 
dependent manner in all cell lines tested. When combining EGCG with an ER stress-
inducing agent, a synergistic response was observed in melanoma cells treated with 
fenretinide. However no enhancement of was observed in glioblastoma and for 
neuroblastoma the combination with fenretinide showed an increase in inhibition of 
response with dose. Finally the assessment of ATF4 induction and caspase 3 cleavage 
for the combination of EGCG with either fenretinide or bortezomib showed no 
consistent effect. 
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Figure 6.9:  The effect of EGCG treatment on fenretinide or bortezomib induced ER 
stress and induction of apoptosis. Melanoma (A & B), glioblastoma (C & D) and 
neuroblastoma (E & F) cells were treated with either fenretinide (light grey bars, For 
melanoma and glioblastoma, F1 = 5 µM and F2 = 10 µM or neuroblastoma F1 = 2.5 
µM and F2 = 5 µM), bortezomib (Dark grey bars, For melanoma and glioblastoma, B1 
= 100 nM and B2 = 200 nM or neuroblastoma B1 = 10 nM and B2 = 20 nM) or  
epigallocatechin gallate (EGCG, Dotted bars, E1 = 5 µM and E2 = 10 µM) alone or in 
combination for 24 h. Western blot analyses (i) were performed for GRP78 expression, 
induction of UPR inducible ATF4 and cleavage of caspase 3, using β-Actin as a loading 
control. Densitometry analysis were performed on GRP78 (ii), ATF4 (iii) and cleaved 
caspase 3 (iv) and data expressed as mean values, relative to β-Actin as a loading 
control, of 3 independent experiments ± 95%. Graphs are scaled across cancer types, 
differing depending on the protein of interest to allow for a visual comparison for the 
effect of drug combinations. 
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  Combination 
Cell Line Protein FE1 FE2   BE1 BE2 
CHL-1 
GRP78 
    
  
    
WM266-4         
MO59J         
U251         
NGP         
SH-SY5Y         
  
CHL-1 
ATF4 
    
  
    
WM266-4         
MO59J         
U251         
NGP         
SH-SY5Y         
  
CHL-1 
Cleaved Caspase 3 
    
  
    
WM266-4         
MO59J         
U251         
NGP         
SH-SY5Y         
Table 6.4: The effect of GRP78 inhibition, by EGCG treatment, on the induction of ER 
stress in neural-crest-derived cancer cells.  A Summary table for the effect of drug 
combination in comparison to ER stress-inducing agents (Fenretinide = F, Bortezomib 
= B) or EGCG treatment control (EGCG = E). Data are the sum of the response of 3 
individual experiments and demonstrate an increase (green), decrease (red) or no 
significant difference (grey) in protein expression.  
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6.2.3: The effect of natural putative GRP78 inhibitor honokiol on ER stress 
and cell death of melanoma, glioblastoma and neuroblastoma cancer cells.  
To Investigate the effect of honokiol on neural-crest-derived cancer cells, melanoma, 
glioblastoma and neuroblastoma cells were treated with increasing doses of honokiol 
and assessed for the induction of cell death or inhibition of cell viability (Figure 6.10, 
dose range = 0.1 – 100 µM).  
There was a significant induction of cell death in all cancer lines (One-way ANOVA 
with Dunnett’s post hoc correction, for CHL-1 and WM266-4 from 40 µM or MO59J, 
U251, NGP and SH-SY5Y cells from 10 µM P ≤ 0.05) and inhibition of cell viability 
(For CHL-1 and WM266-4 from 20 µM or MO59J, U251, NGP and SH-SY5Y cells 
from 40 µM P ≤ 0.05). 
The response between cancer lines within each cancer type was similar (P > 0.05), but 
between cancer types there was a lower response in glioblastoma compared to either 
melanoma or neuroblastoma (Two-way ANOVA, for cell death glioblastoma vs. either 
melanoma or neuroblastoma F19, 59 = 23.3 or 17.6, P < 0.001, respectively). As well as 
differences in the magnitude of death induced across cancer types, there were 
differences in the kinetics of honokiol-induced cell death. Glioblastoma and 
neuroblastoma demonstrated an exponential rise to the maximum achievable level of 
cell death. On the other hand, melanoma showed a more classic sigmoidal effect of 
honokiol, requiring more drug to elicit a response than either glioblastoma or 
neuroblastoma (Melanoma requiring a minimum of 20 µM honokiol in comparison to 
glioblastoma 5 µM and Neuroblastoma 2.5 µM). The kinetic responses were also the 
same for each cell line of a certain cancer type, suggesting a cancer-type-specific mode 
of action. 
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Figure 6.10: The effect of honokiol on neural-crest-derived cancer cell death and 
inhibition of cell viability. Melanoma (A & B), glioblastoma (C & D) and 
neuroblastoma (E & F) cells were treated with increasing doses of Honokiol (dose 
range = 0.1 – 100 µM) for 24 h. Cells were assessed for the induction of cell death by 
propidium iodide stained flow cytometry and inhibition of cell viability by MTS assay. 
For cell death each point is the mean percentage SubG1 peak of 3 individual 
experiments or inhibition of cell viability of 8 replicates over 3 individual experiments ± 
95% CI. 
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To test the hypothesis that honokiol induces death and inhibition of cell viability by 
activating ER stress and downstream apoptosis signalling cascades, cancer cells were 
treated with increasing doses of honokiol (0 – 100 µM) and analysed by western blot for 
GRP78 expression, ATF4 induction and caspase 3 cleavage (Figure 6.11). The 
treatment of melanoma (Figure 6.11 A & B), glioblastoma (Figure 6.11 C & D) and 
neuroblastoma (Figure 6.11 E & F) cell lines with honokiol significantly induced the 
expression of GRP78 (One-way ANOVA with Dunnett’s post hoc corrections, CHL-1; 
20 – 75 µM, WM266-4; 1 – 50 µM, MO59J and U251; 0.5 µM up wards, NGP; 0.5 – 
50 µM or SH-SY5Y; 0.5 – 75 µM P ≤ 0.05). However, cancer types treated with high 
dose honokiol showed a reduction in GRP78 expression (One-way ANOVA with 
Dunnett’s post hoc corrections, for CHL-1, WM266-4, U251, SH-SY5Y at 100 µM or 
NGP at 75 & 100 µM, P ≤ 0.001). Comparing cancer types demonstrated no significant 
difference in GRP78 induction in response to honokiol (P > 0.05), but cell lines of the 
same cancer type show significant differences in sensitivity (Two-way ANOVA, for 
melanoma, glioblastoma and neuroblastoma F33, 197 = 33.2, 54.6 and 66.9, respectively, 
P < 0.0001). 
The cell lines all demonstrated a significant dose-dependent increase in ATF4 
expression (One-way ANOVA with Dunnett’s post hoc corrections, melanoma cells 
from 20 µM, glioblastoma from 5 µM or NGP and SH-SY5Y neuroblastoma cells from 
30 & 10 µM respectively, P ≤ 0.01) and caspase 3 cleavage (One-way ANOVA with 
Dunnett’s post hoc corrections, melanoma from 5 µM, glioblastoma from 50 µM and 
neuroblastoma from 1 µM, P ≤ 0.01). WM266-4 melanoma cells treated with high doses 
of honokiol (75 & 100 µM) showed a loss of ATF4 induction, compared to lower doses 
(20 - 50 µM). Melanoma cells demonstrated significantly greater induction of ATF4 in 
comparison to glioblastoma or neuroblastoma (Two-way ANOVA, for melanoma vs. 
glioblastoma or neuroblastoma F33, 197 = 127.5, 144.6 respectively, P < 0.0001). 
Melanoma and neuroblastoma cells showed significantly higher stimulation of caspase 
3 cleavage by honokiol treatment than glioblastoma (Two-way ANOVA, F33, 197 = 41.2, 
P < 0.001). Comparing cell lines of the same cancer type highlighted differences 
between CHL-1 and WM266-4 cell lines for the achievable level of caspase 3 cleavage 
(Two-way ANOVA, F33, 65 = 21.8, P < 0.001). 
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Figure 6.11: The effect of honokiol dose on the induction of ER stress and apoptosis.  
Melanoma (A & B), glioblastoma (C & D) and neuroblastoma (E & F) cells were 
treated with increasing concentrations of honokiol (HNK, dose range = 0 – 100 µM) for 
24 h prior to western blot analysis (i) for ER stress markers; GRP78 and ATF4, or the 
apoptotic marker; cleaved caspase 3. Densitometry analysis were performed on GRP78 
(ii), ATF4 (iii) and cleaved caspase 3 (iv). G – Summary for the effect of honokiol dose 
response on cell death (black) in comparison to protein expression for ER stress 
(GRP78 + ATF4, blue and red respectively) and apoptosis (Cleaved caspase 3, green) 
induction. Data are expressed relative to β-Actin as a loading control (for western blot 
analysis) or as percentage of control (cell death). All are expressed as the mean values, 
of 3 independent experiments ± 95%. Graphs are scaled across cancer types, differing 
depending on the protein of interest to allow for a visual comparison for the effect of 
drug combinations. 
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To test the hypothesis that GRP78 inhibition, using the natural inhibitor honokiol, 
would enhance cell death of neural-crest-derived cancer cells in response to ER stress, 
fixed-dose-ratio experiments were carried for the combination of honokiol with either 
fenretinide or bortezomib (melanoma and glioblastoma were used at ratios of 1:5 for 
fenretinide and 1:250 with bortezomib, Neuroblastoma were used at 1:10 with 
fenretinide and 1:2500 with Bortezomib) and the effect assessed by cell death and 
inhibition of cell viability (Figure 6.12). Melanoma (Figure 6.12 A – H) and 
glioblastoma (I – P) cells demonstrated a synergistic interaction with respect to both cell 
death and inhibition of cell viability, for the combination of honokiol with either 
fenretinide or bortezomib (for cell death ci < 0.3 or viability ci < 0.02). Data for the 
inhibition of viability demonstrated greater synergy than that of the cell death data (ci < 
0.02, Table 6.5). Comparing combinations demonstrated no significant difference 
between interactions of either fenretinide or bortezomib (P < 0.05), with regards to the 
synergy achieved. Glioblastoma cells treated with high dose combinations demonstrate 
an inhibitory effect on the inhibition of cell viability (ci > 1, Table 6.5). Testing the 
effect of honokiol on fenretinide or bortezomib induced cell death or inhibition of cell 
viability in neuroblastoma (Figure 6.12 U – X) demonstrated an inhibitory interaction 
between honokiol and either ER stress-inducing agent (ci > 1, Table 6.5). 
Assessing the combination indices values generated for the effect of honokiol combined 
with either fenretinide or bortezomib (data summarised in graphs alongside table 6.5) 
demonstrated differences in response between cancer types. Honokiol in combination 
with fenretinide, the cell type to cell line interaction was significant (P < 0.005); except 
for neuroblastoma cell lines, were no significant difference was observed (P > 0.5). 
Neuroblastoma were significantly different to other cell lines (P < 0.05); WM266-4 
melanoma cells were similar to glioblastoma cells (P > 0.05) but significantly different 
to CHL-1 melanoma cells (P < 0.01). For honokiol in combination with bortezomib, no 
significant cell type to cell line interaction was observed (P > 0.05); neuroblastoma cells 
differed significantly from glioblastoma and melanoma cells (P < 0.0001). 
237 
 
238 
 
239 
 
240 
 
Figure 6.12:  Effect of honokiol on fenretinide and bortezomib induced cell death and 
inhibition of cancer cell viability. CHL-1 (A & B, E & F) or WM266-4 (C & D, G & H) 
melanoma, MO59J (I & J, M & N) or U251 (K & L, O & P) glioblastoma and NGP (Q 
& R, U & V) or SH-SY5Y (S & T, W & X) neuroblastoma cells were treated with 
fenretinide (dose range = 1 – 20 µM for melanoma and glioblastoma or 1 – 10 µM for 
neuroblastoma), bortezomib (dose range = 10 – 400 nM for melanoma and 
glioblastoma or 1 – 40 nM for neuroblastoma) and honokiol (HNK, dose range = 1 – 20 
µM) alone and in combination for 24 h at fixed-dose-ratios of 1:5 or 1:10 (µM 
fenretinide: µM HNK) and 1:50 or 1:500 (nM bortezomib: µM HNK) for melanoma and 
glioblastoma or neuroblastoma , respectively. Samples were analyzed for cell death (A 
– D, I – L, Q –T  for melanoma, glioblastoma and neuroblastoma cell lines treated with 
either fenretinide or bortezomib respectively) or inhibition of cell viability (E – H, M – 
P, U - X. T  for melanoma, glioblastoma and neuroblastoma cell lines treated with 
either fenretinide or bortezomib, respectively). Apoptosis data are the mean of 3 
experiments for cell death or 8 individual replicates for inhibition on cell viability ± 
95% confidence intervals. CalcuSyn was used to determine the outcome of drug 
combinations (Combination indices for the outcome of drug interactions are given in 
Table 6.5). 
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Table 6.5: Effect of honokiol treatment on ER stress-induced cell death or inhibition of 
cancer cell viability. Drug interaction review by fixed-dose-ratio analysis for the effect 
of GRP78 honokiol (HNK) on fenretinide (FenR) or bortezomib (Bort) induced cell 
death or inhibition of cell viability of melanoma, glioblastoma and neuroblastoma cells. 
Combination indices (ci) values; < 1 = Synergy (green), ≤ 1 = Additive (black) and > 1 
= inhibitory (red). Data are given in Figure 6.12. Alongside the combination indices 
data are graphs summarising the combination indices obtained for the effect of 
combining honokiol with either fenretinide or bortezomib for all cell lines individually. 
Cell Line ER stress 
inducing agent 
GRP78 
Inhibitor 
Cell Death 
(ci) 
Viability 
(ci) 
CHL-1 1. FenR (1 µM) 1. HNK (5 µM) 0.685 0.068 
 2. FenR (5 µM) 2. HNK (25 µM) 0.772 0.218 
 3. FenR (10 µM) 3. HNK (50 µM) 0.731 0.015 
 4. FenR (15 µM) 4. HNK (75 µM) 0.603 0.023 
 5. FenR (20 µM) 5. HNK (100 µM) 0.637 0.031 
 1. Bort (10 nM) 1. HNK (2.5 µM) 0.354 0.064 
 2. Bort (100 nM) 2. HNK (25 µM) 0.334 0.054 
 3. Bort (200 nM) 3. HNK (50 µM) 0.294 0.015 
 4. Bort (300 nM) 4. HNK (75 µM) 0.349 0.023 
 5. Bort (400 nM) 5. HNK (100 µM) 0.329 0.031 
WM266-4 1. FenR (1 µM) 1. HNK (5 µM) 0.205 0.054 
 2. FenR (5 µM) 2. HNK (25 µM) 0.339 0.459 
 3. FenR (10 µM) 3. HNK (50 µM) 0.242 0.001 
 4. FenR (15 µM) 4. HNK (75 µM) 0.16 0.013 
 5. FenR (20 µM) 5. HNK (100 µM) 0.136 0.001 
 1. Bort (10 nM) 1. HNK (2.5 µM) 0.644 0.025 
 2. Bort (100 nM) 2. HNK (25 µM) 1.398 0.018 
 3. Bort (200 nM) 3. HNK (50 µM) 0.302 0.006 
 4. Bort (300 nM) 4. HNK (75 µM) 0.274 0.009 
 5. Bort (400 nM) 5. HNK (100 µM) 0.197 0.012 
MO59J 1. FenR (1 µM) 1. HNK (5 µM) 0.016 23.6 
 2. FenR (5 µM) 2. HNK (25 µM) 0.741 18.4 
 3. FenR (10 µM) 3. HNK (50 µM) 0.286 0.021 
 4. FenR (15 µM) 4. HNK (75 µM) 0.374 0.034 
 5. FenR (20 µM) 5. HNK (100 µM) 0.398 1.013 
 1. Bort (10 nM) 1. HNK (2.5 µM) 0.244 4.3 
 2. Bort (100 nM) 2. HNK (25 µM) 0.962 0.96 
 3. Bort (200 nM) 3. HNK (50 µM) 0.883 0.11 
 4. Bort (300 nM) 4. HNK (75 µM) 0.816 0.39 
 5. Bort (400 nM) 5. HNK (100 µM) 0.704 1.6 
U251 1. FenR (1 µM) 1. HNK (5 µM) 0.172 5.4 
 2. FenR (5 µM) 2. HNK (25 µM) 0.863 0.71 
 3. FenR (10 µM) 3. HNK (50 µM) 0.412 0.021 
 4. FenR (15 µM) 4. HNK (75 µM) 0.478 0.059 
 5. FenR (20 µM) 5. HNK (100 µM) 0.526 1.6 
 1. Bort (10 nM) 1. HNK (2.5 µM) 0.096 12.6 
 2. Bort (100 nM) 2. HNK (25 µM) 0.79 0.71 
 3. Bort (200 nM) 3. HNK (50 µM) 0.601 0.11 
 4. Bort (300 nM) 4. HNK (75 µM) 0.319 0.36 
 5. Bort (400 nM) 5. HNK (100 µM) 0.803 1.42 
NGP 1. FenR (1 µM) 1. HNK (10 µM) 0.86 26.2 
 2. FenR (2.5 µM) 2. HNK (25 µM) 1.12 16.3 
 3. FenR (5 µM) 3. HNK (50 µM) 0.62 0.94 
 4. FenR (7.5 µM) 4. HNK (75 µM) 0.83 1.16 
 5. FenR (10 µM) 5. HNK (100 µM) 1.9 1.83 
 1. Bort (1 nM) 1. HNK (2.5 µM) 4.9 7.3 
 2. Bort (10 nM) 2. HNK (25 µM) 0.99 2.13 
 3. Bort (20 nM) 3. HNK (50 µM) 1.43 0.94 
 4. Bort (30 nM) 4. HNK (75 µM) 2.1 1.2 
 5. Bort (40 nM) 5. HNK (100 µM) 2.6 1.41 
SH-SY5Y 1. FenR (1 µM) 1. HNK (10 µM) 1.12 3.9 
 2. FenR (2.5 µM) 2. HNK (25 µM) 1.01 2.6 
 3. FenR (5 µM) 3. HNK (50 µM) 0.96 0.049 
 4. FenR (7.5 µM) 4. HNK (75 µM) 0.88 0.99 
 5. FenR (10 µM) 5. HNK (100 µM) 0.99 1.14 
 1. Bort (1 nM) 1. HNK (2.5 µM) 0.84 2.9 
 2. Bort (10 nM) 2. HNK (25 µM) 0.93 2.4 
 3. Bort (20 nM) 3. HNK (50 µM) 0.97 1.1 
 4. Bort (30 nM) 4. HNK (75 µM) 0.93 0.96 
 5. Bort (40 nM) 5. HNK (100 µM) 1.16 1.68 
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To investigate the role of the UPR and apoptosis for the enhanced cell death and 
inhibition of cell viability seen in melanoma and glioblastoma cancer types, western 
blot analysis for samples treated with fenretinide (For melanoma and glioblastoma: F1 = 
5 µM and F2 = 10 µM or neuroblastoma F1 = 2.5 µM and F2 = 5 µM), bortezomib  (B1 
= 100 nM and B2 = 200 nM or neuroblastoma B1 = 10 nM and B2 = 20 nM) or 
honokiol (H1 = 50 µM and H2 = 100 µM) alone or in combination (FH1, FH2, BH1 and 
BH2) were carried out for GRP78 expression, ATF4 induction and caspase 3 cleavage 
(Figure 6.13). 
The effect of honokiol combination with either fenretinide or bortezomib demonstrated 
cell-line specific and combination indices specific outcomes. Due to the variable 
outcomes observed when EGCG was combined with either ER stress-inducing agent, 
with outcomes not correlating with drug dose suggests that the outcome is a 
consequence of an unstable system. Melanoma cells treated with the fenretinide or 
bortezomib combinations demonstrated lower induction of GRP78, except WM266-4 
cells treated with the BH2 combination (Figure 6.13 A & B ii, BH2, One-Way ANOVA 
with Bonferroni post hoc corrections, All CHL-1 combinations = P < 0.0001, WM266-4; 
FH1 = P < 0.05, FH2, BH1 = P < 0.0001 and WM266-4 BH2 = P < 0.001).  
ATF4 induction in melanoma samples, where fenretinide was combined with honokiol, 
demonstrated lower induction than agents alone in both melanoma cell lines (Figure 
6.13 A & B iii, P < 0.0001 for all). For both bortezomib combinations in CHL-1 and the 
higher combination in WM266-4 cells, an increase in ATF4 induction was observed 
(CHL-1 BH1 and WM266-4 BH2 = P < 0.0001, CHL-1 BH2 = P < 0.05). For WM266-
4 cells treated with the BH1 combination, a significantly lower induction was observed 
(P < 0.05). Data for caspase 3 cleavage in melanoma cells (Figure 6.13 A & B iv) 
demonstrated a significant decrease in cleavage in CHL-1 samples treated with both 
fenretinide combinations and BH2 combination (One-Way ANOVA with Bonferroni 
post hoc corrections, P < 0.0001 for all). CHL-1 cells treated with the BH1 combination 
and WM266-4 cells with FH2 and BH1 combinations demonstrated significant 
increases in caspase 3 cleavage (WM266-4 FH1 = P < 0.05, all others P < 0.0001). 
For glioblastoma and neuroblastoma cancer types, the combination of honokiol with 
either fenretinide or bortezomib significantly reduced the expression of GRP78, ATF4 
and cleaved caspase 3 (One-way ANOVA with Bonferroni post hoc corrections, for all 
combinations P ≤ 0.01) in all samples except MO59J, U251 (ATF4 and caspase 3) and  
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Figure 6.13: The effect of honokiol treatment on fenretinide or bortezomib induced ER 
stress and induction of apoptosis. Melanoma (A & B), glioblastoma (C & D) and 
neuroblastoma (E & F) cells were treated with fenretinide (light grey bars, For 
melanoma and glioblastoma, F1 = 5 µM and F2 = 10 µM or neuroblastoma F1 = 2.5 
µM and F2 = 5 µM), bortezomib (Dark grey bars, For melanoma and glioblastoma, B1 
= 100 nM and B2 = 200 nM or neuroblastoma B1 = 10 nM and B2 = 20 nM) and 
honokiol (HNK, Dotted bars, H1 = 50 µM and H2 = 100 µM) alone or in combination 
for 24 h. Western blot analysis (i) were performed for GRP78 expression, induction of 
UPR inducible ATF4 and cleavage of caspase 3, using β-Actin as a loading control. 
Densitometry analysis were performed on GRP78 (ii), ATF4 (iii) and cleaved caspase 3 
(iv) and data expressed as mean values, relative to β-Actin as a loading control, of 3 
independent experiments ± 95%. Graphs are scaled across cancer types, differing 
depending on the protein of interest to allow for a visual comparison for the effect of 
drug combinations. 
N.B. The western blot analysis for the effect of honokiol alone and in combination with 
ER stress-inducing agents in melanoma cells was carried out in collaboration with Miss 
Caroline Brady. These blots were loaded in a different order, thus have been cropped to 
preserve the order for comparison with the other cancer types. 
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  Combination 
Cell Line Protein FH1 FH2   BH1 BH2 
CHL-1 
GRP78 
    
  
    
WM266-4         
MO59J         
U251         
NGP         
SH-SY5Y         
  
CHL-1 
ATF4 
    
  
    
WM266-4         
MO59J         
U251         
NGP         
SH-SY5Y         
  
CHL-1 
Cleaved Caspase 3 
    
  
    
WM266-4         
MO59J         
U251         
NGP         
SH-SY5Y         
Table 6.6: The effect of honokiol on fenretinide or bortezomib induced ER stress and 
apoptosis of cancer cells. A Summary table for the effect of drug combination in 
comparison to ER stress-inducing agent (fenretinide = F, Bortezomib = B) or honokiol 
(H) treatment control. Data are the average of the response of 3 individual experiments 
and demonstrate an increase (green), decrease (red) or no significant difference (grey) 
in protein expression. 
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SH-SY5Y (GRP78 and ATF4) treated with FH1 ( P > 0.05) or U251 cells treated with 
FH2 which demonstrated an increase in GRP78 expression (P < 0.0001). 
6.2.4: Inhibition of GRP78 increases sensitivity to ER stress-induced 
melanoma cell death. 
To test the hypothesis that the combination of GRP78 inhibitor with ER stress-inducing 
agent results in cells that undergo cell death at an earlier time point, CHL-1 and 
WM266-4 melanoma cells were treated with honokiol with either fenretinide or 
bortezomib, alone or in combination and cells assessed for the induction of cell death 
(Figure 6.14) and then investigated for the effect of drug combinations at 6, 12 and 24 h 
by western blot analysis for GRP78 expression, ATF4 induction and caspase 3 cleavage 
(Figure 6.15). Honokiol, rather than EGCG was used in these experiments as honokiol 
has been shown to bind to GRP78 stronger and also showed induction of ER stress. 
CHL-1 and WM266-4 cell death analysis demonstrated that cell death was significantly 
increased in either of the fenretinide (Figure 6.14 A & C) or bortezomib (Figure 6.14 B 
& D) combination samples at 6 and 12 h (One-way ANOVA with Bonferroni post hoc 
corrections, P < 0.0001 between combination and related ER stress-inducing agent 
alone), and as well as the expected 24 h time point (P < 0.0001). 
Western blot analysis showed that there were significant differences in protein 
expressions between 6 and 12 h in CHL-1 and WM266-4 metastatic melanoma cells 
(Figure 6.15). Data demonstrated that in comparison to agents alone, drug combinations 
significantly increased GRP78 expression by 6 h (Figure 6.15 A & B ii, One-way 
ANOVA with Bonferroni post hoc corrections, CHL-1 with either fenretinide or 
bortezomib combined with honokiol or WM266-4 cells with fenretinide and honokiol P 
< 0.0001), however by 12 h demonstrated significantly lower expression than agents 
alone (CHL-1 and WM266-4 with fenretinide combined with honokiol P < 0.0001 or 
with bortezomib and honokiol P < 0.01 or 0.05, respectively). Investigating the effect of 
drug combination on ATF4 induction (Figure 6.15 A & B iii) highlighted that only 
CHL-1 treated with the bortezomib combination demonstrated significantly higher 
expression (One-way ANOVA with Bonferroni post hoc corrections, P < 0.0001), with 
WM266-4 cells treated with fenretinide combination showing significantly less ATF4 
induction (P < 0.0001). By the 12 h time point CHL-1 cells with bortezomib 
249 
 
combination showed lower levels of ATF4 induction than agents alone (One-way 
ANOVA with Bonferroni post hoc corrections, P < 0.001), however WM266-4 cells 
treated with bortezomib combination showed significantly higher expression (P < 
0.0001). Investigating the induction of caspase 3 cleavage at 6 and 12 h (Figure 6.15 A 
& B iv) demonstrated a significant increase in both CHL-1 and WM266-4 cells with 
either fenretinide or bortezomib combined with honokiol, in comparison to single agent 
(One-way ANOVA with Bonferroni post hoc corrections, CHL-1 cells at 6 h with 
bortezomib combination P < 0.0001, 12 h with either fenretinide or bortezomib 
combined with honokiol P < 0.0001 or 0.05 respectively. WM266-4 cells at 6 h with 
either combination or 12 h with bortezomib P < 0.0001 or 12 h with fenretinide P < 
0.01). 
CHL-1 and WM266-4 cells treated for 6 h with fenretinide or bortezomib alone or in 
combination with honokiol were imaged by light microscopy (Figure 6.16) to give a 
visual indication of the effect of drug combination on a population of melanoma cells. 
Images demonstrate that in samples treated with the combined action, fewer cells were 
left attached.  
Time-course experiments suggest that in the drug combination treated cells there was a 
significant increase in death earlier than agents alone. This resulted in the loss of a 
cohort of cells from the overall population that were sensitive to death by ER stress-
induced death prior to the conventional 24 h time point.  
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Figure 6.14: Time-course analysis for the effect of honokiol treatment on ER stress-
induced cell death. CHL-1 (A & B) and WM266-4 (C & D) melanoma cells were treated 
with fenretinide (10 µM, A & C), bortezomib (200 nM, Bort, B & D) or honokiol (50 
µM HNK) for 6, 12 or 24 h, alone or in combination (hashed bars) prior to analysis of 
cell death by flow cytometry of propidium iodide stained cells. Data are the mean of the 
percentage SubG1 peaks of 3 independent experiments ± 95% CI. 
251 
 
 
 
252 
 
Figure 6.15: Time-course for the effect of GRP78 inhibition by honokiol treatment on 
ER stress and apoptosis. CHL-1 (A) and WM266-4 (B) melanoma cells were treated 
with fenretinide (FenR, 10 µM), bortezomib (Bort, 200 nM) or honokiol (HNK, 50 µM) 
for 6 and 12h. Samples were analysed by western blot for GRP78 and downstream UPR 
inducible factor ATF4 as a marker of ER stress, as well as the formation of cleaved 
caspase 3 products to allow investigate differences in pro-apoptotic stimuli between 
samples treated alone or in combination and between time points. β-Actin was used as a 
loading control.  Densitometry analyses were performed for the effect of fenretinide 
(grey), Bort (black) or honokiol (white) alone or in combination, on 3 independent 
experiments for GRP78(ii) , ATF4(iii) and cleaved caspase 3 (iv) expression. Data were 
expressed relative to loading control ± 95% CI. 
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Figure 6.16: Photo-micrographs for the effect of honokiol treatment on melanoma cell 
sensitivity to fenretinide or bortezomib induced ER stress and apoptosis over time. 
CHL-1 and WM266-4 melanoma cells were treated with fenretinide (FenR, 10 µM), 
bortezomib (Bort, 200 nM) or honokiol (HNK, 50 µM) for 6 h, alone or in combination 
prior to light microscopy imaging. Images above are representative of 3 individual 
experiments. 
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6.2.5: Comparison of cell death across neural-crest-derived cancer types. 
Dose-response data for ER stress-inducing agents fenretinide and bortezomib, as well as 
GRP78 inhibitors SubAB5, EGCG and honokiol were analysed for the Ec50 and 
maximum achievable level of cell death (upper asymptote, Figure 6.17). The Ec50 of all 
agents (Figure 6.17 A) were ranked in order of potency for all cell lines (Figure 6.17 B). 
Mean ranks of each cell line (of all agents) were calculated to assess a cell lines overall 
susceptibility. Data demonstrated that resistance to death was cancer type specific 
(mean rank, Figure 6.17 B), with melanoma being the most resistant to death, more than 
glioblastoma and finally neuroblastoma. Data obtained for the ability of cancer types to 
induce ATF4 during periods of ER stress demonstrated that the magnitude of response 
was cancer type specific (Chapter 3, Figure 3.7 & 3.8). These data suggest that cells 
which are capable of inducing high levels of ATF4 (melanoma) require more drug to 
elicit a response. Comparing these observations to data for the upper asymptotes did not 
correlate together, with the maximum achievable level of death being dependent on cell 
line (Figure 6.17 D). Comparing upper asymptotes showed that SubAB5 induced cell 
death significantly less than all other agents (One-way ANOVA with Tukey post hoc 
corrections, P ≤ 0.05, for all agents) and fenretinide induced the highest levels of cell 
death, consistently across all cell lines (P ≤ 0.05).  
Box plot analysis to compare the effect of drug showed that EGCG and honokiol varied 
largely across cancer types (Figure 6.17 E), in comparison to bortezomib and SubAB5, 
and although EGCG and honokiol showed large variation in Ec50 they induced death to 
a similar level in all cell lines (demonstrated by low variation in asymptote, Figure 6.17 
F). Interestingly, honokiol had higher achievable levels of death than EGCG (Figure 
6.17 F, One-way ANOVA with Tukey post hoc corrections, P < 0.05) and has been 
shown to bind to GRP78 stronger than EGCG (Hawkins unpublished data).  
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Figure 6.17: Comparing ER stress-inducing agents and inhibitors of GRP78 for the 
induction of cell death. The Ec50 (µM) of fenretinide (FenR), bortezomib (Bort), SubAB5 
(Tox), epigallocatechin gallate (EGCG) and honokiol (HNK) were compared across 
cell lines (A) and ranked in order of potency (B) to compared cell line sensitivity (E). 
Data for the maximum achieved level of cell death (%, upper asymptote) were also 
calculated (C & F) and ranked in order of drug effect (D).   
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6.2.6: Results summary. 
 Treatment of neural-crest-derived cell lines with SubAB5, EGCG or honokiol 
resulted in a dose-dependent increase in cell death or inhibition of cell viability. 
 Exposure of neural-crest-derived cancer cells to SubAB5 resulted in a significant 
reduction in GRP78 expression. 
 Over the time scale used, cleavage of GRP78 was not complete, even at high 
SubAB5 concentrations; nevertheless, cleavage occurred rapidly and the level of 
cleavage increased over 24 h. 
 Combination of SubAB5 with either fenretinide or bortezomib in melanoma and 
glioblastoma significantly enhanced cell death and inhibited cell viability, in 
comparison to agents alone. 
 EGCG enhanced fenretinide-induced melanoma and glioblastoma cell death. 
However, EGCG showed an inhibitory effect when combined with bortezomib. 
 Honokiol enhanced ER-stress induced cell death of melanoma and glioblastoma 
cells. 
 Combining an ER stress-inducing agent with SubAB5, EGCG or honokiol in 
neuroblastoma cells resulted in an inhibition in cell death, compared to agents alone 
 The combination of honokiol with either fenretinide or bortezomib resulted in the 
induction of cell death at significantly earlier time points to that of agents alone. 
 Comparing Ec50 values suggest that sensitivity to death correlates with capacity to 
induce ATF4. 
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6.3: Discussion. 
Testing the hypothesis that inhibition of GRP78 combined with an ER stress-inducing 
agent would enhance cell death of melanoma and glioblastoma and neuroblastoma 
cancer cells, showed that SubAB5 (toxin), honokiol with either ER stress-inducing agent, 
and EGCG with fenretinide (for melanoma) significantly induced cell death and 
inhibition of cell viability. In combination with ER stress-inducing agents, data showed 
a synergistic potentiation of both cell death and inhibition of cell viability in melanoma 
cells, synergistic to additive outcome for glioblastoma and inhibitory interactions in 
neuroblastoma. Analysis by western blotting for the effect of GRP78 inhibition on the 
ability of ER stress-inducing agents to induce the expression of UPR elements GRP78 
and ATF4 or the apoptotic marker, cleaved caspase 3, demonstrated that the 
combination of GRP78 inhibitor with ER stress-inducing agents resulted in a variable 
response of the UPR and resulted in cells undergoing death at earlier time points than 
agents alone.  
Treating melanoma or glioblastoma cells with SubAB5 synergistically enhanced ER 
stress-induced cell death or inhibition of cell death of fenretinide or bortezomib [266]. 
Treatment with SubAB5 cleaves GRP78 and therefore inhibits GRP78 functioning in a 
non-competitive and irreversible manner [198, 200]. Quantification of cellular 
concentrations of GRP78 and the UPR activators demonstrated that in these cancer 
types, GRP78 existed in excess and therefore reduction in expression by cleavage or by 
siRNA mediated techniques, shifted the dynamic equilibrium and stimulated UPR 
induced death. Conversely, neuroblastoma cells demonstrated that when GRP78 
expression was reduced, cells became more resistant to ER stress. These data confirm 
the data gathered using siRNA mediated techniques (Figure 4.8 – 4.10) and highlight 
the importance of understanding the dynamic equilibrium of the UPR as a marker of 
cellular outcome to GRP78 inhibition. Treatment of all cell lines with SubAB5 resulted 
in an increase in GRP78 cleaved product and demonstrated induction of cell death in all 
cancer types compared to mutant toxin (SubAA272B). In melanoma and glioblastoma the 
mutant toxin, at high doses, showed the induction of inhibition of cell viability. This 
may be due to low-level activity of SubAA272B. 
The liver and kidney toxicity induced by SubAB5 in mice models [321], and the 
gastrointestinal disease and haemolytic ureamic syndrome associated with shiga 
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bacteria [322] may mean that SubAB5 is only useful as a laboratory tool. However, 
Backer et al., fused SubA to epidermal growth factor (EGF) and demonstrated that 
EGF-SubA could cleave GRP78 and was synergistic in combination with drugs which 
up-regulate GRP78 [319]. The EGF receptor (EGFR) is often over-expressed in tumour 
cells and EGF-SubAB5 has a significantly greater effect in cells over-expressing EGFR 
[319]. 
Investigating the effect of natural compounds; EGCG and honokiol, both known to 
interact with GRP78 [318, 324, 325] demonstrated, with regard to EGCG, that outcome 
was not only cancer-type specific but dependent on the ER stress-inducing agent it was 
combined with. Melanoma and glioblastoma cells demonstrated mild synergy when 
combined with fenretinide, but not bortezomib. Although EGCG has been shown to 
interact directly with the ATPase domain of GRP78, it can also bind to and inhibit the 
26S proteasome [325]. Previous research has demonstrated that combining fenretinide 
and bortezomib, resulted in a synergistic increase in melanoma cell death; coupled with 
data demonstrating an inhibitory effect of EGCG on bortezomib induced cell death, 
these results may suggest that the response seen with EGCG is a consequence of 26S 
interaction as well as GRP78 inhibition. EGCG may impede bortezomib interaction 
with the 26S, yet elicit lower inhibition than bortezomib. This was confirmed by 
western blot analysis for the effect of EGCG treatment on ER stress, which 
demonstrated no significant induction of ATF4, suggesting that EGCG alone may not 
activate the UPR. 
Honokiol combined with either fenretinide or bortezomib in melanoma and 
glioblastoma resulted in synergy. Melanoma cells showing greater levels of synergy 
than that of glioblastoma. Dose-response data demonstrated the induction of the UPR, 
demonstrating a direct consequence of honokiol treatment on ER stress, suggesting a 
biologically-significant effect on GRP78. Also, dose-response data for the induction of 
cell death demonstrated that a significantly-higher concentration of honokiol was 
required to induce death, in comparison to EGCG. Alastair Hawkins and Heather Lamb 
demonstrated that honokiol interacts with GRP78 stronger than EGCG, suggesting that 
honokiol may be a more specific inhibitor of GRP78; however this study shows that 
honokiol is required at a higher dose to induce cell death than that of EGCG. The data 
from this study, demonstrating the ability of honokiol to elicit an ER stress response and 
enhance ER stress-induced death, coupled with the data from Jack Arbiser and Alastair 
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Hawkins demonstrating a direct interaction between GRP78 and honokiol, suggests that 
honokiol is an inhibitor of GRP78. 
Data comparing the effect of honokiol dose on induction of cell death to the effect on 
ER stress (GRP78 and ATF4) and apoptosis (caspase 3 cleavage) induction showed that 
for neuroblastoma, the relative expression of cleaved caspase 3 was higher than that of 
ATF4. This was the opposite relationship to that observed in melanoma and 
glioblastoma (Figure 6.11 G). Although all cancer types showed an induction in cell 
death to honokiol as a single agent, the ability of honokiol to enhance fenretinide and 
bortezomib induced death was different across cancer types, in the same observed trend. 
Earlier research demonstrated that neuroblastoma cells treated with either fenretinide or 
bortezomib induced significantly lower levels of ATF4, than other cancer types (Results 
chapter, Figure 3.7 & 3.8). These observations suggest that the differences in activity of 
the PERK cascade of the UPR may be important for cancer outcome during 
combinational treatment. It is possible that the capacity of neuroblastoma cells to induce 
ATF4 may reach the maximum during single agent treatment and therefore during 
combined drug treatment, where both agents require ATF4 signalling for a response, no 
enhancement of death could be achieved. To evaluate the differences between cancer 
types for caspase 3 cleavage and ATF4 induction, a tetracyclin repressor system could 
be optimised for ATF4. This would allow for the importance of ATF4 expression to be 
confirmed in UPR induced cell death for single and combined treatments. This system 
would allow for ATF4 expression to be increased in neuroblastoma to confirm if this 
would enhance sensitivity to combinational treatments.  
Western blot analysis for the effect of GRP78 inhibition on fenretinide or bortezomib 
induced ER stress or activation of apoptosis (Figures: 6.6, 6.9 & 6.13) demonstrated no 
consistent increase in ER stress or activation of caspase 3 cleavage compared to agents 
alone; in the majority of cases a decrease in expression in comparison to the 
accumulative effect of agents alone was observed. Although these data do not marry 
directly with the cell death and viability data, research into the effect of drug 
combination over earlier time points demonstrated that in samples exposed to 
combination of honokiol and ER stress-inducing agents, significantly higher expression 
of cleaved caspase 3 was present within cells, suggesting that data for the effect of 
combination for 24 h may have missed the effect of the combination due to the time 
point analysed and demonstrated inconsistent data due to the later stage of stress that the 
cells were undergoing. 
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Data also highlighted that samples treated with honokiol and ER stress-inducing agents 
underwent significantly more cell death than agents alone at 6 and 12 h, as well as the 
24 h time point. If cells were undergoing cell death at earlier time points, analysis of 
protein expression at 24 h may have resulted in the assessment of expression of a sub-
population of cells that were not sufficiently primed to death stimuli and therefore to 
understand the real effect of honokiol on fenretinide or bortezomib induced stress, 
analysis at 6 h or earlier may be required. Targeting GRP78 to enhance cellular 
sensitivity to ER stress-induced cell death is dependent on the relationship that exists 
within the UPR, with regards to GRP78 and the UPR activator expression. GRP78 
expression has been shown to be up-regulated in a number of solid tumours and 
therefore overcoming this by specific targeted therapy may result in cancer cells more 
susceptible to chemotherapy as a direct consequence of UPR signalling or due to cells 
no longer being so efficient at buffering external stressors such as glucose or oxygen 
deprivation. Targeting cancer cells with an inhibitor of GRP78 may prime cancer cells 
to death stimuli by shifting the dynamic equilibrium in favour of a more active UPR. 
The use of the SubAB5 as a possible therapeutic inhibitor is prevented by its high 
toxicity to the liver and kidneys; however research conjugating the toxin to EGF has 
shown a reduction in toxicity as well as an increase in cellular up-take in cancer cells 
over-expressing the EGFR [319].  
Further research into the use of honokiol is required to determine maximum achievable 
doses, as well as to investigate the effect in vivo to establish if this natural inhibitor 
could be used clinically to enhance cell death of melanoma or glioblastoma, which to 
date have no reliable therapy. 
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6.4: Conclusion 
In summary, this study showed that inhibiting GRP78, affected cancer cells in the same 
way predicted by alteration in levels of expression. Honokiol, a novel candidate that has 
been shown to interact with GRP78 possesses greater potential to enhance ER stress-
induced death, than that of EGCG of SubAB5, even though SubAB5 synergistically 
enhanced ER stress -induced death of melanoma. The effect of the combined treatments 
resulted in variable outcomes for markers of ER stress and apoptosis and this maybe a 
consequence of time, as data for the effect of honokiol combined with ER stress-
inducing agents fenretinide or bortezomib over time showed increased death and stress 
at earlier time points for combinations, compared to signal agent treatment. 
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Chapter 7: 
 
Final Discussion and  
Future Prospects. 
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7.1: Dynamic model of the UPR. 
Studies of the relationship between GRP78 expression and prognosis of cancer patients 
have highlighted a difference in patient prognosis between melanoma and glioblastoma 
to that of neuroblastoma [113, 115, 116]. Increased GRP78 expression in melanoma and 
glioblastoma has demonstrated a direct correlation with disease state, chemo-resistance 
and metastasis [113, 256, 326]. However, a study in neuroblastoma has shown the 
opposite, with a better prognosis in patients presenting with an increased expression of 
GRP78 [116].  
To determine the differential effects of GRP78 on neural-crest-derived tumour survival, 
the aim of the present study was to investigate potential differences in UPR component 
expression and function. This study set out to compare the role of GRP78 in a panel of 
neural-crest-derived cancer cell lines, incorporating melanoma, glioblastoma and 
neuroblastoma. Cellular concentrations of GRP78, as well as the effect of GRP78 
modulation in response to ER stress were determined in all cancer types and the effect 
of GRP78 modulation had on the UPR activators; PERK, IRE1 and ATF6, as well as 
the magnitude of response of each arm of the UPR to stress. As such these studies 
allowed for a direct comparison of the UPR capacity between cancer types and the 
differences in signalling that may account for the opposing clinical outcomes observed 
between melanoma, glioblastoma and neuroblastoma patients with respect to GRP78 
expression levels.  
Current understanding suggests that GRP78 exists within a dynamic equilibrium with 
the UPR activators, inhibiting their function during periods where there is no ER stress 
(as described in Figure 4.2). This ensures that a homeostatic response to insults in the 
ERs ability to function is primed, ready to buffer ER stress efficiently and immediately, 
when required. GRP78 has a higher affinity to the exposed charged regions of unfolded 
or misfolded proteins than to the UPR activators and therefore during ER stress, binds 
to these substrates, releasing the UPR activators and initiating a response. The present 
study revealed differences in the activity of the UPR and expression levels of UPR 
components, which as a consequence may alter the dynamic equilibrium between 
GRP78 and the UPR activators during ER stress, resulting in a sensitization of 
neuroblastoma to ER stress. 
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7.1.1: GRP78 expression. 
Although research from this study confirmed the sensitivity of all three neural-crest-
derived cancer types to ER stress [82, 112, 204, 327]. To gain a more detailed 
understanding of the signalling of the UPR that may result in differences in disease 
outcome, depending on GRP78 expression, melanoma, glioblastoma and neuroblastoma 
cell lines were analysed for their expression of GRP78 (Chapter 3).  
Comparing cellular concentrations of GRP78 demonstrated no significant differences in 
expression between cell lines of the same cancer type. However, overall, GRP78 
expression was significantly increased in melanoma compared to glioblastoma or 
neuroblastoma, with glioblastoma demonstrating higher expression levels than 
neuroblastoma. 
This cancer type-specific expression of GRP78 may reflect a cell type requirement of 
GRP78. Melanoma cells may require a more active ER or greater abundance in ER 
machinery, as they may require a higher protein synthesis output, due to the production 
of melanin [328] and therefore as a direct consequence of ER function have evolved a 
higher expression of GRP78 than other cell types. Also, due to being an important 
component of the skin, melanocytes may have higher chaperone concentrations to help 
buffer any damage as a result of UV-light-induced ROS accumulation on ER integrity 
[329, 330]. Increased ROS load has been implicated in several pathological states 
including photo-aging and photo-carcinogenesis of the skin. Large efforts have been 
made to better define the involvement of ROS in photo-carcinogenesis and photo-aging. 
Both pathological processes share common features; however, they reveal unique 
molecular characteristics which finally determine the fate of the cell and its host [330]. 
As well as causing permanent genetic changes involving proto-oncogenes and tumour 
suppressor genes, ROS activate cytoplasmic signal transduction pathways that are 
related to growth differentiation, senescence, transformation and tissue degradation 
[330]. Therefore, the constant stimulation by UV light could result in chaperone 
induction or resulted in a cell type that has evolved to express chaperones at a higher 
basal concentration. To gain a better understanding of the role of chaperones across 
cancer types, a screen of a number of the more common chaperones, such as GRP78, 
GRP94, HSP70 calnexin and calreticulin would be useful. This would allow for a 
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comparison of cellular expressions levels of key chaperones to one another and across 
cancer types and identify any underlying correlations. 
Data comparing the cellular concentration of GRP78 in human metastatic melanoma 
cells, to that of primary melanocytes confirmed a significant increase in GRP78 
expression with disease (chapter 3, Figure 3.2 C). These data highlighted that 
melanocytes have a similar GRP78 concentration to that of glioblastoma cells, implying 
that melanocytes may contain higher expression of GRP78 to other cell types, 
glioblastoma have higher levels of GRP78 expression compared to surrounding non-
cancerous tissue [113, 326]. These findings also support the previous 
immunohistochemical data for the correlation of GRP78 with melanoma disease stage 
[115], where a significant difference in GRP78 expression was observed between 
normal melanocytes and that of late stage metastatic disease. Glial cells are the main 
support for neurons, not only to hold the neurons in place and provide the insulating 
myelin sheath [331], but also to provide metabolites, replenishment of oxygen and 
energy to the neurons, ensuring that the neurones are capable of functioning [332]. Due 
to the importance of glial cells, up-regulation of key cellular proteins and pathways may 
have occurred to gain a selective advantage, increasing the probability of survival 
during stress or damage to the brain.  
When comparing melanoma, glioblastoma and neuroblastoma cancer types, it must be 
taken into consideration that although all three are dendritic cell types and derived from 
the neural-crest, only neuroblastoma is formed as a direct result of deregulation of 
development, while melanoma and glioblastoma arising post cellular development as a 
consequence of genetic and/or environmental abnormalities in already-differentiated 
cells. Therefore, the significantly lower expression in neuroblastoma may be a 
consequence of the origin of this cancer type [333]. This lower expression in 
neuroblastoma may be due to cell immaturity, and therefore the lack of regular exposure 
to changes in environmental conditions. However, to date little is known about the 
molecular biology behind glioma development and it is possible that it arises from a 
precursor cell, formed during neural-crest development which lays dormant until 
stimulated, and furthermore it is this precursor cell that shows a difference in GRP78 
expression.  
Research into the expression of chaperones, such as GRP78, has demonstrated that 
expression levels of individual chaperones can fluctuate between cell types, but overall, 
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cell lines with similar ER capacity and rate of protein synthesis have similar overall 
expression of chaperones. For example neuroblastoma cells have been shown to over-
express GRP94 [230, 334]. This may suggest that in neuroblastoma, other signalling 
cascades maybe more prevalent and that although increased expression of GRP78 
protein has been shown to be prognostically favourable, this in part may be due to the 
down regulation of another, more vital chaperone or component of the ER, that 
ultimately leads to the loss of capacity to buffer stress and therefore an enhanced UPR 
response (including the increase in GRP78 expression observed) [116] and thus the 
increase in GRP78 is a consequence of stress-induced death, rather than a factor that 
triggers the induction of death stimuli. 
7.1.2:  Stoichiometry of the UPR. 
Due to the cell-type-specific expression of GRP78, this factor may ultimately influence 
the signalling ability of the UPR, which could result in differences in response outcome 
when GRP78 expression was up-regulated. Therefore experiments included in the 
present study focused on quantifying the expression of the UPR activators to achieve a 
clearer interpretation of the dynamic equilibrium of the UPR. 
Investigation into the expression of GRP78 compared to that of the UPR activators 
(total UPR activator concentration) highlighted significant differences between the 
relationship of GRP78 to UPR activator in melanoma and glioblastoma, to that of 
neuroblastoma. For melanoma 1: 0.65, Glioblastoma 1: 0.7 and neuroblastoma 1: 1.5, 
for GRP78: UPR activator total (averaged between cell lines of the same cancer type). 
The assumption inherent within this thesis is that GRP78 is in a dynamic equilibrium 
with the UPR activators such that in the absence of unfolded protein substrates the pool 
of free UPR activators is low. An excess of GRP78 would allow unfolded proteins 
substrates to bind to GRP78 without substantially increasing the pool of free UPR 
activators. This would be the proposal situation for melanoma and glioblastoma. 
Conversely, neuroblastoma cells demonstrated an abundance of UPR activators. With 
regards to the dynamic equilibrium that exists between GRP78, UPR activators and 
substrate, in melanoma and glioblastoma the equilibrium is in favour of an inactive 
response, yet neuroblastoma demonstrates a dynamic equilibrium in favour of an active 
UPR.   
267 
 
Of the individual UPR activators, IRE1 was the most abundant in all cell lines tested. 
The expression levels of PERK and ATF6 were significantly lower than that of IRE1 
and demonstrated no difference to each other. These findings highlight the importance 
of IRE1 within the UPR. IRE1 is the evolutionary conserved UPR activator that has 
been well documented to have both pro-death and pro–survival attributes [335, 336]. 
IRE1 is a bi-functional trans-membrane kinase or endoribonuclease that induces the 
non-conventional splicing of XBP-1 mRNA to produce the b-ZIP transcription activator, 
XBP-1s, which is capable of binding to ERSE and UPRE to activate the characteristic 
responses of the UPR [337]. In addition to the splicing of XBP1 mRNA, IRE1 kinase 
can also activate pro-survival responses, as well as the induction of pro-death stimuli, 
via the c-Jun N-terminal kinase (JNK) signalling pathway, through the Mitogen-
Activated Protein Kinase Kinase Kinase (MAP3K) cascade and the activation of 
autophagy through TRAF2 signalling [338, 339].  
Studies by Lee et al., demonstrated that treatment of neuronal cells with the ER stress-
inducing agents tunicamycin and thapsigargin (Tg), increased the aggregation of mutant 
huntingtin (mtHTT), as a result of IRE1 activation. The kinase activity, but not the 
endoribonuclease activity of IRE1 was necessary to stimulate mtHTT aggregation and 
increased death of neuronal cells, including SH-SY5Y cells [340]. Interestingly, ER 
stress impaired autophagy flux via the IRE1-TRAF2 pathway enhanced cellular 
accumulation of mtHTT [340]. These findings, coupled with the data from this study 
demonstrating the abundance of IRE1 in comparison to the other UPR activators, thus 
suggest that IRE1 is the key mediator of the UPR. It may also indicate that PERK or 
ATF6 activity enhances the response of IRE-1 [340], allowing for a more diverse array 
of responses, in both signal strength and outcome, that is more capable of buffering a 
variety of stresses encountered by a multi-cellular organism. 
7.1.3: Mapping UPR activity during ER stress. 
Assessment of the induction of the UPR, in response to ER stress-induced by either 
fenretinide or bortezomib demonstrated that all cancer types significantly induced all 
three cascades of the UPR, in response to either agent. These data highlighted a greater 
induction of ATF4 in melanoma than either glioblastoma or neuroblastoma, and that 
bortezomib is a more potent inducer of the UPR. When comparing the induction levels 
of ATF4 to the expression of PERK, melanoma and glioblastoma demonstrated a 
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correlation, with higher expression of PERK found in the melanoma cells, which were 
capable of inducing high levels of downstream ATF4. However, NGP and SH-SY5Y 
neuroblastoma cell lines demonstrated similar levels of ATF4 induction to each other, 
yet varied significantly in their expressions of PERK. Interestingly, although melanoma 
and glioblastoma had more GRP78 than UPR activators and therefore should 
demonstrate a decrease in likelihood of UPR activation in comparison to neuroblastoma, 
melanoma cells demonstrated a stronger induction of ATF4, indicative of a more active 
UPR. 
Fenretinide and bortezomib induced both ATF6 cleavage and XBP-1 splicing in all 
cancer types, which eventually resulted in a recovery in expression, back to basal levels, 
as a down-stream consequence of UPR activation. An inbuilt replenishment in the 
signalling response exists in the UPR to ensure the system can recover [341]. However, 
in neuroblastoma cells, treated with either ER stress-inducing agent, a significant 
expression of XBP-1s was still detected at 24 h, whereas in melanoma and glioblastoma 
cells XBP-1 had returned to basal levels. These data support the hypothesis that 
differences in the dynamic equilibrium between GRP78 and the total sum of the UPR 
activators may affect the signalling outcome of the UPR. Data showed that 
neuroblastoma possessed a higher proportion of UPR activators to GRP78 molecules 
that could inhibit them. This would therefore allow for a low level turnover of the UPR, 
demonstrated in these samples as a persistent expression of XBP-1s. The detection of 
XBP-1s at 24 h, coupled with the observed dynamic equilibrium in neuroblastoma, 
suggests that these cells may react to a lower level of ER stress due to the inability of 
GRP78 to completely inactivate the UPR. This in part may be responsible for 
neuroblastoma cells being more sensitive to ER stress-inducing agents, in particular 
bortezomib. 
Conversely, in neuroblastoma there was no observable induction of XBP-1s in the 
control samples, suggesting that the XBP-1s present at 24 h in samples treated with 
either ER stress-inducing agents was a direct consequence of stress-related UPR 
induction and not a consequence of the lack of GRP78 to negatively regulate the UPR 
activators. Therefore, the difference in activity time between neuroblastoma and the 
other neural-crest-derived cancers may be related to the level of stress achieved within 
the neuroblastoma cells, the ability of the cell to recover or remove unfolded or miss-
folded proteins. For example the low level of ATF4 induction in neuroblastoma would 
result in a significantly lower induction of chaperones, folding machinery or amino acid 
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recovery via the PERK arm of the UPR, as well as a smaller effect on global protein 
synthesis. This lack of ATF4 induction would therefore suggest that neuroblastoma 
cells rely more on the IRE-1 arm of the UPR to recover from ER stress, more than 
either melanoma or glioblastoma, and as data for XBP-1 splicing demonstrated that 
neuroblastoma cells generate similar levels of XBP-1s during stress to that of melanoma 
and glioblastoma, thus it may take these cells significantly longer to recover. 
Comparing the activation of IRE1 of human neural-crest cancer cells, to that of yeast, 
suggests that co-factors may be important in the activation of the UPR. The yeast form 
of IRE1 relies not only on release from GRP78 and homo-dimerization, but a direct 
interaction with unfolded proteins [242, 342]. Although research into the structure of 
IRE1 has indicated that the mammalian form lacks the relevant sequence for interaction 
with unfolded proteins [342], research has not yet focused on the hypothesis that 
processing of XBP-1 mRNA may require a cofactor, itself induced by ER stress. This 
would confirm the data generated for neuroblastoma, where no significant induction of 
XBP-1s could be observed at 0 h, but was present at 24 h. 
Previous studies have implicated the time of activity of each arm of the UPR, as the 
crucial factor in the outcome of the UPR [225]. Studies highlight the IRE1 and ATF6 
arms of the UPR, as a faster response mechanism to stress, yet demonstrated shorter 
activity times [225, 341]. The inactivation of UPR stimulation via the IRE1 and ATF6 
arms, by GRP78, allowed induction of pro-apoptotic GADD153 via the PERK arm of 
the UPR to induce death, if stress still persisted. Taking into consideration studies 
demonstrating that IRE1 can also activate the transcription of Gadd153 mRNA via 
XBP-1s, along with the data obtained from this study that demonstrated differences in 
the level of UPR activation, depending on the level of stress, as well as stressor, it is 
possible to determine that time may contribute to the outcome of ER stress. However, 
time is not the only factor in determining the response outcome [305, 339]. 
Research by DuRose et al.,, into GRP78 dissociation, demonstrated that the kinetic 
behaviours for the activation of the UPR sensors could be governed by the affinity of 
GRP78 for unfolded proteins or the dissociation constants of GRP78 from PERK, IRE1 
or ATF6 [273]. Observations suggested a more complicated scenario. Rapid 
dissociation of GRP78 from both IRE1 and PERK occurred during Tg-induced stress 
suggesting a high-affinity of GRP78 for unfolded proteins after Tg treatment, however 
the slower activation of ATF6 by Tg suggests the opposite [273]. Therefore, if the 
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affinity of GRP78 for UPR activators plays a major role, the kinetic order of IRE1, 
PERK, and ATF6 should be the same for any type of ER stress and all three UPR 
activators, however, this was not observed. Interestingly, ATF6 activation was found to 
be rapid in response to DTT, thus suggesting a stress specific response. DuRose et al., 
also demonstrated, using immune-precipitation techniques, that the kinetics of GRP78 
with either IRE1 or PERK supported the concept an additional control [273], as PERK 
auto-phosphorylation occuered within 15 min of DTT or Tg treatment, but GRP78 
dissociation was only observed from 30 min. This suggests that PERK phosphorylation 
occurred under GRP78 interaction. Also DuRose et al., showed GRP78-IRE1 re-
association at time points when IRE1 was still active [273]. Thus, although GRP78 
dissociation clearly occurs during UPR activation, the kinetic behaviour of all three 
UPR sensors suggests the presence of additional regulatory mechanisms. Therefore, it 
may be possible that an additional control mechanism exists allowing the UPR 
activators to be fine-tuned, both in the speed and extent of activation, depending on the 
type and magnitude of ER stress. Furthermore, Schindler et al., showed that the addition 
of ATP and DTT synergistically induced the dissociation of ATF6 from GRP78. These 
findings therefore suggest that the requirement of a co-factor(s), such as PDI, maybe 
important for protein release [343].  
To gain a better understanding of the UPR response to stress, surface plasmon 
resonance (SPR) analysis for the interaction of GRP78 with the UPR activators could 
thus be carried out to compare affinities. Also, to determine if neural-crest-derived 
cancer cells respond differently to stress, with regards to the activation of the UPR, time 
course studies using a larger array of ER stress-inducing agents could be carried out to 
determine if the UPR responds in a homogenous way, or differs depending on stress. 
Finally, this study has assessed the activation of the UPR from a top down approach, 
focusing on early markers of the UPR cascade. To determine if the presence of XBP-1s 
in neuroblastoma at 24 h and confirm that the UPR in melanoma or glioblastoma are 
inactive, investigating the activation of reporter elements (ERSE and UPRE) using a 
reporter assay approach could be carried out, determining the overall activation of the 
UPR as a control. This work would also allow for a comparison across cancer types for 
the ability of fenretinide or bortezomib to induce UPR related genes, allowing for a 
correlation of transcription factor induction with gene activation. Finally the kinase 
activity of IRE1 could be assessed to confirm the differences in activity over time 
between cancer types as well as to compare this component of the UPR. 
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7.2: The effect of altering GRP78 expression on the outcome of ER stress-
induced neural-crest-derived cancer cell death. 
To identify the importance of the dynamic equilibrium that exists between GRP78 and 
the UPR activators, the expression of GRP78 was altered and the effect this had on cell 
death, in response to ER stress-inducing agents, was observed.  
7.2.1: The effect of siRNA mediated knockdown in GRP78 expression. 
Using siRNA mediated techniques to reduce GRP78 protein expression transiently 
demonstrated that in melanoma and glioblastoma cell lines, an increase in sensitivity to 
ER stress-induced cell death occurred in comparison to control transfected cells. The 
reduction in GRP78 expression by over 50% in either melanoma or glioblastoma would 
be expected to shift the dynamic equilibrium of the UPR, decreasing the inhibitory 
effect that GRP78 has on PERK, IRE1 or ATF6, and priming the UPR to a higher level 
of activation under basal ER synthesis. Thus, on addition of ER stress-inducing agents, 
more cell death or inhibition of cell viability was observed. These findings suggests that 
although the UPR was, in principal, already at a higher activity level and thus more 
capable to cope with stress, cell death was significantly increased. These data therefore 
suggest that the possible shift in the dynamic equilibrium resulted in the activation of 
pro-apoptotic stimuli (Gadd153) and when either fenretinide or bortezomib were added; 
their perturbation of ER function significantly enhanced the pro-apoptotic stimuli to a 
greater extent, which was sufficient to overcome any changes in expression of the pro-
survival machinery.  
To gain a better understanding of the mechanism by which a reduction in GRP78 
expression enhances ER stress-induced melanoma and glioblastoma cell death, research 
would need to be carried out to test the hypothesis that a reduction in GRP78 expression 
effects cellular outcome to stress. This could be achieved by time course analysis for the 
induction of Gadd153 in all cells types, with reduced GRP78 expression in comparison 
to controls.  
The reduction in GRP78 may have also affected the capacity to respond, or buffer the 
ER stress [344] induced by either fenretinide or bortezomib. GRP78 is a known 
chaperone with holdase activity [345], capable of binding to unfolded or mis-folded 
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proteins and holding them in a more appropriate orientation for bond addition or 
removal. Chaperones hold unfolded substrates in an intermediately folded state to 
prevent irreversible aggregation and to catalyse the refolding of unfolded substrates in 
an energy- and co-chaperone-dependent reaction [346]. Therefore, a reduction in 
GRP78 expression would reduce the ability of a cell to bind and modify unfolded 
protein substrates, resulting in a reduction in capacity to buffer ER stress. This could 
ultimately result in more cell death, as the time under stress prior to UPR activation 
would be significantly reduced and allow a greater induction of pro-death stimuli over 
time. Research to confirm this hypothesis is required and could focus on the over-
expression of other key chaperones, such as GRP94, calnexin, calriticulin or HSP70 
[347], in cells with reduced GRP78 expression in order to determine if the loss of 
chaperone activity is the main driver of enhanced death. 
Testing the effect of reduced GRP78 expression on the sensitivity of neuroblastoma 
cells to ER stress-induced death demonstrated no significant difference in sensitivity. 
These data demonstrated that although GRP78 in neuroblastoma was reduced by more 
than 50%, this had no effect on the outcome of ER stress.  The fact that neuroblastoma 
contain more UPR activators to GRP78 molecules, may mean that a further reduction in 
the expression of GRP78, did not have the same effect on shifting the dynamic 
equilibrium as that seen in melanoma or glioblastoma.  
Interestingly, this research suggests that the reduction in GRP78 expression in 
neuroblastoma had no significant effect on the chaperone-based response to ER stress, 
as cells under ER stress showed no increase in ER stress-induced death. Previous 
studies have demonstrated the importance of GRP94 in neuroblastoma [230]. Therefore, 
to determine if GRP94 is a crucial chaperone in neuroblastoma, vital for ER integrity 
during stress, future work should test the hypothesis that changes in GRP94 expression 
alter neuroblastoma cell sensitivity to ER stress.  
To gain a better understanding for the relationship that exists between GRP78 and the 
UPR activators, Stable clones with reduced GRP78 expression would allow for the 
study of the effect of long term reduction in GRP78 expression on UPR activator 
concentrations (and the affect this has on the dynamic equilibrium), chaperones and 
folding machinery expressions (pro-survival attributes) or Gadd153, caspases and BCl-2 
family members NOXA or PUMA expressions (Pro-death attributes).  In addition, 
research could be carried out into the effect of a reduction in GRP78 expression on 
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downstream ERSE and UPRE activation and micro-arrays for the effect of ER stress on 
protein induction to gather a more comprehensive insight into the effect of GRP78 
expression and changes in GRP78 expression over cancer types. 
7.2.2: The effect of stable over-expression of GRP78. 
Neural-crest-derived cancer cells, stably over-expressing GRP78 demonstrated that in 
melanoma and glioblastoma, over-expression of GRP78 significantly inhibited ER 
stress-induced cell death. These data confirm those for the reduction in GRP78 
expression and highlight the importance of GRP78 in melanoma and glioblastoma cell 
survival. Further increasing the expression of GRP78 resulted in a significant decrease 
in the level of ATF4 induction achieved by ER stress-inducing agents and research into 
the effect of GRP78 expression on protein ubiquitination, in response to bortezomib 
treatment, demonstrated that cells over-expressing GRP78 had significantly less 
proteins tagged by ubiquitin.  
These results could be dependent on the increase in GRP78 chaperone expression or due 
to the inhibition in activation of the UPR. Increasing the chaperone content of a cell 
would allow for a higher proportion of unfolded or misfolded proteins to be sequestered 
by a chaperone at any given time, increasing the ability of ER-machinery to mask stress 
and prevent the induction of the UPR. An increase in GRP78 would also affect the 
dynamic equilibrium of the UPR, shifting the outcome toward an inactive state. A 
decrease in UPR activity would reduce ERAD activation and in turn could influence the 
overall level of proteins tagged with ubiquitin during periods of ER stress. To determine 
which consequence of GRP78 is vital for melanoma or glioblastoma cell survival, 
experiments to determine the activity of the other two arms of the UPR should be 
carried out to allow for a complete assessment of the UPR. In addition, to determine if 
chaperone activity is the vital component of GRP78, in buffering ER stress in cells with 
enhanced GRP78, cells over-expressing GRP78 could undergo knockdown of other 
important chaperones, such as GRP94 or HSP70. Furthermore, cells over-expressing 
other chaperones could be tested for the effect this has on UPR induction in response to 
either fenretinide or bortezomib. Neuroblastoma, as for the effect of reduced GRP78 
expression, demonstrated a different response to either melanoma or glioblastoma. Data 
for neuroblastoma cells over-expressing GRP78 showed a significant increase in 
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sensitivity to ER stress-inducing agents, as well as demonstrating a significantly greater 
UPR response.  
Further dissection of the relationship between GRP78 and the UPR activators in over-
expressing cells, in comparison to control, demonstrated that stable over-expression of 
GRP78 resulted in unexpected changes to the expression of PERK, IRE1 and ATF6. 
Melanoma demonstrated an increase in IRE1 and decrease in PERK and ATF6, 
glioblastoma demonstrated a reduction in PERK, and neuroblastoma demonstrated an 
increase in all three UPR activators. When comparing the effect of over-expression on 
the ratio of GRP78 to UPR activators (sum of all three sensors), data demonstrated that 
in melanoma and glioblastoma there was an overall increase in the ratio of GRP78: 
UPR activators. In contrast, in neuroblastoma there was a significant increase in UPR 
activators relative to GRP78.  
Data for glioblastoma demonstrated a reduction in PERK expression and this could 
ultimately explain the reduction in ATF4 induction in the GRP78 over-expressing cells. 
However, this change in PERK expression was not seen in melanoma and therefore data 
support the hypothesis that GRP78 over-expression is responsible for the decrease in 
stress achieved by either fenretinide or bortezomib, resulting in the reduced ATF4 
induction. However it is unclear if this is due to chaperone activity, altering the stress 
directly by removing unfolded or misfolded proteins or as a result of the increased 
inhibition of the UPR. In neuroblastoma however the significant increase in PERK may 
have contributed to the increase in ATF4 expression. 
Over-expression of GRP78 in neuroblastoma cells resulted in a significant induction of 
cell death, which was not observed in either melanoma or glioblastoma. Testing the 
effect of GRP78 transfection in neuroblastoma cells highlighted a significant induction 
of cell death with GRP78. Stable GRP78 over-expressing clones for neuroblastoma 
demonstrated a mere 1.3 fold increase in GRP78. These findings support the concept 
that increases in GRP78 expression result in neuroblastoma cell death due to a shift in 
the dynamic equilibrium in favour of GRP78 and an inactive UPR. Furthermore these 
observations may suggest a vital role for the UPR in neuroblastoma cell survival, 
buffering the effect of other pro-death stimuli and changes in neuroblastoma physiology 
as a consequence of tumour microenvironment, drug treatment, or even cell 
proliferation rate that relies on an active UPR for survival. 
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7.3: Implications of targeting GRP78 as a therapeutic strategy in neural-
crest-derived cancers.  
GRP78 expression has been shown to be up-regulated in a variety of cancer types [113, 
115]. Therefore, this study has tested the effect of inhibiting GRP78 across a panel of 
neural-crest-derived cancer types. The aim of this work was to assess the effect of 
inhibiting GRP78 activity on the dynamic equilibrium as a test of the hypothesis that 
melanoma and glioblastoma can be sensitized to ER stress and that in neuroblastoma, 
responses to GRP78 deregulation would have no therapeutic significance.  
Studies using a nucleoside analogue or a GRP78 specific antibody, have suggested that 
interference in ATP exchange or prevention of cell surface GRP78 – substrate 
interaction using a targeted antibody [348], can significantly increase ER stress-induced 
cell death  [295, 313, 349]. These possibilities were tested in this study but neither 
strategy was found to enhance the responses of fenretinide nor bortezomib induced 
death and, therefore, the data have not been included in this thesis.  
7.3.1: The effect of SubAB5 cleavage of GRP78 on ER stress-induced cell 
death.  
Inactivation of GRP78, by SubAB5 specific cleavage, also resulted in a significant 
enhancement of melanoma and glioblastoma cell death [198, 200]. These findings 
confirm the data generated form the present study for the effect of altering GRP78 
expression on cell line sensitivity. SubAB5 is a specific inhibitor of GRP78 and showed 
a significant reduction in full length protein, however demonstrated a weaker effect to 
that of siRNA mediated knockdown. These data suggest that although GRP78 is cleaved, 
it may still be capable of interacting with a substrate, helping to buffer ER stress, be it to 
a lesser extent.  
Wolfson et al., described the ability of SubAB5 to activate the UPR [320]. Data from 
the present study did not demonstrate any significant induction of the UPR, with regard 
to ATF4 induction by SubAB5 treatment [320]. This may be a consequence of 
concentration, as Wolfson et al., used 1 µg/ml, a 200 fold higher concentration than that 
used in this present study [320]. Interestingly, Wolfson et al., demonstrated that 
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SubAB5 induced eIF2α phosphorylation for the first 4 h of treatment; however the 
reduction in GRP78 expression persisted for 24 h [320]. This therefore may suggest that 
the induction of the UPR was not as a consequence of GRP78 cleavage. SubAB5 is 
internalised by clathrin dependent uptake [199] and maybe the inhibition of global 
protein synthesis was as a consequence of a significant intake of foreign material into 
the cell, inducing ER stress.  
7.3.2: The effect of natural inhibitors of GRP78 on ER stress-induced cell 
death.  
Alastair Hawkins and Jack Arbiser (personal communication) have shown that EGCG 
and honokiol both interact with GRP78, and more specifically the ATP binding domain 
(unpublished data, personal communications). These interactions may affect the ability 
of GRP78 to bind to ATP, thus affecting the function of GRP78 and its dynamic 
equilibrium with the UPR activators. Affecting the chaperone activity of GRP78 may 
sensitize cells to react to lower levels of ER stress, as well as possibly hindering the 
interaction of GRP78 with the UPR activators. Both outcomes would result in earlier 
activation of the UPR and UPR based pro-apoptotic stimuli (Gadd153), increasing the 
likelihood that ER stress-inducing agents activate cell death pathways. The present 
study showed that both EGCG and honokiol had significant effects on ER stress-
induced cell death of melanoma and glioblastoma (only honokiol), with honokiol also 
demonstrating a significantly stronger effect. Interestingly, research comparing the 
strength of interaction of EGCG or honokiol with GRP78 demonstrated that honokiol 
binds with significantly higher affinity (Alastair Hawkins, unpublished data, personal 
communication).  
The effect of EGCG in the present study was dependent on the ER stress-inducing agent 
it was combined with, but demonstrated an inhibitory effect on bortezomib. Previous 
data had shown EGCG can bind to and inhibit the 26S proteasome [318] and therefore 
competition for or overlap in 26S proteasome inhibition may have resulted in the 
observed poor combinational activity. Hill et al., demonstrated that the combination of 
fenretinide and bortezomib synergistically enhanced melanoma cell death [82] and 
hence the significant effect seen when EGCG was combined with fenretinide, may have 
been due to the interaction with the 26S proteasome. However, EGCG unlike 
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bortezomib showed no activation of the UPR, which may suggest that if EGCG does 
bind to and inhibit the 26S proteasome; it is significantly weaker than that of 
bortezomib. 
Results from the present study also showed that at high doses, honokiol induced 
markers of ER stress, as well as synergistically enhancing fenretinide and bortezomib-
induced cell death of melanoma and glioblastoma. To confirm honokiol as a candidate 
GRP78 inhibitor, and test its potential to enhance fenretinide- or bortezomib-induced 
cell death, in vivo toxicity studies are thus required to determine the maximum tolerated 
dose achievable, and determine if this correlates with the in vitro range which 
demonstrated a synergistic enhancement of cell death. Furthermore, xenograft models 
for melanoma and glioblastoma for the effect of bortezomib, fenretinide and honokiol, 
alone and in combination should be carried out. Combination of either EGCG or 
honokiol with ER stress-inducing agents in neuroblastoma demonstrated no significant 
enhancement of death. This confirms the expression analysis, suggesting that targeting 
GRP78 as a therapeutic strategy to enhance ER stress-induced death is not an 
appropriate approach for neuroblastoma.  
Finally, apoptosis is a coordinated and often energy-dependent process that involves the 
activation of a group of cysteine proteases (caspases) and a complex cascade of events 
that link the initiating stimuli to the final demise of the cell [81].  Thus, global ATP 
deregulation may serve to hinder the induction of cell death. Data from this study 
demonstrated that the combination of a GRP78 inhibitor (that targets the ATP binding 
domain of GRP78) with an ER stress-inducing agent, resulted in an increase in cell 
death, This suggests that the interaction of EGCG or honokiol maybe with an area close 
to the ATP binding domain, rather than directly with it. To gain a better understanding 
of the impact of EGCG or honokiol on GRP78 function and ATP binding, the ATPase 
activity of GRP78 should be tested alone and in the presence of inhibitor. The increase 
in cell death confirms that EGCG or honokiol are appropriate inhibitors for enhancing 
ER stress-induced cell death. Interestingly, the enhanced induction of cell death for the 
EGCG combinations in melanoma and glioblastoma and the honokiol combinations in 
glioblastoma was via a caspase independent route. These findings were suggested from 
the reduction in cleaved caspase 3. 
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7.4: ER stress and the activation of autophagy.  
To date, the importance of autophagy, activated via the UPR is not completely 
understood. Knockdown studies of PERK or mutating the phosphorylation site of eIF2α 
have implicated the importance of p-eIF2α in UPR stimulated autophagy [350].  
Interestingly, phosphorylation of eIF2α and the resulting inhibition of global protein 
synthesis are critical to PERK mediated activation of autophagy [338]. Studies have 
additionally demonstrated the importance of eIF2α in autophagic signalling as 
evidenced by observations demonstrating eIF2α can be phosphorylated by PERK, PKR, 
GCN2 and HRI from a number of contrasting stimuli [91], both ER stress and non-ER 
stress-inducing stimuli [351]. The resulting shift in protein translation by the 
phosphorylation of eIF2α leads to an increase in ATG12 expression and UPR stimulated 
induction of tribbles homologue 3 (TRB3) resulting in the inhibition of the protein 
kinase B/mammalian target of rapamycin (PKB/mTOR) pathway, and the induction of 
autophagy [352]. 
In addition, the interaction of active IRE1 with TRAF-2 leads to the activation of JNK, 
which in turn results in the phosphorylation of BCL-2 [338], and dysregulation beclin-1 
activity [338]. This loss of Beclin-1 inhibition, in this context, resulted in the induction 
of autophagy [353]. However, a decrease in XBP-1 expression has also been shown to 
induce autophagy, that protects cells against superoxide dismutase 1 (SOD1) aggregate 
toxicity [354], suggesting that activation of autophagy by IRE1 can result in opposing 
outcomes, depending on the route of induction [338]. 
The present study highlighted differences in UPR signalling between melanoma and 
glioblastoma to that of neuroblastoma. Melanoma and glioblastoma demonstrated 
stronger induction of ATF4, downstream consequence of p-eIF2α, than that of 
neuroblastoma. This outcome may result in differences in the magnitude of response to 
which autophagy can contribute to the outcome of ER stress. Interestingly, differences 
in the activity of the IRE1 arm were also observed, with neuroblastoma demonstrating 
XBP-1 splicing for a significantly longer period of time to that of either melanoma or 
glioblastoma. These observations suggest that autophagy may contribute to the 
differences in neural-crest-derived cancer cells response to ER stress and that further 
research into the dynamics of autophagy, with regards to the contribution it plays in the 
balance between survival or death. 
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ATF6 (-/-) knockout mice are highly susceptible to bacterial infections, as a result of the 
loss of autophagic function. ATF6 has been shown to regulate interferon gamma (IFNG) 
induced death associated protein kinase 1 (Dapk1) expression via the CRE/ATF 
promoter site, in association with CCAAT/enhancer-binding protein beta (CEBPB). 
IFNG induced cleavage of ATF6 and MAPK 1/3 dependant phosphorylation of CEBPB 
control Dapk1. When either ATF6 or CEBPB are removed, IFNG fails to activate 
autophagy [355, 356]. However, research from the present study demonstrated no 
significant difference between cancer types in ER stress-induced ATF6 cleavage and 
therefore the contribution of this arm of the UPR, with regard to homeostatic or 
autophagic responses and is unlikely to contribute to the differences in disease outcome. 
To determine if neural-crest-derived cancer cells differ in their capacity to 
mediate/activate UPR induced autophagy, further research comparing cancer types for 
the induction of autophagy should be carried out. Also, the present study focused on the 
endoribonuclease activity of IRE1 and to gain a complete understanding, the IRE1 
kinase domain activity should be investigated to determine the contribution of the JNK 
pathway for the induction of autophagy and death by either fenretinide or bortezomib.  
Fenretinide induced ROS and bortezomib induced 26S proteasome inhibition, the 
mechanisms by which these agents have been reported to induce ER stress; however 
they may also induce an autophagic response in an ER stress independent manner. 
Bortezomib induced 26S proteasome inhibition triggers death via UPR induced 
Gadd153 induction as well as IRE-TRAF2 induced autophagy, via JNK1 activation. 
However, inhibition of the 26S proteasome results in deregulation of p62 expression. It 
has been hypothesised that p62 interacts with ubiquitin tails of other tagged proteins, 
and undergoes degradation. However, the resulting accumulation of tagged proteins by 
26S proteasome inhibition prevents p62 degradation and stimulates p62 to interact with 
LC3, activating autophagy. Fenretinide induces ROS by interfering with ceramide 
synthesis. Ceramide is maintained in dynamic equilibrium with sphingosine and S1P. 
These proteins are known to have opposing effects on survival and death. Therefore 
interfering in this dynamic equilibrium by reducing ceramide hinders phosphoinositide 
3-kinase (PI3K) regulated suppression of autophagy. The increase in ROS as a 
consequence of fenretinide increases ataxia-telangiectasia mutated (ATM) activity, 
ultimately resulting in the inhibition of the mTORC1 complex, activating autophagy 
[357]. 
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Due to the close interaction between ER stress-induced UPR and autophagy pathways, 
ER stress-induced cell death remains a viable target to induce death in cancer types 
resistant to traditional chemotherapeutics. Combining ER stress-inducing agents with 
inhibitors of the UPR enhances cell death by causing an imbalance between pro-
survival and –death stimuli of homeostatic response mechanisms. Therefore, further 
research into ER stress would allow for a more comprehensive understanding of the role 
of the UPR and autophagy in cancer cell survival and allow for specific target(s), such 
as GRP78, to be identified to synergise the response of current chemotherapeutics 
capable of perturbing ER function. 
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7.5: Conclusions. 
This study, investigating the UPR in neural-crest-derived cancer types showed that 
melanoma and glioblastoma display increased sensitivity to ER stress-induced cell 
death in response to fenretinide and bortezomib when GRP78 expression is reduced. 
Also, when the expression of GRP78 was increased, melanoma and glioblastoma 
demonstrated enhanced resistance in comparison to control cells. However, GRP78 
expression in neuroblastoma does not demonstrate any biological significance on ER 
stress-induced death.  The dependence of a cancer cell on GRP78 to buffer ER stress 
and increase resistance to ER stress-induced cell death can be better understood by the 
relationship that exists between GRP78 and the UPR activators. Cancer types, such as 
melanoma and glioblastoma, with more GRP78 to that of UPR activators become more 
sensitive to ER stress when GRP78 is reduced. This was confirmed when GRP78 
inhibitor honokiol, enhanced melanoma and glioblastoma cell death when combined 
with either fenretinide or bortezomib. Therefore, honokiol represents a novel candidate 
agent for in vivo analysis as a therapeutic strategy for the treatment of melanoma or 
glioblastoma. 
This study is unique in its comparison of three neural-crest-derived cancer types and 
confirms that differences do exist between cancer types, with regard to their outcome to 
enhanced GRP78 expression. This study also discovered that this is a consequence of 
the dynamic equilibrium that GRP78 has with the UPR activators; PERK, IRE1 and 
ATF6. This study highlighted that a cancer type with more GRP78 to UPR activators 
became more resistant to ER stress-induced cell death and therefore clinical observation 
of GRP78 as a biomarker for disease outcome could be strengthened by investigating 
the relationship between GRP78 and the UPR activators. To date, cancer research is 
moving toward specific targeted therapies, not only dependent on the type of cancer but 
also on the disease stage and the expression levels of specific protein markers that have 
been shown to alter response to therapy. This study using quantifiable techniques to 
understand relationships which underlie the sensitivity of a homeostatic response 
mechanism sets a benchmark for the level of interpretation that can be gained into the 
characteristics of a signalling cascade to allow for the observation of abnormalities. 
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